From dbcb40eb598f1be6515d1db69247f07839417226 Mon Sep 17 00:00:00 2001 From: Krishna Udaiwal Date: Fri, 16 Oct 2026 14:45:51 -0400 Subject: [PATCH] Link each Symptom individual to its shared ARIS symptom via symptomConcept Same-label Symptom individuals stay one per disease (PR #148): each holds that disease's likelihood, description and source, and the editor destroys an individual when it is removed from a disease. To query "Fatigue" across its 76 diseases as one thing, each individual now points at its ARIS class in notebook/symptom-mapping/ari_symptoms.owl with a new symptomConcept annotation. symptom_mapping.tsv owns the link, keyed by symptom string; build_symptom_mapping.py writes it into ari_t1d.owl line by line (idempotent) and drops the reverse ariSymptomIndividual links from ari_symptoms.owl. 2,249 individuals linked (all 2,243 live ones). validate_mappings.py checks links against the TSV: mismatch is an error, an unmapped or not-yet-linked symptom a warning. Report 4 picks up ontology disease counts stale since #143/#144. Co-Authored-By: Claude Opus 5.5 --- .github/scripts/validate_mappings.py | 104 +- .github/workflows/mappings-validate.yml | 1 + changelog.md | 28 + data/4-reports/4_Additional_Info_Index.xlsx | Bin 458407 -> 458435 bytes notebook/symptom-mapping/README.md | 25 +- notebook/symptom-mapping/ari_symptoms.owl | 2254 +---------------- .../symptom-mapping/build_symptom_mapping.py | 63 +- ontologies/ari_t1d.owl | 2254 +++++++++++++++++ 8 files changed, 2456 insertions(+), 2273 deletions(-) diff --git a/.github/scripts/validate_mappings.py b/.github/scripts/validate_mappings.py index db75d1a..6577aeb 100644 --- a/.github/scripts/validate_mappings.py +++ b/.github/scripts/validate_mappings.py @@ -5,7 +5,9 @@ predictor's `mappings/ari.synonym_blocklist.tsv` for structural problems, malformed identifiers and internal contradictions, that the two files agree with each other, and that both agree with the stored -cross-references in `ontologies/ari_t1d.owl`. +cross-references in `ontologies/ari_t1d.owl`. Also checks that every Symptom +individual's `symptomConcept` agrees with +`notebook/symptom-mapping/symptom_mapping.tsv`. Usage: python .github/scripts/validate_mappings.py # audit everything @@ -43,6 +45,15 @@ # beside it is the generated evidence behind these decisions and is a report, so # nothing here validates it. BLOCKLIST_PATH = "mappings/ari.synonym_blocklist.tsv" +# Curated symptom string -> shared ARI symptom (ARIS) table. Every Symptom +# individual in the ontology links its row's ARIS class with symptomConcept, +# which notebook/symptom-mapping/build_symptom_mapping.py writes. +SYMPTOM_MAPPING_PATH = "notebook/symptom-mapping/symptom_mapping.tsv" +SYMPTOM_MAPPING_COLUMNS = [ + "Symptom ID", "Symptom", "Mapping", "SYMP ID", "SYMP Label", + "HPO ID", "HPO Label", "HPO Mapping", "Parent Symptom", "Merged Into", +] +ARIS_BASE = "http://www.aurint.org/ontologies/ari-symptoms#" SSSOM_COLUMNS = [ "subject_id", @@ -163,6 +174,7 @@ ANNOTATION_RE = re.compile(r"<(ARI_\w+)[^>]*>(.*?)") LABEL_RE = re.compile(r"]*>(.*?)") CURIE_MAP_RE = re.compile(r"#\s{2,}([A-Za-z0-9_.]+):\s") +SYMPTOM_CONCEPT_RE = re.compile(r'') @dataclass(frozen=True) @@ -1225,6 +1237,92 @@ def check_blocklist(rows: list[Row], diseases: dict[str, Disease] | None, report ) +def expected_symptom_concepts(rows: list[Row], report: Report) -> dict[str, str | None]: + """Symptom string -> the ARIS class IRI its individuals link to; None for `not a symptom`.""" + by_name = {row.fields["Symptom"]: row for row in rows} + expected: dict[str, str | None] = {} + for name, row in by_name.items(): + target = row.fields["Merged Into"] + if target and target not in by_name: + report.error( + "symptom-merge-target", SYMPTOM_MAPPING_PATH, row.line, + f"{name!r} is merged into {target!r}, which has no row.", + ) + continue + symptom_id = by_name[target].fields["Symptom ID"] if target else row.fields["Symptom ID"] + expected[name] = ARIS_BASE + symptom_id.replace(":", "_") if symptom_id else None + return expected + + +def check_symptom_concepts(text: str, rows: list[Row], report: Report) -> None: + """Every Symptom individual links the shared symptom its label maps to. + + The label is the key: symptom_mapping.tsv owns which ARIS class a symptom + string is, and symptomConcept is that decision applied to each per-disease + individual. Findings sit on the label line, since a renamed label is what + leaves a link stale. A label with no row yet, or a mapped label not linked + yet, is a warning: the curator added a symptom and the mapping catches up. + A link that disagrees with the row is an error. + """ + expected = expected_symptom_concepts(rows, report) + current: dict | None = None + for index, line in enumerate(text.replace("\r\n", "\n").split("\n"), start=1): + open_match = ENTITY_OPEN_RE.match(line) + if open_match and not line.rstrip().endswith("/>"): + current = { + "close": f"", + "symptom": open_match.group(1) == "Symptom", + "label": None, + "line": index, + "concepts": [], + } + continue + if current is None: + continue + if '' in line: + current["symptom"] = True + label_match = LABEL_RE.search(line) + if label_match: + current["label"] = html.unescape(label_match.group(1)).strip() + current["line"] = index + current["concepts"].extend(SYMPTOM_CONCEPT_RE.findall(line)) + if not line.startswith(current["close"]): + continue + entry, current = current, None + if not entry["symptom"]: + continue + label, line_no, concepts = entry["label"], entry["line"], entry["concepts"] + if len(concepts) > 1: + report.error( + "symptom-concept-repeated", ONTOLOGY_PATH, line_no, + f"Symptom {label!r} has {len(concepts)} symptomConcept values; it is one symptom.", + ) + continue + have = concepts[0] if concepts else None + if label not in expected: + report.warning( + "symptom-unmapped", ONTOLOGY_PATH, line_no, + f"Symptom {label!r} has no row in {SYMPTOM_MAPPING_PATH}" + + (f", so its symptomConcept {have} is left from a former label" if have else "") + + ". Add a row and run notebook/symptom-mapping/build_symptom_mapping.py.", + ) + elif have == expected[label]: + continue + elif have is None: + report.warning( + "symptom-concept-missing", ONTOLOGY_PATH, line_no, + f"Symptom {label!r} maps to {expected[label]} in {SYMPTOM_MAPPING_PATH} but has no " + "symptomConcept. Run notebook/symptom-mapping/build_symptom_mapping.py.", + ) + else: + report.error( + "symptom-concept-mismatch", ONTOLOGY_PATH, line_no, + f"Symptom {label!r} links {have}, but {SYMPTOM_MAPPING_PATH} maps it to " + f"{expected[label] or 'not a symptom'}. Run " + "notebook/symptom-mapping/build_symptom_mapping.py.", + ) + + def main() -> int: parser = argparse.ArgumentParser(description=__doc__) parser.add_argument( @@ -1260,6 +1358,10 @@ def main() -> int: check_against_ontology(sssom_rows, diseases, report) check_equiv_against_ontology(equiv_rows, diseases, report) check_ontology_values(diseases, report) + symptom_text = read_text(SYMPTOM_MAPPING_PATH, report) + if symptom_text: + symptom_rows = split_rows(symptom_text, SYMPTOM_MAPPING_PATH, SYMPTOM_MAPPING_COLUMNS, report) + check_symptom_concepts(current_text(ONTOLOGY_PATH), symptom_rows, report) findings = sorted(report.findings, key=Finding.sort_key) scope = "whole repository" diff --git a/.github/workflows/mappings-validate.yml b/.github/workflows/mappings-validate.yml index 42ccccc..f61155f 100644 --- a/.github/workflows/mappings-validate.yml +++ b/.github/workflows/mappings-validate.yml @@ -10,6 +10,7 @@ on: paths: - 'mappings/**' - 'ontologies/**' + - 'notebook/symptom-mapping/symptom_mapping.tsv' - '.github/scripts/validate_mappings.py' - '.github/workflows/mappings-validate.yml' diff --git a/changelog.md b/changelog.md index 8b0eae9..1ed5a86 100644 --- a/changelog.md +++ b/changelog.md @@ -1,5 +1,33 @@ # Changelog +## claude/symptom-concept-links + +Links each per-disease Symptom individual to its shared symptom. "Fatigue" in 76 diseases can now +be queried as one thing, and the 76 individuals stay separate. PR #148 kept same-label individuals +apart on purpose, because each one holds its own disease's likelihood, description and source. The +editor also destroys an individual when it is removed from a disease, so merging them would remove +or edit the symptom for every disease at once. + +- New annotation property `symptomConcept` in `ontologies/ari_t1d.owl`. Its value is the IRI of + the `ARIS_…` class in `notebook/symptom-mapping/ari_symptoms.owl`. It is an annotation property + rather than an object property because the target is a class in another file. +- `symptom_mapping.tsv` owns the link, keyed by the symptom string, and + `build_symptom_mapping.py` writes it. A merged string links the class it merges into. A `not a + symptom` string links nothing. The script edits only these lines and gives the same result on a + second run. +- 2,249 of the 2,295 Symptom individuals are linked, to 763 of the 765 classes: all 2,243 live ones and 6 + obsolete ones whose labels map. The other 46 are obsolete `not a symptom` entries. +- `ari_symptoms.owl` no longer carries the reverse links (`ariSymptomIndividual`), so the link is + stored in one direction only. +- `validate_mappings.py` checks each link against the TSV, and the PR gate now also runs when the + TSV changes. A link that disagrees with the TSV is an error. A symptom with no row, or a mapped + symptom with no link yet, is a warning, so adding a symptom in the editor doesn't block the publish. +- Report 4's *Diseases (ontology)* counts are corrected for 50 symptoms. These are the + individuals retired in #143 and #144, whose PRs didn't rebuild the report. +- Still to do in the editor (KrishnaTO/ARI-metadata-manager): set `symptomConcept` from the TSV + when a curator adds or renames a symptom. Until then, those symptoms show the warnings above + until the next build. + ## claude/migrate-epidemiology-229 Moves every disease's prevalence and incidence rates into figures, the shape the editor reads diff --git a/data/4-reports/4_Additional_Info_Index.xlsx b/data/4-reports/4_Additional_Info_Index.xlsx index 8e8d16a3746fe704761a3c3033657dd266a7426d..4a1458ebac15afcf412f92ef5fd9d7817a5b664a 100644 GIT binary patch delta 74964 zcmX_nbyQp36K!!V?(Xgq+`SOot+YVVK%uw=End7>ad&qsZl!3j;7)+z4(-eLdvCoz za&uPJT_^XRIWx2Oo;hW&l!LF7Z?)Btkcr;Bd4vAO-cvj2?EnV+%R(=pCgDD5nFg$* zKFEiMc2Otrv|%~dSxJ8qyOR=XC3nfq)W*FmL@(xWe^%mo!h+em@p|q}%HWB&suJ)` z+KMUGLAbM4OFk0V%8H3dcPu5IhDlpbYteQ)%lC6W$44?k(AI#u5o>wtG@9%pVr^ysw3&<+Pj08ru&yFu`rKQ^f z86Zx-C>)w+@QELnHFz;28&W>&q>ip{q6k&-o5)25XP++k*8KScjjU!jF*&UM{n)vm zW-Qq6y2*Mn`a^aL*Qj^Y|iou;?-O>-6!y+nbH ze^b9j1gaiB{FZy5&pIvCpVuacWMB5{#$#5@%XiFoPaoI(R7XqcOL#ZDE2DosiH2rW zR5PbdW=+aZWtc06QWTQ+sx&#%T~pA_2-$U_Iv%S8A%NcHzH?)nh%-*Nt9J5LUM&Y%0t zJ$UTu5DTgrah8wqy3a)Vq0(UNp@>yaFzGx=Je2Q0vWSHaix@k0swDNj^)935?N&sE*c27{Yq|FlD zypQZBm~6JU6br3x`j5R_nOimPnVpC9qr{6UQs#ebduai(P$ssvvy;}Mbni4R#mBZE>JZ_i-0P-^3k~a_n2dXqXRMSTxnJ#;b%A?23D|dX zbU~BtsHw^}zo!PQ_|rAkdP^a8p1%ZnZIg$MZvMDoU7{#(%sQYz8{R0$xj&oSgXnga zI;$YwpU;qz_ZGKlWkWq7Ij|L{d$iwV|e;mTeTiTv71#Fzx4s5Y@Wb%FOQpA0h|Xa(Tk4g zi#rt-Y4GnDDb8qWmGmCi0`s=X(7Tu9?z` zSoLfOtjP;+MjgxMnluRi3Z|5vszkuP#ogT;lF?C+ZWbBBblYHog3RR^HFTe?D!Eqt z^mC5mdCEUtfVlr#+Q$p)Bt^&h3cobWQuYk_ z`#Q;g*tn+o#1Qk6z|_K0qrh28_Oh--Wa{woB9M$&dR;28e(^gX2 z&G0k#Ch*k4fTVyDe_X_CY77lCv>I1G0@=*l{|?P@2H6IUkB)M5=QD7@dtf{3l1rwF z+2|1=K%1h;&o^fwul(@sW{Yn~(g_c`(3zO`)HYShF*BC^wXy{B-r4Xr%vN%IVn*u)t6kfZ6TL~b0pz0 zFRKfzKb8V@VXF46{^2RC!~*^be526Upz5nS=Yb<9%8M+&$d!C_)>oyy742EUTR@x< zjNc-9=olHumdq8Wn3P7$BJH2q&ct9?!I0Mt=Hk`89p_y*U~E(!#op}m^&0nPM$XE$ zxc?#J{)hn**pKs8`um%CZ})^KpBm=~h0S@`^+h{8K|x-+9RyQZj>5Y(qUrJgJJEi5 z%Jwuu=x02|E1?$BS?#|ldJ-IL6S%j-3HjVphL=Mo`9g<^E5YxxoY_C^=YoWf!CTA$ zzSTzsL);mq-Zve+@}gEi1Np|nuPh);d|DDi_GrL3uQx@d(WJ};`nEL-s|@=B>P3FV zCHEtH`zhY|I^T=J&&0ahwud9=VqHJ9)K70%y)CdnLCbZEx_g^tzxf9BOR`=nAMgGL z9-CBOB@TiF@Ge2M_ooNVsjiry-)2MiV4@N3NJov4`}`?0cB*C_=%>~gwfVdhPNVlJ z2_CT*G(*3DIcuwEjVj;ip$4)Si0)D6Z?hgY-i+8MfAL@=jP0Io`567JkW*nP&h{8Jf^KXA>JaEd;EOSB)+R-|A@2 zEzti`19!Kgf8mG&6Y8LC4Zc}-RxDhuoojDgj(asT(cr5;ecj6N^QjuW`+2^u zlR7u|Wg(VC2;%unaA2S$zvn!Cp4+nG=vSZg=Ueyf{qIZ$;28xFhhf2}z`E4C2RYll zaJSTQRmA}AL(xG%HF@j2WW^0@Kx}9u=I-4)^0^aoo9hFV-6ELbmwXupthaK5P9XHL zvL>Z%$c9NMw-_+JLyrrf7bJ@MXj4do)Kr;~)q&UX!U zX!NJ9@gstI?^E~c^hT;==0ILSzP&lw=NcSIoGP|dB1^*gu zW8?DvL8U|$D-v{Zw`2yo_s&Y;YQvJc`K^L3)DW|njubba@Y=QIxMN_?GWdp}M;MI)fLAd0308U7$?*ee~ z8eArw32X}n7z~5v_l^yn0#s|?8qL5+f6p5e_fLd)FSYk4CY^P*pB=4Q*rt;d_YeDf z0S4C5F*pTDXuDJQD?5?Yl+hmJHFDv>jywme2>Uo)ywMks+GDy}ZK%^E?US%O#p>(R z>xXT0XR5$;uv4$}p{^zn@A>9$Cnh=@_=v75p27qaj+{hpceR!I)gHBh0&9Fo8*Xa8 zqp^W}VyyMlreH}q=Ll+>!uMD}?2o^Yu~!LZnx|3ByIHLmzs4tO2<%3R7x%bQLN!q~){^(8;`k876|w1N>sK z6o~}h>7!(@VJIc5L|3w_CeJ~jgY3fB=ar~4*$8ltb^#zRqgPN01`#D^$I>X&3-dO~ zhmKBe*Zj>YsPP&h`3u z(M%X-Hb$m}Ek3^43hCmci*gWCCEHaVAS<%EjboiKpLIJx(;zKRWqc)jhR zxnJgpndDw;e?%8?miRVY>xc|I?TU?Bj(6r)Za6e)wlgWliHJ!q{b|T%@_=}UJ7DGz zz#>CPKQm;v6x^mIt$<~(C(!Ayo;?i3c@KUEW{~%%6gjUo6Lq-uU~Qvb@2uiNbQC{A z-&Iy2yU!~uUA+RsUeOX1*n?typg`K4eCr4%TqpM!OnV-o_8IU%7n8}{$nl0$* zh|c5wtrX}U{uZgzlT6$FYQ;eIr*UMw%C2$*nF8_7t9ecz* zgp#5WLb%8hn|e^8Tz+)p@8@_`ej5akp`Bf?f3Qtmia0-*Cd4+hW~O&){)7Yvx>e9e z`8m1MYdBgm17w7N;7QFCz!RX!mX6USUeR@NxVRSsKVp>&$%r5N3d*No(46u{^@p{#m09$6A~T zWe*em6EHGRa#wkYLJQO^N$kN*6}7;oR!S*PmrHNa79OV-$(=u}=XQB#prU5jiD4M% zUN(Z6WuY|A?#FF{0jkUMnnz`rxCuyUr~x-cs_aSF8)c#jG6!CMOHNU4$dVoA_?C>s z!GWbiL9GVFM5L#NW6L0>qQaS-jhX(EDaT4 zZKUg;!~O@t$#X*@TDu&jl++KPE-W?q=MdyQcC0VxLfxgrrISt+(4jhqY@pIW5ZL#D zSWVvM@|=Umn_WIhxXv*vk-M1*T0R$WW7hkFlWwc%{O72$O4iN#L%AapKg{h%zl8ld z9fSd02)}VNDe;vg{M6e-BJ0f*iVzlbf$xHZhl}EF5C-#DPL#Cfrj*1KUg?KqlLE6Bog2vXBmtA8Jlp!GW;gd z;QkU)?W}V)CEm)!ISMiXJFLzk^K3LVCi$@tq8TC@P0<;jAXMDIV^A7(8jbV(&k4tWcOFoEy!_9cBuNPuswLjvKKswg{^$?JWGeoV092{*~+XXs0?M zgJ-{U+{~y|#_c11HZ*^XcGWz*$b90HqLI^T3tJe{k9?~>ulyIBdFQM#HO*BwO?lb= zuB|ud>f>)q_4lQcmjd(<>F%~KM3oamMp{vuuAY|nl0>AnBvq2X9=G4KI}VcAyU>*| zp$lo7edyGtgbppVt_bN-b{+aU{^u|6@M2bZtl#N&A0WX?+7DpD1u zRQldeP+tkJTTmxv%Ty}Qgi62{d{X&S)<@zUfb)hNb75}tP)F*dD%Ds7LU(p6dvNLx zxWegwCn3jz5#7z3Wg?HGlC4HN}9x={qYlMzvB zEaJ{u^qwr}LxN>h6ANWpzrsi+cNuEy|KmZG=mvZ&-c)i;PPLk2Z>L|p#UrmBaN)^y zOd&VTNzn7*0|j&0FHyHnztyq?+VWL7l?ym#aRKV&a&Sswx4%@_TpXk)e+tv>9}O1KaRZ* zcV;SK|4tUeCgEQYrPRYE)3lcuDDAGv^6jUD!wXXj+#)^07A?iWzt}8fv$xZj^Didc zVTPhLD(8@)zZfNa85Rn32llZWAc;;7BQQCNlIASL-x7d0=ds|GaEvX_?XPi&7sdL{ zZa+#ojM}t&QyiE)t0s#``OfHUy(?%{oieIiK=SQjnaf!id7_=sIfvD)()D^Wfq74v zH6takpgDihbR;GjuW~ktC?0MA-fvw7so{WlVrG!x6ftu{7&bApnW!BSKl~=}-6aw+ zGbi0csT*EYX}qjZgg~gO3pp**?Ws6oN4x`0h!2a$e8kgM`z}gzyNJhUhbGg&$+)qI z(aJQvC9UUANci^N#er)-|BPX(mJx)--lsa<BFIdlk`cNKaqNsMuEp$8g@G_?K^v<)w~wZge6^|yq8}CBYw9jNknNS zXLf#1bGN%cFgdMrwG+W_m(0c7(G1u#B>uoxh!xawef#8_0OGUZ(S&b&&ig|335JSN z`mFprgwg~!DUZs>aZlKEx}mv+ZV5FS3XK@YDlKV0DSZYLhZDS5GNPAnmfz~+j+#T} zCEPOW*;q)09#E%5<5a;Bn2hmtA#!Cuu2EW70dIpGKze~20E;JtHhcCJ_Lz>yAAKX* zgDH`8*HEY|3LFyFOxn-y7dbKc!H%kMyFo*Ux0IKLOxt1vZoY~Q%cDsg`rmCh%1YKk z^RS2w#ME+aXF2~B<8XdzVC^uJPgZiHS1Un)LSU&$1?F)=bKrGh8fgX*My`5;HXPm> z?sjgU7j|~Mnp|4etV3?tch9q@)~ai7Ppl(?PxnUKl|8eJ3$9y}3>$(Kv~N#decC@c zm`v`cJV~THnpAGq$wTgNBJ|O4hRFk?=vs>#e#8-47borixosVrp=yN%CFZx_L%25b z5)lYbwo*4r$HD6#pC{37e4voCu1@@@O`PYCaLYTDZ_Y%p3VRk!p^;T^%a83L#|c&6 zS)|2dkS|zdILF-l$TJDRx8YlH?9>GyJ~3H4KNzvkQAImXKigXeXT&OZijx|~S92HL zHVl3z>syMVgo*6zF$Zq?=i^k2nWV09Xkp0Zyh;wk#Q#7&gx9xJP7k|J2?t{FRje`-T#^5znD_N%EeQsh$JJ;x@&lGv!I)fs!&?0-Yg2sLET0hPT|c4W1)i5i9ds*GtQc|r8V-3pp*IaGy{r~gOM6LpD;ysCWUuRf)2=Y79k^c*|^77tyPEKo`Og7jI$85 z4aZq9_-MimBA509c)ir?8vL@F0pFQ@;KAA#>L7G*ZU=LoW zi~eMqzT8tc{O5Ixe57}rjnSK6>)D>Vu*rpPPIV=p(>4sZz_*u9}|&w^ka@Fn0J^RI#?OV)Wrj&+8Mr3>l*ST_BFN zDJ)!-QN7FpNq@c!N#Es}0#!;@%jSZ#^mo@Veq|Z1KtCQ;URLWjtz+=h=#~V_oY8sa z^3qUJ&^bAap9)Fk(<|4#{G}hK%W%)dugA$6mH|uUNWG3^JyL=s9n5tqGvP6|>6X+R z3s0;qiO;wF-dQnok?f0HzS~!Zi?IPd^t%2&4%?&*4Hs2(E?v80+{9SUDJ734w(`Vo z=MEl7#V_CtocP-(LEaB7;z_S>z>E@Mwp8Xc}JoldKx>;%Ja? zI8(#qbYCg?VtKN5TrLJHCm8FzASuQ02<|qYbn-PTqGw=)716EA`m|}%j}`R-?H1(( z`Z~sc+S)G^h6s4KBZ$~1r#%`Oy3<42;QH{HI5s@mSw$n)f~EOP2sNMhVsnYfr#BMT zbshl_b+$vxE!k3fEmqV9XT)c(py?^qhlZNn|brvm|G$Hm)m($y1^}PV?K)* zQuRkXc01nu(44{ir#=4OE(#2S;qzK~nB&KHGJJnN=w7BUVlk5VznGc2+#txw_%MPB zOHiDngyx!0q|xkeGl#?Hr6aB00B)?(A=kCBCrb~~U%?SWXs5nMqR8;|uqW}tH+jk$ zo1-n37;mQzN3=62qUKn71Stt2t%ZrGh=jO9# zXi(^=+EWp8;6}NP5}Nzrs+=<=o&g)~L^i8l`mZLBM3E?MPav9tOKiMreK5tw&NL3Mu`3Q`9g9 zGF2|=hbP)Ti^5IMF2xAN7f(^}(76)<5DZ=oBK?P5#NG99NakRErzx@M9Bc?(a;|SV z&VlZ&Orqj0t{HB$xj*~z9}ZeHoQX?zbpoTHJi`^JSx16LD;+iAX8D$~?aD5ubdjor z9mHd9B78kmUk$SZf>S3G%lHn*7Q;KmJrWKCyq51zqMvWs)nIb5daB|QAE2I8USLnc zH?i>8P2zL~eKX<8L1dnjNr=(7HH=*(Ofdf>rbwZ7+Kr1bG@WnIv#5NlQ^ZmsK;!Zw z9|Wv~8QqQD?o4d`JXd=Sq;&Y$wo;BP*LSHMp+|^C+=`=5mfRxhB}~A-s?NLV4!|jo98`?s-Qh( z5Q&ehWaMO{)HoXYa&d)(A-oL=o-|V8H~u3Zrz~qK0JkN=`j8M9mLhPA2*uWc=a?b` zfn=>kcGH&6uqWRoXTH55LLP&m>H2q`H&q-^jY9$b#p5D+c!*|jyjlUjnXt2?f2@J& z@(>t&Q7eBPhuDRnV=-4lhz$`wP%j9Yeh*gNg>D*1VU-3qj=}ufiuMeKhR;%p|42;P zu*!i%>Aa6>KdS>2k=`^w?VWPYT&Pidv<~Rc9GSG2{?rcKcbC?_t?y(}B8cGV9lx^$ zhB8hT>A6W@H>xtpyvqgWs5^)rNS1V*X`99^a?s6XfzYI+R-Tv@S-oGV z*0Fv6Pf2va@MR91mbC2{o6BI`8PJNWMwS}9UtH|=K*Uj`c!ZUnKkV|elW^5T1pCS< zSUBo^JBXt7lDy2EDwq40(Hf8zzOTRf%t*R4tsf)#_nnE8bae_x9q^b!W#?B>39+UK zlU{~OwD-Y227FAPNIfkJyZtJn>e__Le{cas;r~=>YZ?=#$~d*|tuQ;m-|PrGm~(8? zONq3;Qht#Zgb~dlpvTS0o8`ahCgYU;luUm$4fLN(16&%oQ0r+XsTpk zZVFl)?Mn2my zColfgs?rr;=rcbcbJ#1ZvR`D>TPIzvgtdeeX?88XNUH{g8~$SY-7p~U(%#?VL|a>Y*Q)y+`z?PT!iVMpU*qso{^x@_d1rJ@H~;eP%O}dIaj!u&&vEII*5ABJe?*KL#_J?Wi#J zt+0hNxG9x>MJU< zMp|4WIe6aheVVZYnvf49f`iP>8&z+&Qql!7t6sxk#sg2p?)YsYF>}2MmB`)$y7kKq zu9ghG5~HfSyT<`MQkjE&KMfV=_X;XiZLzhWS=!tIsM6d`qH!3naBIe4g*#6Sl0Wv( zO8{kh7q`#CvKoj9qdAm0k*o|&=+g)ZCSd|!6w7O>sVjI ze6;%aD(V@r6yIO};GF~=F?=LyNr6}H$RMC%nC@eAad?*?%n-8jH`jKc9HhfX9t|Aw2zn}jQC zlQ7*Kx^M<4HWBLPr8jV)wP8(Fl%BiiM@j2jFr+TwbvmDeu?wvYrJ9jiORfddiJFJJ z<8B`xZ&0-I;Us+jJO&vZJpV&JcwW!gywte&q%?97&t4aglM;W|D<6vS@`vNcPvIo` zpAoA&Vd7wP>|d*QZvlFy=@F`o-Z}e-0`C7Am<2b<$99Fg@G$Y%)@c%mMX8~hWN+&w z`jY6f-2&v)Gb<}7kzwFqdhkOvqAjm*Kl*Ljh@ka=wy$o-cnJT!p)~&>UiA58nBdy2oIsG8r}}h*#qoMq)-kH>Q0! z1=z~hvxoG?Iy$si5*y?tVyIVX=2}`efA|3HZGzU;Za^0CwJeasWeM>@w;o5Gzv_G+ zb^ey59E57|Nba$1Hv{_ZyuB@~OzyMNn*y!nf#2`?>-i71>F3*!^sF&LSvfiL^3<>7 zU}gIs$nVvsNq^|!wM7wt-W{ZlF;?P~YT4 zB(Vv+(0KDQsi@pke$RK9Q!2+0Dqsngk8d|uyi&=p*$#b zX&wdBwC=E}*rdUoCfIW(YkU012P}%5;~Q}}R$l4QCpIB=2&t)D|0*If zBjm-YN}O1*NDO$c`oCbDtXWNd+++loMqMvg#Zh?fCYwO94F_qBc5aiMnBZ5px6!P> zU2(*yN}xo#fgO%cR+>4Ef&NZ>#Z8lTqfuw=EB2<584m(#TXY_0;x71*w&qo~3V7&% zD#5(=tao96H1*d}pvz^q7^rS-7TG|R=*!kc5j_SY;G=awxW@lh!9uTf1;YX!rwFy6 zPM6Wk#(51WEN8INMp^`te#Rkhf7(Ll7MB>{A7mm*XR}kYjF^WQ-ZPNGFAAv@6%)^w zCoY%c&rb>eUjOAVfwlf7&N@)e#07>J%gv6>8_|kaM?5NvqNh<|`H-N5JDlr?zFE-v3w&D6qEAbGf*y^nVNp)p_hsrCl{p@u2-lnk*-2i@r00! zXvr#vUz9};(rtWGcfNGd>q3__%BtmxLz2Fg7?etj{zO~Fo_aMm1uk_l2l9Ps^|*NQ z6@e4ZF@+$oM9eLnQkL>KyP#HaZRV+T$BM5}8#1u?27;F5*szZO?Q9~v>A`EOETnqz zXSG(YyZERol1a|sR|Rn{EYMd!*Wp!c@eohA!{^2A60b~i0 z@ZINAsbsGrDjyreDjQWIJw(O$cHxH?*BJt6rx61T$o@V@qt)f{+HDOWn``{`w73rO zaDXT2;+TL<6{i0EY41HMCxn}Z2A}8{5t8E?MMO1y^rfhGhbOX3ER~_6ehI(71_P#F z80KEGLO9+51|cUKXwRkjD=p)vPrjrezG7k9ywBpml}a@$0E!VUde!jEDBo9}6(#PE z-Jif_fsgbho#e41JS|vaS~%tdT(tHIv2t_o|KT~r$Z;fQAJD$B9MoGnH<$YYy|hPb z#JQN*;>bSsq_hKxldXxzIVA*ydkYgNmi(!eCvfV&cH30^DErQTpTPYUFseGJe?mb* zo77(bmv}2_<}^HFqHs}dLf0|PUiMqZWz@kY%0{=rs*JeL)XBeptj8w*<~R`V5jD!YwWR_0ny8WglkYOBLIe7tV#7Ao*S|Ntv}JLIET$gT-DL26N-M`jv8uw~jnn zL`14p{8;nOSG8$1t4)%@=opSYHCuk8$;Xx3P9mD^8(ovz0VdNfq?xo9&Bqu;|gx*V>R%}gJh@q472@@iPWQn8W)6(R#^o{ zNtPXb`7Bm+vWgYj*iI6Es;qysM&Bog(|EazORI`6lmUCJ$LAye?&xH_IgvF*(9+A>P3qePRJLyHA4FG$ukawzvH z=!uI`;ktRs0jK6a=ym~z$NY=?_K^)N7V$~)mk}1r(f%D5IBi)dk{?KE=8Ib{2Ns>Rwz&3PF3<0l9hbTZx zir0}n%Gwd-AxnNNtOA^_UbUT^HMsHSsP61XSI~wMCAN;C{yImbpd!_JHA$@%Lrz8v z_<#8txrTpEskh#V#^M3wjZhgVGU}rMpl)R!rmSvit8$|QV}=q1duVefhw#SgJt?E`_sV&dfr-|e?? z87}<~2D`v;YQ_YY6s**cYo+;234tv2TM~yA>3I=0ABZX$+Tb$O7GwQ(pwOrJabi3N zn^vdlK9vzi64WZLfDhZ5mJGnPg;aVm%9{Gw%>K3$0L^N16P!D!h*NqPG0NFI!oilK z@U4viAO3Y(xN-`vXOiTjvq8J4I z!SUxGGF)UP5a0l?p$ZyGg2N*|t~js8!Y2JUBCifjL7Exak*O5LF-oW!WWk(lnWy!c+78B;E`j9p~nHP7ZV6xuJN>wuSIz;7cp1TdIW%v>*2+ZIpp~sZ)7XJP%yW zSGwO*=@!+><2a$Hr^mwf>u<#9=>+bET8xN5t<0ctd`ELPTGGhzl5n*QvKf0m#JGoV zcy@PFmxcq_6hpX~p0f}s`mXzeYB*9bXS=N#&|2s(8`N6+SlD<>xPJo`|&nL^QWt1b&B0-Z?{T%@@IB&RaL& zY^PR>Q8yzI5+zY{#k^>iCyjg_oe>(j5ca6KF|Dd(JO`$K#nvs(_ALr6&Spg$ldHkx zT@kxWWVTlK#ZH0F&-O)6%ftl0Wgci2OBSY3NDQ`78AuMFdPk^p4wG4tLYmM*WNk)w z2oWlo;n&ejQH!Bgn`y|M(*^#Y$2}?$qY6R{8WZ+{Uz}GVV=>N~U+~R)S$Fm4_e+h_ zCp+|+3nz%{-eF@;%MZbjbBg@H`SL>-UsuHnnzhlAO4STP#DSGFj*)7RMYc(N?G!aRxPF5z=p3&)$YZW=Fw$lKDhDVvF2}RNy-e*IRo-o z&MjYlIXZyM0~a?la#Jn7h7BJenCy0Ku|MST+thHm- ztO9CRxs3FCt|+1@R-%@kfbx20K?BGe|C zSxSBBIuBr>7zDku3F=I9L3pw*hH-G-jvHMgLT%JiqqS8N-JJykijF-n5nYzmSei}_ zEt>h`D!hbhMR(}eJFy+!9OxD~qSZ=Y=;@u6TKgwKd-k}DO2X~G#pi8ezu|vBEq~z1 z8+^4n#d8+XrKilY*@0jlbP-m%rooCc95ns%))s80(0vy-2NPGM*knohmd#LL@LZ~z zeFhDqxS0)$`J63KUPeG|{9T1!vpCe7PqGoz)pZ7g!IRgi6@n3MM&&qQz5+>a_o(n2 zjkZdHNCMDU?o8Mr8Pr{S>5dLkZ+EWXa$j- zzyY*KNoCacZOf6=XRZ~AQKL8#4NpDFmpXkC=|*|mUG`ioEnnioor(x{S}hv2NDKx5 zE#G2>B*WF61RWictGOEo;@RH!(oB9S$%s`XHfLb93P2014wI{G{5EKeWKyO)x6spv zIVTC9bWx|TW?@*OiO+nOi#^}EIHai;d`a$7=Q4y$!Gzm)`d@@U6*Sa6jH z>vJPlCbww_BwY+9vf-Pn4`P$E(9|6^q}J4JF|8xT-V3sF@BqLmbHI;9faLRV8_ zeFAyQGn9NyEci)b(EMU9pdq;Hy8zw3JRGLg54zCWFT<{B?H5NfPH@T04=us@@uVVT zdk=vJe6X$OYGnpfiPKToJw?3It5?ab%rfPaRo9RJ9Yi)xNI>*xVrvVDe63<5r{7a+ zq04D^WD3m>uCc3nd0OLDQ14{~)g@UkxN=r7Pn)E&S*oaIe#Asf0)Gh*p?Vt0c>kaT z@eU!l-d^hU@T+mjr#NxF7=P-I42!v{cLf;79snB6f zdH`^be_FS_6&(}-*H_cPD-Qv}z#j>nh}}wK+U3{OoE<|HVjjsZPYUjMM(y~0nDl9V zzUUhYTATpdxowb9-#P4){;vRys?c=W4Ct5$tSzU*RU^$Qa;=3^#OBBwZY%O7gEn%_ z@qjnZ*Po{@5M~X#&P@#Arw*s!((QkQ4bPxCoIK_48aPKn_NE(Ze{D>TXW3g;R#zd= z8^)nm-ed&RGIE`6Wb0-ZcF>Hp*a8XaA|j)V&wxO%>i4_D7UN$`)T(U)P*UdiS; zuGYCe>wwvt5u1t+VUxYMLu;^^+k}-chPQ?-dKvdmgb&9#LS%FDQwgLnl_;A`_&7s={%41Z8Y)%&jLLOn81JC~_JOpvswHo{!by`a&*&^+J?5X+6mrtl>#Tc|}LQ@s^&hdwRXq)Ksk%Bm! z6Fpn3V>btT>6`=rYpz+fbfqWsGv}lFuEN@Q=QU;&rA9?WqAs*VjudkHEkLA?kb+RN z&8220@RN;*A{ogXxT~Hmx{hYDhe0D~s5uPn=D?dRAal+h2(mum;R z61`{QWN<>TMGjAIx%fbhV{3k9LfvS#se8SZUGvYpAFLuJdUKRPehqJvlpVb#tI*BP zWI?Q;VcgQ2d!{?9z=iUw-u-Z$0MeI04Ek%cZ8hQDqL58->;PB!sxV>#{8c5hW2e=3 zv`(CviAi7z6@3$GYvH>&^3QnDjI@|L#&~Jp_T{qC%(T)Cch7a~P1Qq658-D+%eQF0 zlCyq5#(dk_s@0ypw$WR4hM0+L9=KJ)l5*3akvz^|VB0)7NCEb<=7pbW`Jj>B)h{x) zLmpf_eZq{nLz0_4WA;9OYOn^Hq&gv@0e+Y_sVM~01j;roxw-y|;tCIg-WZU##jxSI z*fgw^@|(;{?J8#&oA6lIlbDEicJzq|SOEFG*viR@$Y2kln}PBMB1 z;Y$jf{ueiXYM*Q+HKVK)^TM73G>rBdJ^!IlO6i)qBSn9TkBs2r^dgT8JmEW4Xlz`o zRc0vcI${h2(jM=Q1(bfod6xhFY(CLEq7R1nU{20cK(b!Pd@X~+6x(NCN5 zKIlyU>{5mdD#1+#b!XhCT(X@SBVfLH}_qeCwF;cU93NN+|t8nS&ha zwPPspn=5e{txN0Ar)7xhkRz#WaUDD3%ySGRVlDl7_W!W-jq!1G{ohT)#z|w_w#~+N znl!eJ4H`9W)Y!Ido0~LAW82m<*ZqIq?7N+v&(4|O`Eureozh-gGS9D!@1K%~r_aZq zRK+sF<%l2Kdbl?Dt&6MXxr(-oLXwItm^G*iXJI1Rk4=9z1N2PiVg&Q#G*o`@<##wXkB@!Ul4ogeq3CGN2hwQ8t>c z8O>x39(%ErL#Z9;Ds76(EsZT)@u1wcB+L~B5JM`+;fpXTTu#VIoQG6QO(>mN#^g8 z90ecrq{$}A2>5m$HVPHNGf+NKXv^tGQ!LfWhXHACpfO;wQ#bZJeu5dg%YEL>42kl` z-fI=ImJ>`VYp{JS9b<1TQ0=&$@KJN_lxd;Eu2z3z!NN`5W9bj&l$s}oN40uZR?e}{ zAZj?c&A~5*t>jswQam4mNt+LDiU`EKmRi~JNGt+WSzUw#6r(@-pkK|1%ta)MC!ab? z5y+6#Dr{^!q(fV<{_giKj2D6(8Q0^I*tGzn_&=U#)#>ATa_;UecT;7L5l0E+7OJdC zZy^wKcKvna+oUuIDD-QD~zdpmoGV*6b;YZ@dc^` zziKch;@<9Vsz577BLv#ZZHQ*EOlG>IXqb@Lbk?Hh5Qxs>^a5|t`5aVp%QL7}zLBwQ zneRcBx{9D$-6~ZsZ<1=bl{fkn2JBp!cNLfi!+e3U4hDGfOHI)8pXeq7K+C(YYVzIL zyyXv_`%fPZse)y3Wvs68Tt)2X_%-*Gg=+PO!C+?=MkTjnx zFoo2LY;t%>>S2KCP@j?~zclg0U1Q>EWhWsyP5X4#XuWp`*g+%9t<|el$Q$5j5oUMb zP$0R+zt^9JlK1Wsu)kq-m7F%$=^dNA_f@S6?H|^!5ji6tzH$S?qsK~8=RAs0wH#7q z;08j^?ys~<4P2qJ4D*^egSxEv ztDZH_5&nkw31a1rXhB3C{O%uUrS9uoFzDyFR^blsF2XXNib4$}n~7COdQDf+Ho8Hc z@>3QS?ZA)UVk3;pofGL!ILDR!$`2##6M))#39$Li$|5tww-}4%$xB8C;FA@-S`Bl6 z6;+HF62dN7ki!LR6*=T7!L+RjBMjE#7^51n?hj`**|uu7Lqr{KPR#GVYE}oC;a-8w zvWJut@iLIg}TkUY+X>xB83{WU;c2JUS|*RK?Yck=T^VxQE8zOsCLR%t|@i?uorSChIN+`lpH>YX%<86 zz5a%GJO9RTuTS_EhixR*NDo5aeHbDjk3RXN6%rwY;uTn_xmNsitUdFKU$kW6LPrfv z`^SPPpZO?DfvcsnOy@xn>)iPMEAl$0DylxpC%dyDoH>snsrZ_uKmb(#)qoOGcWzF^ ziWP}0dOFL6kepb+XQXUb2d@sGF{iZ75ZqLCyBq?Lhwaw@G&A z!*bZRJqBE5kM3P(Q1=p+cF9V>3$zs6y1@pG)!{;hYOu!Z*}+4tf!aF(oFbE%FIiwUznHEOojXbW z@+B);%L+dV6F{48cbkuKFie0y3n@CRF(zo>toC$vI7>X;jQHqJGEnAcWGPxw zo7t^!E>FQsv>gOQLJSlohOg~^KPwLlgj*jiG>q{JGY7iBsO5f^z zUI+E{=s`V2pYJaklUOY~YLU-!96M)t<;Z@4NJK||6$AYi3zrh(dxIxKnlE;NphorW zC+WJr0rg{NCfIQYNx}LYJlKc3|4-p;7WO9T*c23(Z{7 zQ;_A!Ar*I$<3Zx5hl;remlXX2_uiSA%*m&&VTNA7l6|0p)Cj%JIhz|=m;@`8SbJ4EqSUmNQT_lV4U_ThlHs?*PTl> zq!Q%YP`X2vPgp7XPV}cd4p+& zt|Qv)jt8V+)|Z^B-%_kf>}@?T61Y=5HQH^M zT|r)=?Rc?7+9{6SIU)1GRw?@vEQUT@N9yc=T7P07zUO!S)xo&t>8~E>xirK58*lKU z0<8tAsV@Oz^5LguKL(XCoe&A7e7OLh0_YZLmL5ip<%vIf)_s$gfM+#VN`-3WZAKHf zYUBA0HZoUZw2^TY`3rSZ@BQph@)0a9# zU`nrBuMELiN*!i)-SAB~`-WF|2&=i`;`FBE69P_IL4DVa^f87bw4A!Vvd^QY1 z>YJ&OqKp{2Wi(hR`S_4jCZiOJm?l~0Mh?1eW>0U)i1qd??m>7-Ue8k3e0I&3)Vrzh z<(i6yCW*$*QgPpZD$7>y;WBbCpRF>DkgWsfzSsgdTBMwnrcjVC8)A)v=Sdq)Z)9t@ z+nm;OZR`?wrAKs`x84ojVU^p4OqJ&4%dTvNHhDj&!Rhmei%U56M&^THjB81b?A0+ezO560y|13QdU4ZsTbEIpzpFRAubqeKmXS1cnO zTcW_AWmeMfcq`Dc-oS+X1`;W7f_IC#$fw278O#Lf>sD&AAC@RN_~HuIUQwD}qef_H z5@|6j_x3dQgrgN2%sOq`8+BCHOp zt!2>UFu(b#TaCM0`b_X9*>DsGuQ^AP5S&h}Ll8P?WIv5cwb+I9nTPhS%02V#{ASH` z2-Xnk+#^R+yAaY&EC^4(A7(`C$hc96ribrqLNzLgo7wLNY2rs$9 z6s~Ceo*omJKFY$2w%Sk|ov;;sdkit2SPjIKe_JtSa{p&yn$Az?Wf!yh^**@p;B|t> z6QhFPN-8Jniv%7q^g%SPsrAukJQo*9x zz@VeNl1#Tf+>KnJ0$;SYNa&Z7}yeCSlQS3ChP7){YlR&(AKmR4AL_ z`Z5KVqfmegvRN^{E_i*qYr`5%LIqV`CB7F0$UrI?+yz1KOu+!<^aNsM@NOa4ol*&A zH{OxncKLqqlkCf@IW}UgN|Oy`#n^RpV*Uk<98jXED4LIYp&I*!i>t^GrX5{#TSrW$ zU_%Iftp0|l+o;jqq|>BOF{7m9*f4pt$H?FDKj|K~w&9{rRiOh{{AwRG*7>J=fsIcQ zG7wMlXpct%Z+{`sGMw3Kk_I-MB_doG%an^&E(8U8BKG z4%a!W9Jszc9LrLXR?C0{t94;LZkgt)Vm6dU#~xZXk#vE%IY9aLYmusiIY|0lRbhaNrx@BkLye-lck*-~&T;u4Sd&+Q=^(WT}_gM$` zXUZE}Lq#2VdrjTuD{zsVR-(|^3fTqL(o22DXgbu%oHt%&#QW#2uBP6(#y(q2uY?b4J#e-E-WO(gP2W^|0PDd zc~go^(+fbjI)cInlraA`F7QC3dyNOvgl1Vx2FR{55U1|#5kS0E7$~RC`Q+P=ev!eQ@ zNMO&LZk!{fs{0Wnvt!D8{>K%zvaf(Yee}VkqQt&x#oIkP5T+_7d$OY*g?Ox^JkB!u zD9=@av(Sc*wOuyJl~kD30;fzR4yz5QB#COFg$fM<8RtGBrb>`hd8u=N44fO2sq@+p zZ#q_J6Y>sr+#USbZ=}hiz z2BibdT8{3dPav)Dy_DjXeR^SC()KB>zFN`qN3HC!Am0Uf^!LZ1gGw9G$I9pu37Fl}-bN*8NSDAgfdWCXxM z1zXpALRPl^}D<%lD2VlFk27y^6&IGfnM41E?#SW|5`8;%GHZ>}>{?%QnHe=;N-c?3zc zGJMA$9y{US&Q2DU$8xwS$9VZO-^&|Ti!=gy``nHv>+m9`MJ%%dM{vwdW_6`T(CG+{ z4aUH>uF5dsSvS}*n!6NQ0XurvkG^RS;G$I1dC&H^7TWj%aPqB7dnes{F4hAc!R$)CHLw4~!sb)_47@J1e{DX;dx4Zregc8hjH zx9bagNz-26fay&W1C$7DUTZhV?+l|jgodZw7Dkcm5NtKvR6^EIsq=O5RgxOvM!wjZ zUGd)D;XxwFO-!w=x!*li*+Y5z&1wKnqVcbQjZ^_n#!*6cEuYbp|IAI36;v?6MU~Nk3U3njlg)(E%;0P z*FEfF5I=VEMdr$&f%>;ROs~w&*Q1Owh4Tm?4i@Y+#rn&!_IT| z5_>)DK0ECYiT;QK;-DX1b8KtsFL@ZzI0pzlIzI*--lHzXGVzKG0j0Dd4CdjqqbKA% zc@#_cRZZNSwVT#PAk*5fDj`o%1nL)-4E=!=8e`e>&P)9o7QO&R2Xn{Fg3!pcPcC8_D%TW7P746~TpcFSP=LwO^*Pi#rn%GF}R+eTd>{;tINnuJw1% zubHQ44revC7gOVyMWXLO*ZAm>H4~5*KdS7%c;mPJ{OQL?ahm^l`iqi!G@;I(h&fg+ z>Nl?+Euo|BS~sxCaYi zFb$V(kT&suU9GG~$K^Kuw0Hj%@T5qCs|*B)_)*trT^a%mR-j<67fIb6{sSU6v10c{ zh%RwugOb1tKgM&oNPx9xu2E2oPw^fD&!y6A4stT{bM2`cc5sGpw`HTFX<6qQf(EEalD1VF_xIlAO zoIoP7*hQYOA$82TDmxP{nE4ACJ2}2BidQQ43;}h?+3NEsa+!n(zm3jNi7iAYK zpAKwsmszm?;lhxAFEq!X&ToHI%LTBqz$)OvgI^qbb0#mrEsl5C$v)WbclUrwc7E2n zB9>FM#!brZFIO{sr(a_gz2Vvh0RE@5G#%o&EMT1rL@P3kn_;Z`el2Z~q@h?|$;A=A z1sAhUdU^`E%)`@AH#+_sVo_|G0^HCR=^~8(+?UqKlDQ=bP?8XQRJBBwT>LBPjcPI$ z>*IZxqg|;8tT7;lX=rhp<=l6u=}T%lWWJ_S6s5a={x$4zbBWh~_51!w5ul0gTKJN3 zP}rFT)khR>x#de8(}q}?B|ypG;s>hSKgM}~7OHiC<@(Pg{uY9Fs;1z_*h~Fk&5bPp zhp{2zlRg8oVg+<_F#|L7=Zt?qwDkON&bn21RO$H^o4Vm8TdMtp%YLPyvB?c*Du5~U zJ2@Jw0Yz*VmDjEDr>+)HfrwOrBsu|wZ?NEC#YkWg(`K^Qib^pyc%w=BbAgQ73j614 zN0WLdRh)kr>YPSsF)68b?A`i{c|!KT_q9c1|m!M+aTLw$p*%9kA z+JGhxL7rM1lLfU&`cQpBrTe4>HNLMY5C49%Q_9l zoilQWEb8~QBZi19tQTZOLv{-H^La7n4E`a>b;Uzs(cZ__nO>9raI`HbBw>}QI_V&p z1{CkzBCVO6Ras~Alz7JaTkPAZI2s3Wsx;@ZRqPA?^YAOBM_{acfub#m1kr|y8Kw<= zcn=la5VAxK-Ex#UNp4MdZ1aPUbr@+k#?m3;HPwC8asfXqAs+?LGJMs#^4tvj5KTa5 zC4F*khbEkl1$im8z>k7E=q{W;OYoK3jvy%M9=IaXr_`>agC)jL9h{aH?rN~07fp4e zWRu28Hz~2-9r+Vgs3j}za>h@3#~(SO!hCz5$n0+Cb4W3HYBjV2=dI=q1HbCIYHXhF z|DpOK*MMt-E5y0Tt7O;D?})iS~F7|6Zq9t?@; z988fP;0<@SeetxlXgp&0vz=uCQfDcY%xg>}rtWQuW8E6G(iq;S?4lJ2o?Mr18)&PTN}5=U_ypW9o-lHFUKoY`$i(T|J8IYJD<&Zxz?ga}eTdF41S`au1}VKhFjdz&YDCwZ|#VO?Jqp0k;ONqbA9e-q>UqO zA9yx=G4sZ`Z`lh%zWfq)ATBIfjab0NNa2ZgBa=gm&@Zl?nMk__6;;F^qG)ZgHzzPa z=Y9qu+dzfdqiPFI07ZgM;BHa zu5PKgcP0AV^PDpjt8#Xim8TjNkPC^*JroSuf`#d6%g&L@kS`OjXa6cdx zY`1B|z+qC&x0uPz4QMhGq-_Xl;MVUmi zpWn9uG$^cpx_CP7`)K5q@`i|O8Vp@KpsFAZ7@LMq#ll;azEjSrS*F_&>IM>G&1nIa zavW#v(SE|NWXNliIY_X@5}KAH)})Ex?fEA)tdv=u2VvDDrjGI*Q|b%alstiaF~&<+ zq#yIG2&fU<p%N zOtP9?KBFiB;vNVA6`RLMI!GFfKg)D8wq!m_;6@e9W0B1D$(-{h(&Bb%8>d?c3^mT% zrWdfl*8UWVSzEuzA`IpD{*&c*&!2u;Ka4`jp!{6mAkavS3_q=PGI&3KLAAb&n-U3- zS*8CT?CB(OE!f_t`BDGm-Q2Nd0BUNV!5R?@NIt3dydY33hHS<$-`Z*M`1xZxb%yp0 zbCIl93#Y|f{F^u?LM|OvcL2E(>W{d1MV0`W@w}1q2hkx~&A;Y_35?L_jr#7Zm*8;u zj#Z;_P@^_*W;ukRhu6VwmL!UDUS+Oq`S$BtLy{`XD{W^Nm%PhmZ!>FZp#Hu~{Fpf{ z2Oet~J<`Oc#1VuDErn)B$;DF70T~1pua$`I%Y$1B^aih{Xy-GIe{62wH0S@dWSn%C z;4IX1t;+HvdR6#LE>s=`b_$yCN$*-Mi-$?rQ2E`3#)dLris_VnJ8{U8KdMi>UE+tr zFDL-3hc|SMwQesYGW68nsCfW_XAYU!}y+N zQl*LcGjxCC=IVqf*O$$Gl})4^!s#g30S43_rB*o}>}F?7#jk=yuS~l#@nN!YQ{0q* zOonJ{g5Ot(NL?Y{)twtTK&M+ZYaTck{w4D$YYI8cWY5P)N=T!0pr60NoC#j&7FQ~U zKU6M$9D^X2dE{Q@q+GK#bxG&O)|Y$sHD-=IEDiVCTASuZEn$AhcgW_Zu1Oz1FFpMb zcFhA8XW-^XSh=GamqfLry^B5F@svosN8-UrtzXIaX*O{2z;-@$UWwudQ-}T{<{!Db z{bTfWRw7v4#Sobj&`ysKG)&qLk@8S-%PRIl#yYjDqG8vWh6{2h(HSL88=s-wXOUjJ z`0xn=N_vjO3P{>y>)*zCe`@`B4JR&- zmX&3{P5Xm07E_TZV^)r#ni_k_!*b$Q0nUMn(!#6o352Ickab$!B6D_2_`J(2M#}Y} z;Ap*P1maj0#2hsU`QMN7GZvdt^b0|K?wO|LKMF?|f~QsI>=mgI z+|>z)7h7$FFpL}0_9x*dSyrwz#gai9PyHGVbV^8tHt^7?HbrFd5_j}xrVXrgrmuQQ z!IsRgye9ObAPanvf}~!3G+V?NR*~|7a4YzFy80)RI`3ha)el5F`OyE19ms`lt>=R4e(sYlxDy2fZz4mws6y7<17Lgkty81m^g}DAsSa__beQmf=FJ z8!6~dXVXKJ70L+Tw=m=goN3x^F3yIgBU98JVdXbjiMG{5rZkHS2jpm7U3bKe*>>Vd zaSJrBG#4CeYZ|Hf9t#wfHWx%#_5vE6H6a=gR&L9VXYzFp5@h;i!+N?;l@1 zEet?|ps&+y7YmZVb|3g2)IX}TcePTbS!sqoJM?Qi9^RsbH!$(^_LN{WJQL=rR;8bm zA;e|-;;%=|l`CcktAFq*orWpS=eG0S);KEaC?N6L!0%Pq6xFpa2N2^ui1t zO<;sKs0t8#ySn@?;}r83^KfU6WAJ6VA1nAu3-s1Kh53?u<9cY1?39rou7D(I`)eV= zpx!28fl_XFNeR1Du3#+RqA&TO$~{aHyKxD zx;HmL#^Bq!^OZU#=F(}_SiIMapkL709eQ7ewkwK7+&uzRB=A7FfqEH_iqA8e(a?B zjQ%-!JaBV(dio4eJe%5G0|SR(zr;{Y{4Q;;+?EB-}M+_rmWYPZyp9jR!NYB^2@Ti2Hd4`-*}U?t`5uB3*mFQIt?n} zzIEI`e|Z7!a)0DC!Q8N*{452eJKJ9pNd^YKbvm;e>&ZJ0{yww2_7;9LZDayqx)G_03MfW#Pgg zygejH8dJX$w+U@HJNNQfQHvH7m9V2zxJloHi!7z?_VnAk&F_T=l7Lxu?j?`EH;-hJNwGgzC54)g~rgyyQ(|*=o~_P4LSj z^m6hO8o8YwB+@o(lKh;ZP6d^d%5Tjj#qvrlelpJ3=t1dBtW~@v4mUf{XYUrfFwyZL zmN$rltW~ts5%0q|5(I4hPA`@y#}C_WPZsCY_du%Uf{%W|+QK$a3p}wsd7KaegNbsA zJZyn_*~_T!i>0vVwQK;yy~E_J*er#UuFFK!<^dvfuY0NIuM?yy`{evNnd7#wXsFBS zkN58z?Z}KbO&s4&m?zK?! zc_7kL(P~nA0~GM~+U!5B7-d&qNPWgJJ_O(LoR{P8v&<)y4j5u&cTIuKqim*$D#Sas8}3)2Ae=jn5VY>(Zv|=JR#47~gtk52snP3?SRA`$Y0)VEKq3=VI{{aoxZpSFEjm6e{^lG$XnqJ#@yF>u zxSL6*Kg>*ShFw)|Pm&sxI3pDwBIb*M6FiWteF827`?T986=mC^&4#>tbu_ngCG6{W zs(J0Q`jHHj39-qK7SX5pHF38Q&z7hcHAr54?je=iqE(ri?blo+JJ>7wPQD#yJEZ{V z7Ao(scQ5*mu28rrHE?L2VQ2)(xFLws(FFKQUlMUuU(#UsdaiZ1DUco%^i5g9o z&@#&NS`RVXAGvI~Fd2H6)-Bj<2CtSr%`KcI#e9P*xKz^m+Ln>6H9KPBGnPXwQ_JZ; zLvi}>$b{%<2?^s3EZe*Y1kaGORY<+%7cIhaRa|YhTyYL0RPY=himQ;ZBYgF6xZc= zaG)Np&o(G?Kq*Si^@SHPI&z#zQfefymO)!Fj?QL_UQ$OLL|3hTihpc35ch=mfc9J& zsycRKWp#djGND9*P5_~KzK6E?`*cHkBrhKiIpE%8u`atBF6N2{DR~0prbP?}!0F!PS@2K?%DxsVsro%#IsQ6d1X)dWrB;?^*F?S)%RTGaX#587; zHBWF6dv(-BhP>rpqjpg9%G$ltd{uQLfEdN=*2jTgsGJI;E5F<`9+1W6iF?TVjjiLE zLN}-L1KZ1MO!AxguE2J-amTlcBV*voXhozz3PEQ>T&3g-L5o73>qj*o2tj9l0qvt` z&F=89O2mD^5LI7YAx9g|pKw#VVbl6Dsntv)rYYnLVA}7?2Y5YP1S_X)0Yjxkwi(9( zSPJ@CTx@ud+j;np^cOHq5AAjqsre5AR!j01xa@*>5bL^12?6EY9h?L4qkjkW?&!Yq z+pM8~S@wGb##}lf65i!5uz|dQ7IPYJ6j$6l;Dcr^g_0Y`*LFL<^Q8V&(6tU_Gxw5M z3=(veA;|)c6va7^FgnotSB8>qiPij#a2?~;<^c&$kd%28!E@oSL=1;F3U;JmX z%70miHWOi$eE2uKcHMqHbH$Fe#a&1-Bp`+mxUM-zewy3@I8TulMM{j2x9(*l<>%ysN)!#S4a8R-o06RH7m~H`1wcG`=z5AYSn^a3b#ee1y!#A*`PpDNeaSm^UM0! zbmP3sa)T#qHG23^Mk9`Go0Io&GZgjj=JV04fM}3+Bvc2qmV>8_C0(GLnu-^GU4L$Ty5ZrM%d9k6rtisSg_9fqiE2g3pyikv z)oTqxR4Q!f4>d91k8bYmgkH|~3Rd{I?wwDP={V4)lK!iQ_3_(`l4#Wfg++ZkYZF!d zmu-A_O@^vrU~VH6Q{~`2X~TeHa7hCjT)bwUbMO+Oa6#1#7OAWske}|Fse+TC%U%`|j+8=H}KluyxM(j)tK365}bnuo^bS zrE9`VCu>wf0fD^P?X4ucHm;^&^`&d#pUNF{<-I6{=F4aIHR@Xfm=}@na%+)r19$o$ z_jdnl)4@Cd-w<b-o2Beguxp3;R^NZ13UcMvFZeK{UFsHR zVemh|cD_E{?e6!ZZZ58i>G_M0^u$$SF?eKh0g}l}O2zsFg%1qhN1z=ddO<@pmbj>7 zjIXP79?X;vB@sbk1o$J#z$ESB9hr9r>l&l1t1Oj;v3qQ6U;_-upvn92Zf&S|7}RPZpi{mKqpFKxn0@F_kV&1oJvb80e&&?e&TJ25v6-3ewY0qX z9MZVwb980X)iQ|hb(mrve*)8mx#*F>WQ2>SP5M%^Lw<2 zFPXj&mAX=`fCS4WXBwM^#ML&ZSTwp;JUhDPejoKD-U`BGM6awMz@_9cO=M}9*Yrqu zreM-RPXVhO$55FSKIyVIXsULyrC`s*!M?ZELe0}+qgoZxYFS>55{zOt!2|Lx-kFdT z_3bbX#}hqU>)B3*0gAZK&})b#q>-J*^%h-0DQV(QHGTzF=JsmRj6)RAs-kra`+ewQiqXDFJjG#6Qn+|Wl=HT>+Z#M{u{E%!One$P)tB22 zd71p*Y%q&@yu^TEYs5>^ZWk7*5H;cpL?)|*BEo9cH!g=vJ7~54=CVQ@Eq1MZ3xe4| zzfq_;+ZkIks`nZC*N+|77=Q+-r$*%70!Rc+L}iu}yk_ zIBbI$h9z;wK7p(Wn|6l`>mWY95%+)u_NJDrg>ZZ&<9|Fc&XjX%`XKLtc#mZ4q=oHz znUn1SH;b$T{ft|aQvLwxgBBW4qlkk4tI!X z&x3_<55?jSVFyse87@6s<{n)9BIZwg$jm@K_?hFuJz{UsEy@ID5yb8f+gXH(x8>ap zF!BElCs;w`4A0|*@M1+{0ZySkv6SM|F1;Rv-)N+TUv)_4zB$;ZfxKiwng3&e@@az= zEr*^^ZN$8p@(FkE4bE`O+p}l5E<8l@#XfozJfvT$*5hX30u>Lqgu!(F^Q7=i{Gr`O ziNA8dKH&{>@#z{uWU3oHX{^S!zIRs_P;73)a8Bnk9rm0wgj?Pc$LRD6w>Uw$GVnx7TY$) zK3(GT<-+N8Vm=CO_g*l57v5a&MDx{MuUhJ(G-YS8e&MW6#I9tS#37y>^EQPWbMoU~ z-@3Q!;puD;n+AtdIq(FAC^a-$!jI0wiC%4GKPaLrq?V*`EO;UV$GaiSP;}PdZxZ_9 z6heh=xQuHeYBLAonMAXceq7|1#G|$qs#T zv;PUriEfYr?EPgXRSJbkn*9%MTCZ)NDLs?tXHXw#lRncEGG4O_+0NxtWg9|Pi>=2X z^(ee9zU`A%;aI%~nr!`TV4nc0z1QgNg+0s6Gyrpc&`A^g!QJjb`~~TR79kJ|oypZO zAQPP9`Waec8)%zuodt}DM*{BKwUA<327@38fs&PAz|Qxy^|+w`WQww{fAs~7Lvf8 zoVzPE0oi~lt=S8=q?oX_MK2%n6@j(+v(-Uxh zsH0_`5T(XWa(hCLf$xnZ*N8&^9rt_=E05cd67WObInpS| zE5j(&ge7wQ7F&f&AgwU>E{kDSC26CRSo;p|`>kMMgN|bqm(>Hr#|cALNnv3TlYm=J zAE_ZQ1~_F}UT8m=YZKPnwZuY%E~Xrw7Za4D1@uQNHgzq#&e3W!AxqGCStxv!F;S@Gfmzw6E)R=Zjjj(#NB+G4u7x25P#JfA9x8X+!+ z*SABlJZ~0aXBZVYH(+Yks6>_XC2qW5k_!G=d3()%#dw4~ZCKER$d9f2d4@Fb9w4)h zvv76OAPaXT!AP>Xz$9-MH383*@@MDHLnYL0b{#kSbn!Y842&J*OLE#@d zmOdz6!V4Q=Q#>n>j;iYiQoy6a#7`!*Hz5$=I6UFWd>-8U-%3MSR%wGonkrrSi1t^k zT30_s^}V)nsk=ndu@97&6i<+uesJrxz=<|tx7dhn$&yT&&W-IU zCY7u>w$7tqGl?9co2@7j>)ie4r5sUaN6VzE&mOoQzC^Vh^7C`uJ`tzFQ*X-D#C$s< z;Q+lnv>L%fV6fpZsa?bmvJB33{edn4(oLRVeE}mS%WGQ|y!;rARaO9 zqe?qmcq}1{pV}$@Q~R}&(I9h4h*GuAGOtXBrCn-iF1K_x#mc!h3^C#o42+FjDt=kQ z#NALX=BVDP%zJ~28`;i|2 z4y856J5xs_sho8N>=vz;BD95uRpe`}BJ6M$3SE3i=APFNsH&C3`IJ#A7a^$!^Bd=_ zeF!oY|7EA7W=mvj;-LS;RWJC84#15; zN23H9%SKQF&5~f_GCZkrVht>ae~TN;?x^DBzPPvb$?hfm8|v-fBxYMmVv$bqb0!eQ;AEV)DWmJjtMK?_zfW4<(-I8W09*T*=w!vJ ztME7q1DZRSptEzsfFH3oZRKW7fXYUKkgq=n4hc{}mBpQPNh&v$^5{SmYaB2?5Dn+r zs3mkgM}=n5g4{5dgQqZ-Ty4Ey=4wL<{-R1V+b-_6u3%>Zhs(h$FrW(WNJr zwke;PMkTv~7o;s=_2N(+7mt!|emES%BYwp9!JIqQsJ z*ri`Fz`#-=X_PKSCAgW(8Isut!Z`?aABM19?^YboF zG%^Lr%rEi|zyJJK=_HILqa^V)7uF?(La<^f$pc{7iON(|yoK-H0W1Xl# zH99`I8CJLniAX`4d_!oeao%-a#cg+<_o0)pqjN)nACVTFw!Uq}BuO}egAAeUx|85{ zu%PR`gHM6`uBodslJtd>{TugX=Cv!NMH1E=y@n5{OBRccKQaL$B4zxb;CaQZ?%tng z^!3r_f-Kevire)s-cD{q;RdJ!o_Oqmr}P~^ntyJ%Z6ww!ij7D{wRBi!9C8%tcc?40 zjxGD3i9Y{iS0~vhk0tZ}&liYdT{o$!@#6T5(izsOGcJRH%8R|qv>5`W2T)G>P?(RmqyW^S9_xJo?!JD0(IeX?l*SX?8JepF- zmjsrk6ip;PQqzYW>e#r!)KBs}V+HJq)-VlfeU&jJKs1GCJXMX7ydAAIym3Qb`#z1v zB2w(`m~-b*>6pBcSftEb!U+bpEREi4OWhEZmB#hfGb(S_RmtxG)r@UOBLB0(U@C_3 zQ8TNv_fOfjiH!d-YIbkf65dOL10JRJSQpcfo3+pT^}kO||Mw|;NMh5C!k`|i@eywp z__4`f&kBCa7?)3(P47E(C6sSRd5pG%Px zcf7|E-WejW0Z66GsB=Nnx1Y50k>7<97|q@%K^R_u#ZbqY(?aS!#0D3a%_XTCpRE(I zL>%?r!#q%=Ac(^F?#ufQ^x(A55(qJ)Jb&|^IwgcPS?z+qBfjhlLkX+K`ejg`gi}#5 zrG_yXUAe`%)G1GkeHOIPy}rhW@m8I^^9xDIE`RT%5&&Y6iJ*iqO6p8|F*z6s8#A>> z_$7vSt&+=mN_oEhPeB+-Dx-Ek+Ki zE{{sx2c)eWL7e@6OgPgQx@FTwy%qBf;;zJ*fvX=>eFQawGzjbuZO(mS0Y8x%<<`(7n=hRwa9t_|P^_di&~YYOB6 z{AJ4YSaDrhPeOv-prbCdN`RYmxH^S+^G?`^>)lgr6q{JjDaE*qmK&*cqcvOY9oD`| zAlO&DOywq4AgFOo?zQ}!&`YJadw8p2Exs~)VL@gaoc^g*{Am*nqRd$0n2mY_Z-w){aphvCcCQ{CZt9$w8;xmIgJ& zNQ4pmZ0|DNwB?-2pa4?6nAEjWy;68aD_tct+Pk;Nr#`}?^M2ZU(_SEHVbmQm zRS_$bB3~6-=5|~#V;$gvzotG>)L{iMlgi5W$8j5+svmQNV}Ct;5v_Cz*sdZ>or!o{ z5V&SNQ@v0aV#nXGJhdeU4LLjJuut5cWmAgIlY$c_?I-^k7&fV2p-0wn8zb<&1YCYs zWOjsoeLTgF@?jXJjFDu;Hg%CuWQY996xIi|2kNTO=9nP?aH}uBE%xJECkU6Y7k0Z- z@q}SINd%W)cm7rCt-L=Dyt^CKk{Ds7rH9#Aa2n$zJ)egT3fBaRT`W&U&s27{8DZib z6dldjaQ@sDy))#k^=vg`w?{+m_b;wLf8EZ0r_4gk zNls&9GK9EelTQy?&zoh#98$Jnpt45WFh5`+G9A{=y%ubf(08RKCN=$LcJXlZ@X>DW zYj3iC0i(JYyWcp)LWN6qA!xT_o{*?>HL@%7J9Au{#WY+UvY7E)*K!B+88$TZA|d!i z{Z!CRgql>H^>lVAnS2hBoJ;u;79NFwP>tC=*wFOMFu$due^%8z=JiC)DDF}b4s$ka z5`X{aM0M&lGtDUFSYw~Ec6Y!ydoA?Uj8lIkgFUgS%e;G*zUfhLes*K;q<8d4qpQ1y z5h6q2=r1-SzTmf%C33*l76d6{`bD)iMl!Z9_0Lw3Ol=lxDg%R`vmcXu2y$6;!RP z?uQtg0B-Kx)f%+f`|Be7^n`B3&HT8o>u+W~5Z-puf-9qr*kl`Qte zvAmqB`mGs0O6fA@1g0L1F(TVSKgVh~2Jn{vr9=;s;~)7D^TDN>a9%(kMU$o7v<5a7 z=)%iub53jF40yLWgM5FE=jWp#h|YHp5MKla(6A@YdJyCiz zL3sEDf{`RgifR+V`}(QD^uyW26=;`uNJigWxv+bxKtBwFq$}Y2A-ZnkkfH{1HXA%v z3_*NUbXB3kO0@)qWte)=gM$n$)RaW}G*;^Pl1Y^m zIg0}+es=M`KEGP!O_cgP`cy~;R8A*CofEys1Zy6VSeFs1Ew!-ipuno*-Axi9!fhNX zwz!!xoJg=f+R1=klkYIOskO=HIK-$g4n!AdJl5!uGkB}-&2kdTtOIInpDR$p3Bqzs z!CAx}50gWJ`B0g74#&|Qp7!6CYdodS57kD7y16IMId5T>)T#%+)ouA&Oz~bG&!@XJ z&3LI-j=9X;DMiP0!Hh)rIM8Glq5%7S0qkue**Dv|- z8b2|e+V$tQFo^_V<|E`9yB7^e!6y4o!TrX#mH24S(hr#Pkg$|Tr7RiQQNpF%$rgRn zp%#=8i9FUJ$loKt@w;wYj*gxI3lgS9GY8>Se1j@<_R4Ya$c_W>9v;lB3xhVl z(6BGC3c?pzmFg>ii}cdXbUj3pM>zRGr${kqi3valPh3p z!>0y%d81wUW|*b6g-Zye6gbY&aa@qB#zXdI-?BtGEU^D*HXQ;+;3nqaCcB>IdL)M zqpbGQ;LFN`Q}_s^bl}R$ZviB zQ0Psv>N(q6X-reLDmZY2^+uhL#k4&K<5YM29zm-L8I`=Yy2fIki3rRaM78N~N*R-X z=1J8sYTUP8VlnmRa#@Nrz97%@S?+#~VIw~?|BW-gaB>IAHFFK><4-)WJB`fPty0MF zasH0aY$M+>&{BF8rTC#&V$9P%L>mDIoH1De->~Y@H776EvOz9N4LUZdUkdr)f8D_* z)Rikm*34>&3zOc{j_Hf>Lb#O8U^aHljS~i6l>~UojY*w9Zml+XtOT?GB(s+i2pdip z469rT-E*=4m zMcb|^#wFy@h+N{|Yqwl8W$!D@FTH@Nc=;V0Pc)LmcdQsO4Wl>>bDA-l2UynDN|mqw zfb-aJxx|e=qf5?%-Xs#qd5~b}*97Q{ACJ24wF4wl^U#-Lz$`Sf1CJAes=Jc{Cwmqxi}d{_cP3oD|gS2 z!wdf0J60hI=|QGtLGRDLR@+r9;2UR{5Zj==T@~C^@i|qanaDdhVw<6eC}w!FCnXpx z`r8x)cgJHL$1c>!)uI%q7#~-a6mM_@f{(jaIa8HiMyV?(&NjZ%(<9P>vQ5c59CFUl zXe+?(>e1asRo{>K_tn9Cs+znl?lYGKTxi}`@D^!U6zFHlUREBc`T5@e2HDNCPXssb z5lZ-kvUCGT$(2Wo|4|izgN|+-FIecz;>W8OpCL{uk`)8M80+N1# z{L{$`Q`oX93oQs4V3hX?m`7-xxGT^j>Xa2Y+0{;+ExP(Hu>M40oqrmzQ$_#z6{`HR zI2pWv&Gz!DHgd#`pxOn^bL98(do7pEQ3{c7R~^t^YX}m`Hmbfk$m9AfyGZw?@2!4S z@7*it-^+43ru;I(b@LA~xIIvdTu{#MxA^0q{_tOC@c!XVEoyx6x|c4Ac7Es-bM_X- ziT=a4oVNECMwr#b(J|9}o4AL;sS~`Ek%3@|q-2&PL_srU>g<<#w*@m!32i%e}RR~h@o!eDwC&PQ?$43Vq=Typm7ZD`zG=P3xfX?}m zZ1B?alo% zL3Pu9M+I!)sj^*-@8Ct0dY)5UrGw}(e#X?n5;muv){n%t7if%H9A9E;Bh3&+78;3z z*fhPc_tU0Ne=k#3OLgi-{NU!osis#S9shhLriHAQjxHJ=&XhWi7Nu_GgyD|x;q!}< zkPB<3KKrwpiM?887Ev=bJCCDWOHUw}Pk_SVn|C)85Yd~R0NN0ZbU--)8?Dbe)2hs%^1)Vf)9MA0gWM+tupGBs{wm>Ee5tr}htHb=zNaU#jDO`s@Cie~ zZ33n;ACcoGy*lGTZh7s1X6fr_%P0%N%^f{e z$Z?WFs*Ua5qChD1*mrJaYCb=m%^|xBs81nAW~`w4O4otKNQ}F0n;hd zIpFH6az)7OK!T?|rH6#m zDFBbFD@l4OSQWdHk?#xkc!|uA2vgh07$X{yn$ZiLnpgq{E!S9rKSF!TMj3$%ZUiRG zY^!NHYDO92SqQPMcTu?RpOxgE~N$ViG-6=hEK&#Cw#yH4gl-7em{*{{PLxD z7GfQi>QmKerxhl``S{NIVpfQ4ZmNdIJJ6SxkMmNEV_PnK^R_FNSC+A75kQ3hlgp%l z5J$x1Oa(p|RCaW(X>vLX&MuZ@-8f4LL{89uGmScV)w039%$-UYgB!;UgEe=3K`}kH zgLVFva^Nc$r(|#fTyhgL8HX}XC|Kusg`ob|#nGB#l?+c`IIPE;Heo2@#)+S_mq$=d zjqpDAoT+@Ijq0(W6M4?m9C7riM-DXVtTg}BNIy|u&V(7Z!!@gM$=i}C;)jk6fnSr+ zxGe=|w^Cj4=+fMgEZ5Hrrg3CiWR`cs!Ra7Dbh<|vrm+uH9X7C#W!1fkd&(9noQuU7 ztH9HWHP`AC-G1EJYcx!*?BotBd!=0%AjRlC*VRMgLZN3dMZh_vKK(UZ`qL|$8Ve-6 zrUfBTsTnQvV7U%!Kz-d1> zy_mszu5Jf3v?stz8#MH=h*tXdBkPDmbop)Fc>jI?zf|{S=z>t`+>*Wd$Zvth@%>B) zn2?+eIHm*7YCedR59n;1K7TY3yjZO9~g$_(11; zS*Z8I*Jl`7g#V)oNAi8@u72-H-3kFG@mS$2OiS3qocWtCJSG-X?EeXW`RL!QUXAYH z5rekP(b9xML1Vlg6QvW-77FE^D%+BnbVbiDWoK1m*h3QH3%z)wq5;a_$$;1W8z72X z$ZGV1IIhkneNid#4$joCWpT8NYrN+d5jbCZ&tSc?8)LkRM|s~VnP%a=!&?Gv zSy|RUjkZ6zha4lqpl^Ape`tozD}7IG}i7hX-@|U zsOl{err*SC_q?bp0DJ@4ON^Oq4@QCLzf3V+iRrAm45`!`M_!mjVLNEqWM9AeswQcJlB(}>l1L{`L5YlSir>-`PvIGV!85R zcCQ5{hs0ZgkYeuikFHIIf;%d{Q{fI4tpOc)qbJ@>8L*2)V9jp@BlSDP9s5iDOAY(C zHg9>(3&a1Eu?wZj9{+qJ9>l$aqJIaYCPZ7`?ETi^H)_SNWG(PrLzI!^J1dKc7xQ{f zf35~YnZWib3hCM2TG`UKwWI&YFhWVO&9_|6kb*==rUb4jgUjcuSoqA@fnXiFZIWwC zudY{@mU{pTAoDV9;Nz30U!MyDkC=AiAf9!vuMDHj6xU?Ugj=#OKdmYgkGq^0i)+Im&L-L_pVz31spwGNiK`BRo9m!36=Y!p8Z`@ zQj$WUpRd*S^q_Ix;?&UxB9a}^jcV?X+p4AdDB(UpG-dw6SiAQp0>$kR&?|H5?B+`q zr1HV!5N*GIh`;^Q)$UKnZWF@u?Bf8l`^Rm<4;#nF8{hD*!wAtuBtT-pnn%(snV5Zn zq~E52snjxuz3?2Ou&rV(e^vmu;uIl>OEAyHuljrzacbW-g@9?v$Fad({*Co+G?BLM z79|}J;H&(rZvXIwBPqL4{sBSD7wAaDNcszN;d#sV8L82HaPN2V47gde=-TSFM}he2 zeBq^w%x0BOs**#|WZHQD{6kzJkU-XHC=>FM4G9b!HBxLbW&EB<6T8&^cV^S6*td=S z6mr^_8M8|Xd@Tt0K&yX;4qdO1_wk<|HZ+hq}vM{W~%3 zh5@LLPqYM>ke<@a4*@OZ)VRrOcEO$QwCIi}askJy%vd{m_$6=Vm18 zEcQj5HqcEh?1yG4xIX*weZBQzUaxyLS_=PkK}G)2#Qua?5DQzhs!5R}KGO_bf5@Ze zSHXqC%ULYPpMsKE6tN|8hLS&2mB}UJMmo-%HTYS%t0(V+X=XHm3+7Lde_)!p$Rr12 zgDH#-Z%hPS{YzRsznQVgLWv^3P%>2C#dPicM>pZ=oSs(=N3fLXpB4?6v}K)RA4%sD zbNxrfut*AP6Wom%^{1;D)>NbRofi98{`fmemoZJ4YpMC(N zVa$r#ChA>?3t&PA`2Qn1(?$@z*BTl$eYtcaLo}7ij!Df&lu#4J39wvkY+A^mKvcB{ zy`t*$9WQ~1bx|*ApLSeF@(MJa+58pQ7)uocKIl|VAnfll8m_O236f=12(9y@yX0mX zF!3tJ05;|=71QXtG^$yh14_+JY6|`XDhP}HG60nm&;JYc*du(|5qNt*Y2vid!^@9) zXRRHpLQ;0=Goje1^Zf;L0%$5_mi(?sfZS;`mRyS$%}$MUCk7@iq#Frj#>FwBSpuS5 z#{6<%YKU)*ez}Y#=ctFTbwIz2@9yXsj{;57MUdb-TOAV>iP*uG&NkzN8)a#`O z<<|L^S7FaT!-(x$6DI0z0+}YofnROLpzZb`;3BULLfOh5n*!c#-x$!OcRi0TzU{IX zMjRD`;GS?Z6IPjL@`G1GTY3Q3fo5a(0!;eUrc`qzeB6?IRXMtWxbnxKO0Je1k!k(v zmpfBcoPiBUB6^aA_X+f(2k#90^2p0}50-p}3B!~TbRMh`VSV6n)z!ebJ9}(vO#6lD z?&qp^iT<_iJPt}_?qhXE1k|A+7VpJMO)8)BP#b97hlUan$Zb2%{FG<3mo3SJ?UuxQBT zqI7J)x0~R`I&acM#psX2c*# zaO2UoB-jQ_*TDopm(SEpL2hx^P8wT<(ENEoeDu)H9-77ql<2W86po*WXS(b{6bSL^ zZ2Q?UM^F{FzGd--i7KyXzM zJ;o68`epj1?;qRB!5;XpvE$0HCt~(Htb9J)EqCBvtuz0^9b@@8q{>6S`D%rT4L-@G zrJs{f2;9h~6l4$X7P-wvzrR3KP9p1}|z#wveW)p3vZ$Kjl*p!g}&L00>T&?Gq>p%54o_w=$Zg<2Ux0JtMzR(7Ozs#O4 ztcSKKzqEYHY?3n}@p9o6J8Anm<-`hSqIa(VKybmxUTrRCEJfo%0@}mqC09<-U_Io# zmh+sP*q%8U9^#jCmBzZ&AGMpwpDq%nMqGg`Q9Ttsu8PO!n!D#!TvIY~s6u?_-|m$e zTlVb}Fr{TOok1bEQVvxg;mLoDm@$#gL92aA{0dv>G38H?*ID7|KKRjUPm1O6&;bQ{ z9U*9E%zwqS$(g(6KEvG*+*>3Q{DWFiI zU5rwiS&DvL(`}lWRVUm&dc2E;w@-PeFD5dzgQ|u8=;pT5>ZFvEPr0qulE#lr5J+r% z zia9Z!T?6!g&(NHg2_m?*n#oWr#`%`%t<#t)kFTj9FfJWyXh&kT-WGbPXfSXmM+N-#V(GbAz)|a)JoH9;m zMxK*=uSKKiVtAh^Iwxekn)ejtO802uqseJ3SS_9S2-KZsjN+h9GoG*Y`t%ybBD(Z8 zx!_c`OR&+Lqioq5rFUcL9l>Tl`Xe)F$&G)|x~NW|2Wt+!r}BY>opg}NYb6kDS@eT0 zI`tm`katAr)O2MR1ORFK{KfehUWY>j+RqaU!mGU8LZ&w>qtPIJAq#Oo$vjdL6gF_R zHRm%ycSK~}MU@EpX-aJUwk(ox$rEG2##*D}iBMsJnY?G?A1I#B{6F!0q^$BtL{W8Y zX~#b-6I`V3sQ+0AwPxPlD4iFc$pH~N7CZY|$9m}iR&K;fU4Q7SXRO{W#YZ&XU#MF+mV+f_rHHo zvr6akG=v+%-v|6J+vf1#?^lGe>`d9OnA^{us;#QWu9qfoxy~8aa9!*~e>UKEozx>< z$mJE~D{Vq$4@UO}ZnB8M%)3w@pvH6d(#LH;h;DRR@@njZzJkdM%FSLYno5S3YmNa2 z9HqA7Vcp?--}^u{`@k#AR(LWqaG1`BTk?vKxN?M`UuZ^GcRgFGnH^tQ3+1d4#VEUb zpEE{mMp{pNY}rbJ2s8YZr^FVQi6Uo;3Z`^ zLOgmX=C%NBrPg=l8Mg+{4~N~;@BJj`uEEOY`R_=1= z3ox3u%zt39d}u`D$Ot;F)uN8tb_)!VFfRkt!_s*~LoXpUW##=fyzEnagOTq?fsHqy zAV0ZP;A{*@C00C`oaS1@x}{H$EbGOQ;tv!y8jT&6^_Kz|+svQA$+u$L(_f|r%v>cG11_Rq}ki>&7$lz|CH=KY%|_94}vZlNkd}dR|{azL*Ttu zF$$*JX2af}zut>abX4IPh5eZ0FQE5tE&qKtoiCqyGM!K1F=d?yun*SBD~V)uCzyOk z=rDa9rj-u-qJIf`k!l-BTy1R%tpAP5>{j7;-cloM)_z1J9$-opM~?dZqL`w&nxCE5 z)896plFxuDihNg;LSevGIM zu4{giU>{_;WBso%{C6Le7OfRVxnto5Myd*PGjjkLMQ!oetY7l$5yP{$46Jut453WJ z;)Q3{GjjfBwN3iOMsAT_wp>AV-#;XPRAN8z$-F0$ea*rjcajw5_(xmvy2F47FX74K zz$5fgt3lisw)WXHZZz`?M3t1X?6D3>z+{WwBS1J_paD@aXt9Z zTER_c<(U+<%LM%XAUz}RZWdCedze@on@%?P{(|c%hQaS1>r>s_%Lb&Rr@=kn3^StU zcT0TJdnf;mO6x$uH6#_-v3u>9N`epodJ!s3niSNsrHF&!PF$5y>tJ=#mPLnUopb;qG~8|agEfM zZ43>HRJ5-SKm0*^SSk$}8#OeSmWj0#f`l+O0EV;iFFP^AX*4-0jR!#2h{>pc5p~3| zMQ_Fitp#@XupUhlGgbrZEMVxDzP~kFJ$3ll3hEBedSj$VdG6wef;Dm4W-FuEx~*&Z znGbU1XR0YRLZ1D&y<+}Keg%ey$Jy5wqo0Ztj`H?Q2%xl&1@qgV;#|orS=jR;(fMno zs>Ph%qy#c0M2Y4yCY?{;H;-3{qYZ}J%m z!Z&Qz1)*UOei?v~sSyxIc`haSRb|6~3nP7ii;lF72V7?YzQY8(ZoCEk<-pfoHle;O{mBq(<^IsryaNsu ziqxLPWkl^l-o1fNB?B5~etB0rI(g;mF+%pDOK@@8OjybeDh9yLR{zUa*!r4(ehFt3 zxE3Q`{69_IyL(VxwDR0IP;BvE0SPu_^EcDMBK#~yE_>f^d8mI~1$W3Z&%Cf>(UGVS zsGfA~_(N}XvwwX5x;o}C+tOn68#QJKZy%a8ANBENx8yG+jsqKGGfQVS6#wh&!$Ib04&C&3$8mI;qSbE6uE!H@ zmAOU0A^34^Xd|){1D@UhL#(GQ6jf?N(B@hcok(;2VZ}}3eP~m@1QmohngGKn@()6i z1s{Tx$D-J3GO|EQM_`*I8yQuciGbg;G!$a82{mupIh1x8h7w6O);t7H53br1S@X2G zg1oVP1G|D0VxT&BSYxl{d}Vc2g<|}dIm0TQGe_7m=vi?p{g7AGJ(v)SKvQ$u8Y@5$u#ci7CDXZO-PZIR& z>25LFUG&jgaK+t*79ry$Y7s4Zu;<0_tua4@=z?cxMAGp1+}s11&fq}5dczC)>r{x1 z^e`Kx9^?D+26SU7$?Rk(Gk)e2A|@+`N9b) zO9axf$Qsu9%0jUc>G$)dO?B|c7G0h3ik4w~y`-GDgneAwyR43hm$ z!GfTv%LjNR(t&B^=FoaC#qrSCWq>q!l73CF=k9)&BwwQ}=uHD1%jq%k$mdi=qoN8q3TwNN{KA+JH!NjsacenUHi9(gI-PeUG|26HR!tf6ezyT)<^GMdklXBNs z!p2@4G_BUuVqe3uiVIozHq*Uf2kD6*G?Ymi&|t0*^s953#}S+NfQ$Hfpp=L%H_GvO zprFlrE_Cqo4{T5^v*%%))QZ1a4j_3+$N45>)cmAYUn%Csg{7t7s9!{Nob(`lR7Oxt zn|>D~HwWPP`1m#U;$FEj(#mfeS7rQIUV4A`BUsp@1JtpNO15rRNzeEF@HZ*%vYtx- zmazLGl$3mZteA8P*#|#FHp?hd%973vWUd(AmY6_w)}ryDV5YC{6Ao)7W~&Px`rX=d|W9ucC61Qy~2*Y}TEibC?=(YgcCOl-ZU(q}lxh<>@@4&S5{pIA=3p@U6WAZu~Dy$+dUJU?(Nw3hzrB7I?EU0Z&+n zZVJ=8(v}GIyYbq+cp9MPRFBaw^8od(A||_3j^^pdbam#GfeBftnmcpFIA?u&UW9aR zV&8AMayjiO?EgKn7nafGhUTtNw4?TxsF@?oiTbo!iMnO`MtW;m89!tU*bT9z|6MGT zU3HBEFV1*PI{N#b#LWWD-w)2y!7aMBHpzBC?Hdw#K@SPy+KQMy26f#JPJXLTuWYm( z{7acMdWv{iJ28dy+*O2=+BvBQh-^<_57e&ehF{O`@Uoc|X~KRDl;LLoLNd)Al58dI#*lH#7I=$KxnNwqe_VhlZmW@-i7{wc=6@ z_xvCvn&Y3=($he`w*fJ4UR&KD2G5$aC$RcC3Ly~%riWhPSX!zrR@F`7&xERtWvdy`Ym9qvu{ zPUqCtFR>EWKzpQA`JJx(<(D+1x1UMLj%Xu@vp@CyQnRBdC>Y)zZ2ptLmR`s%sqEk4 z+AegZmE);cF8-&9BxJGM)VdJ(OxIAvS1`pTHB~BdyWt=X^m#B$W@ql;7>V5DbS zyNjSj@r4m=O{ZOR%X#IUv+Ie|a1qlybx5kSgDJPEQEn4nV_+gh%2TsfU#Q(9cqs4a zcFpcFA5Y_~>>K;UaHuJio}tYrjFvei+VIBt_=})$?gJckd?pc{)(N?!Oj*ai@muoL z71-Tcv$ny`CA)1w{14DX8glG5r){M`q!J@vl4Mf^U3`kRkEBU`$}22_$H#m3OX8@> z=6fSz4B}xxm-Y+Dp%+_H-K~X#{c4CS@+l*Xbm zQd-XZo8u_q473b>r_Eh#y%s^%<*Z!SS8Z=ijD$1Wuh<#y^-ne@bF#5?$dR z{bxHujqXHQgtrnuVrVKbt5SlOQAJ8{ z$(NyllkjwjQSeOrmq+$iqlCFE z){?C#cY?7a2|s&HX@e9TzyF((l_zS8+k(0^KyPGYO$Q@aOj~0H-pgZ-_i;+`CAnMi z6fL2JQ%%2%C_lq}?yn}aLZAz7(ey`jH(+R8!>ivGY*7T(mKMl?G5%i9{fFV$>- zkw=rk>KQHmIF04hm9kco%&X)++iufgp8RnK{1JL8Tk;2R_9HL`G!ij%^rCiqtKtLd zD~k5?C}LWn-uq&Ki)qQet!zeef3aRwaC?*)r=^dcEI={(n@^Z`bxf{=cUJ3sPkKgJ zXBMCBOfk?bT>Ef3LUZx-ArUNcC09VNS}LYK4nXoizVPpP5GlFQ<7wj9S3d!XD)Hp` zV1KV+5$}0>v+X%HJz~o9OS@wJoo4A-;~-#;P6X%@G#h*ZPPZ3zZGGp{5iDlqyBa+X zKlte0e!KB|NDlJm$Y9BvUmrmAsl8FRH{)|-Zmsq)uh7^nj58;_2GnT}wSk8Iv?+#D z#i=4^<=<~_nuo##_6M}Im6kz(+!5mEWM%s6- zySUHOwM|OWABD;yH+$Y0&&BweX-iVE1$&;f63#{5$KJxELQs&Jl^WPwD<*Y6=lm3| zk-3?;kii!^Tu#+=(*u??HWXL(;)h?P=zFT@io1GQd!^Rp!J2Cn0o;|q91rXH1)bCy z?@fktb-0@_)BrA9{H5k>@u|daHz;kwn$%&w=Vks3?`n1AYu{G6vLqj)O4XBB)-kCp zJdUT0Isan&O}FCIPkoD~g-MYjTjlLD zmjhGllD9VW8oM%sK(W`U%}qnxCv(-#^y0g~;`HK00(E9RgK#Ye1ZT?pLxw%s3dW?@ zcM+Az7?0zƅ&NTl}_y^&-X9+M@P2B)|fP4#Yt3CxWu7OJJ}2{j>IRdj=<2DSOw z?DjH`*zr~U@?WRMcZdco9y}y4RvQT-t7aAQUQ+DNfsi^gteKlQ| zrj8*}TQo?ik4!hnX|Qu5%W}N&sHzMNC~@Qrjpge@cwYaR+We(yFlDlcaAf@xt)O~- zoB*@VBT9TsKM-y*HNKY9PQ<-leCbVk&cx{Z*$%lODc-Y!RlYuv4tAPBCG7Q!T)0ii zd8xC0C$XrBbuTW8SJmTdyR0A-9niHCLCL2GBsWw44$H%zbw{Gg&}cn6uT)3JTG_jb zAknYUQa5jSyq=2H_`_1{4iuk3YhS6)!SWK8l5eYT0oljemAKp0?W%*jz2CyNXsWA9 zElJPU$IrS`D^A%H)jBg%@T`EsEFY43^}NS|_~9J->QCu8D*UVZlD6qOPi(Ybk+kwF zhvCS4Ga}^oOrwjZ({w+i`IPi zXezICQ0~+mEe8(?3kWh}x0O5di^6N`u`+-O`%o#=hD758$9+ zx$bw+(@k(QUjUKjnli5_9c$K@$Zv5q%w$Y6s`B{o@8?vKOJ8EvvU930?yVQM^%k7 zMHT=TBhR=eF3V5*z0xP&O!7D~#sYRSR+@Nr$CYYqp4@5bP9H4=tr zQ%cMXKlXd%7RFmx|EvkkUpkG9-bZX+9g{m4t&XqUABPw1`?^>RwxyOf`SKs|+=g!D zKS?8;k#H`J@8-8Jz0{(T_`j9Z*00FYLKeL!bD38OoG4?9-=RXnKmvT?>W2HX&q&?E zUejNHbdSO)y6rX_X08=fi`JZu$gR*@_uuy1yZfb@Fw)# zU_V|VpHy$ZI@?!)zj4@7@-d~h2j>-%di_L%7k`QM)r*!QzC%fl?uUil>JiTdu1VpE z$hpZOrdJ$R9}H|`!4;L~F1?yW-R3)Zr9d=WqOeWu0zRwlIny3AA`Z-t>jL?KBW*9{ zBE98^M#C##42u8pj@Xc~w=TSO_>xRR>RW9IKD+EqGR@AG&_3BdJqBQiLc~l}U=RrA9AEs;h?{MiMET3;7e)4NY?1i)7E{4}ohLgr{^(urL12_!TqTV#3DCEuSCy-Q555=HcHdf2kn|a&$KJ9Gj;e{xU02z@Q`32+KFh9*z$+jPX}|fx{L}hl!;s|k)?vj=yd6)G|W=Ln+9?#CH^(tH?kX)FO6wsH%+~C8IHZq^MdNfAEr+M z@hlmzSajie$*q;NT>exY@lBaH?V0DGILBa4oTc&GDs)>E`I^WmKJe`FYH-azO%PTX z77>5)v|fE4z<8Q9Z{K3+y-OC#qFin1HbOB4p|n2HI7vwHmePhL`XT%J+zeG$UWmgKoI&#L z%g@SeCRP#w#{O4YoAD29*PR)Nv!VyO+JiB+|^Zd+IS#H#K;pUcBJTs?sdcjn5xb2!9 zX(2F+Tyr)It#P@tw%E7$9CLpLHUas{!Freb6pfDC1C6|>h99>D_XzEC&xAjfLYQCa zm&zF!)W#>>2UP!}gaiIKo_qw`A$QiNcWT@G&gI_F!>2LS=f`PGC3#d|dbdrs74(os z_9WI2{(EBCGp2W7SsBg@&y~tE+%Ir>X=0B~s?R)QthS>=e(_%+G&n5|wZ`|F`(cev zI<6Q}?5nb|OZ&J@Z!oi&Ys`5w=kl^>zE^*Hk7R3CCXv#zv40Mlqtl{LD$&$V^uJcF zGN_w+n-G0cfn+&Y?aa}3|A?t0(VV#$q9+##J-IOL&9qyeTB(oWK#+tn&Sp{*in0*s zfUtdmp1WD|iYi zEf?9m!@h}xz8(uDMJ-s4k3B^jgldhs6TuLEE(kNns8UH_eClTV7iCnp*E|I$xt$+ktb@ZC3rC$h-Q@t>k}BRTOY`X8nu}E7}CDyGU)C<*J_K> zgEs`M%cRNW>hQsMZ#v`X2pr0?x%bw#Y2#qLJF`;`H0we;^>xPsa?=L?_%1bT8ahyf z$nHLUwmUQC&}1${%2QRJ3N&(8pv0i%P=gte#?rrdY4-^a*cbpG@a9*Vj>#pkNa;Ru z7z!iXAGm*63aKax&AyeYF%Kll9T+cf)z`)y+-|;Ayfw#k@Q}@WT@*i@E@F|u5^wIj zUl1t!dde|iAk_DXo;o`dYx+{7bLGba_Rd6J=v~SxvPVh(yHfCb_J7eV^;(UG2c$dh zAKz9KtWcNvGUyMku3Se|F4O@c4c^1Tall~bP%{4Q^* z{w=+^b&kvh7i0zCs!eeyoi#p0I0jxMtRvqX)f9Z4yPGVWUTc8pdTK+`H1|bqp>C#V z*`BCk)c7)qd}Y7y*mE$0U9!hO5x%#|$O`BA>RH#EsK%VSOgg_5DxNT$gMbL|B}Te@ z-0$%E&N>wtMVEND>Y;I5_T_3{Xi0EtXXJQ<&i=zAD@Vizb|}8=Pz@x>n+o2*(u9|-egT1HTrnaZ@l$p|rkCuHsB#5Q$U>KqO0hV2YEd?tA~+;)AU zsj8XMsUXoEmH}A+zsOP(YdBCK{H^4$slmOrR#!>c{&39K|LizJG4!NPC#0+9*m7<; znH$SpD<27<4VB*?CFv)4@HK#5u9n;P2OYjo&wJrq)E2jL zRwC`9F8+8p4lzhYAGhCBZ+myV5i_l(6Y-6nb+>mK(GlSFP{sRG9zeIFh`d>GSYl-!os;p}?(NY~fE@@mc7W>q#2?|*h)%Hh^>P38IjsQT)FCciK4uZe*mAl)G%Ap+7czRC!dkQg8-EiEw` z9u<@>kr)!vF+xB+n(zOh3B`# z&S?*6uFY7_1~RCTCLkF!D?6nItQErgUXV&-twW4LbbGFyy;$6F{ywG;MW2E7v>jOCsJ)GjwSm7rS>1G=d;aq zopT?8gW;q{al7lASB0_4RI_GvzWL23A_{D#zQelQb9Z9Uo$LkjKNMF4-=h)7g{soK zK0nuUeqEfC&@GKA{B^Nek9C#OVXNK_gLu!Vl@b@4eStyfwku}c&fz^p67w`L2Ey2| zRfdS_OYZ0>F-u2aGcUZ1v{1Db_A)6;eNwmFKIas(79RIA`vN^QD`$_{dr#58U3lQX zYMNr6up_5;zD8w5>QA$}qlyy(se*QErNBq>^Bb=4RQ=r6vl z?aQ;|q<36OHnb<$Y7}CCaVaeNQ4`cE?Ph@C)cS3iB(M)3ZW?Df6KYLGm%xY1-Cmpv-%lQ8$7=ttgnE!)_K8hM$? z8+6g1Vkjtjz$We)6GHmOWMl1@Wkn|2xu?&{7IqgdBrI`OFFyH_BC!bj`}$sv>$ygr_bEQhBWqmR!=-u`w#6K!52~c{^Xw4lDHRtl9?mvRW=tPh z^aJ#AuV&Cgx>@V!HN#G+G>hL|ogt6*1R&}v8Utq$?Ode){f3Vy9 zYKi%1y6z+h**#0Aci|-sh`tqmA;itfG4#fGb$7nL#keiy>{L+82ec>O$$JMEy^d&e z-3aRiCGuO^eB-s@BRg*_#=SPgccvA@+){)%WW4#PuyrZsUaBJs+|w@~+9I}0%jRvE z9HX&I->%;?$CBjiwEHuGo%%?_IS=^#MK8vfHw&ig5PF0XH`bJCD{({e5^4AhEVieI zWJg&hMbYr+bBIlx_wcxXtX8WwszUe8(XJ>=;zc^UdpODHVysF^-S+v1qdVsxdXHUx zw@Z}7vQTUd9Mat6Yr5xahNI%uLDY_K`YpqipaR2x^S94-@@PnE?j==b%&&X?>dyfF2jk`B_xNKi=NO!^h(bYZ*_ETIRtU#JM|L7#Q96pqiqDDlWNnB)PbE5Y zr8ao@%e+-JIdl_6J@jS1RSJD5;KpBg@nCoFW`bAplP+zl-!?p!k2!Pfu0@YS6f{~$9AhKKhM0I{OIOyFGi%sw9O9n&A?~U ziL`I4x2|eZ=Sk1HJ*PVK9`w?yZGDr^gceyl`VnG-^%{O)GfwxQl1VRSxES(e|Cu&a zJy32BL>w_=QDnWa``lkkpF*u_#jr){p6Y2x@co)r`wm;qszk8d#-?6+x0EM68DgI zeEuKi{C|r_+|YUw=hmR*M;9JbVp5+ioWpVHEUtYmdNyntHCq*>ojG3h(J1%bHlbZPu;xSK6JMnppI%&~&j!wqrs^7KYm3-kJYN+b#P}Jp^ zZH@EXh##3G`@4HHs3p#xy<%_iHiMzB!eJIsL-t1HIqemOmEf3XZ(cK}b>$!7U-m=? z8}7V=el>SC-oEm=U9=YNG5lOw+HMo09X-LdO82BV=IMpJOdemlbhI@G2rAPBttHbr zFx_M~SIr&otzWsi$!QpZyeYXgw^S)}xIm4qivnRFf*1O1bb@RxI=hkP~kMf<53>=!QP%jHJl3ttSBb~wT+;kgh zOxqW&LP6ECD_akjw+0%y9p1ktJy^_fN4qsO>m+{l0OT}v@VS;e$;&+Y4N2Pd)(PRmCn6Sj$5+9*}suxJQwmsq0}qjq_SCaU=RO~&&$ z`lB@+QVs_+@P}-|i>4WKavEyR{o+e3{YS`AZM(NP#qCKxQPJL`Yo${?+2^KgXgNb7 zMfn7k@NxYr)|JR6>i`aG$qe0?y>jClg-eHCburR|zpkR%2F?NWD>iQ4c}^9?_uY%g zy11=A1`2zZDP(hv&PISP#E*lSp#x_aAkFXPC0Ww5ZS^KcUX)q2(5;s0jDsha(;$9` zV%94Uf-rv+2i_`_@nQWMcT8+xs$J!_h!w+NZ<`XV9pd4&U9g6ycX)Tuh{p=sbdSPP zf?LSeke$lw3G~P(!*+fux8NFYE}{9=mdYX3pJ_TB_ueRsjV=_)9P2;$Gl|a4FFnZA zH&3=j){~bVATZ4nUvkm<8)@`oKb)Rco-5Fm&=-kkF1lfa=-i}O+~9loL)_n;D>i}I zWzO||7c(OmYp);6l_5}i{gOEH~6(1@A91>Mqz(kmF%lLGtIiKSeT3e1A})GPh+ z*^#sUE=rtQEoN!1O50g9KCq0Ek=SZTKD6SFVaHpQ-VEG~{WFUY)r&=#)h|(~#Km7b z8gh5C9yut29Kry1t7_WITfz^Y*ui)`d~Wu$rgi9<7AP56wiy?yjz(PKGmtDe7wA)Q{wUKmZ5(2U+Rf;*SI|!BARgg~nbs{z zILwJl@Nk$_e-RVZLAqa%xVh#xg*_ay#Lb>r({~+z>Bfsy=a1E$zM7ksWujMWMQ<@+@Pg+Y2YM zKlbK`6cE9!v}=ue9fWX6QmVE08WGj|>Yd3Q3c|wQHxQNA(7F;nNKd<*q~otoBx~;s zs1#i;^T{isSd)zNaUGEykU)+D3RxDUEy4M!m^xOrbMt3RCZRC<=N`GERtP>^d5pm2 zO*OUpU0`==WU`hc?$fQVyKtaCUCb|B4o)#h1Lo#w?!-jdV8&~Hw=_9SWS+Yhj?SG_-;$@22#LX*yl~fTVc057uPn^jb()w z)6F~bqM?f82DHiW0&pgd?PZ_#1_@&1<;n*CJ>I(r1$jr9%-o0!KA01-->d5B7>Tr= zPH|+`sv_-oeBny=$7CvXD+fdfau463^LX?M!tQNXZWPlco;afF{`i(`EPvxn5jLzX zLK{7nO&EzSQuSMtJ4Wzz=Ee_V6)n_rVpWPrRvbf{UIp$*O9(taPsHe9 z71>n|ndp77pD6AL2I+wMr6(bg*gO{={@4W702d*3^oOXtvCw|c0-vbwwI9N$HCCof zj4+Gua}g^l6mw%AdPaZW)tSR-JHNCtU=op$#$a~FCM+8jdm!uQ3(cM{@;VFzT2mtA z?C#``E#`9P;WDG#K)!fWlvaz02_=xZ;h+x5+EHbBxb6|rK0q>&PAS4*Y2U^xpMd~+ zU(Kx{wh04yS(LXM$TSABX3P$7S7ux9;redJ81(A-#E7E+RMw@6aNcJQxc829JU8A> zbZ9tRt-!#C4#NeT&;1t(v7V*R#k2L#px@vn`lBitoS|zo*+5YMa&Y>$ncQ zjN@Js)#oiEby5_TEXy0t-B12mfzw=0sH_ZUIu1Lw%%6+8OaZb!5B<=?li8~P8ntF~ zre#8K6E8-nan8euD^>>DuEYPfK~9dx`+mMWJ5?XHbB(=zeO}J#9}i!gz6L5K(sgex zyUaRkI)Bgb9gDk?t#EX1FuFAqOm-nH^}?VThp4{hfJsHyQrtJ&U1bfIgYBwc#I6|K zLtnFTdU4T9Elw8?Cv?h=Na4K-_F*F9aVQn=(*a6I4l^D^0qXECBIeVZgXdsL(B+gKfYdPuZGhr_JfQAw9uFirS=04!PYeG)#q(@opn#(aBj zSW|QVlRfpd-*XC$QCyHNZbGMI$GK_CQ0iN_G?mk;+dsol`uOpZtuk;?PIL=`az_$& z4ecu4h@0*s(YEQDdL8C7_I_YbJN&GRUT9I->FG5bv*kO#4h_HkYiiti+AuM#_WVK~ zYTp4n+_m>RnIfdT+UBx`dHTdvI>|o#3+`FoF&f7% zBJ?B+doy|g{G=!>n~A}pkCMa7Ef9nnwI54{a~YY3KSu^;X{4}Iy~)3qt*h(HCHe+9 zjLa%UVnxte%mLIer#~_ zI+$mNXjm_zE;nu8r$1n2U71q+t0+QGI@+a1Q{fY_d(xv%H9Cehg^g#+_UBGjuau@KaxY$FANGj!Za;} zr5oON8jw^B*Jn#;N6ZFjEm_RkjM+Xm4}5EFwU;_t1p@M98zX~Z!E~SNq4kCo4|wl$ z-V~E7Pc4RTP4z(KUS$qv4YOyXiiHHhwpKxR_qLTFhP4$)4VuNuWVQ5`Ww}K*sWwAUzS%>l+{u$qd#SnTHHa}U$%g=yA#_a zZkyNdS`gEXaPD|K1K~wxt8aQ_KyV>NmlK;A+eVpdo?Lk9Vrl`|gb`7hj4`3o5osZ#>Ny>&@kNIlfmP5=yvXVG+xS_H$i!!1FZ6E( zKO4#3obt&ne3r0Hl9k&pG=uIGDmd=x#GZ(2RmVls`bIGm{mk3s6=wHQ(=N8Bii@NS_J5^H8Nfy?4L#N+H0i|lSp_k{j{#XB+ z4NX{6{@i_qU1b_W>wU3tl zs^|J|B717qH9e^p)wX=*3WJ4$3di$zQ4mj$>BEJZrMX>%fjzE1XUS50buxcx)AwBY z*N78~*cIkjIre!3vJ95MH2Z7O8r2`&T&#c1iJebtfZw9LN!*(GV!ezvzZ3f#%d?HH z;Aaw%Wh6!yTSmA98IJ=PD9>_~H#vQ@UkJVO+b=+lGd{eEXVJl8^%X?1R2$S$(;`OI zQ!NpjKh`vxZCZvl?7+Mn!}xBxa$)T3Qf?-lyrg`pf1n$?qWoOu^*>JwL85-jSX%wGhOfe&NNBX+%vCR&96}6OKZidu*Eu(KFM9)(8^mGY{K7Pjb zZ>64{>e2&8oYl$A7j_v72;^m$NFPY%-rP0B5ILW%h%&RO^XF_9gc-yCtvDAzvtMvL zcaCYGj6Yqwj3_MM=jlCS?W3XQ zlb!vTT=?7r&3-|u^l^kHsPG$pTeybJ9W-N*6IMa$2g zBx=cLEOp5FXAN5|RvGLU=-9BmTSkJ6T0r^lfVBO|+H<%XsS-CL;fd_VpwWf_Y|hG4 z{jdDw5LD<`;}dIFNI#~Z_+Z;@t(q~snY9MQdDd9RcB2qDTC3)Sdc(jp-Irf_l|dw4 z&lcn&$Y`TKv9nO*-f#rfPJZcLGdUy@)75^kB{)RN>OMRXialt@ zfn>x&UAoPf+t#^JH)Ee;B< zFwrX{D#}J6TltYc8{DGLI&>6el~)Qe{xGQ^S2$Yaij@o@_Q9707|+4epWY*DAzjF6 z*880?z8lHkG+W$vs~5ZQ?t5%Yg@_N|`1CjP2+9vTK7T_)!Vt;z4Q!Z1RTP0b7O~wIxl$xL3S&1a zHKN9^j&(ok`&MwVhIa?yn~$!Q>P+vE=<<@8ogASwEdP;!y_k3>2@202Z&O@JvR&ks zx%eX(q}7bYbCs~#z&WGSU19Fdumf@3MQErqWSr?IMUS`4{1CJqacQMg-x*ZJgp;MR zu4yunjp$mF(7lLtktp%Joj$Pg(VE|UAU!T^cVRy%d$u!Y-nu% zyyo{dp@K2cX{TT$*;S$Oy-z`%@KlEx>9zSc@Y%83OwfK?nePA}L)#Y%LF#0X@mr&3 z3TkS@m&;iyuCbSUG8gN{Is~OCD~$d@r3_-wVkZ0YCp@u@?RFBFzL`(oxs-%VxkVpn z4$QK4jCmX%u?vm>d&;;j=|6(_4}#R*usO7+6&DdAQt0M zApa0z@JPZgx|N>{+VoWH8@WvXo7ZI&KC`(ww`MYYEN6#$u((l-h>O51zNqx-wLmOs z4La!B+vUZ2+6a-rGO{%NG&_9^so!FKx#Va)_&3CF2DiwfRx&4#C!4?#05*_C{$4~J zoi@rC5~txjo90_R@G!A@=?@a?+nX^zzM$h{9fvB_mD>~B7PC2!t~z|F6xEtDoVHA+DGUl8c}9I8V;;Pj#eimT(=JYKV3DlDtMJ6LI>EJ4ah?D8L_ z#-V6~J|jKmjwB_Z!SCA2?x41iZPOBQO8Zr2DScHtN$ubh*N2wU1|Vn9mzUiV{ZE{& ze}Y-cR-8eL6ILDU|E8yPQxdmuZEZ-H_`*`O&!hSAIEedTI-^2W;_*D#2t;dLmezVa zFF#y(XK-ob)1DQSwF z3-8w%#lhy|clLg-cz=XJ+}BJWy7t4akzrbqRX_a>fu$I8J_z&8d*&k+ zt;Jl&rC#Cy;GVy`aJe-%$6BGA$io6dnhkAy!5Vh#=je%ln_ez;@jR*SpWmW>?9mk9 z8dEhsWbGJ=p=xYGRFB4 zj$bd~^2VS(2y$A_xA_%IQ9V?!OYU9CyMIf%FNpWts!ndX_SopR!5cqPRI6jimLd%* zdWuOg^Q$XA(oolm_VcLE6iJX9;Xtjg*>zwDcigTWR}w+O^zA6YY{vvZUkzuY0peyKmcdNo}1?#zG8KUF9GkedHg|K%B|e}FrSYHmI< zZ`rE*E=Gxo0jb)~w~0$MdVCp<%PyS`Gp;tDh4?wNOHE~JX7yy%t-9|g$nR=AT_G(A z4cNyX2{M6b91#s$olyBcv1u8N!CbZM)8%kK1GN>W%^zsxGCq=)(L;zyIs4NP)h{P@ zxr*D{VTH53L(^|BzIY-*&Yg%0i+XGaf^qZ|QU;Hrq7iBpGoq!;u0E!(J;~L0!_7Q? zL^;Tezdkfw>5ra2N(6~R_hAzoCPpWYXSTRo-yeQapm$nW(kSzk)UsgHwHM4Xa1@lW z-b^XE>V+Q9RUE=^u%SB)BMtGLW>&W;aYwo4JJ;wXg()w$k%lAEZWYrp25x?gkSCk0 z%rjDc^-v~deaMn=uBx|W-?uUZf$aO@dK?E!Xd^Pb6Pw@`@LA%!7TPpltC^nCVc7IY z*io)gugqmyzM(XSbMnR&#?5?B`}@P; zd_QHfXChfMam5H-W>x9OnsG#>upT5%qLm1(Y}lSQy~ymu7iQtC4U?fS2sLfw_id4R zuOP(m6~UERf$;SROB6Pk;nrhEXGsondqY2GEP}#g#2IS2+Z}?jou0g5-L<|Vh54PTJthzq68Z?LGr?kX2-+K%-cLdQ*E<=_R3WL{O%7uAM?zHOp_irbY32I zrcezR%UDW!VLuq}hzxX489clJOqN2y19L&wgZZBm&`o}G-xO8wIk;^5GivAJc&+C6)g8k*kct}|4aow(gZkq!f+1S-Ms;$ozD1!Gf`Oty zY^&m^E=O-Ad#>NrCV95wqYiaZ+!@*f)0nAMO)W{2>=qM3w zDHOCXzd2FTfALBb*SARSZGJfeEu4mj%STYf5Axz$u(tw5=xD3xn%mhOM-F0SM7y9G zW95KZT~i6qTFR_rt$G^ek}MbXq;Nmw@f*Y&4H~%Gp(+*QU-Qtw{;T!^P%A=)ltr6T zL{WJanKE_d_-Q*P{yY1owzVevN~$h&q1GyP$HmZR*!fF*gBiL&VL1=WG3HES0rCcsmv&4Q&=9zfTXsa3@BMDt+D%H&WRb=PvQywAe zM%yCMtY-!e8`P-M#p*CuQ{iY~Hr&mF$RI84Lp4!1i2{oOnA6w8_6ZDgNGJqqT__UP z-fF(3Kno^57u{gq>)5;QbCk7Kc{pudP=gK7w+sE2_m9b~14D&^5FdjARZA1yulicQ zk`gb!?R~O_NihF$SC=KDU9vk{%t~^ zzNGKAov!cZijkth!3I3;N<)J-$5!#c=wY501Cw-1*7G(6I!=(*(|hByft5*bUcpR^ zpaOshk4%B8b{@n)k7wqZ%AH#}@@ygN_v<499`9!s?wO{f_hQ18CfGh4< z>_nzRamG|~Aj@-fB<0ioKGOU|iZx^{0R7-VRjPvXlG2`iqeAU0pW@( z8=Hix*k0t~dMT-=ug-lwpsnEl@I7KVON-f5(DCGRN{2}`Q+~*t6M~7C^;jO*W;r$7geP&B|Zp{*b3_=M_6KA=nj*?wFc;TtMY)!lqc`-{6y3y4!w zF}cjQ?99X+RjF1t&X63>OD-__tfj z7ndoFDS&mGPVXwA`*H?P?s0jQ|bih%Ehn0E#VU12FN9}i>{&7Q;M6FPU8DDxLYt0iWAGJAjQp&$%>QLE5k7?UtlE`d1W*%u=z#zVp~3)ZLJO za>%DBlVE<}_CAJH8xvD(y^yQB1@YC#Eb;px4W^6cibI-<4$|&~jOB?XlIBX!QO^z< z>)r5je)0Qrk*nXDhmiF0XKHAR`y*wuSz5I9!hSD(`X}b2C&#_$oDbgB(giMbPM|b% zU@BVCo+h_7!r{Q+SiSZ=`qdgI6RtjOPG90v7$=l*Smee5TLoU&BfoY8G&`i_0Yh|b z#`M0_(oxBanMo4tcvv>z44IN^kw4kp7ACv&(53WB0RL6Ghjl7;CEty{M+?K_aDc<%@KtM$Ft3U0p?eE6u$1-|U~ z0{kBPk>p+NEQ|dD8itS>Em^lGLY5-*ZQSDA`$u)74tctTBi^1#vm_L%F^3dad9~a4 zTP<6bpo=yjO7s{V6U~{DqU4dT=fSBlz8FiALcH?(xl?DKMaU+V{F?tb$MCG76%K%(7Gc< zMh2zN;tDdi_1+hiC{#Q;u%i1jANL9~Cs5fA74;iYQhoRh0{T-}TJLxF4^u~%;^S^1 zPZVW?4|`t-zI)2W?dtk{d`?fTWNm$uM|h{+aF04+oAIo7vF7|UutiGJ3X(~B>u#ym z+ETA+vm`LBo@2ex*($rVogT$2nVFXGw4N!2nEPjTv3m)K!5b!9{!8P161j{&f3XAA zn++>u*ZK^2+_(>NTLavq*`?Q+5iK0!^UzmMa+FA>uEf~Ad=nWu61lPwFGh@#{>B%p zc%?%{vWFT`%-5VE{kC(5h-!^D{{&}WtTC!=b}1f^63%!gQ+8#$|2JiiWBLcLl&1X|~+R85}fi9TUU!t<#bg1V+Fa%e)w!^=jPfCfAYcg2(sQH%dc9cIu6W zrKiSMt#&9m8F$_n3GRHZBI$R0>6I{;u$+9RfT%JoOIKo4X!m-MAdyD%y`H)Co=-v? zrskhN1|QZFJ4IUh)?N7RQ&s|5hI@Hs<=6c3viwGwh|aa{md=`1ONaq|ob$We4dRhq;2P{AJx=rG z@tT=y-u6*lvVM2r4z4xPC5mw%w+wKE#2Ocr<;mW_N0U$IdBXyj&H%qG?e+`kco--; zC{eicWo`rDMAYoKrAw8$XMx@bA4}s`Q{RVo&@t?2xqC_b+N&Wb^P~R9Nkt(I&g%s^ zq?QucMLvhmXA+?8)%_1-83rGsSvlESyO-@GGTJX&V*2*hQw%Y;>#=G_KKq>^zQa8V zrYOB4lV4iZjm1*Q#J?~eS0jA1?0maqL3nY)Jf!eRTN^@H;8WFOjk29jw}T<;P(4ih zl`5w>jWU<>V-xHwlc`gn47>U`6cjop;qpHJKHy!RnuFpj3qMR3Jo{~}!4U4}r)C}F zBk1yqLd^=CCVee<4_^7m$H@X0Wno>^!0-(Gu0p_UQ*+ky?;j`~&Izg6ywIV2NJZgF zim`FzH415*&{-Y7_)FB{pGHuy$ZvU_J8`Dd=?AE*xsRnWkjqD?9Z=Z#?6`=}-XnVx z!L%j0-@y$PQ5sI0reHqoyaolxlf_*Bl-u&f_{4+kVL2usLCzj4A~ZtMQUhb^TtBQ5 zOI}Rc!#Zj(5IfYgk{XRz)QeX;=ZD5QY)pOJGa78(@0eK7T&uh1e3D$JGY4I)?qBME zn)H(4O8$^|lpCl)0??Hu=YS1R_jyWSkQbb87xPma7XEFVfhzjf)c(Au%3f&!`* z%LfF>A+%g)6L1)_(ciIE)}y}=Q%m~7b?u0Q#HEF!PlVH3CN_n1PQI2F$UY0xIP_}g ztBFOAkDazPyg;d+^l@s!brq{UcQ{0XjCx6}M1ix3duLv#_qnymt<_$YumBpZl;SS`_k%3^S^Q z_68>fbVQ#zC#4u}rfeh2csjRKXKY^uTkI8&l56oL`7(?+^$+;D3~at@y~8lz_<=+& z6GhZQ=MyUT{44+cbm?9017r$GqP2^&u-xjdo_VI8TY;e*OS3 zTnHOByEw&ncKo-Z_)p*B0R|zsx19xY+#(k%P){7*y!r%K;cOG5!jRdW;{vhwvtI`H zCibnWyRJqLFsVS*DZxfNF$*3EJT3d54?GL?Tk9BDMze0v!(^;y3I(d}>}L7AcJMU# zqYRn-SrJN=7j`20_1WzY@=;|JIxhm8U_y;F31xl;M|Z%vk+Reo+s(4k1dS7aN@sI6 ze~>2c{{idOgx6x#t|6B`7myf**co%uoF`WMGuCMy_zi;B#1I{69hbE4bZJhn&8*7t zQ9!=DT@hZ};7GU0@OUUyp)8%N5ZYK&-jKC5op^cyo%SdE;|)TJ5^TX)&9f==aH6X>;FTi>`}Bk42xxQ(U1N zfC%SMeF6v7SNW~AQ53%Sj63TMY>;B$NI`;XP$<}PIPVk> zb%<_2)IaTT2AKZdYkb)^^oFW3+o6`{O5f@N)86*fhCeM-BB}067TSD};y2CpF5;hs zuN9b8=IkU?f!RH?E`!#CM*L4^7*EDxE*n@Pw6f)5dkmgyquhM&iGcIQoR{R}$mk^HcA)5iIs3~x@>|RcP?yuQ zVr0IaMEzcB_FFd8_0;rP)ulz8)TPhhunBf9kLt~AZN&>K_t55r2GVeRK%I!Mv?s5t z$alWEY^l!H;r?SHeaIj(h4e$3*!WD#q0z}r8Af#eC{u{%6Y3slf9!{bVWRsh z>#HVL`7cVPgoz%ntW${?p4I6oej|D&KRYb$Y_fyNZ{;&RmQ!8-^u&#T|0J6@bD4$Z z8}B6+wk9RJf8n95FJH1aiAABiL{3`y%ZFXtv6}Zyg4?QC=*L{AC z6yC%X%y!nK`!)V0Y42Yjma`@*@?>WOEboJtxo&TNnd@f+Zlwplj4%Bd7%0`^y)7eh z6etzI#&K zya}TKN<3io14Ib?IQIk&mu|Tc24;d^C0M**jNC=IZ6OVZiCZ%Zt8u`Ow$9?WzkH2v zbG*)IWFd<&({TCBLY8TEF=%4pt|I)KsWqC4gKa7`^3t7+*Z0{xb+Y_z@3ST75R>;p z&4T7OSIK+7n?zo!Bk_aVmMbC0U&EKnX*f9chaNinPjFh^Aiu9tCuDHxDtYk~XqLy~ z=MQIo_nY-nJ1zd*mCHdejz-xR?}aV~1;Vn>X7}0BNZ-JJyr(86k2;8-MO_GL^`YTl z+2^I*qCO+iUo}QCbeR9RZhIQpHP2sQYYA%(A^DEM%3WesImCYkZxr!3DI~r{PZc z-=Ifbgh4L{!meJq%ql`3n{rA5&`;-stAHqgDXWbvti1slklrOv=kF|J-e8VH9<<3h z7r;eL@qDvK0~jPCwNW=Ra5R80Y(p7gSUl}D*#f%(?WbWJx&BYU@EkkEtO}P3Hw_wd z%I~uFJtL-IQ+%G>`OROETu=!tOQ>RF@3-RsfA&^ zpFOw{FU|?4iZM2sj7+)|#-iTIK*1K?ewTG4hx3X~{PkCwZ-b)D%PBsQDaNBr*!o!C zUj8j3N_2-;NfFj`m(?*akJ^+YftHhlInDFiC32VV0%QTI;+z~LYBOf%NhPM@X@cC} z-C~LVLE8d<|0bdT0TpN3ohAX+k}hbL$IkeH{|EfDY{5h9=b1t4cro}Q=Oua24Xb0T z89Q_Qbu!EF%R#d67LW7Ba?VQU1)@wJY_O&=OTWIJF3y<&gWtS@*6t`VRzf zar)mHW2h~=%ZdZ5qs?l(%X%PKS_;T{APDYr!TsKKwGYhqGg839m<176uTs1tRZ}`| zx?d1A8mhq90FD;7u?&}}fU>OcQcLf{+rxUJUL^jS< z|B<^@vyo3pk-;QBaz8Tns~)%zmOz82q0qnb*F}U|{HJBjVk&d74QZl2FaRTd_>$E1v(Ie z&wgyWeiN)@I4Icy{H*95&CNLBp%WVaQGfqBgo6Ji%|L*9FrHI)gK5|#yYMs+q(AM}zoiwwT*0W* zTQj5YgxmM0x11zViFA$GS@D-(xYwrmSzE{w_kJXhElcEdWk4?Q^wj!0HhDnn=Rlf< z>~0!P=(TF?1YY1bVCPeS=>KJ9YkV;Nd$GSKjO1ruhvMmX%2Pa#ds$AO-!>3#qYOY=ST>IpWbZyEE-*)J56`V4q3x5=aNQwNSOXz5Wu8;Fzh?hC}>#3 zG!O=Ox7^X1h!TK<1wUAnHJk0A`AY@22{-2w#5P*I-M`P*u7fEcWG*}?TJo^(JIj3NAJ;c}<U#ivILrl z&jC}3m#=7imju0H#id@(tz{*E?mz$@ZQ&NFr_X`G-r|AgFb2#X`oACs-F!6<1|>)X zfWqTPuL;w}GX*aZkI&)-6u?`j(ZlNmc-sJ|@?Sp|c!hCN#;f^Xg;9UpjE8l+RlzTB z6W=?qd>&q}#lb??J4#!ejq^&q*>Y zoO_vI3h)*a$oDWU#s7z4HQ{)s2`HUU@oW&l189-y>s~x+`_K}=-mv9-BZR--zm7^0 zXuvNX$Sq;DuHOM|z&F09E&tx)muO8uvQs1yLU3ILfMg2Rey>b`pq2oG-u*JcGroa2 zxGgmDRBW2+csYe`auV1^=E(K`yob0rok=Peabd|GNv2 zL!Fszki`p(kUBx90fw$c0^1H;hbC4*KNdNlB6vV-ftSMGoPq?w+h^3_HGjhf&>uR77!=`UHK1*9xM)+G5vdmfWn*R z5MJNvLatSJe*=C2F@Q>7x_}PxWt@%!w9V^uVt7^8ki~aT5pap~wW<$wbS2U4zfhA# zup{mSnZbjfIc)80U!0dn!a|F8GXn-BkU ziS*yy_#dW1yy}3vjsBQzXdss zClj2X!3X~>FmT+RKx&|24T(TsIIBP3Wjz8mb>Y-UfPlRIT{0kB3BM3+!5iQT04Cu5 zs14TWO6b|CT%2-;%m8oX}u-iU?rfeIj0=;`lgwcU=n`*oPF2vsT7X14(J}H7I1J^_9 z48bV_LIjEaZ?sbkIJJH75ZBWw_g2is2k!qE(iG%79bntsG;LFozzE=lgef-k6&L?$JVcT1Qk?0yqi zg|}?Nz*jll8<7VDcCX#QI~{~sLdzY2<$r*XDhpTwLdHM8+Vj`@fa|%RN+0lS0DHO{ zEC?D2pv45gd)(%OFxk1V6#HRvJLT2}y z7KjfXR)PIAlK%|7u>@9H04PfbnAd5u4B&X<5sZ@n$awStzRhRQ5Kkz)?+R$*`CaH# zM7#sRlnHhc%*uf117XmnX;}_z)1TbioNrZ?w;U|-It5PztOREDd2crX!htYWeG-CB zd%FKugR7FvjZ19?k$6dls5v=mBuYq3*VWiaP9=un- zi7Ns7V!Txs$M1FaBKIDF$^W0Wt~{=(D+>n_A29_=AWT_>yrdH8Vi80Zk?mn3iiE|P zR*PChz#8hpB7*wZ8>j|DVPaJfBOuUGDJY#$wADcn6s9OHz&I94E1;sbj3Tnkx%VZl z?Qi^t``)|DIp6utch2?ag6>)a``e8F<8n-xB`;0(6RMTfqe}xhm0k}r0=ARd8#X3F z@}|A~%ILL0e|JetdW*ly(<{>{(m>8vFeRESntF3zo>|R^sU&B4v%j#zm7K6Oae4T$ zDQ{V!lC#CF`N@}_l9*$$;X7?;Pw}oxnmJ@2>1$ohX+@98r3~k$ql2lylGiSIaKQm$}W#<-WhePiQGN zEof86^9uSuOoZQ63s!!&-7Tl?q&NIlWwBY!kMZ38s6;vUsh2RCzS?DWscAHWT)o*| zPN|B`9{mu{6|URi$M+03g2RTM3$$@}4K7pSiA~w>)p<&?vd#}>klQPA;#b4rv%Mdn z2U7_t4OSMXxaB;lgF}|CF%pFJtW>rqx#h^#z+TA}IYTR?fy%!pqYrSJbKh+BdQ~2G z37vAwAc$*~?8iUf*j!wnAg4~9K%R_=RE`_t?By#c?Y#)@JLlNEHnp-d*)7Mc!J7eN zyO=y>Zz5cM8v=21pE3%p@dj%GQWB_9FB@{a$J!{@?6d{B1ST0jGL=-QAQZ`B?Nz{7 ztb2Ch)A>Ki%*s-X1YJ{)A-G~K7p6zT=a}0q{=#$aBoCfP;EWY2%EFbq4h+ecQG4M4 ztG*A61Vtjg=SV!a>)Y6JKE?4CW_5>g!Y+$uz9WXAVc6t;z7WLT6b7H}5AZm18zrt0n{~G66@ZRABQ*g`8mfG6bfDNJ*W*2)p zy~+CyKY-n0q+=EF~jC6apBZY4vWx#LQIwTfT6wia&919Gz4?>07@Eu9k)@b zwh%fG2?9*$X|6t6$oL7oJ82)p?M!LG0chTJ6>QuHCZ{D(vc=d%UeB2?UavNRAKSou zlI#o1=~qC;Qse?WjQEb9*ASB2D7EUO-Hmd`dOhNeKUf={Xyu=TA{=#S*^B~_8ZsV$ z2F{#aaA|9!wIr(nat{a|S+_gqdj(_%K6ksg*4!7qdrIa?$(tpxbq9)OMY#x&&y4oy ziwxVvoR2cV)4asRfjP%6zx@DRXmba3|>5O3%b@0F?wMl_e2C70Gly7^?&uO@e=I75- z_kav_V@cslX+052J#Y|yW2;uxZ4lHAd+tu-bRo?cky%7+KI0E!Vk*(9+>UzniMT*K zi24o-=bb)`!Dv0D5V)6kK8$3sHJr3Y-hCN(R?c^PK?3xgWJLFR=h*M5LO z6w!QEkRHU|VFtt^(KaM$JLe-bKvW4D&3nwugZylIgF)CXKcmI0^H~nBvDFNLA1)mz z-|uCYr)j zen3*V3yKadK?qkQCm>}V=`N7+_zZ-b(Ob<7Zc=TwWi%(w`vHvvFXS3S!jELvx3OKA zWK0%&ed3rm1Zl&Gd-+K~t4T8x9ZFm~=^(;liWR8c-F}f7~u8_t+gGK(z0U4ZZ6Gb^kS^jcdZ6!AKr-_DxVw*i@!5pZ?}WNzxX^HUd!(POu$ z%vYRyXV}rB&)Nt?u_h&LFUs&0R5U0Vb;DAJTJ_$Y_&wyZb3rR8C{nR%ZL0odb^x7{ zFxU4hRB2364uV;js~`zTu8T}jG7HbU^SoN%6t^jCG@KxlGbVy#ZR!@r=ds>u?u-@Y zPloa|2n7hkr0-H41%W?Gs$_;S0zfQX0y}z2Xj~MKd%PMEkQqEZl#Mi_WfwM5W)FSG zh%EL21UWtl9jL!Q=d#rz}-wZf0|i62&QWrN)MJPO@O1uxHu7rwKNd5>MaI9pg|6;BaJF% z^-5$|bUEZ-aI48)ect^z!;qm`1U*Y~MX}1(DiG(OibAuzARVcV-jzQPOjLrZ)fJI1 zm|efKGPeWrNwxZqmj`9En@gZxB*;k=ROse9pG5@+jq4x;tH3LqVV+Qo;ql-e#>vhz zsCGjG1Ln8*S#aaLE1jRt#ya~%?N!cQ5*}PRY=Nl=HAGeH$5aQQBnvMs3!#j00e;%bRjF<^JAt5ebp`)OvnDb&iawg-$Uh-c>N>cQkJNMJjt zIcq_M&$-twDTRE4CW^7|&`10}WF|@}4`|nxT3)tb(so1^8MfFTqdM>*w4z0b*c@F; zfXYH`X&HlsT|TXQekGH$m`v98IO60(S{aHO7f>-!L8%rnW+bX4fhg!#9O7<4`ohkQ z1Zo1;0SF8^oVx8XbE=X`ZnVJMM)QUg$0Psk4feeO%1x_cF7z@P0L8<(zzHYESnrBG z(Ws+9!8q1CJR2G${87@_3G2bk2Ei7Dq})z zu3nLUjergmmzH1ESC_F+Ko6c=k8}r`&9jIt_`)#E!|~zsHw7m*G9=}ztH2RMltuiz zGtfW0^sO{61;)}q*`evsn)(3_65gPsnd6aLwlZ5aCqbtH_F7(G@aB77FRpzOf^(g_%gH+$x=SG1ikSp=aRls+hN`{}7N2sg=*dS!->9#=2?^_5TYt&eCdi672^a znWd+q>TC92HJQLo+_GHx$aUDZuE`itcleuF!NTvCS)+Q;Y>W{GrUcI{JXTG=box<$ z8LACgl*x!Av^tdd#{GH}$LyB)HlL}+O(L1*cps7VKMqWc+gi9CLv2FED47yO%Zn$NIDm| zLB{O7X?)87jKTQ?=pQ{1%YAMAPHVWpQMru=yTlnzmF1vB^I%nM99}gpi`?T3c?H2m z-5h96d+5T%Ke4V}^%Iuh8%L6pX%}1xKw0m0*Of7siv6R$M!7WT>EaXoeMWE3XM?t) z3Kn*`ap_GvWH&gKx>|J3BsH7|x^^$52A;Z%Q^N^;4RKd8EryD+?6W!l0mf?MA?L=0 zy%iZw8&St*8M+*IKs6%kIaMZ5W6_Nuc+*p!PL3G;xpQmieM1y~)bE?CjgQ_oWLm<( z4?*8RDtYTfzTEfM63hlrMW5Qd>G$o=5E?w*y%-%0#2V)5G|RGi^XcwAI)3m57VklCj)N*R)`TT{UiV(HfnK?k14j z%dXi33G~nCUb1B?-~>sCzC$dXw|hWy1eB3#$xkDY0FqSz0BY!hODt`D9KQXT1{Y2- zlkeYAat&Tdg1kWi25Hpy=6*#*GAlF~mymhzbb1{NC<>VaK+!p{ zsm~y2Q0D4<|4w}H0xhdY->zr04jk>uj_k1mbp)`0TQ}gnV8^e3KtdE1|eK7 z_%&>NX#p%f&7oz5vIVVKTEAjuQk6D-o9?+k|MHPvCMw~-j_MnDF@F4>$;@|SX;(EJ zFX2ymPaWCw#?&WIBJB%rZvN$8A?j0~^-jKCbkC&h%aQSE2ckcH744%a7#Ke_<11gz z<_K6U7N5(CPnJi;9(r5$<-07_K5CZ6Ab>OH>$lm&H}A6H)7PUeM3o~RX~GGW7>^`7 zhy_-76jexEUx!Bv9ut-vG|~kBLi~hZxsDMzhIn-L8DVFDM?KGp1U%9#dqH^5Mu$i2 zI#Kvsv+o7r?tmV@`0%i3Ho;;Yc4DzCz(oD841))nffoenh$ih=v+~ETw^*!yMH;ZI z^fTaRW9FOO&%a+}sqvg3_}H3|3BuO!Z8!XqhL`w^6}-qi{aBIon|MFP#xOP&3b=s-SOV?9Z@Fb+); zw(Kbv0#BnSbsl90eI;KbX0f8%Sbx~DN^@#b?-5$MXa}?OwJF^R4pZ<}QHbBlUEceD zPTe^vDtW|au{!NpER)|k<^Pyqr7GqpChb&gO#DAfHAi80gAX+4rwAKtelL0s&^((W y=3pp}w7NdI4_gY2SS*|0ZQb^a(6m1zY&G&}9r){}VeOD6eVUj{{P_iNg!Mo0I54&V delta 75062 zcmYhibyQp5^95Sm-Cc{jyGxMZ?(R}3Zo#EE6fahs;O+&AQ=H)LTHK+Zm+$Ybx7Pb3 z$yqDw-kdu#XV0EJliwd?6(3|68Y*z`_@6#~LjJ^Hte%Q7hywjE4Ma$tY{J9MRtk1pb&ME5CF>?Jb_MRQtdJ^ghtNAOBw_eugaoH~fFoul_Ehd+ z=nPfCbKb$YA~nr)n%JL|sOGA4oYjF_Ax8V+hgP;xlLWi?Lbx z&?K6TU6XW^aFI61#)yC3L5MNV1aWoUANOw57 z)N`lT&dDh19F+Vp!=JWZ9yD$2z4*sbWSBUPDuQHUzdUW+y84%r*RZK++%WwvV3bvp zcYsQQ;e7NR!)t4$_rv_ah0s}ZDO}%ok06Ep{Z;S<;s0+C81?377(qm=|JlUXSnY6* z_0y*r9hmeTLE>gTP^EdgjmxxC)-jiDPDhMbaqJr=_nA=Uf)OsN$ zi9!S-XBSK^{YPghZNhfSw%AUUgH9S_4t=}CP$0!01KS~&*A%Yxp6*wuz-RR`A$(hf zn#rbRX1Db_P|Up*OxMLA9?fA+y1yuPw0;-W!ltWY`&G41D3Zrs|0+Yx`ELztV!|w1 zj*2;+ZblB;)_3M*6J0_qC5yn6WkzjMYHTEOlZXWA!g9{0u_msGaiuSg&4#`Aa8kM_ zUdUUIc{{FDhHFA@!c=fx(nG_9HK9z=|WMBNzytIm@;;o1l-cKiS+T+(V1j`MH4FW(^Y^ ze(>1*cU@|z-di7hwX=pqKVJJ=ya*0LfZec8le_Hx)BmG5XLFTbOp#6h>n+X1t;}CT zTu`+*N+upN8@1qk~aq_}nAs_Rs>!2c^&M zVXn8lfr*iP91&RpcLd#|r2$=o1rzm-_|;xH)dcjl#&WOJM??f*j)mt)u`fz^Ya$JB zJRnPb7?@&;@Q@FNlVz-g$Z4G+Emx-T&!9kC-Ic39oV0z_$T%vCEc@wMO+tja{jXFt z08C9lZ>8Oe(Qn&ZQ36t?=tjmbs4d_$XysFL0WCGq^B~OMU_&ai#dmCSp#Z#RdwbZv3Ea8iS;mlJ}DsK;KVbO8!HR$5n$@#T7?W1m7AoBD{u9e98J*{uA6KzJx6m_eOfQc^U#r@^MU@{lu&o~Ej zU}fsbsH}Kedf(SIq`a+#HgM=Y`0_7pb=U0B1`^jjS^W1Hdf+j3x~#%k2JLA-{evqL8HqkMn6=$dv(Q1k_Yo}lXCeB7i1qT2$V6mr z&|#y>Q~M)##Vt>PPu-XxXQXq z%C+oT9L;>yibetMs%8@YL^!s>$}0uG1If%xkei+f_0ZlfFqW{_bieG7#5imh#XVwJ za4`zYqugmx9?2-==$F#oJPUFR1lUJkE%tyOdQkCQ}4>PU@KFt)jRq42uK?VZ|7p#<8~`wBxvv zQ^%ZLQT`r!!A_Z?xUA_zLaDjh8^tS!#@5QMIUWY>TJq>HoAc(z84S6g-S*QL3(|wy z;FMsV|NQh}Krr?cG64|`rGlX}y>ftm7(oT1Hfjs^L0x@OGC~XmX*nUYw7)-$*AkYh zLg0AfD-%_g)dTI|aFkLf0lha+LliXk#+F=o#&?r1q8gN*DM4}R2l!jUsS*Ug5rOCm zWlhcniAyT$KWJo zoJ6Eu1I38#I^BwvI%&!GWPO{1ZvdGp|8{D%w4_!u+p%*%4`5{PRI4CspARUQ%uf|}0HwTA$&Hd_*kM#l` zxDp!x?6KH(jrs8D7kp`EGaL{NzZR3k%BM*%Qaf zlRCy$XgwGX+`m9LB_dvFDd6z=@X|Dk`l9lwL~^!R-tO=Iyj_RhAI4HE%qb`O9#<7E zeyfj`Ujo=Sg)4uSBnk$y(Ft^=`W0fXj~Y+Nqj;Fk zWg{z?`b zDUT?RK#~WgZ?bt$YQ;=$yrywvzj0m!!lQrbL|B>gwq7qITB(8=-eSXbwGm2{LZHU! zK`B7w3fBY5+J=;i3@MG5w8L@Q(wF8IVQFUS##o@9Rts^C{`K*FTbOE!vF+!%Z zL#MFB6_Z~JD&5|{m#IFeUs#9GnDaeTPGzBWdLzK@X2r`0{S7FSpdp;KA~*f{gGx-# zH!lc1pM~Il1dfHs2Ei31j+P^sDSr6nmL{m{nMv-?FtetA-$u{6^Ep?G_HB9>>^v1W zG~^WXh@C!JSIUDpeomGFI*81^dK1>a{&-2{2TjjtnLO@&oH1T;<~^97_{NDNWpc11 zhL!uqea#7H?zDzq3%X(+H?K(02gyt~fcqQIPHG>W4RN$TUX>`4YL@=CljFWV%+nGO zTKVkNI>|D9i$uS1zl_){OmnV6MLsf%k@BB~pNQB+x_fPJgTRNvfKq(I71mJ7)w#M> zmp(?Lk*$RDZURvNLEAkB_J^-2R z8Xys`;Ptu7?g;^l&Im+4C%z(_ggK&4KqSjyV252=;o0kn6SF3RUZEdu)PrU=e#T90 z-ZQ+grEF2y1nR;eNRHKE;X{tq7_VCX#zN}v&hS?C0{Y5ZtXRwV5C7T0yu80#D?a2Y zrV#kt179MXaWV`Cc>W^aEIo0})J~`NfL`y5bl(*HE81`G?>XkWD0AyRM6FdElkUd~ z=FRbAbo{3&Dnu^7au&xwjIbR7aNm>E!?!<_u0_RB{z;xIfgDm>wl~Svli-@bxt|K) zk>b8A0wU>3VWte8Vez_Xl=H^N<;PDPH8p59`g+F`chMX)^G~AsFkKbSbriae^jHh) z3Vo&!X*GD-gIA<@d=cQ+vt}WI)BI`M4i?ulWa%-g!8qmIXp<$R;Gc{1SeLeHV|UZX z(7Ho$(?%QwCC95?Xb#%C8v?)rx7LxEgS9URwIRD=iMlv7(n;h{w&v7s9^&H{ze#_)#pR-_qTTW5!;M^yWZ*kOQgCjG;KumV;q$m8_9A%6S9 z)oHMnMweTHP;SEtG}d5%t5_uoIOt`5-d>V zyQ3nadN;SewHWsaJ!oC;sxFke{E*r*feghuAsoV6AXhOIU!QgV2U84( zc@pBQ=y~15cNEugjTb-OByn9}G?e+?5g`Rv1Z|CeB39_o& zK2IFyyd`*CehS#I1~YNAf7w5x+i18HB7_!ee2rHev{r&m!^Fb{_HzZcsUr9+%DJ${ z#WuTWE0W0WWj8tRs*zH7g{E*@5-;fNMZocszwEAr?xH~-%pY;cm#!N<-EO<3Qw#YU zK3?Z_O~{p}MRW;d6qXyHZ@EsBAn+5F7-rcsbCOv{4tS~IA(n#*E{vh>QPi{bKR$ia zp=fD$nJa~u$0LT2HX)*iaU22klO;>3@o{@7*SDq+piCqqutL|3efpaJ=s}ZlYfRyD zznTtF+d89WA|%8yMZn%NDPenwLkwe>5V;bh9Zo@LG0e|@`3sZQt9CX7@`KMrX_I*q zP_H)@a*2rf=hm-uwno5sYtaU!Rg2y!Oe2YM+|jsEA@n&uQaSVF)~$@9cEt(bt;~)j z{KevO#5Q%>X12njZmWMF@~#$JCN3Rhk-_IWh+mYqOXm^xPT93Dt)KAHHOBXuKf`X; zMl}nti*{e09GKb?&8|s<9*G5;Mu{gV+kfzAtD;-AVySy3Bf#fopRxt2j_vTa7>-&~ z^iBWZOEGg-)$17AdMzk@a;1G)lOaF-8}2%)xuOd!qU(aZk-VW*hXf zlj*6*j;)2})Xot+R`GqN$97+l0a!>Gv$B#+&e4mWpBXvQO9y%MB{kujOnjg$QkDRifXMOC6*5tEUJ=|JhCGR~ z_qYqk7^~k;))|fU2af0}XBnW3w=I?k&UW+KX}{#4N4Z48O{rk}Lo<7wtC!7D@92W} ztK3z90ObvIxT{Z(k~;hg+_6!HEWgxK?I_bWo90rYd^hL*;#n6On%oCRMMmK`@4H`8 zojO!G>VbGwaGIRE))53Q;?fz z!AD|HS#|WvRAvtGSq)XC%9bsP`yP>0O5Q?!ScC^+Mxp{t5Qe9?Iyh=!uBFYl7$cbU zFxt`~0E_T#o?D`+RVI(IV~LV}Cz+79?d&z+5yeoA4OjTqO3AG^i?&bGNfk15fsMTA z4(?NH?}r211W;$_8yX_h8*2jz=MFbkm+GNu9JWbsES`{HwB&G{)h&M)z08=O`4v~A) zA5|i7E9S=vze-uPRl?a*n5AWxv<>k&NStROYCN*Wouap>UR?N^XE+!XIH#i&Q!f#UMQ& zoqz@)9IGg^_=-5Y!OML)!}(a+4;S#Aj#R%AQojBCiCB6S9HV(o!r~GeL7et~qnv@` zxLkp2hlMoE|49|aRV*Zl<+tsew&1B(P>n4R8fVq)19`mHGOM)lv?&DGfMhQq`?Y3n ze#zz@3HPCWmd)4K@p$1t_TZe`p~*;{x9hEG%}N$Lb8(uGUl9MzI}MW#qncZ;;}}p` zC5CZPXV~{NC`WaTI+byC!P8#1TTpeqC^)YA-+5t`W^(FIU{<q|#`Ap$2Cs%W?ds8@t}%kCYJ`Fpqnz#X;vm zO@w&uwpRX0%M+?JT&!M=t%Q(`Jc@F+ZD%yHM>3par;~eQ=Q?=iMuHfiQTiismT%Z8 zQUpMw+`~ph%aC)@ARe`tLybN2qmD(pP=XuFh%Gt3V^D&_H5yE-GmyRE0Y6pODMBMC zcDH>>K3yT+5*AB`<*!#awYVGO`27dZ{?O@}W1&PykrNWd020wv=jsV?p*S(mX^TGo zLAr7TsO23l^#^DV0map+Ag~t@D4{Ab60O%PwNjqQ1kWC=S$zFyaTmbe?YkRX?X@_T zheVPck0eKya&F-@rG76ruwwdoaS=sJ_|WwJCr$S8WlT6n2==PsjAnRn6@oo!cuRh)zeUe{c>SEX=KE3D)rw^&Rbbi+ z4uud+`Kl;?c_>Iqbm5Dd4>xiqVO5r?R8Z97gF2u`=&zn8?i!!o_ZCBb{qIAVJUZW9 zc7I?D5wj|T)<&^(zSo5A4S`se}IO~*=|uZ+&IrCm1%D%ZfmcHc0tz@g<| zOO?Tb&$a7utY}z)T??WWXm8>Fd0;776yILk@T(8Bt@dw)C9Rl!u`v0|@3wt|i)w{X zk_Bn}+rUJY(vUplAe{R435qDO8+!Wl*_}WK9fl~11imkw@ZL1MZLjEgwNsVTWF$`j zk#+LqkKPdtq0Y4$l4^F5M2?qQZMstnk*-%Mh{B=fFKH_Jc-$){Kt9s%mdA7%EQLX$ zAQTS}nn7BI4B?91_l98qmEcxX?hy-PMsvj0?1ZMWr$hrEy4cFs zfr->bAtg(S{*+&J)vtzZ2Y+Up%^1?)7udCB9-h-^C!SEt6hip+_cY-vX(OIIY6+%Cg4PVP9=J~H7b~o}V12*7OBEw% zKInJvx_92}6M67MSX<)HpCNRhHRWNgT>AzEqAW%=;2@}#^p>Z<=J4gttNlvmGFb$- zCurNl9BuebTqQ8+$LQIA+tcrvurXSy$IoVnAcMMmynP5( zN&o(@au44YXP57A-kN1I3;e60XQM>R6}WoWQ&ULWD@el|a{lMC!P|2h6j9zPoc!-P z46wjz6t;mIe_|B0!lGVsd-2TF^HQ!FrC`+9O5sFF{_6Dl`B-}8oBRT5DM`D>#t4^M z+q9eMNQdIl)FR-z8d0ChuTDPcqc7?>&DO>hHDS>~nPJ+ZG_`!1436P`lEer>+{6f| zXD*_Bd)YFG_^Vowp`ptSw4aZG_@R)uDuTW}TQS^<8b^H6K-T}%dh$#1qac+a)SL!j=h(WK3Sow zMCs&uUBNbFsz^Oq4!Sk4{C^+CtnRu0~HQ^tq0vR!@C|-A@tr#BU5G2^&hGS0&!D(_LWzI@^f4?-&x1 zP11rBh_1}*418A-i+r{bOW*l*t7P=4n7~o{AE~ueMQ5lAPNqfa?$q-Dt>w@lsmup+ z3owM+mJOv7RUi|zONgeexS1{DG`UDvR!y$3@@G-gxtuiOe&-BMyOp|E@-OM{?A<`V ze42LZ8SeQp!{be4Jg!DsaEx7NZ=g{~2Xg1)j#cQg`!h zP3H2ie;)A8I5jn9`ji6G?#{9cmZg+3g!+HwwG=wT8kSNYMnfA$48%HKr3}~!ulBJ! zzm-$&pR2Ftl)YOZYpgyACpcE&(I&Fx`(S7Q3o$i1FP(|+KZ&Ofm}iSz5h_*|NQ}YD zehG3~6Okwbol`|zWdqE6?XAr56kmJovri}tE6<*qH_(R9YdZ*@26>M;+jEfvNhs6~ zmDNlEath2|UtJ*7C1T53^S%)F(5rq3(zYXuGF7=j^Fh?4u_5Q}ZWQ2hw=Bv$c4)9Z zyyG&7u3d+%0hkHZMNxEzXvTCKR_m~E=%3{3(L+F5hGGm0P;74M)|}l8NX#5wupB)x3Tj5h5rBm}`7n_(1{tt= zDZ?76X0XodLB-(2j!&_&hP-9x_TC^Cj!I7?kya_2A$Vk7~u{#BpcCxYyGm07?BWXg=vk3JIq3#n?RxVbp4haJ+D}NBb*g9W8I4G z$}`$KW2OiBH71j}@l%%h_x&N(FbkDbJpxJ<$Znt8xN-5Yrk#GVjO?TtJfW@R?QRBxu6qt1N)jTl6T zOVw~(ypIjFN0H%*yv?aItqRDd%rgf<5@nNo%3{&OySsgY*>df=$KErG#nnzUtn z?+2JDq4u|mGg&pzQFdrI)mS&Kn&zRLC3n;{k_b5v-Vt#ol3um`o8+OaIwCSEq5~XPKr1e zdN6nr$;)(fO@J00&#$n_RRi$k_x@CThS-r3o#c<$ti<#s*e z-{lJWDkOF_n$wF&*JY0t5Cr&%4T{|cHRJAZOuwo$zIfZI(T{}_@g^(*RL_sG9qAkI zBi9@dM{=3m0LA!E;L zQnr*hE-RtOp5Gm^B~OMf&96_PfQ@fjn@TWFiFW&Y5{rH@vK@xQoM70Z6OEe`#&MjO z76aZ3Z{fX4ePR*Kg;x%mV-oeo0TPB44v@jB^JCNIffPLT4jmlH-z<>1`f3;6{7DVN zisWc1eX7{XaeELPQ(=D8L3_1ICqQTFbMYgiejx%a+xG@NeFKC@Z;crTLs;5GcaZ)A zTQ=+jE%<6PDNP@Ts9im+>xwTuAHH=rbfdU?kbM;!R;^Du{iWP=hG=+IJzfEvp;@3WZERwB?s;azfBiRQX~ z;(%>adI_rJcU4qa>teEl19Foku>bq^|0;={pARzb#qYi!(yCY&#G*-ZH{sr+ZyOum z&7%lmJ05`Z`u3AYOAVm3apwJ}Q+8$l(V-T-n*5q;ZIu<0HPsNNhOy7nzVuzklurfL z#Yfw@!Nu7Ub#AwVD;&_7OqGpKUG5eyOC|%fuRD;EZMx_mcY9Vw+qX4ec$3^d1YLVR!>P2tQV{JxZK!|Ccqj1(ik%Uk?b!5Zav1&*q)FbAuR5O?n42LEDVx zf0hYjx?8SJ+rU}At*%3cM7u7PDE7Y#a+(V#as)E=G&Z#UMcs2~2F2DFJdSGMGm2CZ zZJEJ4QG)ys%UB9}&Y zZ`3b1Mjv?q@{Jz1{Td9!VD5YGbFNYe4N4YztJ?Ty{>7ns%k2@P7mgDOT86`%X5&>9 z-9R3#b(p)`gW2Fe?w@~3nt#JSxRbFaO?4bbr%jaeS^jf^&+G7@;U9hkYSfPV6_T6) zuBoBBl|birONi5GH z48bT58nJ@;>Xk^H*0WC9gb&!Z#U12PrJqrtsAKc>wxv5`!14;C-~8@ez--;??|mD1 z+t(XU>K3NswcixzMh24UWKR=R!dUtls*%{(viB)fVWf-7Qa#44Sl1wa&~9FfjewMo zNX2y*$`c2y@E><&hnZODe-_1a2rPOv(&*UkF~!Lcj_N0y*4esf5Qt@pX)9&h-mckS z;eJlllHrsm9NB<2S3mC_G){bV84nRNL6EOUC$hDzWM-8mo(Cnzs}NRE2Hk2gd~F43 zP^cLElHu5URM1>|(#+UVGe9L2eVkIEcRwa}3=+$qDP#Ql46W0cBE@tFsuFe`p>3n6 znf?k}!Wi!2!sX*+kFXS=zYv|IUqHp_=(0#pum*3N%+Jwfc~=rAr%CK;cF@~dem!&6 zyD{-0#6J&I1NwKLHu7#f)I;?m=p*7W?%4__V$YNO@+;_;Lmy{^mbppYjN?UqmQ10@ z(N$cXks8VY_V$xr$Y;;)UdY?p3~q%jR5tE}jXJ(8Z2n!coYj<2jFS7>5&w^8@jh#J zC}8Oo0|^usX1LxrV5fZE1ckM_W)mrezfcE{ z9nj#`vvteglk@btxOO^PMxZd`*8ahap_*s!X>+u7I_GP-SCor_H=lu041WGgYU1q5 zDm8=R5>f05@6aV1n)$IQX?-_LiKM&;w+-@^Jv*|_qQt7&g;`iP(pH!+4`F$^0@&z4 z&_+U<$b_VOtEMg^IX3{$cgDY&ZjToUs3l6J!m7wph>j!t-U3;W-=h{ zVL(q^)a#?iSb$h-8F=SThJNAFvCVKa61!UZWBxD<1F< zaObpP#8X>T`QpX(ulU8NL%e_YQHAvGN1)`jTEXZ>D(4lpKyxP#61F0s+Xvek5#LEby?Vb5l~pYs{6T>+`{yRjO54Zh?CWw zjXp7jzAY8#Kd;Uxms_BQ;JIG*sg%d1^{mVmXzwgln;sT(PXbyv7xhDW_l!z0TsU4w z$-EbZSSAcK8_^6%BR~VhxV7?StUXZOl@2&_p`+)&typcqYTr4rRRzK{;uXu`b&)RN z%{N0zRS*%)s-^|gvN!0qu3sM^=8m`_RKfBrb`9Er_;XC#J?0T31eBPBC!Ytb9VhMp zwFMVt7w@_c+S&bmLLAD*Uy#i$4zH{Xq21NCX2r*_i$%~5Gp?^FSi!% zzBx^P?%xr(`HJBA{thZ>rE+LJ6`QiChztaw_Bj=;ngi{YU4OJVI=Y;5Wy0}b+3M5b z7@EQ!(Xm@d401#050uP;iJUK_NSHM$od+9~w57}6eY&_j@tXK`;fh$vJlLX?aEENyPbV#7rm&i`Qg2SvlWC#- zC4*39C!a5E-Vqdn?MPkaY~dsZt0HcreQWY980RWyh=9WNh(I6G7-_@YMj-I-DK8vZ zMMS3PCRmtJ)7_9 z+)#1>r(i5Th*dWo`FaM5{mo^+I-Fr`m|>yVp;uBWVv|S=MvRvM;TrnG*8KP!UHjNY zsUlVF+SJ_n@n&n|!_pt^CuH{LXD&)C80c}=iJwjS5=ls)9*V6J94o9qS}A;Kum-m_ zWQ*q_0Aeo_FYq~i^&f>wRJIfkwcX&;`M=#=N(3)`$$;?5!mBaiCD;>d>l<7GceZ)s zIQX^hu`>E$qhst$t3J!L)yjBCM*eCZ26obGp*Xz+3`)+125**Sgn;f`a?0^mF$ zvFnxFq?_LFf?6kmtruUMY>95#6mK--H`VqEx|LP-<|TADaU$|8An%AYl$ebsj41u} zk7gb}LWf##O7c@rbVc2EXZTUu{v4(a#ZJb6uE4^%!1S6ISBE$8GUW^Ml@ooe@}_AN z{ZjbxeqY>B==aBo&j+urP+_iWiJwh^HbNGPYC7VjIVboyROn;y-2`pVldkEY%%%iT z-5E@(0_CG9eZFuv(dT^KCHDlhzI{5VK$mP36okINpVmAH>An>rbeBXiq@?ukE2m9V zb3%(*^9mum1}TuF`a&WGXUq6aemwGj3DtTKV1muxZhpr(`O`Sgv>>jdPt+m$#f;40d4d3I*%N;1{S5qD}0d?l7Wl_kuf z<#`V+u&fbynrF_$cC@K-u4_@ZOJZ+;+*))smGCLWxM?oY-=S?Jo{WTF zrG9KAPg9(~bfPyJ?*eFB19M4bKT1;$!!Y+w2plKMh!pQ{Fs?C4*-sBZpP`ij&xx1Y z1*~yvzF~LET3xxiWKp}Um3pvbaAsn$|Jo5>%u@cAkN0z3TO#qfR;WXblD>7RMvx_u z&mMG|>vydkjQUE{D4*jc50byY9ywiNDTVjv%Sv&_e4b@#kLZj6ZSTV@QTKIBA=lkL z;MCnw}xLqW{ilzym}ZcLL?q;2m{@ix3ozS@RSD5{ExUSH5 z4pH_yfo}W6E;^2)AUKLO8^Bn;M+HT2L4IlH1g})ii(Eybkag2gr|l{3trTF4tMU!v z`NgFZ`B)*G{#Ccc+(8=3w|da7H%EOj>^k~>-e`IaH_s^G-B0a@x+MenkfQ-e02838 zhBRI)FsXY3N~2t{4ej;%?~JP>Akp0_z+Y;XGlTi+x}aA{0{jR=`RtXr1=XTNp?lEg z&$rn#&dKfF^dX#8Z6ykPI=w)S<*W6^ul(KlgyzzU?*BbT;IptKfvqOL|HCcQB80|nw5!-@;Rtpkb8U|#%(IlwM$Zv|_kx$}zwX^2%<(!mJOkV?Fjm5nTsjKd^R)lj zp*@Wuaa8r#WkD3@GqQ^xRpP3bCxRSl&L!#jRcd2y)Bp>bxq)AK764C>-xe^f!0O^< zcYWEF7$b1$;z}`+I*qsq0bm>Ub)!}o0mXCBRfmEOZ3*m{IRdZyXRayul;<7su^mfo zmIpy%>B+2rtesWLB$LOijrH`l8Gnxb*)rb`Brac1_Jk^B78hr2MNtv)YCLmZP}?Sh zc8|{oQq)nxNaGyCNNF*gjrHS7mn+gi#ZwWD&?50LV1FqEGrq;^>eZjom5ZL))9@1h z*Y%G}d2-vVb)RcE=v**hvb8R?ZJLoa0p#dk??nEyHa?eUZt*(`YBOk;yZbi6H*GI5 z;e3Wm&zj?ZvYW@NH^w>EfF7y?zaFQm$Nh8r_Za1cn!TYXTgC^PBwS80#hYDK`)Bsr z#M%?el)_rpjYVBy@-68^%&Dj2CzOw;7u$7jY+r9{oc~N)a^lLTR22yS>D!wEK$Oky z?UzaI&D2dM-wsOKXphn|ymLrK^eO3?#Or2E%Z$%_Zf&q-i^2gZwM*(};d50DBw0&!>)56FG< z`$zvv#OugQ;H60xH})pU;zuL{34LrI{WJ8&TAi3`z;8c_Al zxS$iJmdx|vZ=zj)GJ(&!8W)0ibuupgOOA6ITsRbq4Z6#J+# zu`f!OI%??_sim{DtXXQc@=tie!?>i~;lQ(-be_8SoO3-oe5*~d_=W(LxN05!v}< z&ANBLkM}(G(nYJH|KYnJ`MIe&_(*b+ z{<|Y@x)d?$?(&Fz;9%L)(Z;FJIQo|T-Ciw*hg!Krs5U~D{-1yjw&1Qe`qGAm%uuk2 z(Ny0u=Ff-UAb})P$*Tg4Xfb2KvDKMMHw{P{OVXohHil^kbwxRWTCpB6MY2h?Jv)A* zhW(dY*2)&Nt76Rzy>6O$Au=Qi!8#dmTOwFs5~8C*^k`(+?fhWNA(N4d!_ApC2Q$?& zgBJF`ai_B*Xl|>GHr45^DnA1%>XqBgUD@JGBwB&`b-Fzj8J7QW&vR9EO(+N7LVEfI z3~_B~@o`JZ*U`5fMDoK!$$ZkrFJAqLT+ywoDH2(e`~dA7vZSG%ibS4lr!1=XB4)vbIN8Q+UXbkS z5;mw_yriWIGj*hWymY@D-~j1kp0|5@EJ6&vFQVNjM?b5QL&`kVjK!mpq~qXAf3Ld%V{3vGNE<3_eGLQyM8jAoIM^&1Te3XP zMNpkqX%dnY z+w%KtRb|$tmPg)+Cr_tMe^wY&bjA`Hs@L6WU<_%TZNF#)*zEvl(RnzK$PxKegaeC@ z3u_k)(#BQzaWxmDnNOcc%j7=V9uH{Ew$WJZG|lw%|3tkCFfps7L+Z*v=zvaax1_wyddDo*gcAK)wyai0R`#A_~!L-Nb;@`tTF`|E77~zTzJMJ*@x3JTmG0`Ca=o zW~0yBUh1rp*wH|{)Ad>7v)cH=c_R>-K{OQ#CkyoCr+VNd6)cC+vE{7DS!?DzDr5g`yKdaJ)HQJsk-4C;vJXNeR9X) z!9NQcRpw|^z|1er`gH2sNOk5Iuf`| ze08<|OQwCeM&o-qfkE;L1uDxCZ-{HOHV@UObukm(AgLC}-@r_QA{MXafwNbCBv&pu z0(Q%hQc2%qOc1vCmB5;q9%5wH)#<5ob;4EA1pe7Y#_IxPy_pTwT^X3WU`gbso!C&i z7@Jx?zI4?=gk>CTLNgMPVJ$o2n&dO%B6ipBURXhmj>=Nj~%q1|tyHS}#& zYd&^SnbOp`kkLc9me1!0|J&K2D%7!a@6Q zbLa$JPlST8k$)tB&NW{iJ^%@}?X@qTUjKMKo6)Qt$k)ql=(MuabOp!#lxN}~(q38r z1mgyEdA#W+a+eM)bne6sID12}_n$jkG}RaEZH=5QtmsrfoQrPv=^{MIBB0OAPdre3 zB_UfayPxD)KH+@v2SL0JpsR)fYgjQ>AkAl%8`q7>5+9{L#bL`E$1e!Da|47`PxZL+ zw7p@r(&g!|^_n5G=R66L2~u?BrK^>dDfOVF^Z^e?)~-2o8z$<{`zNz0^zd|iLypXX zampmZz3xc-xzKmDUYE2D894=-K7sUU()od-qq)<}S~MSA9FMk3KdXg<{B(H-2SgPD znHLMX^cm57e1TQ;G&a^yAG2AlCTNqa zzgU0|31GyCZqfMqUgx9+A(pcz;vZdJB&PxkJF?Bk`p5hfTZ{!we#UG62C9QtPo`%p zWjFHwep)(Fb#dFJ9XfDS-Nq| z&3%j)gLaf$sW;AM5YX$c@gy^9&r?UZLvwHVz4VN-d1L)f`@4;9P#urdp;f;7 z(0LRh+E5{0*-dh<(9AP)ku6PKqnKeC)DzWMS2DhdVEzz~6E~pZukLXdw#45?0GZ2- zz3cgDO+7p8KxYxQ^JdR1qU0id=JZ~3+vZ2tlo@PFM{q#8dZPx3yWsv7U{M;q2qSH?3A46F>Vk}3Lh{I$eYA^Brer|8Sa_W|1fPqeSRE^UI zv!&ZK0dz?&ZyQDmw^q=e2Azo)4&AO3Tl^5IPwxWa!aJgl8Sa;e9PYlH`_QM|Vk}Vo z^U?!XDpG-FFT6L%cxlmgcLaiUM`~$NBgqV1+8kAvT9Ti!PnHO9<;4Eh4R-1-sJ|LW zc48c{KH=gVRb$gnnId&Ysx3tV_HX+;>xhFzKD9ZW9L_tn5mrmfk&u3n33R#b7Xewd zjbk*)Lotk@P2V|rgi~i002P?paD)kHItdQd#sGuX!UveDOCLKz#L-_>L!irxS-9u=U*+A6!`k0psnjQs`72p ztjz3xEf)XGLJ0TrYArddhz{YlIUQF%XbvS+0ai5TWW1Lc%|%xU&WSF^U%acOtw_S$ zM>Ugs`0*ENt2M{{*82a$(p82<@po+jN$D=>?(XjH?vn2AmF`&S?hX+akOt}QZlqHh zDc|`&*ZYNU``fvOnRCuvXJ@eoOHMXqXhRC~el8|*exiElyG-dI@aD$+u_jG$;xLAA z*KOfN{&)}!q54FrZpD^^uq72I`t{(t>BYS}6`gi(4!)bEVe&C?t?CStV8@3)UraIp zdIM6U$2&Low~2t)i+-wY%@@B$VK%md=hiR^BWf411R56L&~!BmpY?A3zC9vvE_H_? zGRGHe_mz@4$HT6R7fyy1r8pofhG%%lGwbu>Lu`KdlT0x5Ewn9RJrT5b6i+Q7NtXS_+|EJjl~71)x~ojs2Fmb6ftqU-K^w_{nuoPkljG5|C~sb zA^$ogLSg!WhOS~Cat(zXeW4-;t*dhicL0mS5zpr$tP?(eIm}Qf@a{>uAIA(fWlP)?}P=zxSs&& zzoJtHI9UiT4QVf18@3C92}nsicL~a06Hkh;TyJ^BHwoE|xnVM_Dnqem*PxS}(Wc%& zz~`+qjt76v|MAb#=EYt5q46dinPO-Sn$e=fF$}&$Mzy_*TXE~8M5fL|{uTrl3|HN5 zUGvzR!2t1N^K`dsHstWyc@(dcv%PnrkOx*QnA2yHzW~+%!1BWnYH0K#7$Y$rgGf*? zz_Dm8gl@p#@2BhfK7W$2Qz~sLBAfDs#LOGr@qo=(6auNPu5U zkT1Jr{8Ih&u_Jft-tX9noH_s|@7&nw?@-@~4|3UefF1s1jAnLhU}ApVLJ(<(U3M!> zKF6ltK2-8zNiI^;MTItqa4i z5yo9X6SFoQ!u!NCe_a6D@e0BiP(j*jl0j$y(}VYQ6o-4ah9gjmf6}akTZ#~0DCk{% zRUm=EcbJGb;cLyK)o1&VOLAmSJhyYe%JnVssdd41j<-8%iNIhuOb$yLXN3Jze(-^0 z4PwT31<UrFR>u95aI^^K$ zR@+qN=*373%b|gJz|l#T?m{mM`t4FR#<5oeio@n!D6J$Hk`I&5-GEUil(xe`qCmm+ z66wih^8d-UV)ZS;=GoY#$vXtxx+(V@kl!ILt26%?&uH;2}asHlCiM$TXIAL8`(S6uVwTsw~f4kU0 zfU+gft8HF9Eoov_qy1>tEr1K5i1Lnb3Xb4ecG_tAVNjf=@q&*!I-LM~(c0UlHlMkD z^_;6Ml~Z~X*7Unvlii8{R8eRs%<^S@aq+06vNJwhxymcmH$c;OOcVSj+hzb7l=f58 z9nv2HOkf5BcK`Z*9i^QBC zF~TN4%N~=pPPzIMYl-$07QyRwD>&G3z4RIcv1~COw%6rF6kcUneUnsv!cQb7iH#E| zzoaEsWxCb_$GOjk6NWO`G}bn#mA{bcW15IY9np#8Mif%g&E!8AKqtu%fkvf51TL&Y zbT)mOR@T&nKWR2tq6a7uA!gq=xxWhf0C?l1qa7vsH;ev1No4_o#Ls*zf7O{g7hv90 z+_ZNXk6I_Ob+4GmrcHd)DPkn9l(kRP{$4AMaaQ;cOLR;+d_Y(PblvtEG4yzGI=E`q zpFm+*^{=K?oiR2qxgDDa!TmntNnA6V!E>}fW6Kt4(+>vZt~}$px2SBue#$q)-&4ME zn|Avkbd=?@>qgw?0^30+siNW$&xN_DO^F{GJ2hjkvCpAFo}{`JapcIlN7u3Oa89gc z(J42c{bOi#O}zHnt)0+ut)~iVl@DcvaC`8N{HyBiXv^8xi_;-c5pD06{$4dKugG~+ z)vpFMMtZe-wX%9q*akD@&H_y^6bY&WkTWdyH(C*ld1uvuJIVa$qs{h{A*^Tl%$6K_ zA8t%xXci6iLV0PZ*f-Y9kEVO*7XL867m~gE```q{z-ODF7mD44e$jPd{S;`%6>bkB zCYp&J6V`yV_n`LxI<}lHnruw+R2sL2OyT0spV8a8>$EM7$13GDVqH+)6DW%~slM2U zkzbspwRMm#FxISn)Mx<6k2U*7@elp$yH~Hjf@4eYF6Gl_v-HsG*fXXELIE?ebO>>t z>?ed7hU48i`$lUP{XbS;JX}~P?xz@%<|ZhgnW0?FcbG##uQEO!XKcw3$DcJ|TS71X zDWRFt@DB=z@WDl*^5jyKg|`iAC@w1bRMTOA(G7b*_dm>27Zeo;$#13iXP*_{2rRR=I>VPahUMg!i*XgYDxeXr@|cCfwR}M~@7z zb9lEU-@&?}!})i)^16w0$Fq;Fp^TNcx&^dy3?iry(?kBYhM}x<3z@;cNQ<>aH2RaO zNX?xm+!S88&jNztkru#EHq;-a2CAXs888bHRsC9udOTg_@-QyN-6joHayV~zgxk4F z^CJ50B;e!!KY)%HJ;LIySUAcIm1?+fQg4I1eV3}b6@alQK!PL7!9ce?^+%bTWqwo_ z1iT%MHR&ALGi7~++B!J)^gUsgxqVHLmLe7BENG4n6qw0oIL2nf7%S8Yjr2)hhA{&-^;+gD84f<9`>< z@vJ70B3!z!FS-%=8`H|R5_r!1rlleXD$5l=D^KM_;1Ef~RrLJ2E|N}nP%BYfF-zSm zJO{l&iNBLx?Pxv0%)M*<^q*p-g%!=!#eqF?!7Wr4HaJtgzn1P46^>=7Xx|qpROYj| zdg~Af|H_O+Zu+-XqAnz!rWG|znCb|)rjPoOfQaJ4?PU3}IiX#_OK+cP*B<0B&YQk( z<7R#UW_dL>=P$c+<&gTjvc6z0CdXix~l)RYM7!R!i%2QGbR)SqV&saF?_P)M!YWZ&x_lFlo1O9CglC0u z1zfv>5zt|hvvoK^L*879)+`>!T-JlZm&n(I+;*D;6bTESX)6B023`F+ZmbzPO^c2K zS##X#KT=L7?cmNFka^jfqO*l2Xb>!iya;5 z=X>=$NDtKj5!<xs)(r=(_LJrZ&JTZoZUS8h=ykL!AB($!EoHKaISCC( z!)sS~#bc5O%~LCNiyliJ1etE=UhtmnTvv`HKK(|w3nUyeE{MDy7DZt(P!>hd;`cnY z`#Lw;|6yhV)Q!3t)nT^orRVLHgMMYap9`iriZ2|wVa_Wl~4!8A(=g?hRq^@GABx69wg zTCp6h+^!|ODt%L3uc#FkbRJ0meb;;!eck%^57hHsQ25yM&-7~B2UM~mG~9A72**Ho z+8js7wX{&kzCcyqIg!N2iOBO?vhu-A3FIwC_09)4cfH&tY(87$qytu*mgRd~isv5# z!Oy`ML*F54h*#$RObNz3!r6&aLti2o#&cedlD(-k; zK~jXir`34Ky>2`+hjj(7U#n?Y>slE7ILMO14b8_}SmEW?j(9uFq7xd88O^oRT}p|A zWc8mx_-KTJR6phnHo%q1zdp(WzCOF3(igJvUD_I$1;n`-he|sj#}N z?mFq}UfGXFmj&Ua+wV={$MWi44jPrEgJ#_b5f#tp zV-jD1`&3-RO~hAj138SFa1JpSP)E&Y?v+U(K`HQ?<)b?=<)b_XO5>=2WaJODkNMI# z2F@j|EOxCg^?~0%*x<^u;_jp}AS_2KRCoeZLFH6Y;7$A`;C4Md1l%&17%&`Q&o6&8 zm^4U2I}341fPrUirmwD_5A-m)vs*7iA<`aAX{k(1AnCS0X4$-Lgaj^zd_q`)s0bLN zP@vQ(9{m;-+Y*Fi9g8AK8EQTXtmIA4uVdcgZEst0@P+#CbP+ z-PK9{XTG5^j4yI@lcv@oA0R2OD?D~9mRv?lSPq@H#AY+uLR!m^Ou~9&T767T#+V0) zXdCZkV=7CvRak>Mg~uMZ2k0bnh<=aVQ5ObXmd&mEn1y@OTzdkrQLMfF;`G?q=`;I+ zv|MKEBOxpc6wHQkL@OOJtUnA0W2QX&D^El<>QP%p8B@pCw0dKKoVhum0nwjUPsfjZ z7=boKq3%$Vj|7GZB7S(78+9Y|xE^eM{M#H4JB1ecXCDq(S@#P|{^NP@22#w*@wY3{ zMXm4jT3t_!s}}^3wnC-UtkGPZPsW3p82Vz~Ax0|%+3|4x+mnPE_BZ^{Z3 z9g00Ytgf?J#<$%$eOjFm1fH0Q4y2f+OcsS@EzS0Ftfm|-dAu7ekH{iISi7Q66baa# zIOfNiOn55{=fCIdL6B?)_~>x8BMBP7$kk+LZhOWS45g3ip-VX{xF$W7ZSTJ1X}@pw ztN2MLP6Y4ufz;+I_c%rz;WV9I#{v7^ZGeL~ z+-C)bUo=RDHRTDdkMnJ@1SMl+r#0G_~HfvtdI`tW#$HC0KflcwB0E$nfC?5;IIX|9u06I} z|2nAgx7&pgUh{RoB~Jt-mL%g%WUeSdtv>{J+34NRD5NpRf9AC_j;hrm zGmB;LN3TvzJ)!&swkpXCX*{Fj^Vz2)zxU0bGap?rRE7!}`k>O1Jn%Qg3zS-_z{dx_ zG36hci_M^DWru%^dh_0#co#{(kuXy!NtarD!mv$}o&9yKx)Ov4$FwH*f$G^MhX z4p}Qfm{PZq84wmMe^y>5YFw-1f!vSuOX#kg;)N}G5dn&NOYv`Zq&U8wYAU+()Lotm&XgI>F2b|g?pl#Xro=sA zQZtSIzYn9~z$x;oNO;657+HppbiZ&uKMuBK%};V&R204>Pj45sT$az=hb|t3$1esfQuZ1D0`Cur6Slm|gqr5YNT*S+sn9z5Wu&VvD;_ zW+XR!j|dOKE-?PFPvxhvH2M3$Ek>PWmZ;}i8N`J&4=hixD{b%~aKGC{i7V92EB||% zd~osT|NBGW(Tb3=$2}m!8r-|AFV=OeF%_39E^I9qKZw|m#6l6SmE7&)p7P85+GL|1 zm^9ocv;x|jB@k;?l@ODx`1wj!ct&8}r1<~-&Jiq97DFG|`EAwz6x4K7`W+aM>8FVo zy2AGMnEfxfbSba+w=PypPLVD}7-=ezU*%xbjelPR-Sl3-w%DEi=jE-}mdlXleHt0<~}mo#kajy%6{v%wNVxM%tP0Z=Zt*{(o>Z*RkVx5z7FrqGDG@O3 z;V{v*spNH<(Q;BZLI^{yA_YPP7hpS&4noAOTL4;0Hzx;>N_Xjk5H;=7hJQ5)RJY$5 zfy<5j9YN@L_3yvjuYT2UJrv9L|A~l&{z$*AU^!e|HM;wouk4FBr$r7InQ9` zZa+DuRm{eGX^a1r<3f?vf)GJvD2V+#s{5I%oB(aw#@PVspcEGnEQUsxR_prlA4gJ) zfi^4TgQ5MLT{#Dm4Y^Jm@u2@EYGpDuM*+9}j$Y4nv?-N@ya$1)n znlj)yuOfE+$!9VrvOVggJAG+iVjHtloN~vVS1RgxpZ&NxUW|30IeBf2Y!TD( zWesg;;H9Hx1}$4-PL}*K%?eO+HI*(7L*YaAh-_W31eigFCv&{A_H% ztjqXUzTkZ?-230WtGcT0Am+h^Ex)=_|m~#_^M1L1mUPPWXE4Kt8rLcS{w)#mpB3 zxwvSlsQ>{fE=Z>v2H$gb?<{F6pO;UhdAg?05q^xMC(_)(xs~I*uXp2O{oiw|uq0#~ zTG6Y5gt7n`o_5km@gq0wa&ZzofMJ$Vp6{)`27&X3 z`7D)xpFaojthSne5$y~bPe1z!zWDCyzJAbr1KPl()Wa#asTG`3UPE zw?J5DjIbro$&`2$DxykDXbo>F*Ihh2l9|g{>=(N4IKQ@50Mp>}e?Ez2eMq;aDyw9lTUY#vGi$PK(bjBeJG%a@{fH21+tKw7W>T__i}i zD*RvNh~Btt80>{yR_mZJq*|h$`XIF z51jArCDdSq1Q}z<*yGq^avU z2r8;t>1g(ZmsVw!^~}UC?*9mz)v7_<{6|?d+_@|yzDv}CDpAcAffFjFvF#Vnv~Rpa z#i}#WN0sddxATYK$8)xi!PxCKXhGO5Bi>23le*;Xfs&$<2APFVw>q)y#CdXg;%+hX zdbEw$;1MsvPm{HF|7^wxW8idM;94t~V2hwZo+-UE%Fx7H8GqPTF#C~z&HbfBx1)CC zW6J{Y>!>G7N+Jb#rm#!S3hnCrd3DX>5S_}iMGjr)gRTpoZ8R+uuBz1@&X?EtU#W`m z+|hEhQDUWO(Hs5Hx3EvxVemK%Z^Cu4^(>qvBxz^X?Qq#v0aYm7Xk?bN+{)}0gR;)yI#5l^EuwCVXxB*as!TsN3|9YdK-ks3ODm_ud{2_z!=_9R zsQ^~grO8Ybp{&#=WDI7#6<^a_?X=^T@2W9;p}nDoij?D1LKdZIqj5zYv4cJvAnk@R zvjp6oJKD~)X?>RY6eS^Wb)4L>4i>soOnFf2kEUAB5I!pAH3d|&uLBh^N$6861N+)=;>isIT@N;31iWcxWaq{^XW=0|Gtyge2p zk+K*ktL-f(q^)b4Ul19?7`kXO*@X0SpF+r z7}#?STFL-_R5*%*x&)8W@iu<=r+2nf3icsc`poc;^_R`2{^Y|rbQw&155BUbVu+k8 z7q(GXQDISfgc@@krz{zi1PaL<0Rp;Rz<~ogE2><#4KQ?qcucR-c{|5J-gs-!`Uo@b zZ#Y+ZmZzROxcy9l#E*$;=loa#Wj((PsGg8ubY0}^DlN#h2KVq>_YozKIpz@I(CzfG zSKmZN_y&>IYdssw#ER3$or$^$!7)BWj`!bjYt~;rL;BH;gBws$2JGln(^RY%CSS&W z(lHnsw!VE9p*3tKZ4a;q>EQ?Wt3RKj$fDRWhR>yA`jKB(pWxPy2;cyw8u^w{SzNjnYxH5OctBvh8H) z_pLv($z>9BirRK>lPUB;>EGV{qs+omA=yaaC0%~q-0W|#zB((Q)AfoEBo}LT-NM_P z@Xhaq*Z+Q6SK^Q0mM{$vvyHu}(UJ<>9$Q9fDl&0#)u7w!X!}#dG!Ed0Wq1Z+Q`B|t z+iU;+(76oO2B&g-Z&LO;*0aiD`iC{;1&4rA}CI&PbeL1hdC}prJNVL+4WblSM zS!2YztRp}$DHb2YOV8ExB4_+h!1O#yWud5pAN}>8D^C4H36?hiW5at2G0c44p5JSi2 z&(_S^dtFgyaBDn7P4sVFQJafFk=&fuhhE=yg^hqhcJMOd^x18bGXeDgBGBa+N)Ij0!1X?dR%u zxZ3HB{VRH(8|gz0o2{x^1r~WcAN7M~vD5f>G z|7yPk6#;=Yv7pcAKU`i?K|krU4}wlx#nGFVAM)8Rp!8)=X2>yq^Gk1(M=tT?AzQq{ zSBu8T`Q*$=-=4os7O5+aCx-C)KbH6%Gf}8|ph_yE4B8T|z$F{q3#$1t%(d3uerpu! zjuuj>_sZlQkEp**rqaENx)%L+27ynmvf!svhw>dYA?lfrx;aUn=z;yCswi3+?BD3%%?xh0ig|rLq40{)^1D-sX&>oS&e(*xOf=75E_wI5h1EIpnQT2=FV=6XJxUq}9-mVjx+i)m zqa-*AG;uuU{QxW66=rYhb-)MUludjGZL#C}1*az@KWqs!vZSN=UM$U9d!8ao8Td_# z-OH7&p8#N@~P>f4%$04*M+94qI_j=Wn)d8 zDi34(*t+}cR?^nBfz)$l9-X#MGO1wFldO~J3&O4D>uc>9I9>O9vIdBD*+)vy#@q|_ z$Z>We+0vS_)k706Bm&h)k}4gKJ3NCOZOle8hux#s;Yhf1aju-y`}}6X z+&`da*c;!1ut{Xbu^`EMq2+F76Pj)VzJAMf3EjlHJFZEZ=60OcPry&r&A+xIze4s( z|L}S8!H{#$27^|cr31^Oqo>X;@ww}hTdUfi%HW?!q}r5;qLRCddG#6~eA?kAjbT*= zW~&onZTVsV2Hbqh`<*h!&n#V3Yz=RCWn?O~z?~LQY0C7O2JHWN!5GS_DMWdE|1`$t zvu^FbVI``Jy*@@Qinv1u?N+CvWw^)dPmRpClrn2AaD)Sv3|XaJje5#^#Z-0mc{+y7 z-ct4?L~%(1%q`sYcBgBgk9V%?sA1^|=Fc!w!mX4X;QJYJaa@+4{|%sAM4xMy8IuiAuKo*Adl-)WxFk0hwr*g z5AtAEiYhbM4cS1vbf=tysdZij`OlW3o??)94+#fON(fJmyO6IsYx{og-F}+EH`43r z6{8PW4bm*%9E>UV^$qXt+yWNNyWemI=u~>Gtv@Tf=9ME20^Ml zl^gedBaPfZe_b5_HI}fInzaAo*^ZL$sj?2c`BS7XOY*+S0-zqB=&YvAB#Xm~$s+h1 ztmZ5N^_5HZVoNE`erUPeFG2C9zfZUmN+)Lh7ig_3C9HT5?y1Eg#cwE^O ziXd{mwbfwFZAs>N8XPhR&X+0p`#STQ?YtD3heX)8r7bnQ7?42 z&x`#L2}4Oe>iTwHE{oRY)BDpUMjk-8 zop8&nh)()Z9Sgtde~>y}Jfm1L<-4pHb4laI+?c8)Vz5`h-RROQF-Ln^BHr20vyZrr z(-I5c=525>w*EEV)YfD0`nn~l!W;kYZ|zO{YF4m3SDFD4MoEsFKPbd)3UH3;e-@xZ z&;?!+U0ljN&S8uKjq=Hi6ctddYLV}=mFTe#3~0oRC5YuSMcu?fBxzvd{w|VXgr$*S zf_EE*Rpi9b9z~Q-YfvDhzt9w1By342=}yn*DJP|*!ZQCW`iRL@NH%UopkIACL*a{; zI(?-J45)u4eKt27Bu7Nc9o_0cHXU2vu;`pgH^1?vjr zHUBdw!h862=d2eI878RJ0fBX==Y#6{igp(Zjf{#YsJ0YTWX1tKy{)$Fa^i%2 z_M|oYjfu<3(d|Rm%U$^b*%odT(@xtj9Tb}x&%?Cqyc9$fBFD!ooelsnuH84c*eKb^ zEd}s<$~7=8{&mIa7K-OPfrh^^(Ym4dbfqCJpmLN(a zz!QNjfbz>|6@e9p={`+TJjLYR@;d&Dq}MkfG@BDX#R$ zSQPNe?J~X?!K_3|<{0D6@GXWVXnvk4jv1eqk+Bpr@&qE0o4pUgtrtulclopz*(bu5 z<+7B$hG%w|z{#zVd>jNFzBMLaENtowDabp}L@i34no7iB@?UXU{I>}~5brJdj!PAB zbi%FSM(?(q&c{!*SRL|;lWIduNh1ag0Ch2d1)TIF(w8HP51*(?>Of$qwx>TQH29)h zobvP^;Tesgm(-g2D*_?sPi0yS08Fl@m?!*g(6+G@skmr$QGLc{d01%e!`Q!aBK>~x zjOH&2YQrI@_&wPIIZQ?u7hpu zT_ma|G#InGEUb23ky1QK!gs7Hf5=k|MsxuaF{SFlS%tvAxquk) zxpT~avDe9SghEmVq#E9Bv>XpDzjSig*Lt}8CSl60^g+8QJZ}{aTCq}J3X@3(^jicF zZd$EV_3QI7{h+4HJ8)R^$*+NdQj-5ZA6n8BQ3f^AM5`((EjT76JUF7))YpbK%l;`E z%;Rl8Q>Z0m+bqkFe`cKxIUc1eL=);W{M+X3&ys_CwWAF^o7sdLrp&8y^_0FNb+aVA ziq)X*0s?<+1?qweiZZpU9Rq`lWV%;ep}_gFOy(ZfV#Vly_MwZqh+kP#c@aU_21Ee? ztmFOyGw5%-NWIj-)OzMDR!-x{6ihK!AZP0G;_JBV)B93XFXEYwQN(YdXco;JqUbnk zMPg%9)#Sw#0Q=|*xCB>6L(shu#Z*kNfNgamFOiH zRQZUu`T6VbdEh4apwLsh4&E!$hn&I}!MWHiq5)_T1+F@HrrPk{W7Qd75M|_U4W;E( zk%hImeky}+qiayq!rWmS<0{JkWoA{zfk~Dc5jl;j7wT2_ioPnqubP3mFC$B^y1Q^u zBznN!w732xynEb?^w^;)03+mQ{llTy~ysk_CaO7@ZVI-J2h7=6T}Ts&N2iC`1W3 z+k}+gZZbDrXkO{{Jk;vLufx_X-Rv?bNT4FuQTG~**JMx^FJMqIf;KtELv=oq&oyE; zomGLo05opxH??>m&yQ=h#E%0~SrS+?``y!?05pWUw|f{ihI54BO~HKklhW5K#sdK?jYG3UsiegQpA z-uR7hIuG%qccU2x08MB~M_T_2ucs&&_QBsowY?;~O9$r_HY@{j0}Ebye7C4e4$KcDDYoIOM+1gJQP{;5{TwHj4I~Ar*TbTQ$ zO%vl!%}>-${SBioO1w0oiIA)C;0ej_VjV8%qLWtEnDM+%@YLYm_3-lL1pq+7sGGte zLC`<_``sn^J{7s@l+mgo5Lj#sLmASw2Ne7mM?^`Z3TGI-|CV=u$d-7@KNiQqVhQ$@ zU)17UED*fAJw>im1&K!hXjbIA(O`J}H=yZx=v%qfs~#A4JjPi&dZtHo4X2-_uko24 z&zolbiS#}cvZ|_OQNXJ%Hsu%2ZR?olx*u(@nfR9}wB&l6Y}RqN%MkbvKU5*Q_*^tj zY9PAnl4Od~pb*#?=&_7$jUpg`kK$yqgTAa%dUR&ss!8oZs=Hx zPqtEGCH67ytyq3EKc*3AJ$#ir8=DZJU@uBxEz};TTUKe>w2nDfZ|alLT^r?Ud*Kpj zTc65j2hp__gQSbo(kM&9BjYh6z1L2iH3|l(755qi6gFo|Yq?AvB9|1Zbq{Z#32%B$ zdDG1V4xlOOxDJq*MY1S?yS0nItWvT$d>sCcA3+0>rfChzZ8|fzozCn*cluCUryyb! z!Nnc^&DFkw{_x8qcR1GDt_zU^{R-`!x*C@)zI=r+NN&slS_F#Uab{oVg=lT_;d-Y2 zd$X`5&9G&=nQokv=RvL*B8oOuF8{HCQHclBm{20&u2%k_Vl7w5djI|w+TKEXZlLYE zkM_Xel^t}4Drfw0AbB(dGn2OX=~F>%`;SJwAfK@Nl6c)q2Oemv$V-Or`dwG&mtp0e z1(poxAjqrrp`Ep0g)dhTqhE{MfTPOw_n8@uUu|itquRO#&aewiy2|M-m-soOuX{jc z(B29~ zPwb2?QPQRv<&VDLh0pinZ}|2Zlbg z(=%N_8^SOP6Tq4(ORGg<*1x zAyI?O0Eznb(62scF84vUBv}Z%tFIL_5QydY^3$DnaQH6mI z`7LoEt93+BjDj@J?}=_#=F0X52Ho%==tH}6?=@8P=HT;(^WCP+Uh=D`=hvCd4-`za z&O+RKLz?)!i6urcci77XByRh82h!BdPfT;|d~TarNBnrSZ+fSwJG1;O3e0Mt6w;og zmGlEFyW_Vk-m-B$-qpmx2o^Qa@p%y*A?+4F_g>!o$-n7!Q;UEhBncaSiBd1v-61iX z!bE6@zuVs^6E)w_{ZHuqSE7b@&>kS3zdrZF!N;$}?Jwdc zCtJ9PDsq5!WyK{?INvs@+8n#>86A3&xXX%PMqztTLQ&_rZ=IGj@_UxiaZzBZdEQlV zRncKkbGZImYoy*jEt9 z=Fip!8Cds@q=K8b2V0W10hspaTGrD}L5%5E?-o6Z4s5X+jI(K+65-*fOKzeV2}Ep1m>NIr->WdxSThAkwjw zwl54QuGzpxgG!eisplX0eiMl)?lNhla;vo7S-)_{-Rg^E)W>mvgy`3m6v+I`(=Fo5 zfc3Ak^f9%DOMnsFDVK&|Ys-3ZnBJT|L-Cy)4m?28V9y_wR=aELn zyJYwnot5gXazjczmU*X-4#=23Ha^h^&nCyTtx29UJ|izhTOyw2vti@2$kvh8Y&mSJ zv7hpL3)r3%K(t!`VE8V%PApb)8A{8tZhS4@7`g;!_^w@bb8aj(#}rh^h8AvU!tvHY zgnV~f)Rd4ph5>IK$;TG9CuSr?F>NVcfx^r_M@E+?1_kB|k&yHiB)gf}Lt5|bOiH1l zRYXG=)-*uddCDk1c*F4}qsq{)Pt?}xc_%1Sy8OcfBC|6Sq(G|QN?t(!Xw9}`l7aZO z%}FtyOHRQCU98j#2L--b7g(y^<-RG#*fQ0Jp>|$hpOWtQJb1QFCyiLSP8$)pG6JxM zpkwDk^Dj>*Hj*-`rCCLd6J{GG2Xlg>5Rq)nfeOfp%i@=5p<@6v-04+{z+KYwzvp3dz4!1c))91Y41+|9yZDwqst7BsOaEZMxKlrd;wxedvyDN>d_ zvd=IF{@5}O?&u6y<56T7sQk|W^7*MbJ&MO9`)Ax@kgj#NJ1{dmXLtdO0`A$+KtZRBkkL)HM zb`_z4wgJ9wkDv1zNChaPF0FezV1b$p!SK&}ah7Sd^VmY0)j!Y>@&(gLS22=+j%OT; zilxeM_;g`G+vwfLe^8|i5T`Ggh`(uj>aJ8DcO&oJNmFZU77qSuZoV}!3ViH=-+saF ziYolf?rC7)s``>C6y|oEOqTz?%dp>yp<2-I>yJ}a$sk?57y_R+SKz%;S3%QxE8_}cF<`Yl9**X_* zl04%P-a`dt79?gxV(Zb}IdLgH1<~p(|K9PWr?Wa4{^=Y$Rk+u{X7|hVi~;?9JCLAB z7O^P3XGe(=DK{?|PQ?ICe|AXmoI;1_gZfQH>cO7fYG^hWY?T3gC-5`;B_&@IH(TVS zfSu34_ij#^pSLg+OZls_un_qA{Y=>$_OwQq+MD?n`G-&b!BgKn2hXyQi(Oy;A_dVF zdjG~191|*%>f4&*jeiq;=r)}xTQKom#8a*?D5Qqhh%5B`HVd?=Ib9s>X;!wifsM9x zP~C0B`i!OJ;>qItOQ57pb0!CpbM{%7o%2$wPEuG-`?uy|{0Y$e*xr2zs1wQm^(tl5EY4 zE-&*VI2}aoF%j$)MvbMjW;bLoRN)b`tdwrgjwtCL$3HL&NX5SxR!?!U~-$hnyc7hKci4M96U=%2xh?k+U$;20xZx18oRFN*YO zH*8Hu0}CQJuagauXh`>C+vwSRGU|e4&3&)@we1CDjYPHr>yS6suTVeWAAJZ(|2mr2 zX;BkWu^a%-oGQr~nUl5t&|=W?MSe7g!#N567!A>2CtjgKGPu~L8uL2cqDt15KLqk7 zjS{LyO|j8Qz|?QCEhOjS$}v8rR3gcPcoRYZWf*da2*x#ORP_uuGnVGj*+)A@;Tc+{xbId=MSCzeLG$*V-o&8K9Zwo8M{$k$ToHXGJ zootx(@7&?7j780Gj!pIM8%rEgzcS`uA2LLh&Z4r`BApyrya~6ruIfKWlEKDv=0KpA z$n6A*Yj`~a@rdrWaZU3|LC&&8%Rz4^DdQUDw(Ier(GhoY$_{)x{c8vGtDn+x*2R`J zxx4jw59=i$%A3p!IKzL8{XkV72L`SA_0b>J^ZeIZsvL1SJ)Qq*=gJo|>l=tbHML}hoo0qpKCaEH z0o;0@(j+f1=`H>jq2yAHByc+XHzF#O6Qsr!>)8Js9zg-p-`r+Q5;wQ5@;^s<3PL>| z32hHT1<7>-_JL}%aIyZ`00ganP9FKV*%aD&Q_2-!22fk2e`&ED1ohE3eui%4_kAU& zX_)UfgiUo4!@6OWlyoeN`(e(T|6}T{!=mcmuu&BSgHTdhx!R)5FHm#b z^rH;%hB)N7&hhHlVq`5C;%CbtX}!$0T0xrvqM!Yl-a1vp;O}sb4@kNTUdEK5f=lU{ zapiB*9JAFexn{1*T`>6C(Q3J~u1Ns41WZ|pJ&Y{*rKj@8~63Fh*+Pya4V*|Xqfym9_K*}p&ntb;uu z7oVH4)5MWPEzuNRJ2AK_O3%1<{P$GJe^0Road{l2e{Xu*vmgyVRmem2kdEF$xpN2c zpb2UC@x8&RYsl{{61rU=;HT2HPOXqm`z^|TE#niwQK$C)JC07f^Byvp+TnU>Wo#Pq-(yXX;U5Izo%Wl~9FRzkJ9khbGSU9U-N2s!_)rIVv)Q3pkA zqe){5(|WH8m})LRPrJq=y)$X~MTbuEl$M+Q{kXyh|37vbT|L^GqH2l*sS|KK{&b~2 z8b{Lb;9Ze-y8W-woNMwA-d#ZM0G}--8Y8Z-n6IsGIM1BBYGPJ+r^WxxNsbM37e|4= zJU?}Ym&LeQ(i|!^pk-K8&C$rL{w@eQOgeoeqK>r6Pvi8Uj~aQWhwiEjIm3bry_oD4@=lpw}voeh#hjPnct0f$hemQ3`O0g6~iaI znpKRWRgbbflegXdGGe3K(Mgx)u|U%|fepbfE_C%f4SkNEv&5Yb2OWzbyf4T#+zIUN z+hUsgX5-WvTV|Sa!FsM+NHlR~c^T&?D_2n)G7fQXOr1#9qG809GSkieD1K35EI`|n zYP?Y=1#A7dgg@E3^A{kpJG?IDtj6%l2AA6kFJ_ix|0&2ia`-Cj_jbQoCQnX_F#P)F z^sVtK5BtdREL>p1#W7*`A!Lg75+&2~n!Gnyj>U4$tz^5bdv-^$M3H=+f3{iSkLK~a zogi*39?P4jAE*lT1MtqSnToinQ)4Ia-ADF4RW@JN%HjL1bcq6fH2d3~zcyx++zOnNNz@4d%2wG#b0q_Q}h;rIX}_f(bFHCrtgoqD+c$>{k)tu+jm<8aK%Q zvA{>l9n_SK2bI=+qO9M$jsnq<<=_!6Y90nMA-;|*bNs>E6U{8e!7sN*C zTR-qZYR0qzg8=wWrLLvhj`Pxo!D(W{XQXL>R&t3#DsJmuI+D^tbfK<#$Wh9Take@? z5qqLuu0jX=Ha%^n>U!@DJzBdS^`?VRP-4uzn&dUwi~a%PpQBcABjIzWlZCcE)iGh- zL4%lrZm^&Ql4LT@+Gqc^Xp0Z4Uns>t>-_KFC(t~Rj;L2Peot}- zE)ob=qG(Y{7$X+#$CL=V_xvWe8$ZN;tipGqYl`4a$9wSv*S=s~#i4-I19p4*(bjA- zI19AqezMJ!JG&5TV$rrAxu=y`V-e~$_oEzK50ezQV?H{HMuQ-bA)#A=Xf&=Kd;Rm( zcHsK###L&6GchCZ93Jh}Ex1JlI)^18R&eJ{VnawE(~n-E`psR;aMGQ-G*!M_&#F20 zRNsu8uyb}e|GaoZ!}jB^9Y@YHJ#KW=SB5G>dX(lHDm^?C*LnzO&MkwfoV>Hjbl>!2 zDg-<9jz{KWFS6ArkuFY$Hnd<5^nNpk1bpVtG29HbUIe^~VvOBHu?-8EqqP!=CfyxF zfq{2S=_5~Lr};&j76gddjZ6_2y!yt%2f3mIVIy{s1=Sfz9XLXxCgNP(xCBpS!hNa! z`-gC;U3yttVp4^{S?w1FgG}PZ%^wrSY?nj56B`(QM(t2*9>|OBPA?jU5*Lz5LV7~B zX{kXb5|EOHLmmJ_L)wWR*8QV_c@w9Gi<2n#U(TVY-ODS&iUv-&4ej%z5$^6UMRZ;u ze33u7+u;{Y*rANWV=(%lX|Bq|^DPBx(ITA`U6cm<5e{)e9(UxsaTz@<5;Y?`kUput zZnxJQSr<3>R_?v_fjuAjdiB?WuKKsp9&fbc0a_hFZbgnZHr!7j74c7TR-2M9x=sp+ zw&?d{Zo#QTx=3MIe_|6Ip4WEpMNjje&fCsaatF8@3I{f&*Hn+PD=W3}b1Lhtrx~*T z@`flu;3*NrT@Eax0sLaOFU(nM+_7Q_#g0|KAjhn1PCVI68lEOkol8@Wum7zW&d3}F z{wpBQF~o2D`Nfa(@!9Iw6e$HsYM+JKn&}U3Rj6L^)+^7zCOVvBfdw#1U0#X*Y{Kf<~X;KYUb zf@M6sz$_)qeJg6j^o^Mey}`$db_n3>RfRm<*El$D$hCcYnxA#{6bGCK1R|LF6`O?q zNM2XWW})#7F)m1YV0qD*MT>brZz{mJWqZak+$OezY_U2oNkPM`*^vM-AT%sd8!or^ z6@nX>mzznS`&3b2e1GgDlmJXLUG)mpaAW%k8Df%5rfb6AlZ_wxpY;j>@jNdITI6jA zd_ag0m&9zeD_?nQJVr?ADtAD`P{`{-ujsgwDP1eknYLS#x@D$X$&E2&giP1W^q9e74cqjJsdqKfNOJ2@A&12leiiE_NQX_en|ME*j81=OjNp zii}wo)XA>tW!daBy7I8&M~Sh|FM<_}6iCfHjE?$$2(uKA-XZagca$3qcgrpPe^B@Z z8G}4z)_}g!*YQkMe{7YG&-O5xFdQ6pxjR!KhQ%S#FbZ(lYYuhaU5Te2Kws{tN`Kyr zdGRLlIu*se;V$)4Tof+XWgn%2|5ixdWGZw=`7>SCr_dvGd0VgN)E{Z5G9^$?YzQ1* z8PJ0r->2GX348>sJnBp9M%>N|emlZxllpxM_ESB}3B1z7i%Ys7iHoFJ%@1A&HQM!$T6sY&%kj9Cij;vd<` zkjc_d?yTHGI7k4i{?SSDnM&ztoymDH$MB{Ahk|NBaYiG4YWRTWT{*K;J)}eN8Fbbu zbnh)@K9mPM>YjyPAD6Dy4_VCWZ>T^`QN5f^O~b%HLGIusF72ZyAcwb@%IN858oHb^ zbgCQ!q7!j{fdMRSsE5c82b05)SZx(_G@MZgqO9|TebA6ey>XqZ?q)Mz>hVI{#it4E zKy97bT)WZlihvA;42;%{Nfz}S^CQi3V%90IcIWi|(}XVRBE`c5YjtnxWFsTXYh8Rl zM`GZH?UrqU&e+{BKF&)Xr$9mDOAGSsKP;~i(GQGB4=hRWj!Z`?H^a;06K4iArRIVhP^`YWj#Z!=aH77K*!rxcT2%?q`Y8dKu^Zz zY^ge;OxV@~?Nojnt2J7A*F_f_2(J|2=o6gyUiyPLe{P<-J?vH4QpFS!D)}HxW~;xN z;Y?=h1DY)JyR3+_HX`#oi8M4%%8_9S&j%{fU4sdpJ-@zuY3fwK1r8!cEghAC`Hhs% zVakh=eGw|LAbFKP*d6xbV7~?zd$$Jne79!26D(VPN!RXJO4o+buD+A)eThZR^5d5P zWAu_{o_N-d96|{%Hsf#LMS|i{w`Ph`T2)i8L9jqo@nxHv$$P}h1M0FRy=FPpT%$y* zQ2cLlimK!U>pcKnD^cJCT;`b+OiA}+Su4C&3F1V9q?Sk zY)5pdvYX>>`zR}mtUO&xsPfL{%c zZ^}{QIqOD15MkRmJs7`P1yh}Q6c|~;hl@4yCJauQ3c1+B29|yW@9jN0Ep#||F)8sx zN1O|8w`HVR5=2WB>*FTB!T~Fr+6-+0FCCyhW2aIvwlI=&${FC&**@6%MsVL;Suq}q z4zkNjNV%LN~`sFZTdMYeU1S`gc5}aM=CNlL3Dg&2;=$hLVXi~70 z0q8)-ix%Sm?P?EIB;4|a)%_Em5{uzS%JX8W#7{r&I=<^M*;X#`f%Teuha;)qxC*|U zpHxHU>q;oD_2F4Esrd;#=jE${EAUIfiuy$t2m)3f)i95jSJJligP1+4?$`4a^@cwU z|6wU~JBMF?Ki(&<1_Y?1jVOd@Lq394T_qmca;Btamso@C@=>}VV%FShLn>TA#r8SJ zhi^%;1}WG$E_*d7dedi_vBn%Tjt3rKp;RNKZ7V&M8?YYraQWc>fub?ZrjW=Nq6BI@ zII;HZNgA6krXh7BpD;w+c8&jj0?%oOX4!M@XNDH6e1ir+jdB?3k2m)I@%%ewH;a!rp%p~$xzV6z9bg`M=ys#}Se*)i) zsF|jA0F3E0;CvPR9CZWs$GeT6%XWFL=$hL%0J|2Y`08k_Z`O6cWUMne{t@Gm1nhXQ z;U=7b`mgV{g<6^=8tZw}vC9-&`vK0>ssXwC+yKlK7XL+#MSjk@=C`x14b+32v5#$Z z-nQ0s<9ivRzOqq&(tT_|unk!MapAK&>eF^sT2KReDLWF_B)&bp8+dtfU)k0pWx0B0 zUX03HG1+n+8@15K4pSOtzb&WK%^uwp%7%WX0GVttwOs)|j_RSG2}23hu6JaUMleO~ zfS|L&;}VskMn-Z1FGBT_pDu6G&$7Ln2`%q3UJ*ZNuU8%V>v90sN*V9I5=MMtVk?u( zjqD-mQuL=w`vf{<_X^rbLv57W_IDACs&+ncNE%9Pe@>8X4DL2+`lw0+MjI08|0|4e zDuwF9aOP8L%e(ETy#66P+L|!qFLJk)KsgmAZqym}Px>q;%?`IUcUZcvurmM7Rv&|^ zzf;AZQ6WVfVNaj7H1{a=^YNRMpS|9IkE#jLBM@hwj>)o8dm7uXSjt7y+Bj+++igzC zIo{~t0?j8TMjDtR^tjbf7jc80D7cl9w$}XV*%2WcTS80I*&B1}_U+$ z8BbtGaI?kcr53?bwSw83{^Cot;S%|Sqzg9uNK469I>#O}M!f3Zf=S8Df}tWZkQdiD z-QH1aolpUMnk3P{G3At=ZUUj68!6j+b9D`D>wQcZ1h(>4&ztSWdVTII-bfW1-lv$ zb$=7brlmd0OtLy}TRr#&-HQMOVs#hJorm}Rg?)PdjwKp_#e+8qu7ze+UlG=>{1UaS z9BCpZSG-}0NB9iRUT6Nl45pHI=?Je)tlxCQ4oj<3C}30drAji=rWBQyil!bRwu3!> zuB1-TZi4 z3JQZx+3hmh>Mt=qUZ)OAPyn>b<^AgZdDH|v+9S2+NM8Xp zGG#YtEC8MaqJk@SFgJ(m4UbK^(&Ycbti;fTiC|{DTDgiXkQq*7NP{mNoF$xS5bZ1j z$g^>d=-O|Wic6WTe}H`7hQi4R=Z73}48VA^|9(XaD!vIC<}qx@c=3>V3z6R;dlkMa zb7;6CX?6?;mwE~zZprau)ZJq}fgR)`8L-M)V0gC>GB;v6q)j&yK2YsSMx1Drx38DU zzXlw}2?!~sr=6{cLPN!tjx%*OG>A~lZUfrX&K-n2_N)!?4niqdvVnj6+lrR&vtM(q za(Q+ItzXFGJe${1BHPCBHvXd^y!EGw9G!fnW}kRMi2l|6e@tE8O_TP8=gXs}z@-tL z4w44E67Jv?C*vu0Y|^*yX~z_CdvV&c`9@$_mMwWMDds*z#c6MCcJFR~&h&W`Wc}xX zS)=j>D6H#JP?0We$m$w0?K3KB_V;fQ5$l%KN`1D9<^Ltpj#64C@H?mEZ#9eBE7l^^ zvt5bgV}#>Z$O$i5T|m&X`QyDDU=)+`)_)6=tTF9T2Nsz5n?Qc0sD6CvpLn!w;LSkG zC|M(6d^mnU({J;dLl&Kk;;T05Gi>ceGcN4Ub6;nw3H$#vFD)8g>w?k7TQNE~z#clL zhxp_S2;5OK%NC}PN)D5~YY2*gr>Msus*pEg@ zmGU(ksKy5@>U1IJnlMvDSyowk9qM*YFvYB)!JOJfFYGo1I~?T6ItELK_e&Y9SMsX3 z&a>^rIPXA$rBLWmh1~p7>4IfrxobwLE#;fP5)6Y!G}+5!gpT#P8VWQHii;OmsADZ~ zgh-Mm^BQ->GhEJKHo)I_e8I&i?4`hVPaz#L>e7ge>Jw6lgeO$?PP#gdOD}>dRT)6Q zXz)9wA3qQ3Kz#HO6#y_`)cmp@`t+QOM4uMcB*=wYh?(0^vl_H?R;EdmPp5PdN`~3T z$r?g)UUU>Ti?FnO?~e6|0B%az1LP)BsOmpI^BoHw5os7U1}^`O#e!t^HH_3TvZ;@& z9DT<(q$9pa{QaCJ31qt-)B17uk8|4M3zB4O8h-_`j68LV_AoY=Ze%|LW1OOVU8 z5_2@~=*YH0ey_})=v4+248yY3wRj$IpVa$j3J%5j-3m64 zeXKY#UhJv&BdhDo4D>#$l1ku;%_AyeW-CI&@#%RQ-T$^7%(`K&H5uQs?pQOWOef`m z=t-uJRSK($^sCMO-8Q)4iZ3;OCSN8;o)P_1xUSI~duMgVU2(rUpad<$bt}H1oP063 zY5%6}j%e5MYZm1dBb85}({}9l*Qtwssg;<#P1ZwqA(QB!qZmu0p=QH;WBZ0{%deSm zPVa|V7FxGzv51fSZ8WnO-!rCHiCvk2z`I*F^OSs?JCI1UYVeun-C7aIp&CZx3D+wg z_k4=0o;8)hs$K7AP*Xh{mXYD+4);0>(=nvKAxO{oq{_Tl_@7|XL-2a60~t-IiSDtk zld?PdIUoB&QXHy~?w-w@6P+|n%q|Z7NK(Ke?dJbg=X~@MVyI^3o81Tl*492!s_wnt zswO1eA^FwFCC@JH<;WMi7%}nJji`v)Clw5isX1gdVQ*8%&8EYf&%zK7uJ}abimR{6 zLT*An&UT31?T5RkKpQSU5i|~|u@k!Xl%`7=css+I$)$?wP4(y}%>6EDW>kERrI=c? z{ZhE$qBIC;QL|h(rWI{KnR!mdvfz$)nfpchON0oVklmWmZNe? z&X65SB726K5^mj#V#*hC$`KBgab)AWq{n6tcH$&dXnJerk7iNDzNS!_#Mv*FE-_8D z-6zoK-8t{!CHJsr_0gy51RBO6*WN8|flLzN`5db~??MptCI!8+LwhmsKX$hDErZ2^ z=Sjr2At?K>mwVV7G*Yq`*fc2Q_Xvxo zR0})Ek@5=_3S$}sfhDKuXH8Jzu7xN_ndz{gdFn-kZN5h+ID+nw+DCANDVYZ>*@VJV zT3~tI^*~UE$ZrGp{S5IC&eo)KL=9Im0vXZw8U=Ei3SO0f(aqy@k@r=V0^2PP+%>Ix zYenSfrL8h-mTdncHI4n`uSsx_(Q*29T{gbeW@ymzACn+|LV#?X=AMphr007nK8H@{ zv1_)Gt;g(0Tqc5l-!uAVw~c(?^AITJ8Jr5g29v=2uw%`X@Ewg!s+n$P@Mrb)$Y1_R zM2VZ$&eYLKCiXpR${U`hxo1aK^~N}i`=u4oU4a>u&N2*NzJHGooWDN}{DpH_a)IU; zZz*QYRHreS6DraSUjh<;WHaDj}^eZWiQ?uWR5Is9VEFekR(LYFF9LcaS}$9Td2G+#8;=vdoVL8VpR zt%7?V&Gd@YA1lsAF?YeTIjX^7{<@XZis;mDHzr_>5-5|5BDITgdP6^c9pm#uZ16cn ze22Kn)$f4sZGD9Uu6HJSr4)_Ek0{@+>_ie_Mz+`6U=|gR%K@Kw+p*O_i6wsndNM*z zr809_=8!)U<2&}0WbWDH4Q4E{xmAa6rFCfadlkMvd)`xHG*|xGLE%zeJHka_NUnnD z6Zf~1J;2OwuS}5c%J9L;CU#43qYtx{iu;l;!{#iu@dxcp46)CAx9Xs(-{knr&7TO2dUz_y3?Au8_AKn?Z(g7T)EEqIwsVSS ze!+04amA)f20K-F!GA40CfY0Fng|gkaZMwnTMGN*bS|v_@!`pBclQJ7-6#z^f)zsU z$y9jowEUlnUcJQ=$x2Igm+P{Ndi#ge>?`HD%|K(hSKX>|g~yo3bU*j{*o$~A=BQ{MW$BrPjS z7vkwRv^C;0Yo*^raz6Sg)$vMzo-!DVuepwNY3U%JJjmBS(GABtHEdso!vb>;Nj1hm zEPHZ3@^zN{?N6x7+_~ z8JRbgd-yGYdSHCNw1h`3Doc2brPr5%lA|QrY@ECaoY^mrLzFRVGeq#t0ZPY{U;8qO ztF*?5DndUoOP<=hJSdrJ(4^E6B2rlcQD z|CxT|d-z#UaZu122bq@N;ZHnue`aXX_GBt3l|KGkL{v~T)MA~e7;8+?JR`!cP&yWV zsz^=hRjo#(*F&`Up(X1Akk4<7#aXG=KbQDiCsq}We&j-p_L@mn8-&YUd3btGJZXtBDOE1F)DG!`Gy|Mg=Lfl5O72 z281aJU`nYQRv^IE+I9AzBukztO0)B!ARbicw2^eVTnGT~SpJwI8hlm$>g-~q4_@kX z3F!^ur`@ku#f^yi){?%Tyi*gW6k2=t_wWyMZf(|SgtLBfd=jt1XFkl=wyYI!T}
  • f;F>QW7eDhbc7A1;{`Xw)rvDKpg6Z;A0)&- z<(2xyISy#tQ?E+e39fD>a)}Py$}VzVH7GP|kt6>4rDcjgr4Z4x&;V34o6J*}_qio( z9`EN&+9G4L8E1=g2*M^@P}*MqCT`4ZJf`>_O`K$fg~4#@-$u4wdSk=IC%Zu=LN=dl zIw|SSf~Q$QUD=@iVIvH{R|p9GgbNms#~px zfa|YHFTf?KnOZNjH-{LK25T#1X-QQ*_HX99|eB-Iz6!uW^ccc*NWIJkIr~3ug zBO%75svo zw>7KD{KG|YyKkG!9nf4y&XEx4^>}KtX_@P>1}veusK0Jx!F4-BAvmdcgnD^!V1{gG$p z-4YR=SF!20(#D`h_j$*>c4EC{n?SaQaj!JZje=mXwWI}G#l}yVmPx7f6CvQ&%Wa3} zfq1N#8*w{4MPOF&c3n`bUJZ~ zwD<1&Tyq~|`}_cq@pNmz-D7dgiYrQqSxG$`;wcAayqvekem{q0qMMlvr?4$%&k6ET z&_8YuiTYMot8xz`EBGN076`GQb3Psi$T0Mzp2-;J55jf-&QxAD(mP z&i_C8V%EWjC>3r_ct&Rmp&S*QMDs*$wy6)AG~z#RaIW>H7-glE~>2H_e;|9C7jVqb2HY@G8U6^7M~ z>4UDhQc$+Vt`OU>#^{k4^-|C|vA6xBkhZu3TP?hl0hyByC&HaCbPfMBFwC#iMVq^O zq|I?#IpW5pQwr0rQpm1B<*KP&sBy7iK{4|TD^wk35W9Mb;lX)Vi2 zImy3#53o0vc|AIo8Gns8K-6SdKgR6NU3D?qv&s`S0j9e3H|#XaIOzf4$qAUEER)nG z<&s@l?%ug*)a7z2<_9@ud6;f3^uYD#!*#|{pD==%qd6xe9w9ciL*89`c?2Ec$o&1f z8N>XQWCqV?xn1txqVfb^uGx^qe+X00OYpR+Ip^%H1NX{yh{FIHS0kI%3qi?e5)olh z5k=1k$n|Mg1vlS9O&HDEXZu|Z$*5V%g;3H?s@bk(;{xNQ>#8+Y=)i<-({?F0*fnP` z(OHs9pr%6`Y}GN5l$RdqSM_uNJ#BG*2=v#s!4lElBxlS}OJ!U9)bbIgvwnI)FbldI z5F{md`%>>cF`$hJiW}N>q1zMmuWceU1JHI_r|D&X0ER5s;3W$u-GRAuR+!Tm$7q> zs)_`nXvkO#TG2N&zS0xVnLhc#>5tA|@6<6ro`yf20JzYB5D&a}eIREjX8!f=7o_w~ zy%L|{MmB!YBu%O2wMsv)M#^N<3qLXG2YW-6>5_ipqHuP9_O<0=gY3vEO`_DSNEb?V z)j&_p4?S)m*aS=TDoGy0IG|QM%8mQ=i$^^x$2T@~VCPrB+0jb+BrG8C>)~`=&(kqg zDM~Eh@c(P7lmtZCynUN(8X(f20wAi98bNmFNTx!6dc~CNVavC~u{ihdcZ69Ft;&`Q z5nGk%+$|~g_mkIsOxX!gL zw-JcG*Y7LZTwSfir;uo-L@AeO2et?y^J3)rn+0wbTQ9=Ai)iMkR$86%lH(dSh<=+w zTB-VFKTgY_wD@7Ku7L$0-)I-QN8Fq@k^gSIM<0u%OW%gzc-nHjUEc;df}&WO)1#+6 zO5*ejsAt1H1a9}pgvf{g13N;}>lCI8ZKsRWc&jHms#v@T|K(86+tKs*PVWU9;D5n6JSJv_)l1S+ z z=vmmTfY>wMg6Nt94L*emd8f*1!KGXV*H>NheVaQ_Q-nj!|9qe0cm6Y-tpOLelGGDP z%s&%u3}-pSN|36OG4$nLRSoNBgnZ>rob$&P9nTwXVVp0$-qU+4VD#(%*K9-L82LOd zm>WYs4Y=Nar;9y?ZfqL~4(ywb#X5^q%JuTRDZ+!mI)7#F@o19)_tbZcRT?SS)|}6e zn=BPEcn>MIN~X{y7vwsP|htrW6VYP zE|z%zQ*_8vyYhmv#hA?}PgH_~Z^G7@i%$eKIS$>1Hnmc63Okk>O(>gK$Fpf>xmFCZ zr5)FbE42W!1Oq7fcD4-#AfKof-e`UJ+u=xUswL`L zUAjElf^27?M9K1Sv1`5g%W*%j)jS*Bn71Z8e&dzwN8~rP@O7h<%5ts#cjXiu>ujTU5sD*ofToxpn04T*b%}BcbQOa;z>TLO7c>C^U`<`?Xnao|} zm8ANNHw)!vi`6pkXu2KNIh?eJ ztmW_aCi!{J+iQonnq+*R8aLe|jPm$MF?&&*OjYj9T#a9rlsXYKIaZ)e?kD6b1nlv# z6t|aYMJ*NgBy|pmaDgLMw4)Vu!vSw} z1c~*4m*)s&aGyOf9_-+D1}|I$>|-h2?1Ode=m9qgHnb&cYUZpG62)OQh&K^8!h=&& z`qT8>{$4@&*Y7lLjsLA)s*ANjExcia^_Mvn1%303`W(@H!h`p?=UQvp;oqVWX^)Mf z;=KLry9|#xk1?HLWkw@}fu)f>FOL;7hJQM=$Iwz0%f_a!g%_M^5uiSbl@vDb7r5S3 zVDFnA!j=@QvU^{sF9>S=#jmRlc6E6#;OSf@Q@z?y*mbIgn02=<*XmJznFx7Z$#>J}2W~@ycqIN!I}$}ityF&DL-!cux6?SFYI_}axm@}$>v1W2 zikWBaWQTp<*te7^fFh*`ujAx4I`F~V<2qx`M1Or0xLzDhTeYFZyU&0?#fX}2ADZtk zGOA9BnlTwKw++(6+_VYi4u&MwqF)7GyxQQn|B-??Q@yEv#M{KQ{I{I#YcvbxYaj-| zbGAmGoYKc#ktY zQev(B8suIL=+m4z={l=9zD6XClzZDOdQnp}G|Z^;cOSvaejZ2qU(%j+7!TfRstfE( zU_4mr{~YL47j#3U3QC%cul){xNVmf4!x;ZH*wug@?R$0{b(4E z*tFlnfZnG91UG9YhWpXG9hlyQKyFiW+*~Mg%zC$rEVLHxI}AY#WKV{r%$72pHM&z$G2zPN! zV}xSKhuY(X`%=g4ke}79*aEw&0oDHh`^ey!K+tD=|A*iFd)}g8SJ|M2-BvKqCB-Wb z+MH43whr^IxU@=jDL6K?wl&Ux%Lv#2?42XNGT?Q8ZAgJPujyZ)v`;R``rm*X{gA=gVLC(JoNSiw<$jtgk zqSt?@I=&Z;!p;6pXJO4W*)Q39DwE|K-#W9a9zs_ny2Iey(nE~tB!5!eR1mR%ug#V| zLUM*rq^{1N@rEcRczkWWI$%dxWbzfTcYzvBjs&_~Id0e=iW{)#7&OYbFzT4QPt?Do z%}C?U0cdvJE;qWhlP5IhxOGhte;4z@yb8ndQOEM?bZNnfp$xG~c52Rm^D1c3V+kAk zEkk;a)`kbzN$PsWL^O72b#4)Ob;nQkxLh?5RwB`zKTfrN&K%b`oN?%?Fa!K?P{rVQ zbo<$m>S^%sgqK_%)eNuO!FIY^`TlHVpLPdE-EK+v-`+~H!SU9ziHi5B%BN*El>U5s z#&M=3cg!_cz-Hf2fZ`jwfmY)fu>RSg- z0-N3)0LkV@k98vR#yP2VrYOsyF&U~NW%{XQvn%>_H%U0m`WkBIz*qotsnQE|wsbKP zn5U`~XRHsoTRJo?+jqwQdH;Ur&H-LtL0S32I@aa%edXXwcK?MZtT(L@P*;vr`(XT? zP3t04n zeXH%LSrCV^rHg+?0>^&Yr$4o{dNuQnX7iuWwC-S#pH8=RMH>>@Wsxp!s|^O!6Nloh zfYaC*ruuf<0PV{dU07P!f|Z>x0|SxQ>y}z5UW`GN6p_^xnTJ8phm>mk=R>llw*IKm z|0pip;m$WgUf8wyhDaGxV;xrxuCl^&+V-LgL{O6xgn)(YS!=gc$wL`v^wl9DSFVUU z@eCibv+Gwn9Zuvnd#rQh4tFB{M==lJSv+0zS~d|rz<21hqQsQ`6NEtye^WOEzN>u} zX#?7Rv+HlS;@7c=FiO>6%5>rrr+Uido3*PmH6jUBRI#rg7Zb#*Z(X@3@*bm9faUzm zO)(e%Hl*Fy{r>dV16@GSTfdc4*i(A0B zi*Dt!GJPR(z8c&2NvfGUg{9WX24Fzio(*nx*EN9O?$wHV@9M~=?;1xN3h5zjr@GRs)T~+5tX;+>P!!O4MxgXr`m4-s9 z9WLPhZ09q!(M=N%5fAUlCTS=v>v3!rLL)sF$G6Yr+c=|y>>fCQsHL=~OF(3@?pvri zGW`r@k$iw$zri9hpSw^lO--Bd70)CVAou4%8*WQ)HU2TZar*t=-^Y-|?z&)b<&RBF z87kfV%5!#bQoPkk*{JmjKJ?z^38fwV%8rmpKGWNhd3AP_^!VTtE%zyjVv1R@p=H$N zSR?qBLaX+5gFk^NOK7}BYcs=qvaxaHgZBPNvg^O)lhpgXBE0PnNi$(BINy}fudceo+C-brse`Ig^Zc)|nO+`eZ zE<$7XnzE9MJvJy?UkI4a`k0k+&Z*HWb(6t&)**g>+}lrA*eC9Ubqidzg9*iK$1^>@ z30bYD%`>_V{|nv}A*qnqDY7t;;Vejl4>#nBy>n&l;lBJK9aCF8x(BuU`cm0c;0DcA zLknOgUD$d=Nx_Qq3dv?jLG~?!Gq!$!*{&Kld-K|){7Q=_!2^wXi$iG3Joy<6{so5K z-0jIu(O}O?0MO|`fm$KS*a8}O;Q$1hz`Hj~w)3teb}+f9L~rwIWqEL>pxK+4ESyO2 zvRGGJh3-NS%xiXK?k;JCiboiZz8FOv1DMv-yyxv_LL%_=UiR=BWTbC%TtI!%p#o@+ zzClQ2W2XedL?S^=&^_!e@#Pw7*WQu-B4vEy>etfx{&ehhaH$&0fdM#fTToq8kZS`+ zdG<9W-&wZtF2_XH>aU&HpH^pg{718vi(tyJ>{e*`doXc(7ty2Px*S8OVFA>}P^)6B zX{ZCk#u>#9PT20{gLmRPf7+Jqo)m|+b6m9wST;!*CCZ#gJ6i+h@;~Xa^o14$Ybx>k z@g2w$*#rI!XLTahy(3=w?FRb)tI`dp7;XI5ghZelxNgPxYgnAcQ>%(^i;vFbGnbL) zw2$V$Qqz_>7t*vYTG|382LN)5{ZPAY_!4p>aA>}5Mtygaa0=XFb~yy4lfR)uZ5sv5 zP3*t^RU3MX6_0V~CGIU*lvw^wi|D490XNz$Pi_{T9#(qa1k$v@u|?FUKTLB%GwE&; z@Rwa+T-*Uopz`&`FZp0H{_W&7dQq1J_H>e|t<<&FsdA{hcAFSeYN2d}9V@Rj*7k2H zZ4CNjxJeYMO6U$gfS75wzqivK!-rsq<5bPGB)4ZjV+6kJiu8iUvy#wAX@;pIfQS@F zIt9p*BbHmrSb>Eov0B$ zcnzcgopHq5c&{H$SIH7=S!0EYe*@31682oH{ZQ*sY^e`ji6SWq_3&$#!%!A=uq}~n z=~O3&D)WsCvJ&yfpvw>G?6jPmQqtDrwo_sEDwxPugqmD ziel8N@H$I`S@Y481ryf$zWA(d!--wx0qz5f$MbR#mIe1T@r>ub2qa1v`bf<2{> z{LR#_g@^h3sNP-1@#wpi!z3jPEzrdWBH0aDM>nR`qi4{I*D#Zb?v6F(WFT~4OZbqs zXIBi!JY^y`!FGZ}SR$SQ_&{%pn0fA-@ zKlWx^upr-Rvzwavwb%?DKSo^tke^gfzyB9_c3Hi)`1Hy(I1jcZqXL|_sSan9CxwZF zNrt$-a&v4`=tbUsns|nXF*@|#fvjoiLqb#iOqGy>eI-)!Dm8s+xBtLvD3eFF*LZaI zc#DMt!EfqS-<$$YWQlx!FMvfnj^c1FB-Muo(ZKJ*e-R=(^TmXtsorh4ZRu|>#Cc%(nFjwl zXE{OUvGHJX^L{S=&6=0aKMsS4t-((MWVd^p%IEaewNv_)WCkM&T8afgV6=BtEp(Fd z_w@PVg0Q|mdtqVyxlNnol?O6U`Vz&~U3K6C|Nen+>aKUN#!YuK@@qOr&TQtK>NiX|bqHVO za!w`DTB6udo5G|KV?UcUrqn^7Hw3i#8qOwk;kmi`h7dF7d67dq<7RH`gvY$D^%^!8;hG;7jW3@p@3Ru-NIOXzG_DV&^3} zKL&he+OWl9o|-(iPI-)g6|ZL0%D?kb+jvy?U3N4u-{@cXLlm$UYhbq1+!dW+T=>n= zCHbI=-_^5>xh;cMaK`dCX=In?GHBXP24X0t`gYVK>C5O4MgP`MR*D9=kK`Rs#Z9JK zEdCEw?;Qw7_r;BWpC^eFLPSYKixQ%D(M9w`?_G435WSm(M6b~af@r&XiB1wkC(06{ zMU7R1#j3x%E6@ABzdx9rojdoQd&=jWd+wQ8M+9tjyT9B~i$A74oAp2>|5tBs+ht8I znCtwLk6z-xQ#@Ih7gp}rWT$H}AxbMnW*v8~ZCtjQyOEA+hK%~D;ufTKlY&^2Q$q|k z3WxZoq`7J)PsW>uU4vdpt@BE$)wnI=jkM5+Zp>GV1mF(FlS*0M^_8u7O)9Ag{x!fo zDrDJNqEq)CHE|3!Dx0icHPX^tqp*CJ1zWwA{bko8A-DzRy(eZ179j&G>0#kAMAONK ze|GU}pzq2_%a$zx#U1B@^7Iw~NIljSPF&7P?z_SUFX@{5eyOVXq5sIA!Wq0|5rgK$ z(iuFAA?GHU(_ZTfq;>+ePO@VR&y5kXTUY+wavwbiNum}k9OR3nx01}uKCA3MSX$k9 zozzY#4WaEs~gI$4M#agR62>6=UWUDo;N357yJ?YZW#A@j2$--TwvE(qR&mjG zS3$UvAf{iuzCQ?V{wWRS1cn?&ejomZZQwO_VPv%Uu;+an7C(a>cMkj?=^!EM95X&mn zSyBqg%%2*>Dkhg$_T96Vg~!>d;T2@*R>KLfqJpMxj1Eif?YkzOVrlZ)MAe5c%Q!{f zUH$1zuJ=MDz~?nsRknyNI~EW?#*?Xnkyuo_! zy>*Y zlXoioYToGUv0CoeF_XyjYN{_5+)>5I)z*mV=c9ogGdd63|JigOE#=}z&%_VbGfRH0 zZ+uUO`DI_RejK3FFK!3X7R6p-s?Z*aLFSZsx4+PN;UfJ#!C3Ue3>%3Lz$g2wM2o~% ziniRf$n#Y(WiZ`QPm=MmW)tUZ4wk#=a`ps&(L-~sD!w|7I^O@)8(Uj)xgW9AA>29T4(!prds2ttQZ02;AD3cxw3lOby8VmCvW+1^pk%^Nec@3f7~QChcm8a;6AXq| zrk&TDZdL^i2}aa5RIJr6l%|hpTOj;I5)tbYCFYwy^!vn@%JO?{_tk@XJ!Qk>0(hH# zJZc7frX6%1G>;9RY`(kL$gIkvVERRsG)RPfdA_p@fb_Axz`;jh?`s?Z4%!=?1Mt%t zNNvtz`_-Q{-a%=Q9&?P(yh2B|OLB#7R{8J*Bd@iIl$_sNp*5{13ZR2a{>;PFEe!(d z2X&?c*5N;&#Cn{=v=VVUfXT#774&B7`W_aF0F0p~LvdroyU+P^w$<=(J z%mJk4CsVfBhz|{G56Qc$h+5n|awP)-z5t7V)-o8?@OnhKP1n#_Q^WYhagj?ZBn;Q~ zr$!*hjWPbZYhRm3Un4`+n%PXo@$EB_%oSd_m;B2A?SRdKTmeDTZsv_7R=D(+;j1Y1 z^3mDXre7-C=sDaN%APi!zksoB=stTpFJB4^NY|_RDO0kzF~G&u;f&}hM~Vl@tL$*D`Wbi zJ|*zMoUQ7H)-&A`ez|5CBP;CSUf5P9%!%d!gOzI0%up+}%Py12t}=`09<;JnFL|<> z>_6KDuV?O`mhM7^X|F2Fsd$#{^v|uH_^35asFspv&Fj>o_*%IN{?+$8Ov!XkE~Sk4 z1K+}25-}f@BPXS4-bUP($wuH)36kEgRF+ z>xwG3CRFzIATCQzO(KAOoxxRVg!$MMxTP8BoMGI?yzMieCPL)ecYFN zzjD2Qqf6pv9$C)4X+N?088lc=u4Z@X8-gJ^gCAadpwq^nPD!&=`hy^Pb~ghfhWuIS zUJrFwWptZ(TCoT~bHI<=)R#|{>2Od_*gq5qV4{(48t19S*jtZES=HVY$+*=|N?+U} z6ZKPKW5Y151@{`Duf5 zKRDAtYbjS0OgFrqz^g2dx99*?RBxw1=Wk9n%$)nbNB;d|+TKRVa+kmP=|;qyH~og$ zaB(&67X2`VU$cJMC8>0sK~xbx018?dG(m?2C zqr-5r6qljIZReU%DzT5Fq7_e@Noo!Y1gW%0R8xASrAju)3xlPm9*j-0C;NFXeT{NVO(DJM(utNuzCqif8EO zGI|Fnx1*N~P)LmkKf0RHFzsg6YoR-;3G7A>8pw`^8Muj) zHBM`)cXzZ?PJiFgs2_nFpkA<9++NPj3HZ|-?d=CCP0$AMPc2L+=$PHqGoB!mY?Q&D zUaZpi^2NSH@rvn|Oaz=x`%jTJSr%N|d4z;p;D}YUXW^}uX0QCx7zBr{hJXC_u>1iB zEsK_VBC}F+Y(J;*`fEv{u`xdnve8aXMAi4GGvi==yrz~4-uOLOQQZgN3qBxAQ&0>> zg96MOyv2yj#5xX-^rxeyt;qA}T-m%yud8oM?is$Ic+&Gr6G0`R-TP~$z`36Pnh$k{pHvLs%4fPv`e+gN){GnEJWII%jTAVF`w&8jn4Iq|i{i&womZMaou3jP# z3$;km&*th0U->wHh6yxmqN&W`{df;!Gxaucv(1g_y)jbDSoqEc5SPP;?V-m$hLt{Swxj9nkK3El(jzaaG1Z{qH!eH`&SN543W21DmqCYRa<*olx2J- z6|9!g*(UTZCZ@35lk*2Q$M^f%CjzhJAvLC1V~!eH^J_)ku*9hX7zRDbl4v|+=$|N@ z3ib+HvIUu>XhZB6X`3{8(jCjIRC5g)p(B2{dT6Qi_9goULft*KD^(9V<++&ClJ#Ua zK`DfT4mYA_H$anUI9{CTLm@{zlh!kv?X-P#s-0(+V)HiB8`=D{k~iFmkKgOc>Wd?H zyLOd1H68&M(M-SK|D`e)uSrY4^%tzjKUNw(p@~Qn*PeCV{gk=mFaBtJsI7GfI*&w) z@tQrUaTBq7DPVXqI=xodI82pzV$(uFH5k(5!-=XAk6P>Dq9N`pj z*h){Lb|0Hi&uB6On}k}3H{uz`RLJ){MJ7aV!Ot_Czd|$eT7YgFY;9i)P;}qCLnbi0 zRf&4=h%#V=bh^2j=2MV=J#i~oe;mkh-uzne{vS!9q>XX&TE0#%6lIqnrbW!MprlxF z*zEe9GhI&K^`@#$k!O=V+NcUX#7A*TJg;>LQ;2L@yXF&(biR3E5~rttT(iV6E9|?? z?A5KXY}Ps&Y0={0ujfx?V+gzxE9D2?!#p%5D&DW_*_q23#t~7@J^q-WPdQ6xQ zx2d0h?<5JU+y$Z<5tbIlFf56shd-qq+sL6iIk6SGEsLO`dbS@BoiY<4|D&Sq3Fisn z{bQ%m2`HoFI@sqmMF{X{8j{TRPIEr8QEJ^xc##0JuP>f@p~jKHNm=Y|A=j+PiO4=% zc;fQX8>ZGumllpnB!Z$7c@b+pZ)x2P{Vy%~7ojipYEQ%_v)&0RO}aDt%pjA+)GE`? z{hoEj3SB1ehUgX-djyRO!cgRtck?(S#@BykAz&7BxI2sC6#ut#&8?%m&h@=p_|J#B zsgDfA11EkgL}50IPDC1B00Ro;tuq*aW{jS*S=r&8!u=+i0^r z$v2s^&k-gY%#!$B-nvL>^G8#_&95A5UMCR~y{PQoJjbKl_56v3vVBGRe2vU&}$R~g~V zpYB6rj@TMF?Z3iP-v|IIQ+R{&VFC4}rD{`N;Zr}}iKWq?1?7f7%N4>Q7B#EI% zHz6?#%B_O2H#WDwalW_@_~&i0BKRGt zfgeHl;zKGDFRkByMvuzUX0P@Nef=retj%zqIdB!a9dkbh&@1rPnu30Vh)0Wk?{lolls=0J{Nv5KR37kO> z0@;%XdL|rYCgbykcFC!_2Gm*Ji+_5`j*VDS5c#yKbgU^;AnRQac_d;rI?a+BphAIu z*~9sQYRl05a^I_Q_~kxCp2jt>$39-2ChTfD4JEfe%v>!yig+JxIIXdwb}#;Ov4+HE zp84j^okta2S2wyJYCjjx)lz;xBZMM_809m97P}tg6d73s*w#2Mw~Y0dss)22AYfDp zC32X8?)a0V*64@RD5A5k4B>JX7*fqH-d+jty05C~B7c%?5rLSR#0uFyMxawqr<{ZkL!D;Mo?>g{x@G~28fZ_N3niPGu&kH^Z>f%t8#=l)E#pp zN9wj-TlPbny*a(w;CUUW?0882#aekd{}Ygng-%r7em{}jL0^f-;MDl0aAI2R z5#^N}$8PL)@tEE0bCC@irGnGI)oOX}jbY567A;-w3=hJ5%>o;sY&Hg`S@mV-uB-=K zHhd@aqBlLPFlZqm$B0uy|CeV)tR|ld3>up<6$%HvG|ku_C26F~f@wubr^{CI0q8AT z!c@CAI_nkKGSaO1evhM#{8!fbb}e3vagyCHA53ZCWWAwV&FJmdv5rGiDDr;)jJI3b z&ZAVrv-)?tZ!!SAj`dHDZM;GQt#}L}HFo=6c?>xm4sr6Hdq}h=`+OVN^|n#*$neCt zzlreppXRx5Qf)W~pzBboe&>l znW#61cn{uSK&wo&>*QY3x7vN81%8k*j=UFfhtF{Sc1=vsEN$ybYTQ@8*Jhp%IU5W* zxq>vUNK>QFrK4~BbKB5dSgqDg?(O!MHhK~z`RNtpBff*rtzqbycJ~StpP z=2g2zQ^{o=KA$&H<^G}&IqK7=-glejT`Ja_Pfbc9a*3yZ5=0j~y_uHrAoHFkv=MYmjWYA5B&=5PZCSo&H>b7iQ0)<;SSqr&56f3hq)&o6%Ux*6Dd};-x~2y1|(4Q zw~DJabQ56$EbtV@X?LYtI5Q*A&;RUj3+}jhdyp1fT7`t?D2(|nH&}hY#WW;fYF8+T zyxsZj&Z;OP+)@L<6P8!wL3nlUGxVl-2VH+pOcw)X?w;Ct77@HZz?6mf`S&~$WigsT zb^T*MH>@yJS}AZ?_$meR9s3~h$=7=V&4TJZ9)OD-r!=Zr$$gl|)CVm4TvxjMaDQ#u zJD#mnVy)$JX%v4myy2)*ZW8SDUY_km*{aNqy>mb(fB&clePfQi_S|0H0AAN|c;fe@;O$4jPfZt+aaSDt1ct&^5V62=duTfelU&*_tF!)^=rB-}(aH7ad zc*PWN0u=8Y$nG!AXZ<|!y7#`10p^l?L|e0qIZYA;XcPD6Ej9uFHjEhfQwOATfRn6eyD4q&?P~u|K9*R7u2NK ztM~h7O0=J!IxujYp4gxH6n56wbov?F`TaH)+^5_3r??x;|VyjO5yJ(mz z_k|$!d5@!~Dy~{puS_{8u8;Zr55wyFKl`=Yc9fB=%lQMv(B|psjvnLNwIo*bC&B9@ zLm8o!k|N99=!Bv>heyq-i@T*F>s&j}G4j)2F|KRb3HKU4!8Kq(0nYXMy>v^6KDrWr zYkqej%lfiLx=K@JNmCA;7k&7=sm*_4T)1?hH)Y=@xp+P_OGFg+Tk*R}){SU8xw)=g zWpVlC{%obdW$b`icFqT z{A9pM8Rjens#iKa?Oxv`T3JvX?AYYJQ74qSgF3X@HlR^XT`|BbB7#Hp@A-MpSDGL} zdSla4dVaKu=J>|2Q-=XboMjoPM-i*ODM^aF12Q_vOL5Jjh5txWsw@)bgIeCf`5OU= zhptfz8b8C+Mf7$bZ|T9ATJ(DRWH@ zbYxe`8|r^j74kws7V>MTc)DZ64g^*&r?-O^Qj7aH3@z{MgZ(G_?DU6r*h=YdVN_6A z(o>DcrSLP`#C16X#pSY}=BEO)EBS>jLlgJm%}WU`+A1|}SClPAZEnG%?@3%k`jY70 z9(l=n;D0H}=w>Q4`HMf7GQB4}e_`uUowe$FPR8JKQF2ldwk=YGb`MUWLA_13aR@lR z0JcwhFV3qkZa}?wAL{7PFQpw*wOOTfqKo8J*IbIPG%kj!o^x+yz-xkkm;o*lZHKc~_OZCgwuas%8+doyH%TR^4CO1W#!kXTyiLWtYw35TbK zlV6vv`L5n-{O>h4WeX@`#4x^P*~#TsWm`B$gT!{_mPXk<%l<6s@IMTQyOJ6ae}0~XKwIsKqMe^pMY0J2bT4d(cDuZ{g{=kV_{4QQ zmiMTOH8G7iX3dq5~Q(N zUg`Mdp5N?Mv}$MpQOxjn*!fG&7x-W!x zy$g0izk}+5@6fG*nJ!dbWWM87ZC{pL!e&zBGS?l>4^j!VlZwNdrIjI{jvm52Q$qrL zcxQ=rr>7L1xuL$X|*h?-*oN2j5q}mNj^8Zey{)XgD;8ljrW-}`;6yB zG;on^EJ%snpBo(caK3)#wE%da?v z_t;8o*Wf(~bHo8L!U_|7sPEZ+GYey<*%Ho>53-l$!o^ehnjFT2_K{!t`K(a$Io>vRZ8JN=|r4LuBb* zOH)FxWEbi)STcLZ6$Ze?_JlNCY$fmSv zWSw;gU)V2bs~5TJ{G0)HVD(ZWb8WP0ipXQ>ph@G(I=aXtD(q{4T%URL29Qvy0qlimru%8V$e3lbR#(BwP&Wlqw32ew^1-prxBi4u! z#!$>r`K)W^_&<9ttmj@mrAL>MbH1PW#N8*vFE!kEaRrYs$c^d`@=deC*OY3B(D#%r zoX3wpSj^aT*7m+WS})>`d@!Nh$Sd($qkU5A8G2Y)v&$fV4` z|1d|P8>{gxLR%AYn(D~t_e48i;j{ybkaJl^5?a01Z| zN5%fYiY`k5o0CD9^5`6sEw$)D6z>nTP1u$eO;IE6R{9%CE#8>(n}jRU6;QnEQ#6-h z+V!0=@Vr3-?00uig&4V_d`Z^O23(3+JfB1#Z>mB=xvZh(Z3fE+$*co=hB3NE$7Bmy z_|Wvv3MoEH6SOwhB@=hX78G#xUH4-V@JEI(@+u~ESfdt4=n$2lmDg545hXpENZ(m! zlLnD=6x@|^d4Mgc^$#nQ?>*PX38@QiOU$i3_Y}_d{%!_2Uu;r379J(`M6dcs{n66W zb!4yMrgSN_aHxs>Rx!fUO4gV$G|=?Us6YDjFl~cCF;C*E-MwF`vfe^Hyfi4&gI+Hq z=O3Rz|jXo_zzo`#hQA=ozk|B9g>)Fa9Ca;DBdS*n5egKJ@{T~UEH z>dNgbq$10*1x6lYpLhS6|5X)27;$un$qGWP5DE7)%G3;pK!15QsDVRw5+sfp;4G|7Uc zSh_rPg|-3hpx84lGWjZrL2Zmk7v94C* zKi=1^u~99~G0#CJoLMK7cf=Abf>;sJ;B0^b#peO z?qaR_(|V+Cc9C*09VCV)WU^08ITHEb7-<`i!=EszzgnY#&m#{J!hz|aI`P|y{GUIR zlny%!*+NS}tWZ&nZ=Z`&%&iKXpuw+Fc`W#@9|l$qlY z5G(W}w*``1S0AU{FPtUv9Yu#s%XWTbnB-k_AF%vWiO5?{r|T$fXZ3hsAdGT4USJs% zeCu;VzouGD!#V|?q!L50AQ2N8S+*X>3j4$-ZT6mwn${<`teC$}YrP}DI0>2mV;nwH zY2lIm_`vIj)oh-L!0)Fyg+^8qFf!Koil6eccwCS^-R?2S=PNFKOM(?`LEuTXX1SpO zb)G?5$9GQE1055ojC6Ltx`e_9{yn|qFoVK@2s6T9X1{a$e#9gQ`3dZxd+{-k>p zdW5=~oFS+dDnlHsRRMJ)a*8v<<1d|7^agUcT72zr!OiC8*f5wVM3ohLFLcv zd2EikIT;yA2{*bH)nWS%nHRs~ch8}!;d$)M%$_aGfcuSOx%1pHA}vQyN)la2X+WJG zTKxlrxR!F%P2mfdLD{hOvOoM5TpRkH?&Cd}j7&EEgr7GVG~T3gb(?pthOlG56O?q` z4!jlUZccWeq-6h~7Vg)5fL1-TOI~^UU=91wSx`?D6>|93hc8qxb(%$!&f=^ZepjBp zeINT9V@N^YIAKJ~Pg_Cod&CSHrj$<_2#A?gY5skklJA1sdl4Sa>YQJV29{2My&2))dE435v3>UDUZb zghOYVTxM6wR%PBRR>NKA)B~P1#X}-d*DpgnRL!|PqrP3QW5y459dYa9U!+!*>y>RJ@!|*=5aX+h;(52`z`ESQFpY7$W#f}VU^V%bF_y37Opr#h)f_)0%*IW2 zPGc>Xt+Y#b!0wpO(Nr*sc0##C;+y6CnVsYvj3eKV#lemSA!<-VoEfgkXW^6HN)Ao5 zh>=b_cWv1wtd+GUM32T7AWjO|kD>_e-BAgr7I#kXT8s{MFpC?B6)zA+Ji#Xt*;_c? z=?$39oBri;723;ii*E5?&fP%L`A3H#S5lOu-yhX+sxH~*%RF}~uz+unO3towGnus$ zTb<>FW2)Kq(+$|Iz_&3WSOXv^Mv?DrInut|&DB|!k6 zSKqwD%h9sQl*ZlItAf5Bvh#f4`n|BZXQBby$I{j+Pwy1WA4*!zqCG|1Q}aQ>ny+r) z2ya|JX71j{hkQ!G;a9J=l1wBwKJ2OEKAjO;Tkq#902R#qOgi!wIUfAsnoweTP|INB zaNYLO+?wEV!Kg_ysLUX0EABsiudhnd1V|8U)OjkO4>1tNid!|G-cTS!Y za=s^83fLA$6oh0D&BvHrsm@7Ja?{{2mh`b8-Or`%k@O*RPv7uZsZo(uY5p!IQbUXS#dupI!Ylv>20cj*f2c1c}h6c53xK5Y7QqflIFaZmQxmYWOkJh5HAwG0u91P9*oj>On~HFF7eZDxER9%dkaDI3fd!< znv2gIJ}&Ki#0&jcSt~QewVHzA6JVH&U^drjJqoo#i zHMYc4XoD8E6SvMCU2+~p zkq6{b8fgB{>RkeCHT1{A9DS+MvFGzr<^DZG385wZykKbagY|%)<9zI5&Ap@3Y$1o< zr=^pAJ{jbMB&vxgB>3#Q-DO>OI_a-3U;klOVncZG5+2i8mlC3;|VT$2TGs?&@dc6>!h-0yv>@zr1;6xDG3B1T} zQ7^K7mI-N_UtiU!^>|@~91cLE(ylbZ*lT8U{1U|*v?sGvF43Hdlppaj>0;cE5MRyt zPC${wiAaztZ>VGfaA!v!H)-t@;w0~>$noOKcBpXu2ytM3x-T9OkVk$t&UXH!z&PZ8 zrW|AH#D5&tN zT#=GDF}8ku*Y7-b9aP_b+HSR+khjV3AN3}c0^4h&tW&BhbQ17r#ik+Le(4KrA(Ne6 zM*u%nIIQMC1fE*A=sd!mdKgFlE}vfV-s1hM8yXcvK5fgt$W(87wYo&C!oXg$0`w)o znrz*sjb_j}H{CaLL8o?9^3S)A$;t4P04}tdZbxbKKE; zc(tQXd97h>c7f3S`|m=k1cp#9+wZ{I}Sy+zD7nrE56hL;T@>_OIBk5u3GmB4yDv zPmt|-#-r{SRRnyP_pIETaFoXY_v)#hdaIVyIn{i!@yGI}GM)XtXz@I-`tr68Jwf)N z9``Xh{sRr(Q66|AP(7u-84l+1l0r<->mfcqJY_Z`Cer6=JRK3l3eLQ$L&Iv_( zqJ65f-!mAoahy4ZWW+Z@#R;#{ixz6ygLEg=D2k+iPcG1qTTfu`VIOd)gjX~66YzC- z{9V3CSjHH=>|F9cIicrh8vO0nYiC+pZTL7Cdfj>Q&Pa!P1V-F%eU^A^Zmoa5r(u=u zxBVXKMJ&7>s0rwWy?E8o+=#KhZ1-r{GBoU3C7*9Pq2|(?Dv-Q59Q1MT0hui*O9DJ+ zbg(<5w>*aUQM+{J#j0Y{=IK83)goEjaL@a<)$9XPf!{Y0-y3O@TtYPRYx)xX6gw|~ zzSU`$6n|jzl+b=A|NW-Kzw|UBph~cHZ7{{h3~aJKrEKZ_ihDgngW}jV^3qz&AAX^G zc{&r!(szW269skpIUY(&Cm=?dS9ECYO84*e{S#bZ>|CsB2{~sz1Pf)fhQU<_30K%}c^3GxXLP3)XlF z!XEnVeV83G9n;U-rl)Nzp2;B@<((sok^QF}$Z@?b0nt}eA~7oF()cNL$V1EuxoR7| zqKjEI+URdp`FUdNwczb>GR%M6Kartn*W{O;frmb??0IC0r@8_=&&xbM*n>Jm&iQ_1 znPzdKroNT`XkFit?2^0&nOZVEGS_~#LPU=`4hju8A)>!Q%9k+m0v)|M6J2ljh$_)T zI^>Gc$>ECWzCSZ!IkS3JSs}#1(YA=}sP=>Dt#@y*{@U~?1hEU6piTMtWi70;mcnDETjz4>VwPPgK@ zti$|5!lNEFLv@Wa>uOKmH_GWL7tQ(+gn`Jk8J;puGJ-tH!oW69|o|S#v?MCCwt3e|TAk;YF#3;SD~uvYx8`PKk0A zsEU>Lu6n<5{eVY@5&^C#-mjgtEtDV^#kCep~-R*;+QgxT@=tR>pxTS0esI@})OF6U^IIpbAH8!{8B@H-UIH1YRKw`m{L}3C9s2-T8)A89YNgZa}Ttv0KGNl1*ut`S4Q< zP)lY!q6fs+dBD@~{+aD$`^`Ue1HUP}w?ThkIPYNJo@>;1m|&JH3CK@3@*74!1+NQn zgBZy@z_vXVbq%7AN3wxxd3Go2WESJ78=#AJ1C_8W9ps-Ji*|Tm@#S1Og}+>Z`>~I2 zE3H{kYW|*lUpRb`;jzf}i~93UZzpRuiktebcXrOUcYAAIrqo%vKN;6gMB2qJx!wUp zXV6C71P?xYvWiAy%K=rKBMJ;fnjpUFZxSTvC!6kl-$WC!y()J+5mP_;aEYr56mJ#F zzNj4J8hY|*b&8A7)IHC1YAT*xG}qXwDVg(Jg;uT1BPjK)nY1Qo!$`Yy~En--Qz+`F_m=|8hjHf!$rGSSH(hi^GVL z#=_ZWJILb8jMHbS-u3@C$6oFB8F>YRsq5bzG4|*=Lz{xPe<(#vvy_47=1vM`Pfdqt zxyB^V*IFHB3B7CB_Dy5PTCcXYZ0>hT>VVgW?7NAa{8`D0S$lDoMt!bEvvXQjCfXL$ ztI{c%fb4|^mv&t%2DWG3INNK4RfIj< zcY2*X>6JT6v&H#o+x+wHgxA6>jg#HNgI8!OLobrgK9gRWpLdnnn<(Zm4o$*ynEd@M z|7%{4|GgFp{B`Ix9zM!j#1_}?-|w30fARQng5vf2(EUF4>-XsgQf6na($f#C$;cG* zNFKz*h|~W7pR2P&Ltk2$Pl8J`;8aJNnAkh&`V?(wXkRe>zvct)u>UeJBL4UPHCK6h z%i?igJ>Qq(OT-l+Iiasosy>2$t~L^CwBQ)8A@jITAN#MKkMyC2TmSGd=YiWh89M-Z*k1N^m{`sp%dD3?q|eE;csEZZBO?yJHdj#!KMzg8 zPK8kR4dhn1UMKQ;ukad{48thUC=+`rdSdD?1zoNW>FJkKHb&(y-6F<)2At^QG5iLa z_EC^vKU3CWKLg@ZEIvho(XpKiSXL>XK9(7cy`Dqy)w>aPf0bK7 z=D`FhHHQKu!;&gR?*j9Z1$#AKjM zb;VuAz_Pac#OWNG8MXI`8#(Z!0Q_E?Yd7l6k_Rh zEzqS0`{~J(9HQ>+TU1L4QuH}7tE~F5p}(c+h#~%^2SGB668YZNQuHpgc-KQEp5cW( z#H7$!~deI!onC>4hW3>EzK)-*-F?7`-zTj$mYp^ z;|R+W{NmtKxSSm#^+e@EycqctV{2@qK_%%NqPK5kXm5mtN(9H40ZJgEAQ>6jwtp(_ z6Ay)8DQFV~AM1(0Y*Mxe#ybLKM#0E3SAs0PZqe`s$?P@VWz1QzvXvnRhmQNirykPA zmG_Bndg6t3`4bqUF5P}&V;vhh)u~p^t{}4sc%^M4jbDX5;9&<12h+^KjVTR*Z-<}| zsef|@-#vK}+8?}RgJS`1`=z z6J9Wg#qV-*M*0IY+^{b>aKi$QGbUckaRt1uCsJgk)3U+4-tF(uMI5;1r^^TDPzvS0 z+xF(#Z77Yoikt4;8v+t_@6xa-a;BWUJ|5zll{9fjGy3pBDw3h&`IK9VS_=ZSDYvdz zM_-SVwMt15vSfb35K79|`6e`%S1D8s9`-Lelg#}@Gjq$-jmr*~Z(HZ5gt~>AJvkgi zzsAQWc}K*fq(GH}>bM(b9elkzq%e~^@N$NWQu{ARGx~a%w3aZ%mmn2kCOP`d#p~CY z+nf8> zd#c5g`CCKIG*Ws)R3uVLiz%^wp}*y0?zh`UUoRpezPU>L=3YM!T^m~{eD|7EvCR!4g~-8&+whr?7Pm0T8}hpzQ@b|nRgc5XT}UHJ81isSN5 z97+oQV0OW)+)7<7ee1;>;1Fr{L=MFb8p@0=%imhHi3amjLVo@FW>K1y5UXMk5ZqlW_TEd<5L&qYhh_-Pu}F%*AxE7ZeHX| ze3IKCcbPs)Sh8-Dg9B~~SpIhr#1g+z2Ase^w^HMXrK@v=nLes0FI%=>lW_0hp*!Xs zQLo?zhhV@qAUZ(K?@%5;Sn%~^9T)cJ4H3{@PERVat-10*uSUfq}hX??d8RDOs<9ge-!kzL7 zT$}=i%+r6{E~3D8PIreVShb&<4s$D2^OnWoD7GaKk3R*4_ATkl`G5dg-pI??$*U`c ze&g>1V%*_q!`)14j#Y%dz>6t#1C}t-(l6XMznmokEv4L|Vd#+AF4}^{$>Ng?WBUxC zNWD(Xa5(xO_a$VQ)cd}ygOu?$kaxU$Fz_vH* zy?2?IXo1eiqyp)H`$!cChVqwzHp)Q3uP@r{ZFDxzC}4H6G)|0>f?7ajH^89AcLuGHQVX+e(~r6M5?L9uX=Gtm=9-39-gm1L;k z1rvVHpB#c~fSZJPzcgL3EWzA*quS5I;~Z*kJ|AnmMJbJKP{D;LAkj|=^`~fivt5M4 z3MzuH1-QFfZ-Oy;KFcpzYneSQ?ud!P~HUp+~sz{y@_6nvMXVywzu#ZBxE ziw+BuX50$;4Mvrj&9tCDvO@C<;gbw;Eu@6Dh+~IYEAj;R=`@HXW^oi}NyMkT(P6)n zk@5TNN;0irW=B?7SYg<8`*sT}nctA+xF!LB6DsqRYiGAQ-;9QIiDmHoozWuGEq@pm zN4gx+d1SIKENh_eZVs3*03+UAD}ujFsCk6rHNY{{bI@@oR*gE%aaVzU@jbwaiU&K_ zgu54tJqoPqql65!tQSdl1URNqz~svQx0yRE7)*Bmk?3nI?>?#ks{^BT(qEinVFVbV zMciX7r{59936o#H&`K(LSN7YX7sCewShw_$3&iQ?MI-F2=rFNnjCxpeGy`}S90r9+ zdk`k!dLjWz3oxCE;7h>;y8B)GJJH~_i?x|T6B|b^y?ce7vFStabqR^90)5oY)+F4t4Z{(*0=u? z$qpTkC+}UYa4?jri0ct&R!7kHH={EbV2F|iwgxCyySNdI)`mrzv!{T3K<{6+x4wJ4 z2L{Dy1Heb%ijZg~8l{it@~{SUOy5 zgPR`)+r2Q;Vw3on_h6=;3_!^)_zSd_&y?ve=Yewl$8`WLgcGyt*Z+3Tgiz^w&q?F0>Wor(h8ri!KGhIK%ww zxIMmIbcVHw^4`Ap&RzHpyJ2mXC7*082T$FKz*W%!5=QGZ36C{-5!& znuf#T2?|Xd&|$F^jCvL4ul~c1jK6dPu24nbSol{k*i#&ny1adZudgP@>EmnS;mt!OLH>jgeYlQf4 z$hru`1b}ApCjm|r?y#JCQE8m~Cz6T#rvcTtxN&GI!widcE+AG1j@Tk+7uO0K)W#^w zc72r@1x7_rdygbz_F{Ay34THChxowWLHHrT&oud!539}C0G0%c*=7*db}arI4KRGs z@INnAZF@m7vA-`CB%+ibj9d(0ZYszm(#m&XUj7q5v>Z4tf}VXqk&PIRZV)m!V?mtX z(+0d;!-GTq#P&dEzf1l)dGT;u#{(#EA-cWg`--0Rmva1`)qc z2C(=N_8S6Zf)L*pe-OAdQddI2$goe_RR3Yw+m*k{ixUr(Lo^N|F8ut2_be55LO^jX z+V;!;`lHy4pnkf)7;tk*_(BIV(tcA6Uf2~_-H~U4VC}C1gpRCa47~`43TS|XY>fnT zT{Jra)&mUM@n39sbQudks8MV~>?zjq1GNXNmj4S8p@8JSF~@{^`Ng105;88zz>>_( z4@Uuuqp`@)?(K^W#zM(Au#{sXFenFK^r9EsGKq@bpxX7no9yK@vQS%47kUI5euhG1`luvh_vvOjU* z)|^Avt1dXOZw0Pj@cXL;z zKPud^!!U-**z1sPssLB8CjR1K^wq)4-#E{h{rW(Jl{M{n*~K(~2vPd+Tb*_brc>OO zNMnJyQqljh8!azwwsI0XQj5J&y#@Cgv3`?;-w{U8j+mNz2-i6RHbE`zsEK!)1B(g&374-oCWGe_=EYfrgz^>R}v zr+fdga-yUw6@@$9=*;urFC~piqT&itWs#s{+E)guh>Mjz{Orf6#s1Reii;pC5VkiY zxTPvWE}<8otvrus*uz99IyV>1k*6LAG!`^&TjlTEPD%#b)+0~6ySPES+Bnx~@yOD& zAIn4XGlk0D4?%(JR|Xgiv6On!*2vTDM1g2i+yiUQSAaEJ?yl%QcSe+aDlbmX_4N{U zH8=9Ae}qu<%Y=d;DRuc)BhRl1-!l+5bws-UgGex|V*-LJrBpw{>lS#uD@G_N-)66c zd+q)X&h>7Yn`_EIB^aWhYl=a^g}f>sk*B%(3;<>tO-}cv&s$J3I|U~AuxSJXERq{I?I8|@2@^nhgppPCp!=;XQa3m37myoLtVb%@qde?Pt6TUdZ{jRkK z1-HUiKin%Oi2;l1N&bn)7Y$TOnF;b>%Wi@1V1=g>?SowX~%$jkaf*Ap>jkR=K#QQ+Hs5hqVXxs*@K zL8_<3FSr#9E$Lu5Y43=Ya}!^KHvje7KNV_|uT1enfMwb9ZAMr>AxFB}0#iGqi&z|Q zUAjf41p@#DcUPp=ur6kX<_;fd%g+q8oeJht<#rMP0xv7@(!lN?9__*5Od^09FPD{l zp7MR>!?zY5;?pR?t(C_Ie;^^Lq2kNyQNsD35liJxFkab}6?3ssrm4OSLY4 zp!X@8;>1CrHXs`1wajQS#Kp$xV8v?7>r$-08!8~nKG5bVtEZMx7atzx0(1aSo%>qB zOg52%S_@TO_BcX*ablO>mL~T`<9O~5n2gn6q6z?*13&1`k>@>T6PnMD^xIj*8U~!B zbQZSeD-^dmur{=OKEv0e9q&J8e%usj2vG{7ow)<6ftYnD?Qs^r%2ui$_Rw~bel0~( zULN9%bT`+^_icepfNuI_7Nr$SAyZM*KV5V>>n>|BJ|#=vva%I&SK5VGLzS2@Ycc4S zrPJ5HVMPICUH9!3Ov5f?!D&$|M>3#x2oBtbg8Ih3O;+!sx+>Pbz-7pxnzB;-5~>`7 zzu%|d$kt`Hs}42S&k7JRy+RbT@g#_)dCM?}z!y`2(sG_dR?U$!{`4kP4o^2sqEMg6 zB3!HHMwmQ^4k-R85iY;to3SnK$pWle_Y1fY^!0sI$SRf0Fh%M}gJQjMx^ zV8Fo3~S4X zSq~ny0{hkYf;FWt+1=ckN|%WnJOpGlz>S?&pgTk-xH3`6Lllw_ZVBi8OfYV7;>90` zRxsPEaJy`*F~Ld5J1DkW#AEXyNUHrWxk&+KBiUZ{yFT1xkRTnA7(WD(0qbXYx0LmX*z5bc`8j zNY!7+nh4!O7^y?1>~qyX2F@QNg$#%S;$Jthc`^mfpmPKdGuQ|jt!?YuY{DSUz)bm-+^l5_8=V% z#DlBOVgZ91Dvp;gjyC{Cy?g~&b6mME)T>_F_Nt}w%($v823jR-^^^)O60`k1RG)xntB8U6F>l3ja~*-Ex!lu<>Fm^*?H zRfpPUf4ycFA~lq0z&R^7I3mYlAxzfh!!khL6E@1;%kWO1( zx4@Z?F@i8=y9T_&4h0^lFxvVI>2L-NMRPTK|GJhPb+w#h3JI!XOMM-WVNcCZ&BDzp zs5J~m>?-AeJ1~r^T(%WvImmXv1=qi)x#jaUSSyrXxYsq*t;Dbo67i@i(UHqEJS#^Q z+*;R8Le*eRl0R5Y8**y{qVZ^e0^zk34%@H;4z4F0KV0IfE*&PGS+$-qz-0g(R?IfN zt-1Zt0Xz(#h5F|61QvV9hM$`a8C0?`UhHdg(9I_SAHhz9omb02|J78(yY~0y^&Jzr9%YcT{Y>8(d%6#=Y@Dq=cZlOp# zVubqQhG#epfhZ1xBRIXZqd#*b2@~N=ur{89+A9qIHf!HMfwNoj+r;61(>1K9W9hd! z;B0C2BAq~KPN3ztEZ}@kkT|fK-FQI^{DJLNOh`U=A?!uGb7*LA*VQNUU&YV!pN{YszBNf`0vlVGp(U3%>mh_+lSSW^ zy@H|Gi2{^1xQA8tIq+C@P_l|GBOkh>@%=~ZCk0p={-E&gV(YE7u!$LBGUZo~AeHpm z7yXUL4>)c`4ZJCPZ@#$mT^mSgb;AFh+{4`yM55rNmCdMq-tO&;qVJ+u1YTh^Ih|Hc zsb~m6Fs;jo)dNE%PF0mY(4NtQ5zgE5^wMstO>SHz;exseF7EzgEzEaW`$r!>MEzu8 zS%2g*WB`l`Q5#xPb`k+~KB8y{zg@qdcm8V=_=d$}tx;FY$^+Oxp%T_3dvxJr%K{&n^=7X9qEx*T@ z^3m?gA!s)Pz#IG#wa^7yN^6t%RIadKBM;+}u4=zXzzn8q3#9`s$qTSn__l$3%sSSh za+;Po1{+_ZN6P0m1piNLkF z%0P8f-2)=;9DPx*xn!WaS6N@5Udu^C)Xd*m;MtPN{Bvk3!i4`zTaQq{SNDW1k4m8^ z=<9qn{vkxX7^wP03I#t47_4g@AGRBMQ8p2GbHfww@Rn5|#T zOVSGKiF`@g>OF8JkqCh%_oYsK8G5V=VjsWb@mJrFMgHwSpPu*|K@5ERSKn+k{4wwi zx#2Yia^xAL#&?9Y)O +PREFIX aris: +SELECT ?disease WHERE { ?disease ari:hasSymptom ?s . ?s ari:symptomConcept aris:ARIS_0000190 } +``` + +This table owns the link, keyed by the symptom string. The ontology only carries it. +`.github/scripts/validate_mappings.py` checks every link against this table. A wrong link is an +error. A symptom with no row yet, or a mapped symptom with no link yet, is a warning: it appears +when a curator adds or renames a symptom in the editor. To clear it, add the row here and rerun +the build. diff --git a/notebook/symptom-mapping/ari_symptoms.owl b/notebook/symptom-mapping/ari_symptoms.owl index 22feea2..773c292 100644 --- a/notebook/symptom-mapping/ari_symptoms.owl +++ b/notebook/symptom-mapping/ari_symptoms.owl @@ -9,7 +9,7 @@ xmlns="http://www.aurint.org/ontologies/ari-symptoms#"> - ARI symptoms grouped into a hierarchy and mapped to the Symptom Ontology (SYMP) and the Human Phenotype Ontology (HPO) for ARI#132, generated from notebook/symptom-mapping/symptom_mapping.tsv. skos:exactMatch names a SYMP or HPO term with the same meaning, skos:broadMatch the nearest broader one. Strings merged into a symptom are skos:altLabel. ariSymptomIndividual links the Symptom individuals in ontologies/ari_t1d.owl that carry the symptom. SYMP classes are copied with their labels and is_a parents only; HPO terms are referenced by IRI. + ARI symptoms grouped into a hierarchy and mapped to the Symptom Ontology (SYMP) and the Human Phenotype Ontology (HPO) for ARI#132, generated from notebook/symptom-mapping/symptom_mapping.tsv. skos:exactMatch names a SYMP or HPO term with the same meaning, skos:broadMatch the nearest broader one. Strings merged into a symptom are skos:altLabel. The Symptom individuals in ontologies/ari_t1d.owl point at their class with symptomConcept. SYMP classes are copied with their labels and is_a parents only; HPO terms are referenced by IRI. @@ -18,9 +18,6 @@ - - ARI symptom individual - abdominal cramp @@ -1881,7 +1878,6 @@ ARIS:0000597 - @@ -1890,7 +1886,6 @@ ARIS:0000001 - @@ -1899,7 +1894,6 @@ ARIS:0000002 - @@ -1908,11 +1902,6 @@ ARIS:0000003 - - - - - @@ -1921,8 +1910,6 @@ ARIS:0000004 - - @@ -1931,32 +1918,6 @@ ARIS:0000005 - - - - - - - - - - - - - - - - - - - - - - - - - - @@ -1965,7 +1926,6 @@ ARIS:0000006 - @@ -1974,7 +1934,6 @@ ARIS:0000007 - @@ -1983,12 +1942,6 @@ ARIS:0000008 - - - - - - @@ -1997,7 +1950,6 @@ ARIS:0000009 - @@ -2006,7 +1958,6 @@ ARIS:0000010 - @@ -2015,7 +1966,6 @@ ARIS:0000598 - @@ -2024,7 +1974,6 @@ ARIS:0000011 - @@ -2033,7 +1982,6 @@ ARIS:0000012 - @@ -2042,13 +1990,6 @@ ARIS:0000013 - - - - - - - @@ -2057,7 +1998,6 @@ ARIS:0000599 - @@ -2066,7 +2006,6 @@ ARIS:0000600 - @@ -2075,7 +2014,6 @@ ARIS:0000601 - @@ -2084,7 +2022,6 @@ ARIS:0000602 - @@ -2093,7 +2030,6 @@ ARIS:0000014 - @@ -2102,7 +2038,6 @@ ARIS:0000603 - @@ -2111,9 +2046,6 @@ ARIS:0000015 - - - @@ -2122,7 +2054,6 @@ ARIS:0000604 - @@ -2131,7 +2062,6 @@ ARIS:0000605 - @@ -2140,7 +2070,6 @@ ARIS:0000016 - @@ -2149,7 +2078,6 @@ ARIS:0000606 - @@ -2158,7 +2086,6 @@ ARIS:0000607 - @@ -2167,7 +2094,6 @@ ARIS:0000017 - @@ -2176,16 +2102,6 @@ ARIS:0000018 - - - - - - - - - - @@ -2194,7 +2110,6 @@ ARIS:0000019 - @@ -2203,7 +2118,6 @@ ARIS:0000020 - @@ -2212,7 +2126,6 @@ ARIS:0000021 - @@ -2222,14 +2135,6 @@ Weakness in arms - - - - - - - - @@ -2238,7 +2143,6 @@ ARIS:0000608 - @@ -2247,7 +2151,6 @@ ARIS:0000609 - @@ -2256,7 +2159,6 @@ ARIS:0000610 - @@ -2265,7 +2167,6 @@ ARIS:0000023 - @@ -2274,7 +2175,6 @@ ARIS:0000611 - @@ -2283,7 +2183,6 @@ ARIS:0000024 - @@ -2292,7 +2191,6 @@ ARIS:0000612 - @@ -2301,7 +2199,6 @@ ARIS:0000613 - @@ -2310,7 +2207,6 @@ ARIS:0000614 - @@ -2319,7 +2215,6 @@ ARIS:0000615 - @@ -2328,7 +2223,6 @@ ARIS:0000616 - @@ -2337,7 +2231,6 @@ ARIS:0000025 - @@ -2346,7 +2239,6 @@ ARIS:0000617 - @@ -2355,16 +2247,6 @@ ARIS:0000026 - - - - - - - - - - @@ -2373,7 +2255,6 @@ ARIS:0000027 - @@ -2382,7 +2263,6 @@ ARIS:0000028 - @@ -2391,7 +2271,6 @@ ARIS:0000029 - @@ -2400,7 +2279,6 @@ ARIS:0000030 - @@ -2409,11 +2287,6 @@ ARIS:0000031 - - - - - @@ -2422,7 +2295,6 @@ ARIS:0000032 - @@ -2431,7 +2303,6 @@ ARIS:0000618 - @@ -2440,7 +2311,6 @@ ARIS:0000619 - @@ -2449,7 +2319,6 @@ ARIS:0000620 - @@ -2458,7 +2327,6 @@ ARIS:0000621 - @@ -2467,7 +2335,6 @@ ARIS:0000622 - @@ -2476,7 +2343,6 @@ ARIS:0000033 - @@ -2485,7 +2351,6 @@ ARIS:0000034 - @@ -2494,8 +2359,6 @@ ARIS:0000035 - - @@ -2504,7 +2367,6 @@ ARIS:0000036 - @@ -2513,8 +2375,6 @@ ARIS:0000037 - - @@ -2523,10 +2383,6 @@ ARIS:0000038 - - - - @@ -2535,10 +2391,6 @@ ARIS:0000039 - - - - @@ -2547,7 +2399,6 @@ ARIS:0000040 - @@ -2556,7 +2407,6 @@ ARIS:0000041 - @@ -2566,16 +2416,6 @@ Fluid-dilled sacs - - - - - - - - - - @@ -2584,7 +2424,6 @@ ARIS:0000043 - @@ -2593,7 +2432,6 @@ ARIS:0000044 - @@ -2602,7 +2440,6 @@ ARIS:0000045 - @@ -2612,9 +2449,6 @@ Skin blisters - - - @@ -2623,7 +2457,6 @@ ARIS:0000047 - @@ -2632,7 +2465,6 @@ ARIS:0000048 - @@ -2642,12 +2474,6 @@ Abdominal bloating - - - - - - @@ -2656,7 +2482,6 @@ ARIS:0000050 - @@ -2665,15 +2490,6 @@ ARIS:0000051 - - - - - - - - - @@ -2682,13 +2498,6 @@ ARIS:0000052 - - - - - - - @@ -2697,17 +2506,6 @@ ARIS:0000053 - - - - - - - - - - - @@ -2716,27 +2514,6 @@ ARIS:0000054 - - - - - - - - - - - - - - - - - - - - - @@ -2745,7 +2522,6 @@ ARIS:0000055 - @@ -2754,10 +2530,6 @@ ARIS:0000056 - - - - @@ -2766,7 +2538,6 @@ ARIS:0000057 - @@ -2775,8 +2546,6 @@ ARIS:0000058 - - @@ -2786,9 +2555,6 @@ Cognitive dysfunction ('brain fog') - - - @@ -2797,8 +2563,6 @@ ARIS:0000060 - - @@ -2807,7 +2571,6 @@ ARIS:0000623 - @@ -2816,7 +2579,6 @@ ARIS:0000624 - @@ -2826,8 +2588,6 @@ Forward displacement of eye - - @@ -2836,7 +2596,6 @@ ARIS:0000062 - @@ -2845,8 +2604,6 @@ ARIS:0000063 - - @@ -2855,7 +2612,6 @@ ARIS:0000064 - @@ -2864,7 +2620,6 @@ ARIS:0000065 - @@ -2874,25 +2629,6 @@ Burning - - - - - - - - - - - - - - - - - - - @@ -2901,7 +2637,6 @@ ARIS:0000067 - @@ -2910,7 +2645,6 @@ ARIS:0000068 - @@ -2919,7 +2653,6 @@ ARIS:0000069 - @@ -2929,9 +2662,6 @@ Burning feeling when urinating - - - @@ -2940,8 +2670,6 @@ ARIS:0000071 - - @@ -2951,12 +2679,6 @@ Butterfly-shaped rash face that covers the cheeks and bridge of the nose - - - - - - @@ -2965,7 +2687,6 @@ ARIS:0000073 - @@ -2974,8 +2695,6 @@ ARIS:0000074 - - @@ -2984,7 +2703,6 @@ ARIS:0000075 - @@ -2993,7 +2711,6 @@ ARIS:0000625 - @@ -3002,7 +2719,6 @@ ARIS:0000076 - @@ -3011,7 +2727,6 @@ ARIS:0000077 - @@ -3020,7 +2735,6 @@ ARIS:0000078 - @@ -3029,7 +2743,6 @@ ARIS:0000079 - @@ -3038,7 +2751,6 @@ ARIS:0000080 - @@ -3047,7 +2759,6 @@ ARIS:0000081 - @@ -3056,7 +2767,6 @@ ARIS:0000082 - @@ -3065,23 +2775,6 @@ ARIS:0000083 - - - - - - - - - - - - - - - - - @@ -3090,13 +2783,6 @@ ARIS:0000084 - - - - - - - @@ -3105,7 +2791,6 @@ ARIS:0000626 - @@ -3114,7 +2799,6 @@ ARIS:0000627 - @@ -3123,7 +2807,6 @@ ARIS:0000628 - @@ -3133,8 +2816,6 @@ Massive hepatosplenomegaly and chronic lymphadenopathy - - @@ -3143,7 +2824,6 @@ ARIS:0000629 - @@ -3152,7 +2832,6 @@ ARIS:0000630 - @@ -3161,7 +2840,6 @@ ARIS:0000631 - @@ -3170,7 +2848,6 @@ ARIS:0000632 - @@ -3179,7 +2856,6 @@ ARIS:0000633 - @@ -3188,7 +2864,6 @@ ARIS:0000086 - @@ -3197,7 +2872,6 @@ ARIS:0000087 - @@ -3206,7 +2880,6 @@ ARIS:0000088 - @@ -3215,7 +2888,6 @@ ARIS:0000634 - @@ -3224,7 +2896,6 @@ ARIS:0000089 - @@ -3233,12 +2904,6 @@ ARIS:0000090 - - - - - - @@ -3247,7 +2912,6 @@ ARIS:0000635 - @@ -3256,7 +2920,6 @@ ARIS:0000091 - @@ -3265,7 +2928,6 @@ ARIS:0000092 - @@ -3275,10 +2937,6 @@ Sensitivity to extreme cold - - - - @@ -3287,10 +2945,6 @@ ARIS:0000094 - - - - @@ -3299,7 +2953,6 @@ ARIS:0000095 - @@ -3308,7 +2961,6 @@ ARIS:0000636 - @@ -3317,8 +2969,6 @@ ARIS:0000096 - - @@ -3327,7 +2977,6 @@ ARIS:0000097 - @@ -3336,7 +2985,6 @@ ARIS:0000637 - @@ -3345,15 +2993,6 @@ ARIS:0000098 - - - - - - - - - @@ -3362,7 +3001,6 @@ ARIS:0000099 - @@ -3371,15 +3009,6 @@ ARIS:0000100 - - - - - - - - - @@ -3388,7 +3017,6 @@ ARIS:0000101 - @@ -3397,18 +3025,6 @@ ARIS:0000102 - - - - - - - - - - - - @@ -3418,8 +3034,6 @@ Spitting up blood - - @@ -3428,7 +3042,6 @@ ARIS:0000638 - @@ -3437,11 +3050,6 @@ ARIS:0000104 - - - - - @@ -3450,7 +3058,6 @@ ARIS:0000639 - @@ -3459,7 +3066,6 @@ ARIS:0000105 - @@ -3468,7 +3074,6 @@ ARIS:0000106 - @@ -3477,7 +3082,6 @@ ARIS:0000107 - @@ -3486,8 +3090,6 @@ ARIS:0000108 - - @@ -3496,12 +3098,6 @@ ARIS:0000109 - - - - - - @@ -3510,7 +3106,6 @@ ARIS:0000110 - @@ -3520,9 +3115,6 @@ Lack of sweat - - - @@ -3531,7 +3123,6 @@ ARIS:0000112 - @@ -3540,7 +3131,6 @@ ARIS:0000113 - @@ -3549,7 +3139,6 @@ ARIS:0000114 - @@ -3559,8 +3148,6 @@ Stunted growth in children - - @@ -3569,7 +3156,6 @@ ARIS:0000116 - @@ -3578,8 +3164,6 @@ ARIS:0000117 - - @@ -3588,7 +3172,6 @@ ARIS:0000118 - @@ -3597,17 +3180,6 @@ ARIS:0000119 - - - - - - - - - - - @@ -3616,7 +3188,6 @@ ARIS:0000120 - @@ -3625,7 +3196,6 @@ ARIS:0000121 - @@ -3634,7 +3204,6 @@ ARIS:0000640 - @@ -3643,7 +3212,6 @@ ARIS:0000122 - @@ -3652,28 +3220,6 @@ ARIS:0000123 - - - - - - - - - - - - - - - - - - - - - - @@ -3682,7 +3228,6 @@ ARIS:0000124 - @@ -3691,7 +3236,6 @@ ARIS:0000125 - @@ -3700,9 +3244,6 @@ ARIS:0000126 - - - @@ -3711,9 +3252,6 @@ ARIS:0000127 - - - @@ -3723,11 +3261,6 @@ Concentration loss - - - - - @@ -3736,7 +3269,6 @@ ARIS:0000129 - @@ -3745,7 +3277,6 @@ ARIS:0000130 - @@ -3754,7 +3285,6 @@ ARIS:0000131 - @@ -3764,8 +3294,6 @@ Trouble rising from a chair - - @@ -3774,7 +3302,6 @@ ARIS:0000133 - @@ -3784,8 +3311,6 @@ Impaired color vision / dyschromatopsia - - @@ -3794,16 +3319,6 @@ ARIS:0000135 - - - - - - - - - - @@ -3812,22 +3327,6 @@ ARIS:0000136 - - - - - - - - - - - - - - - - @@ -3836,7 +3335,6 @@ ARIS:0000137 - @@ -3845,7 +3343,6 @@ ARIS:0000138 - @@ -3854,8 +3351,6 @@ ARIS:0000139 - - @@ -3864,7 +3359,6 @@ ARIS:0000140 - @@ -3873,7 +3367,6 @@ ARIS:0000641 - @@ -3882,7 +3375,6 @@ ARIS:0000642 - @@ -3891,7 +3383,6 @@ ARIS:0000643 - @@ -3902,9 +3393,6 @@ Discomfort in legs that is relieved by movement Discomfort in legs that occur mainly at night - - - @@ -3913,7 +3401,6 @@ ARIS:0000142 - @@ -3922,7 +3409,6 @@ ARIS:0000143 - @@ -3931,8 +3417,6 @@ ARIS:0000144 - - @@ -3941,7 +3425,6 @@ ARIS:0000644 - @@ -3950,7 +3433,6 @@ ARIS:0000645 - @@ -3959,7 +3441,6 @@ ARIS:0000646 - @@ -3968,7 +3449,6 @@ ARIS:0000647 - @@ -3977,7 +3457,6 @@ ARIS:0000648 - @@ -3986,7 +3465,6 @@ ARIS:0000145 - @@ -3994,25 +3472,6 @@ Dizziness ARIS:0000146 - - - - - - - - - - - - - - - - - - - @@ -4021,17 +3480,6 @@ ARIS:0000147 - - - - - - - - - - - @@ -4040,10 +3488,6 @@ ARIS:0000148 - - - - @@ -4053,11 +3497,6 @@ Daytime sleepiness - - - - - @@ -4066,8 +3505,6 @@ ARIS:0000150 - - @@ -4076,15 +3513,6 @@ ARIS:0000151 - - - - - - - - - @@ -4093,11 +3521,6 @@ ARIS:0000152 - - - - - @@ -4106,8 +3529,6 @@ ARIS:0000153 - - @@ -4116,7 +3537,6 @@ ARIS:0000154 - @@ -4125,7 +3545,6 @@ ARIS:0000155 - @@ -4134,7 +3553,6 @@ ARIS:0000156 - @@ -4143,8 +3561,6 @@ ARIS:0000157 - - @@ -4153,7 +3569,6 @@ ARIS:0000158 - @@ -4162,7 +3577,6 @@ ARIS:0000649 - @@ -4171,7 +3585,6 @@ ARIS:0000159 - @@ -4180,7 +3593,6 @@ ARIS:0000650 - @@ -4189,7 +3601,6 @@ ARIS:0000160 - @@ -4198,7 +3609,6 @@ ARIS:0000651 - @@ -4207,15 +3617,6 @@ ARIS:0000161 - - - - - - - - - @@ -4224,7 +3625,6 @@ ARIS:0000162 - @@ -4233,7 +3633,6 @@ ARIS:0000163 - @@ -4242,7 +3641,6 @@ ARIS:0000164 - @@ -4251,7 +3649,6 @@ ARIS:0000165 - @@ -4260,7 +3657,6 @@ ARIS:0000166 - @@ -4269,7 +3665,6 @@ ARIS:0000167 - @@ -4279,8 +3674,6 @@ Epilepsy - - @@ -4289,9 +3682,6 @@ ARIS:0000169 - - - @@ -4300,7 +3690,6 @@ ARIS:0000652 - @@ -4309,7 +3698,6 @@ ARIS:0000170 - @@ -4318,7 +3706,6 @@ ARIS:0000171 - @@ -4328,9 +3715,6 @@ An increase in perspiration or warm, moist skin - - - @@ -4339,7 +3723,6 @@ ARIS:0000653 - @@ -4348,7 +3731,6 @@ ARIS:0000654 - @@ -4357,7 +3739,6 @@ ARIS:0000655 - @@ -4366,7 +3747,6 @@ ARIS:0000656 - @@ -4375,8 +3755,6 @@ ARIS:0000173 - - @@ -4385,12 +3763,6 @@ ARIS:0000174 - - - - - - @@ -4399,12 +3771,6 @@ ARIS:0000175 - - - - - - @@ -4413,7 +3779,6 @@ ARIS:0000176 - @@ -4422,21 +3787,6 @@ ARIS:0000177 - - - - - - - - - - - - - - - @@ -4445,7 +3795,6 @@ ARIS:0000178 - @@ -4454,7 +3803,6 @@ ARIS:0000179 - @@ -4463,12 +3811,6 @@ ARIS:0000180 - - - - - - @@ -4477,7 +3819,6 @@ ARIS:0000181 - @@ -4487,8 +3828,6 @@ Facial reddening - - @@ -4497,9 +3836,6 @@ ARIS:0000183 - - - @@ -4508,7 +3844,6 @@ ARIS:0000184 - @@ -4517,8 +3852,6 @@ ARIS:0000185 - - @@ -4527,8 +3860,6 @@ ARIS:0000186 - - @@ -4537,8 +3868,6 @@ ARIS:0000187 - - @@ -4547,7 +3876,6 @@ ARIS:0000188 - @@ -4556,8 +3884,6 @@ ARIS:0000189 - - @@ -4566,82 +3892,6 @@ ARIS:0000190 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - @@ -4650,7 +3900,6 @@ ARIS:0000191 - @@ -4659,8 +3908,6 @@ ARIS:0000192 - - @@ -4669,8 +3916,6 @@ ARIS:0000193 - - @@ -4679,7 +3924,6 @@ ARIS:0000194 - @@ -4688,7 +3932,6 @@ ARIS:0000195 - @@ -4697,51 +3940,6 @@ ARIS:0000196 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - @@ -4750,8 +3948,6 @@ ARIS:0000197 - - @@ -4760,7 +3956,6 @@ ARIS:0000198 - @@ -4769,7 +3964,6 @@ ARIS:0000199 - @@ -4778,7 +3972,6 @@ ARIS:0000200 - @@ -4787,7 +3980,6 @@ ARIS:0000201 - @@ -4796,9 +3988,6 @@ ARIS:0000202 - - - @@ -4808,9 +3997,6 @@ Flu-like prodrome - - - @@ -4819,7 +4005,6 @@ ARIS:0000204 - @@ -4828,8 +4013,6 @@ ARIS:0000205 - - @@ -4838,7 +4021,6 @@ ARIS:0000657 - @@ -4847,7 +4029,6 @@ ARIS:0000206 - @@ -4856,14 +4037,6 @@ ARIS:0000207 - - - - - - - - @@ -4872,7 +4045,6 @@ ARIS:0000208 - @@ -4881,7 +4053,6 @@ ARIS:0000209 - @@ -4890,7 +4061,6 @@ ARIS:0000210 - @@ -4899,7 +4069,6 @@ ARIS:0000211 - @@ -4908,7 +4077,6 @@ ARIS:0000212 - @@ -4917,7 +4085,6 @@ ARIS:0000213 - @@ -4926,7 +4093,6 @@ ARIS:0000658 - @@ -4935,7 +4101,6 @@ ARIS:0000214 - @@ -4944,7 +4109,6 @@ ARIS:0000215 - @@ -4954,8 +4118,6 @@ Gottron's papules / sign - - @@ -4964,7 +4126,6 @@ ARIS:0000216 - @@ -4973,7 +4134,6 @@ ARIS:0000217 - @@ -4983,15 +4143,6 @@ Alopecia - - - - - - - - - @@ -5000,9 +4151,6 @@ ARIS:0000219 - - - @@ -5011,13 +4159,6 @@ ARIS:0000220 - - - - - - - @@ -5026,7 +4167,6 @@ ARIS:0000221 - @@ -5035,8 +4175,6 @@ ARIS:0000222 - - @@ -5045,7 +4183,6 @@ ARIS:0000223 - @@ -5054,7 +4191,6 @@ ARIS:0000660 - @@ -5063,33 +4199,6 @@ ARIS:0000224 - - - - - - - - - - - - - - - - - - - - - - - - - - - @@ -5099,14 +4208,6 @@ Loss of hearing - - - - - - - - @@ -5115,7 +4216,6 @@ ARIS:0000226 - @@ -5124,8 +4224,6 @@ ARIS:0000227 - - @@ -5134,10 +4232,6 @@ ARIS:0000228 - - - - @@ -5146,7 +4240,6 @@ ARIS:0000229 - @@ -5156,13 +4249,6 @@ Prolonged menstrual bleeding - - - - - - - @@ -5171,7 +4257,6 @@ ARIS:0000661 - @@ -5180,7 +4265,6 @@ ARIS:0000231 - @@ -5189,8 +4273,6 @@ ARIS:0000232 - - @@ -5199,7 +4281,6 @@ ARIS:0000233 - @@ -5208,8 +4289,6 @@ ARIS:0000234 - - @@ -5218,7 +4297,6 @@ ARIS:0000662 - @@ -5227,7 +4305,6 @@ ARIS:0000235 - @@ -5236,7 +4313,6 @@ ARIS:0000236 - @@ -5245,9 +4321,6 @@ ARIS:0000237 - - - @@ -5256,8 +4329,6 @@ ARIS:0000238 - - @@ -5267,12 +4338,6 @@ Red or skin colored welts, can vary in size, shape and appear anywhere on the body - - - - - - @@ -5281,8 +4346,6 @@ ARIS:0000240 - - @@ -5291,7 +4354,6 @@ ARIS:0000241 - @@ -5300,9 +4362,6 @@ ARIS:0000242 - - - @@ -5311,7 +4370,6 @@ ARIS:0000663 - @@ -5320,7 +4378,6 @@ ARIS:0000664 - @@ -5329,9 +4386,6 @@ ARIS:0000243 - - - @@ -5340,7 +4394,6 @@ ARIS:0000244 - @@ -5349,7 +4402,6 @@ ARIS:0000665 - @@ -5359,8 +4411,6 @@ Hypogammaglobulinemia with recurrent sinopulmonary bacterial infections - - @@ -5369,7 +4419,6 @@ ARIS:0000667 - @@ -5378,7 +4427,6 @@ ARIS:0000668 - @@ -5387,7 +4435,6 @@ ARIS:0000669 - @@ -5396,7 +4443,6 @@ ARIS:0000670 - @@ -5405,7 +4451,6 @@ ARIS:0000671 - @@ -5414,10 +4459,6 @@ ARIS:0000245 - - - - @@ -5426,7 +4467,6 @@ ARIS:0000246 - @@ -5435,7 +4475,6 @@ ARIS:0000247 - @@ -5444,7 +4483,6 @@ ARIS:0000248 - @@ -5453,10 +4491,6 @@ ARIS:0000249 - - - - @@ -5465,8 +4499,6 @@ ARIS:0000250 - - @@ -5478,13 +4510,6 @@ Inability to conceive after ≥1 year of unprotected intercourse with normal evaluations Unable to conceive Unexplained primary or secondary infertility despite regular intercourse - - - - - - - @@ -5493,7 +4518,6 @@ ARIS:0000252 - @@ -5502,7 +4526,6 @@ ARIS:0000672 - @@ -5511,7 +4534,6 @@ ARIS:0000673 - @@ -5520,7 +4542,6 @@ ARIS:0000253 - @@ -5529,11 +4550,6 @@ ARIS:0000254 - - - - - @@ -5542,7 +4558,6 @@ ARIS:0000674 - @@ -5551,15 +4566,6 @@ ARIS:0000255 - - - - - - - - - @@ -5568,16 +4574,6 @@ ARIS:0000256 - - - - - - - - - - @@ -5586,7 +4582,6 @@ ARIS:0000257 - @@ -5595,7 +4590,6 @@ ARIS:0000258 - @@ -5605,14 +4599,6 @@ Itchy skin - - - - - - - - @@ -5621,7 +4607,6 @@ ARIS:0000260 - @@ -5630,7 +4615,6 @@ ARIS:0000261 - @@ -5639,7 +4623,6 @@ ARIS:0000262 - @@ -5648,48 +4631,6 @@ ARIS:0000263 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - @@ -5698,14 +4639,6 @@ ARIS:0000264 - - - - - - - - @@ -5714,8 +4647,6 @@ ARIS:0000265 - - @@ -5724,8 +4655,6 @@ ARIS:0000266 - - @@ -5734,7 +4663,6 @@ ARIS:0000267 - @@ -5743,7 +4671,6 @@ ARIS:0000268 - @@ -5752,7 +4679,6 @@ ARIS:0000269 - @@ -5761,7 +4687,6 @@ ARIS:0000270 - @@ -5770,7 +4695,6 @@ ARIS:0000675 - @@ -5779,7 +4703,6 @@ ARIS:0000676 - @@ -5788,7 +4711,6 @@ ARIS:0000271 - @@ -5797,7 +4719,6 @@ ARIS:0000272 - @@ -5806,9 +4727,6 @@ ARIS:0000273 - - - @@ -5817,7 +4735,6 @@ ARIS:0000274 - @@ -5826,8 +4743,6 @@ ARIS:0000275 - - @@ -5836,10 +4751,6 @@ ARIS:0000276 - - - - @@ -5848,7 +4759,6 @@ ARIS:0000677 - @@ -5858,8 +4768,6 @@ Restricted mobility - - @@ -5868,7 +4776,6 @@ ARIS:0000278 - @@ -5877,7 +4784,6 @@ ARIS:0000279 - @@ -5886,7 +4792,6 @@ ARIS:0000280 - @@ -5895,7 +4800,6 @@ ARIS:0000678 - @@ -5904,8 +4808,6 @@ ARIS:0000281 - - @@ -5914,7 +4816,6 @@ ARIS:0000282 - @@ -5923,10 +4824,6 @@ ARIS:0000283 - - - - @@ -5935,7 +4832,6 @@ ARIS:0000284 - @@ -5944,7 +4840,6 @@ ARIS:0000285 - @@ -5954,8 +4849,6 @@ Absence of eyelashes - - @@ -5964,7 +4857,6 @@ ARIS:0000287 - @@ -5973,8 +4865,6 @@ ARIS:0000288 - - @@ -5983,7 +4873,6 @@ ARIS:0000289 - @@ -5992,7 +4881,6 @@ ARIS:0000290 - @@ -6001,7 +4889,6 @@ ARIS:0000291 - @@ -6010,7 +4897,6 @@ ARIS:0000292 - @@ -6020,12 +4906,6 @@ Sensory impairment - - - - - - @@ -6034,7 +4914,6 @@ ARIS:0000294 - @@ -6043,7 +4922,6 @@ ARIS:0000295 - @@ -6068,7 +4946,6 @@ ARIS:0000298 - @@ -6077,8 +4954,6 @@ ARIS:0000299 - - @@ -6087,7 +4962,6 @@ ARIS:0000300 - @@ -6096,8 +4970,6 @@ ARIS:0000679 - - @@ -6106,12 +4978,6 @@ ARIS:0000301 - - - - - - @@ -6120,7 +4986,6 @@ ARIS:0000680 - @@ -6129,7 +4994,6 @@ ARIS:0000302 - @@ -6138,7 +5002,6 @@ ARIS:0000681 - @@ -6147,7 +5010,6 @@ ARIS:0000303 - @@ -6157,16 +5019,6 @@ Difficulty retaining information - - - - - - - - - - @@ -6175,7 +5027,6 @@ ARIS:0000305 - @@ -6184,7 +5035,6 @@ ARIS:0000306 - @@ -6193,7 +5043,6 @@ ARIS:0000307 - @@ -6203,8 +5052,6 @@ Microangiopathic hemolytic anemia with fragmented schistocytes - - @@ -6213,9 +5060,6 @@ ARIS:0000309 - - - @@ -6224,7 +5068,6 @@ ARIS:0000310 - @@ -6233,7 +5076,6 @@ ARIS:0000682 - @@ -6242,7 +5084,6 @@ ARIS:0000311 - @@ -6251,7 +5092,6 @@ ARIS:0000312 - @@ -6260,7 +5100,6 @@ ARIS:0000313 - @@ -6269,8 +5108,6 @@ ARIS:0000314 - - @@ -6279,10 +5116,6 @@ ARIS:0000315 - - - - @@ -6291,7 +5124,6 @@ ARIS:0000316 - @@ -6301,17 +5133,6 @@ Mouth ulcers - - - - - - - - - - - @@ -6320,7 +5141,6 @@ ARIS:0000318 - @@ -6329,7 +5149,6 @@ ARIS:0000683 - @@ -6338,7 +5157,6 @@ ARIS:0000319 - @@ -6347,7 +5165,6 @@ ARIS:0000684 - @@ -6356,7 +5173,6 @@ ARIS:0000320 - @@ -6365,8 +5181,6 @@ ARIS:0000321 - - @@ -6376,8 +5190,6 @@ Peripheral nerve hyperexcitability (myokymia, fasciculations, muscle cramps) - - @@ -6386,7 +5198,6 @@ ARIS:0000322 - @@ -6395,33 +5206,6 @@ ARIS:0000323 - - - - - - - - - - - - - - - - - - - - - - - - - - - @@ -6430,7 +5214,6 @@ ARIS:0000324 - @@ -6439,13 +5222,6 @@ ARIS:0000325 - - - - - - - @@ -6454,8 +5230,6 @@ ARIS:0000326 - - @@ -6464,8 +5238,6 @@ ARIS:0000327 - - @@ -6474,7 +5246,6 @@ ARIS:0000328 - @@ -6483,7 +5254,6 @@ ARIS:0000329 - @@ -6492,9 +5262,6 @@ ARIS:0000330 - - - @@ -6503,33 +5270,6 @@ ARIS:0000331 - - - - - - - - - - - - - - - - - - - - - - - - - - - @@ -6538,7 +5278,6 @@ ARIS:0000332 - @@ -6547,7 +5286,6 @@ ARIS:0000333 - @@ -6556,7 +5294,6 @@ ARIS:0000686 - @@ -6565,12 +5302,6 @@ ARIS:0000334 - - - - - - @@ -6580,8 +5311,6 @@ Increased urination at night - - @@ -6590,7 +5319,6 @@ ARIS:0000336 - @@ -6599,7 +5327,6 @@ ARIS:0000337 - @@ -6608,7 +5335,6 @@ ARIS:0000338 - @@ -6617,7 +5343,6 @@ ARIS:0000339 - @@ -6626,7 +5351,6 @@ ARIS:0000340 - @@ -6635,7 +5359,6 @@ ARIS:0000341 - @@ -6644,12 +5367,6 @@ ARIS:0000342 - - - - - - @@ -6658,15 +5375,6 @@ ARIS:0000343 - - - - - - - - - @@ -6675,7 +5383,6 @@ ARIS:0000344 - @@ -6684,7 +5391,6 @@ ARIS:0000687 - @@ -6693,7 +5399,6 @@ ARIS:0000688 - @@ -6702,7 +5407,6 @@ ARIS:0000345 - @@ -6711,7 +5415,6 @@ ARIS:0000346 - @@ -6720,7 +5423,6 @@ ARIS:0000689 - @@ -6729,7 +5431,6 @@ ARIS:0000347 - @@ -6738,7 +5439,6 @@ ARIS:0000348 - @@ -6747,7 +5447,6 @@ ARIS:0000349 - @@ -6756,108 +5455,6 @@ ARIS:0000350 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - @@ -6866,7 +5463,6 @@ ARIS:0000351 - @@ -6875,7 +5471,6 @@ ARIS:0000352 - @@ -6884,7 +5479,6 @@ ARIS:0000353 - @@ -6893,9 +5487,6 @@ ARIS:0000354 - - - @@ -6905,9 +5496,6 @@ Pain when urinating - - - @@ -6916,7 +5504,6 @@ ARIS:0000356 - @@ -6925,7 +5512,6 @@ ARIS:0000357 - @@ -6934,7 +5520,6 @@ ARIS:0000358 - @@ -6944,9 +5529,6 @@ Tendon pain - - - @@ -6955,7 +5537,6 @@ ARIS:0000360 - @@ -6964,7 +5545,6 @@ ARIS:0000361 - @@ -6973,7 +5553,6 @@ ARIS:0000362 - @@ -6982,7 +5561,6 @@ ARIS:0000363 - @@ -6991,7 +5569,6 @@ ARIS:0000364 - @@ -7000,7 +5577,6 @@ ARIS:0000365 - @@ -7009,7 +5585,6 @@ ARIS:0000366 - @@ -7018,7 +5593,6 @@ ARIS:0000367 - @@ -7027,7 +5601,6 @@ ARIS:0000368 - @@ -7036,7 +5609,6 @@ ARIS:0000690 - @@ -7045,7 +5617,6 @@ ARIS:0000369 - @@ -7054,7 +5625,6 @@ ARIS:0000691 - @@ -7063,7 +5633,6 @@ ARIS:0000370 - @@ -7072,7 +5641,6 @@ ARIS:0000371 - @@ -7081,7 +5649,6 @@ ARIS:0000372 - @@ -7090,7 +5657,6 @@ ARIS:0000373 - @@ -7099,7 +5665,6 @@ ARIS:0000374 - @@ -7108,7 +5673,6 @@ ARIS:0000375 - @@ -7117,7 +5681,6 @@ ARIS:0000376 - @@ -7126,7 +5689,6 @@ ARIS:0000692 - @@ -7135,7 +5697,6 @@ ARIS:0000693 - @@ -7144,9 +5705,6 @@ ARIS:0000377 - - - @@ -7155,7 +5713,6 @@ ARIS:0000694 - @@ -7164,7 +5721,6 @@ ARIS:0000695 - @@ -7173,7 +5729,6 @@ ARIS:0000696 - @@ -7182,7 +5737,6 @@ ARIS:0000378 - @@ -7191,10 +5745,6 @@ ARIS:0000379 - - - - @@ -7204,8 +5754,6 @@ Inability to move the eye - - @@ -7214,7 +5762,6 @@ ARIS:0000381 - @@ -7223,8 +5770,6 @@ ARIS:0000382 - - @@ -7233,7 +5778,6 @@ ARIS:0000383 - @@ -7242,8 +5786,6 @@ ARIS:0000384 - - @@ -7252,7 +5794,6 @@ ARIS:0000697 - @@ -7261,7 +5802,6 @@ ARIS:0000385 - @@ -7270,7 +5810,6 @@ ARIS:0000386 - @@ -7279,7 +5818,6 @@ ARIS:0000387 - @@ -7288,7 +5826,6 @@ ARIS:0000698 - @@ -7297,7 +5834,6 @@ ARIS:0000699 - @@ -7306,7 +5842,6 @@ ARIS:0000700 - @@ -7315,9 +5850,6 @@ ARIS:0000388 - - - @@ -7326,7 +5858,6 @@ ARIS:0000701 - @@ -7336,11 +5867,6 @@ Increased thirst - - - - - @@ -7349,7 +5875,6 @@ ARIS:0000702 - @@ -7359,8 +5884,6 @@ Increased urination - - @@ -7369,7 +5892,6 @@ ARIS:0000391 - @@ -7378,7 +5900,6 @@ ARIS:0000392 - @@ -7387,7 +5908,6 @@ ARIS:0000393 - @@ -7396,7 +5916,6 @@ ARIS:0000394 - @@ -7405,7 +5924,6 @@ ARIS:0000703 - @@ -7414,7 +5932,6 @@ ARIS:0000395 - @@ -7423,7 +5940,6 @@ ARIS:0000704 - @@ -7432,7 +5948,6 @@ ARIS:0000396 - @@ -7441,7 +5956,6 @@ ARIS:0000705 - @@ -7450,7 +5964,6 @@ ARIS:0000397 - @@ -7460,8 +5973,6 @@ Progressive exertional dyspnea and exercise limitation - - @@ -7470,7 +5981,6 @@ ARIS:0000707 - @@ -7479,7 +5989,6 @@ ARIS:0000708 - @@ -7488,7 +5997,6 @@ ARIS:0000398 - @@ -7497,7 +6005,6 @@ ARIS:0000399 - @@ -7506,7 +6013,6 @@ ARIS:0000400 - @@ -7515,7 +6021,6 @@ ARIS:0000401 - @@ -7524,7 +6029,6 @@ ARIS:0000402 - @@ -7533,8 +6037,6 @@ ARIS:0000403 - - @@ -7543,7 +6045,6 @@ ARIS:0000404 - @@ -7552,7 +6053,6 @@ ARIS:0000709 - @@ -7561,7 +6061,6 @@ ARIS:0000405 - @@ -7570,7 +6069,6 @@ ARIS:0000710 - @@ -7579,7 +6077,6 @@ ARIS:0000711 - @@ -7588,7 +6085,6 @@ ARIS:0000406 - @@ -7597,7 +6093,6 @@ ARIS:0000712 - @@ -7606,10 +6101,6 @@ ARIS:0000407 - - - - @@ -7618,7 +6109,6 @@ ARIS:0000408 - @@ -7627,7 +6117,6 @@ ARIS:0000409 - @@ -7636,7 +6125,6 @@ ARIS:0000410 - @@ -7645,7 +6133,6 @@ ARIS:0000411 - @@ -7654,7 +6141,6 @@ ARIS:0000713 - @@ -7663,7 +6149,6 @@ ARIS:0000412 - @@ -7672,7 +6157,6 @@ ARIS:0000413 - @@ -7681,7 +6165,6 @@ ARIS:0000414 - @@ -7690,7 +6173,6 @@ ARIS:0000714 - @@ -7699,16 +6181,6 @@ ARIS:0000415 - - - - - - - - - - @@ -7717,7 +6189,6 @@ ARIS:0000715 - @@ -7726,7 +6197,6 @@ ARIS:0000716 - @@ -7735,7 +6205,6 @@ ARIS:0000717 - @@ -7744,7 +6213,6 @@ ARIS:0000416 - @@ -7753,7 +6221,6 @@ ARIS:0000718 - @@ -7762,33 +6229,6 @@ ARIS:0000417 - - - - - - - - - - - - - - - - - - - - - - - - - - - @@ -7797,7 +6237,6 @@ ARIS:0000418 - @@ -7806,7 +6245,6 @@ ARIS:0000419 - @@ -7815,7 +6253,6 @@ ARIS:0000420 - @@ -7824,7 +6261,6 @@ ARIS:0000719 - @@ -7833,7 +6269,6 @@ ARIS:0000421 - @@ -7842,7 +6277,6 @@ ARIS:0000422 - @@ -7851,7 +6285,6 @@ ARIS:0000720 - @@ -7860,7 +6293,6 @@ ARIS:0000721 - @@ -7869,7 +6301,6 @@ ARIS:0000423 - @@ -7878,7 +6309,6 @@ ARIS:0000722 - @@ -7889,14 +6319,6 @@ Frequent infections Prone to infections - - - - - - - - @@ -7905,7 +6327,6 @@ ARIS:0000425 - @@ -7914,7 +6335,6 @@ ARIS:0000723 - @@ -7923,7 +6343,6 @@ ARIS:0000426 - @@ -7932,14 +6351,6 @@ ARIS:0000427 - - - - - - - - @@ -7948,7 +6359,6 @@ ARIS:0000428 - @@ -7957,7 +6367,6 @@ ARIS:0000429 - @@ -7966,7 +6375,6 @@ ARIS:0000430 - @@ -7975,7 +6383,6 @@ ARIS:0000431 - @@ -7984,10 +6391,6 @@ ARIS:0000432 - - - - @@ -7996,7 +6399,6 @@ ARIS:0000433 - @@ -8005,7 +6407,6 @@ ARIS:0000434 - @@ -8014,9 +6415,6 @@ ARIS:0000435 - - - @@ -8025,7 +6423,6 @@ ARIS:0000724 - @@ -8034,7 +6431,6 @@ ARIS:0000725 - @@ -8043,7 +6439,6 @@ ARIS:0000726 - @@ -8052,7 +6447,6 @@ ARIS:0000436 - @@ -8061,7 +6455,6 @@ ARIS:0000727 - @@ -8070,7 +6463,6 @@ ARIS:0000437 - @@ -8079,7 +6471,6 @@ ARIS:0000438 - @@ -8088,7 +6479,6 @@ ARIS:0000728 - @@ -8097,7 +6487,6 @@ ARIS:0000729 - @@ -8106,7 +6495,6 @@ ARIS:0000439 - @@ -8115,7 +6503,6 @@ ARIS:0000440 - @@ -8125,11 +6512,6 @@ Ringing in the ear - - - - - @@ -8138,7 +6520,6 @@ ARIS:0000442 - @@ -8147,7 +6528,6 @@ ARIS:0000443 - @@ -8156,7 +6536,6 @@ ARIS:0000444 - @@ -8165,7 +6544,6 @@ ARIS:0000445 - @@ -8174,7 +6552,6 @@ ARIS:0000446 - @@ -8183,7 +6560,6 @@ ARIS:0000447 - @@ -8192,7 +6568,6 @@ ARIS:0000448 - @@ -8201,8 +6576,6 @@ ARIS:0000449 - - @@ -8211,7 +6584,6 @@ ARIS:0000450 - @@ -8221,8 +6593,6 @@ Apparent flashes of light - - @@ -8231,7 +6601,6 @@ ARIS:0000452 - @@ -8240,7 +6609,6 @@ ARIS:0000453 - @@ -8249,21 +6617,6 @@ ARIS:0000454 - - - - - - - - - - - - - - - @@ -8272,8 +6625,6 @@ ARIS:0000455 - - @@ -8282,7 +6633,6 @@ ARIS:0000456 - @@ -8291,19 +6641,6 @@ ARIS:0000457 - - - - - - - - - - - - - @@ -8312,7 +6649,6 @@ ARIS:0000458 - @@ -8321,7 +6657,6 @@ ARIS:0000730 - @@ -8330,7 +6665,6 @@ ARIS:0000459 - @@ -8339,7 +6673,6 @@ ARIS:0000731 - @@ -8348,7 +6681,6 @@ ARIS:0000732 - @@ -8357,7 +6689,6 @@ ARIS:0000460 - @@ -8366,7 +6697,6 @@ ARIS:0000733 - @@ -8375,7 +6705,6 @@ ARIS:0000734 - @@ -8385,8 +6714,6 @@ Severe neck flexor weakness and prominent dysphagia - - @@ -8395,7 +6722,6 @@ ARIS:0000736 - @@ -8404,7 +6730,6 @@ ARIS:0000737 - @@ -8413,7 +6738,6 @@ ARIS:0000738 - @@ -8422,8 +6746,6 @@ ARIS:0000461 - - @@ -8432,7 +6754,6 @@ ARIS:0000462 - @@ -8441,7 +6762,6 @@ ARIS:0000739 - @@ -8450,7 +6770,6 @@ ARIS:0000740 - @@ -8459,7 +6778,6 @@ ARIS:0000463 - @@ -8469,8 +6787,6 @@ Symmetrical proximal muscle weakness - - @@ -8479,7 +6795,6 @@ ARIS:0000742 - @@ -8488,7 +6803,6 @@ ARIS:0000464 - @@ -8497,7 +6811,6 @@ ARIS:0000465 - @@ -8506,7 +6819,6 @@ ARIS:0000466 - @@ -8515,7 +6827,6 @@ ARIS:0000743 - @@ -8524,7 +6835,6 @@ ARIS:0000744 - @@ -8533,7 +6843,6 @@ ARIS:0000467 - @@ -8542,7 +6851,6 @@ ARIS:0000745 - @@ -8551,7 +6859,6 @@ ARIS:0000746 - @@ -8560,7 +6867,6 @@ ARIS:0000747 - @@ -8569,7 +6875,6 @@ ARIS:0000468 - @@ -8578,7 +6883,6 @@ ARIS:0000469 - @@ -8588,53 +6892,6 @@ Difficulty breathing - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - @@ -8644,8 +6901,6 @@ Trouble breathing when you exercise - - @@ -8654,8 +6909,6 @@ ARIS:0000472 - - @@ -8664,7 +6917,6 @@ ARIS:0000748 - @@ -8673,7 +6925,6 @@ ARIS:0000473 - @@ -8682,7 +6933,6 @@ ARIS:0000749 - @@ -8692,8 +6942,6 @@ Sinus inflammation - - @@ -8702,18 +6950,6 @@ ARIS:0000475 - - - - - - - - - - - - @@ -8722,7 +6958,6 @@ ARIS:0000476 - @@ -8732,9 +6967,6 @@ Skin stiffening - - - @@ -8743,7 +6975,6 @@ ARIS:0000478 - @@ -8752,7 +6983,6 @@ ARIS:0000479 - @@ -8761,10 +6991,6 @@ ARIS:0000480 - - - - @@ -8774,14 +7000,6 @@ skin sores - - - - - - - - @@ -8790,7 +7008,6 @@ ARIS:0000482 - @@ -8799,9 +7016,6 @@ ARIS:0000483 - - - @@ -8810,7 +7024,6 @@ ARIS:0000484 - @@ -8819,17 +7032,6 @@ ARIS:0000485 - - - - - - - - - - - @@ -8838,7 +7040,6 @@ ARIS:0000750 - @@ -8847,7 +7048,6 @@ ARIS:0000486 - @@ -8856,7 +7056,6 @@ ARIS:0000487 - @@ -8865,7 +7064,6 @@ ARIS:0000488 - @@ -8874,7 +7072,6 @@ ARIS:0000489 - @@ -8883,7 +7080,6 @@ ARIS:0000490 - @@ -8892,7 +7088,6 @@ ARIS:0000491 - @@ -8901,7 +7096,6 @@ ARIS:0000492 - @@ -8911,10 +7105,6 @@ Throat pain - - - - @@ -8923,7 +7113,6 @@ ARIS:0000494 - @@ -8932,7 +7121,6 @@ ARIS:0000495 - @@ -8941,7 +7129,6 @@ ARIS:0000496 - @@ -8950,7 +7137,6 @@ ARIS:0000497 - @@ -8958,26 +7144,6 @@ Stiffness ARIS:0000498 - - - - - - - - - - - - - - - - - - - - @@ -8986,7 +7152,6 @@ ARIS:0000499 - @@ -8996,8 +7161,6 @@ Tightness of the skin of the fingers - - @@ -9006,8 +7169,6 @@ ARIS:0000501 - - @@ -9016,7 +7177,6 @@ ARIS:0000502 - @@ -9025,7 +7185,6 @@ ARIS:0000503 - @@ -9034,7 +7193,6 @@ ARIS:0000751 - @@ -9043,7 +7201,6 @@ ARIS:0000504 - @@ -9052,7 +7209,6 @@ ARIS:0000752 - @@ -9060,41 +7216,6 @@ Swelling ARIS:0000505 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - @@ -9103,7 +7224,6 @@ ARIS:0000506 - @@ -9112,7 +7232,6 @@ ARIS:0000507 - @@ -9121,7 +7240,6 @@ ARIS:0000508 - @@ -9130,10 +7248,6 @@ ARIS:0000509 - - - - @@ -9142,7 +7256,6 @@ ARIS:0000510 - @@ -9151,11 +7264,6 @@ ARIS:0000511 - - - - - @@ -9164,7 +7272,6 @@ ARIS:0000512 - @@ -9173,8 +7280,6 @@ ARIS:0000513 - - @@ -9183,15 +7288,6 @@ ARIS:0000514 - - - - - - - - - @@ -9200,7 +7296,6 @@ ARIS:0000515 - @@ -9209,13 +7304,6 @@ ARIS:0000516 - - - - - - - @@ -9224,7 +7312,6 @@ ARIS:0000517 - @@ -9233,7 +7320,6 @@ ARIS:0000518 - @@ -9242,16 +7328,6 @@ ARIS:0000519 - - - - - - - - - - @@ -9260,8 +7336,6 @@ ARIS:0000520 - - @@ -9270,9 +7344,6 @@ ARIS:0000521 - - - @@ -9281,8 +7352,6 @@ ARIS:0000522 - - @@ -9291,7 +7360,6 @@ ARIS:0000523 - @@ -9300,7 +7368,6 @@ ARIS:0000524 - @@ -9309,7 +7376,6 @@ ARIS:0000525 - @@ -9318,8 +7384,6 @@ ARIS:0000526 - - @@ -9328,7 +7392,6 @@ ARIS:0000527 - @@ -9337,7 +7400,6 @@ ARIS:0000528 - @@ -9346,7 +7408,6 @@ ARIS:0000529 - @@ -9355,7 +7416,6 @@ ARIS:0000753 - @@ -9364,7 +7424,6 @@ ARIS:0000754 - @@ -9373,7 +7432,6 @@ ARIS:0000755 - @@ -9382,14 +7440,6 @@ ARIS:0000530 - - - - - - - - @@ -9398,7 +7448,6 @@ ARIS:0000531 - @@ -9407,7 +7456,6 @@ ARIS:0000532 - @@ -9416,7 +7464,6 @@ ARIS:0000533 - @@ -9425,7 +7472,6 @@ ARIS:0000534 - @@ -9434,7 +7480,6 @@ ARIS:0000535 - @@ -9443,7 +7488,6 @@ ARIS:0000536 - @@ -9452,7 +7496,6 @@ ARIS:0000537 - @@ -9461,7 +7504,6 @@ ARIS:0000538 - @@ -9470,7 +7512,6 @@ ARIS:0000539 - @@ -9479,7 +7520,6 @@ ARIS:0000540 - @@ -9488,7 +7528,6 @@ ARIS:0000541 - @@ -9497,7 +7536,6 @@ ARIS:0000542 - @@ -9507,21 +7545,6 @@ Prickling sensations - - - - - - - - - - - - - - - @@ -9530,7 +7553,6 @@ ARIS:0000544 - @@ -9539,8 +7561,6 @@ ARIS:0000545 - - @@ -9549,7 +7569,6 @@ ARIS:0000546 - @@ -9558,7 +7577,6 @@ ARIS:0000547 - @@ -9567,7 +7585,6 @@ ARIS:0000548 - @@ -9576,7 +7593,6 @@ ARIS:0000549 - @@ -9585,9 +7601,6 @@ ARIS:0000550 - - - @@ -9596,7 +7609,6 @@ ARIS:0000551 - @@ -9605,7 +7617,6 @@ ARIS:0000756 - @@ -9614,7 +7625,6 @@ ARIS:0000552 - @@ -9623,7 +7633,6 @@ ARIS:0000757 - @@ -9632,7 +7641,6 @@ ARIS:0000758 - @@ -9641,10 +7649,6 @@ ARIS:0000553 - - - - @@ -9653,7 +7657,6 @@ ARIS:0000759 - @@ -9662,7 +7665,6 @@ ARIS:0000554 - @@ -9671,7 +7673,6 @@ ARIS:0000555 - @@ -9680,17 +7681,6 @@ ARIS:0000556 - - - - - - - - - - - @@ -9699,7 +7689,6 @@ ARIS:0000760 - @@ -9708,7 +7697,6 @@ ARIS:0000557 - @@ -9717,7 +7705,6 @@ ARIS:0000558 - @@ -9726,7 +7713,6 @@ ARIS:0000559 - @@ -9735,7 +7721,6 @@ ARIS:0000560 - @@ -9744,7 +7729,6 @@ ARIS:0000561 - @@ -9753,9 +7737,6 @@ ARIS:0000562 - - - @@ -9764,7 +7745,6 @@ ARIS:0000563 - @@ -9773,17 +7753,6 @@ ARIS:0000564 - - - - - - - - - - - @@ -9792,45 +7761,6 @@ ARIS:0000565 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - @@ -9839,7 +7769,6 @@ ARIS:0000761 - @@ -9848,7 +7777,6 @@ ARIS:0000762 - @@ -9857,7 +7785,6 @@ ARIS:0000566 - @@ -9867,8 +7794,6 @@ Vitreous floaters and hazy vision - - @@ -9877,7 +7802,6 @@ ARIS:0000567 - @@ -9886,32 +7810,6 @@ ARIS:0000568 - - - - - - - - - - - - - - - - - - - - - - - - - - @@ -9920,7 +7818,6 @@ ARIS:0000569 - @@ -9929,13 +7826,6 @@ ARIS:0000570 - - - - - - - @@ -9944,53 +7834,6 @@ ARIS:0000571 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - @@ -9999,9 +7842,6 @@ ARIS:0000572 - - - @@ -10010,7 +7850,6 @@ ARIS:0000573 - @@ -10019,7 +7858,6 @@ ARIS:0000574 - @@ -10028,9 +7866,6 @@ ARIS:0000575 - - - @@ -10039,7 +7874,6 @@ ARIS:0000576 - @@ -10048,7 +7882,6 @@ ARIS:0000577 - @@ -10057,12 +7890,6 @@ ARIS:0000578 - - - - - - @@ -10071,7 +7898,6 @@ ARIS:0000579 - @@ -10080,7 +7906,6 @@ ARIS:0000580 - @@ -10089,10 +7914,6 @@ ARIS:0000581 - - - - @@ -10101,50 +7922,6 @@ ARIS:0000582 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - @@ -10153,7 +7930,6 @@ ARIS:0000764 - @@ -10162,8 +7938,6 @@ ARIS:0000583 - - @@ -10172,7 +7946,6 @@ ARIS:0000584 - @@ -10181,7 +7954,6 @@ ARIS:0000585 - @@ -10190,7 +7962,6 @@ ARIS:0000586 - @@ -10199,7 +7970,6 @@ ARIS:0000587 - @@ -10208,7 +7978,6 @@ ARIS:0000588 - @@ -10217,7 +7986,6 @@ ARIS:0000589 - @@ -10226,7 +7994,6 @@ ARIS:0000590 - @@ -10235,7 +8002,6 @@ ARIS:0000765 - @@ -10244,7 +8010,6 @@ ARIS:0000591 - @@ -10253,8 +8018,6 @@ ARIS:0000592 - - @@ -10263,7 +8026,6 @@ ARIS:0000593 - @@ -10272,12 +8034,6 @@ ARIS:0000594 - - - - - - @@ -10286,13 +8042,6 @@ ARIS:0000595 - - - - - - - @@ -10301,7 +8050,6 @@ ARIS:0000596 - diff --git a/notebook/symptom-mapping/build_symptom_mapping.py b/notebook/symptom-mapping/build_symptom_mapping.py index ba5465f..55d699d 100644 --- a/notebook/symptom-mapping/build_symptom_mapping.py +++ b/notebook/symptom-mapping/build_symptom_mapping.py @@ -17,12 +17,14 @@ - Symptoms sheet of report 4: mapping and parent columns after the existing ones - Symptom Mapping sheet of report 4: one row per symptom string - ari_symptoms.owl next to this script: a class per mapped symptom under the referenced SYMP terms + - symptomConcept on every Symptom individual in ontologies/ari_t1d.owl: the ari_symptoms.owl class + its label maps to (the Merged Into row's class for a merged label, none for "not a symptom") Usage: python build_symptom_mapping.py The database folder is not tracked in git, so pass the path of a checkout holding symp.owl (http://purl.obolibrary.org/obo/symp.owl) and hp.obo (http://purl.obolibrary.org/obo/hp.obo). """ -import collections, csv, os, sys +import collections, csv, os, re, sys import xml.etree.ElementTree as ET from xml.sax.saxutils import escape, quoteattr @@ -60,6 +62,10 @@ def obo_iri(curie): return OBO + curie.replace(":", "_") +def aris_iri(symptom_id): + return f"{BASE}#{symptom_id.replace(':', '_')}" + + def read_symp(path): """SYMP CURIE -> (label, [parent CURIEs]) for every non-obsolete term, and the release IRI.""" root = ET.parse(path).getroot() @@ -243,21 +249,16 @@ def resource(tag, iri): return f" <{tag} rdf:resource={quoteattr(iri)}/>\n" -def write_owl(rows, by_name, symp, versions, individuals): +def write_owl(rows, by_name, symp, versions): """A class per exact or broader row, under its parent; SYMP terms it references, with their ancestors.""" def iri(row_id): - return obo_iri(row_id) if row_id.startswith("SYMP:") else f"{BASE}#{row_id.replace(':', '_')}" + return obo_iri(row_id) if row_id.startswith("SYMP:") else aris_iri(row_id) concepts = [r for r in rows if r["Mapping"] in MAPPED] alt_labels = collections.defaultdict(list) for r in rows: if r["Merged Into"]: alt_labels[r["Merged Into"]].append(r["Symptom"]) - ind_by_label = collections.defaultdict(list) - for ind, label in individuals.items(): - r = by_name[label] - ind_by_label[r["Merged Into"] or label].append(ARI_BASE + ind) - needed, stack = set(), [r["SYMP ID"] for r in concepts] while stack: curie = stack.pop() @@ -280,18 +281,15 @@ def iri(row_id): "and the Human Phenotype Ontology (HPO) for ARI#132, generated from " "notebook/symptom-mapping/symptom_mapping.tsv. skos:exactMatch names a SYMP or HPO term with the " "same meaning, skos:broadMatch the nearest broader one. Strings merged into a " - "symptom are skos:altLabel. ariSymptomIndividual links the Symptom individuals in " - "ontologies/ari_t1d.owl that carry the symptom. SYMP classes are copied with their labels and " + "symptom are skos:altLabel. The Symptom individuals in ontologies/ari_t1d.owl point at their " + "class with symptomConcept. SYMP classes are copied with their labels and " "is_a parents only; HPO terms are referenced by IRI.\n" + "".join(f' \n' for v in versions) + "\n\n" '\n' '\n' '\n' - '\n' - '\n' - " ARI symptom individual\n" - "\n\n" + '\n\n' ] for curie in sorted(needed): out.append(f"\n") @@ -307,7 +305,6 @@ def iri(row_id): if curie: out.append(resource("skos:exactMatch" if mapping == "exact" else "skos:broadMatch", obo_iri(curie))) out.extend(literal("skos:altLabel", a) for a in sorted(alt_labels[r["Symptom"]])) - out.extend(resource("ariSymptomIndividual", i) for i in sorted(ind_by_label[r["Symptom"]])) out.extend(resource("rdfs:subClassOf", iri(p[1])) for p in parents_of(r, by_name, symp)) out.append("\n\n") out.append("\n") @@ -316,6 +313,38 @@ def iri(row_id): return len(concepts), len(needed) +def write_ontology_links(by_name, individuals): + """Set symptomConcept on every Symptom individual in ari_t1d.owl from its label's row. + + Edits the file line by line so nothing else in it moves: a symptomConcept line inside a Symptom + individual is dropped, and the one its label maps to is written after its rdfs:label. + """ + text = open(ONTOLOGY, encoding="utf-8", newline="").read() + if '' not in text: + raise SystemExit(f"{ONTOLOGY} does not declare the symptomConcept annotation property") + opening = re.compile(r'<[\w:]+ rdf:about="(#[^"]+)">') + out, current, linked = [], None, 0 + for line in text.splitlines(keepends=True): + match = opening.match(line) + if match and match.group(1) in individuals: + current = match.group(1) + elif current and line.startswith("{ending}') + linked += 1 + with open(ONTOLOGY, "w", encoding="utf-8", newline="") as f: + f.write("".join(out)) + return linked + + def main(): if len(sys.argv) != 2: raise SystemExit(__doc__) @@ -332,13 +361,15 @@ def main(): raise SystemExit(f"{len(missing)} symptoms have no row in symptom_mapping.tsv: {missing}") write_report(by_name, symp, ontology_diseases) - classes, symp_classes = write_owl(rows, by_name, symp, [symp_version, hp_version], individuals) + classes, symp_classes = write_owl(rows, by_name, symp, [symp_version, hp_version]) + linked = write_ontology_links(by_name, individuals) counts = collections.Counter(r["Mapping"] for r in rows) print(f"{len(rows)} symptom strings: " + ", ".join(f"{n} {k}" for k, n in sorted(counts.items()))) hpo = collections.Counter(r["HPO Mapping"] for r in rows if r["HPO Mapping"]) print("HPO: " + ", ".join(f"{n} {k}" for k, n in sorted(hpo.items()))) print(f"{sum(1 for r in rows if r['Parent Symptom'])} grouped under an ARI parent symptom") print(f"{classes} ARI symptom classes, {symp_classes} SYMP classes -> {OUT}") + print(f"{linked} of {len(individuals)} Symptom individuals linked by symptomConcept -> {ONTOLOGY}") if __name__ == "__main__": diff --git a/ontologies/ari_t1d.owl b/ontologies/ari_t1d.owl index e34cc72..57d3cc3 100644 --- a/ontologies/ari_t1d.owl +++ b/ontologies/ari_t1d.owl @@ -236,6 +236,11 @@ + + symptom concept + The shared ARI symptom (an ARIS class in notebook/symptom-mapping/ari_symptoms.owl) that this per-disease Symptom individual is. Written by notebook/symptom-mapping/build_symptom_mapping.py from the curated symptom_mapping.tsv, keyed by the individual's label. + + UBERON:0010000 @@ -689,6 +694,7 @@ Polyuria + Very common (>=90%) Excessive urination due to osmotic diuresis from hyperglycemia HP:0100626 @@ -699,6 +705,7 @@ Polydipsia + Very common (>=90%) Excessive thirst caused by dehydration from osmotic diuresis HP:0100627 @@ -709,6 +716,7 @@ Unintended weight loss + Common (60-80%) Weight loss despite normal/increased appetite HP:0001824 @@ -719,6 +727,7 @@ Fatigue + Common (60-80%) Chronic tiredness from metabolic dysregulation HP:0012378 @@ -729,6 +738,7 @@ Blurred vision + Moderate (20-40%) Lens swelling due to hyperglycemia HP:0025147 @@ -739,6 +749,7 @@ Diabetic ketoacidosis (DKA) + Variable (25-40%) Metabolic decompensation with ketone production HP:0001953 @@ -749,6 +760,7 @@ Recurrent infections + Moderate Increased susceptibility to skin, UT, and yeast infections HP:0002718 @@ -759,6 +771,7 @@ Nocturia + Moderate (30-50%) Nighttime urination from impaired renal concentrating ability HP:0000017 @@ -769,6 +782,7 @@ Irritability / mood changes + Common (40-60%) Behavioral changes from hyperglycemia HP:0000737 @@ -779,6 +793,7 @@ Increased appetite (polyphagia) + Common (50-70%) Excessive hunger despite high blood glucose HP:0002591 @@ -1632,6 +1647,7 @@ Polydipsia + HP:0100627 https://pubmed.ncbi.nlm.nih.gov/26494507/ Common (50-70%) @@ -1642,6 +1658,7 @@ Gradual weight loss + HP:0001824 https://pubmed.ncbi.nlm.nih.gov/26494507/ Moderate @@ -1709,6 +1726,7 @@ Fulminant ketoacidosis + Very common (>=90%) Severe DKA within days of symptom onset HP:0001953 @@ -1719,6 +1737,7 @@ Flu-like prodrome + Common (70%) Preceding viral-like illness before abrupt onset HP:0033273 @@ -1818,18 +1837,21 @@ Blisters + false Blisters on various mucous membranes + false Widespread blisters that are not localized to trauma-prone sites + false @@ -1848,18 +1870,21 @@ Mucous-membrane blisters that rupture easily + false Scarring + false When blisters heal they form scars and sometimes tiny white bumps + false @@ -1878,12 +1903,14 @@ Tense, blood- or pus-filled blisters, mostly on the hands, knees, knuckles, elbows and ankles + false Widespread redness and itching + false @@ -1987,48 +2014,56 @@ Swelling + false Blood in stool + false Blood in urine + false Easy bruising + false Urogenital bleeding + false Excessive bleeding + false Nosebleeds + false Solid swellings of congealed blood + false @@ -2132,78 +2167,91 @@ Vision problems + false Weakness in legs + false Weakness in arms + false Confusion + false Drowsiness + false Unsteadiness + false Falling + false Blurred vision + false Double vision, horizontal or vertical, that improves when one eye is closed + false Difficulty swallowing + false Seizures + false Weakness + false Double vision + false @@ -2311,114 +2359,133 @@ The cause of Kawasaki's Disease is uncertain but is believed to be autoimmune. Swelling + false Pain + false Irregular heartbeat + false Peeling skin + false Joint pain + false Hearing loss + false Vomiting + false Diarrhea + false Abdominal pain + false Fever + false Red eyes + false Swollen feet + false Swollen hands + false Skin discoloration + false Red, dry, cracked, and swollen lips + false Rash on groin + false Rash on torso + false Swollen tongue that looks shiny and bright with red spots + false Rash + false @@ -2500,24 +2567,28 @@ The cause of Kawasaki's Disease is uncertain but is believed to be autoimmune. Bumps on skin containing pus + false Bumps on skin containing blood + false Red patches that quickly turn into small bumps 5-15 mm in diameter + false Red patches may be covered with a fine shiny scale + false @@ -2632,108 +2703,126 @@ The cause of Kawasaki's Disease is uncertain but is believed to be autoimmune. Pain + false Joint pain + false Abdominal pain + false Muscle pain + false Weakness + false Fatigue + false Weight loss + false Hyperpigmentation + false Salt craving + false Nausea + false Diarrhea + false Vomiting + false Irritability + false Depression + false Body hair loss + false Sexual dysfunction + false Mouth sores + false Fainting + false @@ -2896,96 +2985,112 @@ The cause of Kawasaki's Disease is uncertain but is believed to be autoimmune. Swelling + false Pain + false Joint pain + false Joint stiffness + false A salmon/pink-colored rash on chest and thighs during fever + false Sore throat + false Difficulty breathing + false Stiffness + false Muscle pain + false Weight loss + false Swelling in armpits + false Swelling in neck + false Fever + false Abdominal pain + false Swollen joints + false Rash + false @@ -3059,24 +3164,28 @@ However, based on the research available at this time, there is no evidence that Vision problems + false Blurred vision + false Dark spots in vision + false Hard to read fine print, drive, or recognize faces + false @@ -3166,36 +3275,42 @@ However, based on the research available at this time, there is no evidence that Beard hair loss + false Eyebrow hair loss + false Loss of eyelashes + false Scalp hair loss + false Hair loss + false Fingernails and toenails have dents, white spots, and roughness + false @@ -3293,90 +3408,105 @@ However, based on the research available at this time, there is no evidence that Swelling + false Weakness + false Weakness in hands + false Loss of feeling in hands + false Weight loss + false Abnormal lumps below skin + false A feeling of fullness or pressure in the chest or abdomen that can cause difficulty breathing or eating + false Cough + false Vomiting + false Fever + false Night sweats + false Nausea + false Fatigue + false Swollen feet + false Swollen ankles + false @@ -3476,102 +3606,119 @@ However, based on the research available at this time, there is no evidence that Pain + false Pain in tendons + false Heel stiffness + false Weight loss + false Heel pain + false Lower back stiffness + false Pain in ligaments + false Eye inflammation + false Hip stiffness + false Hip pain + false Fever + false Fatigue + false Difficulty breathing + false Pain in buttocks + false Back pain + false Stiffness of the buttocks + false Stiffness + false @@ -3673,54 +3820,63 @@ However, based on the research available at this time, there is no evidence that Pain + false Burning + false Fatigue + false Difficulty breathing + false Vomiting + false Nausea + false Burning feeling when urinating + false Chest pain + false Weakness + false @@ -3939,54 +4095,63 @@ However, based on the research available at this time, there is no evidence that Weakness + false Fever + false Weight loss + false Night sweats + false Headache + false Numbness + false Pain + false Fatigue + false Rash + false @@ -4083,24 +4248,28 @@ There's no cure for antiphospholipid syndrome, but medications can reduce the ri Rash + false Deep vein thrombosis + false Miscarriages + false Stillbirths + false @@ -4197,60 +4366,70 @@ The trigger for antisynthetase syndrome is unknown, but it may be associated wit Pain + false Joint pain + false Bluish coloring of hands/feet + false Cough + false Foot pain + false Muscle pain + false Shortness of breath + false Fever + false Thickened skin of fingers + false Weight loss + false @@ -4424,78 +4603,91 @@ The trigger for antisynthetase syndrome is unknown, but it may be associated wit Irregular heartbeat + false Rash + false Rapid heartbeat + false Frequent infections + false Easy bruising + false Fatigue + false Shortness of breath with exertion + false Pale skin + false Nosebleeds + false Bleeding gums + false Prolonged bleeding from cuts + false Dizziness + false Headache + false @@ -4625,48 +4817,56 @@ The trigger for antisynthetase syndrome is unknown, but it may be associated wit Swelling + false Swollen lips + false Swollen hands + false Swollen feet + false Nausea + false Vomiting + false Pain + false Difficulty breathing + false @@ -4853,24 +5053,28 @@ The trigger for antisynthetase syndrome is unknown, but it may be associated wit Hearing loss that may fluctuate, particularly early in the course of the disease + false Ringing in the ear + false Feeling of fullness in the ear + false Vertigo + false @@ -4980,66 +5184,77 @@ The trigger for antisynthetase syndrome is unknown, but it may be associated wit Seizures + false Vision problems + false Euphoria + false Fear + false Panic attacks + false Compulsive behavior + false Unsteady gait + false Cognitive impairment + false Abnormal movement + false Memory problems + false Psychosis + false @@ -5149,84 +5364,98 @@ When the NMDA receptor antibodies attack the NMDA receptors in the brain, certai Fever + false Nausea + false Fatigue + false Anxiety + false Confusion + false Hallucinations + false Aggression + false Paranoid delusions + false Difficulty speaking + false Memory problems + false Mood changes + false Seizures + false Stiffness + false Sleep problems + false @@ -5393,78 +5622,91 @@ When the NMDA receptor antibodies attack the NMDA receptors in the brain, certai Pain + false Burning + false Abdominal bloating + false Indigestion + false Acid reflux/heartburn + false Hiccups + false Nausea + false Vomiting + false Weakness + false Fatigue + false Feeling full quickly after eating + false Gnawing ache in the upper abdomen that may become better or worse with eating + false Burning pain in the upper abdomen that may become better or worse with eating + false @@ -5549,60 +5791,70 @@ When the NMDA receptor antibodies attack the NMDA receptors in the brain, certai Pain + false Weakness + false Muscle pain + false Fatigue + false Difficulty breathing + false Shortness of breath + false Headache + false Dizziness + false Rapid heartbeat + false Chills + false @@ -5710,78 +5962,91 @@ When the NMDA receptor antibodies attack the NMDA receptors in the brain, certai Pain + false Diarrhea + false Joint pain + false Rash + false Fatigue + false Muscle pain + false Edema + false Abnormal skin blood vessels + false Dark urine + false Nausea + false Vomiting + false Abdominal pain + false Yellow eyes + false @@ -6099,24 +6364,28 @@ When the NMDA receptor antibodies attack the NMDA receptors in the brain, certai Low blood counts + false Fatigue + false Yellow skin + false Frequent infections + false @@ -6259,48 +6528,56 @@ In chronic autoimmune neutropenia the body produces IgG antibodies that target a Frequent infections + false Mouth ulcers + false Inflammation of the gums + false Sore throat + false Chest infections + false Diarrhea + false Chills + false Fatigue + false @@ -6389,102 +6666,119 @@ In chronic autoimmune neutropenia the body produces IgG antibodies that target a Pain + false Abdominal cramps + false Burning feeling when urinating + false Absent menstrual period + false Pain during urination + false Pelvic pain + false Infertility + false Bleeding between menstrual cycles + false Pain during sexual intercourse + false Heavy vaginal discharge that has a foul odor + false Difficulty urinating + false Abdominal bloating + false Nausea + false Vomiting + false Fever + false Chills + false Burning + false @@ -6647,72 +6941,84 @@ In chronic autoimmune neutropenia the body produces IgG antibodies that target a Pain + false Weight loss + false Vomiting + false Yellow eyes + false Loose fatty stools that do not flush easily + false Nausea + false Abdominal pain + false Yellow skin + false Fatigue + false Back pain + false Diarrhea + false Shortness of breath + false @@ -6725,6 +7031,7 @@ In chronic autoimmune neutropenia the body produces IgG antibodies that target a Increased thirst + false @@ -6792,48 +7099,56 @@ In chronic autoimmune neutropenia the body produces IgG antibodies that target a Swelling + false Hives + false Spots + false Swelling beneath the skin + false Eczema-like rash + false Circular rash + false Mouth sores + false Rash + false @@ -7031,24 +7346,28 @@ In chronic autoimmune neutropenia the body produces IgG antibodies that target a Apparent flashes of light + false Vision loss + false Vision problems + false Loss of low-light vision + false @@ -7200,150 +7519,175 @@ Several names are used for autoimmune thyroiditis. When it is known to be autoim Pain + false Stiffness + false Joint pain + false Heavy menstrual flow + false Muscle pain + false Sensitivity to extreme cold + false Tenderness + false Hip stiffness + false Brittle fingernails + false Memory problems + false Loss of feeling in feet + false Loss of feeling in hands + false Hoarseness + false Fatigue + false Constipation + false Pale skin + false Dry skin + false Hair loss + false Weight gain + false Depression + false Sluggishness + false Decreased sweating + false Galactorrhea + false Muscle cramps + false Daytime sleepiness + false @@ -7437,18 +7781,21 @@ Urticaria can also be caused by allergic reaction to plants like poison ivy, dye Swelling + false Red or skin colored welts, can vary in size, shape and appear anywhere on the body + false Severe itching + false @@ -7461,12 +7808,14 @@ Urticaria can also be caused by allergic reaction to plants like poison ivy, dye Swollen lips + false Difficulty breathing + false @@ -7639,108 +7988,126 @@ There are many types of vasculitis, and most of them are rare. Vasculitis might Pain + false Dizziness + false Ringing in ears + false Hearing loss + false Redness + false Numbness + false Dark urine + false Rash + false Cough + false Difficulty breathing + false Tingling + false Fever + false Fatigue + false Malaise + false Weight loss + false Joint pain + false Abdominal pain + false Blood in urine + false @@ -7825,42 +8192,49 @@ There are many types of vasculitis, and most of them are rare. Vasculitis might Muscle spasms + false Paralysis + false Seizures + false Cognitive impairment + false Difficulty understanding speech + false Fever + false Difficulty speaking + false @@ -7977,138 +8351,161 @@ This disease is not well understood but is believed to be autoimmune in nature s Swelling + false Pain + false Headache + false Weakness in facial muscles + false Throat muscle weakness + false Blurred vision + false Unsteady gait + false Swollen legs + false Leg pain + false Mouth ulcers + false Eye pain + false Arm pain + false Raised and tender/painful nodules on the skin, especially on the lower legs + false Painful genital sores + false Joint pain + false Skin pain + false Abdominal pain + false Diarrhea + false Fever + false Disorientation + false Eye inflammation + false Vision problems + false Weakness + false @@ -8204,66 +8601,77 @@ Cicatricial pemphigoid is usually not chronic, and most patients symptoms disapp Pain + false Seizures + false Eye sensitivity + false Blisters + false Eye inflammation + false Blindness + false Weight loss + false Pain when urinating + false Itching + false Painful and sensitive blisters that are ruptured + false Lesions + false @@ -8482,48 +8890,56 @@ Cicatricial pemphigoid is usually not chronic, and most patients symptoms disapp Blisters + false Difficulty swallowing + false Large blisters on lower abdomen, groin, upper thighs and arms that don't easily rupture when touched + false Blisters in infants + false Blister inside mouth + false Hives + false Blisters on eyes + false Wart-like plaques on areas of the skin, such as the armpit, neck, groin, and breasts + false @@ -8536,6 +8952,7 @@ Cicatricial pemphigoid is usually not chronic, and most patients symptoms disapp In childhood-onset bullous pemphigoid associated with vaccination, the bullous lesions predominantly affect the palms, soles, and face + false @@ -8799,30 +9216,35 @@ The first reports of narcolepsy being an autoimmune disease came in 2013, but re Daytime sleepiness + false Weakness + false Sleep problems + false Paralysis while falling asleep or upon waking up + false Vivid, dream-like experiences when falling asleep or upon waking up + false @@ -9002,192 +9424,224 @@ CD is generally treated by eliminating gluten from the diet. Patients with an e Swelling + false Pain + false Delayed puberty + false Damage to dental enamel + false Behavioral changes + false Joint pain + false Abdominal pain + false Headache + false Swollen hands + false Bone pain + false Swollen feet + false Miscarriages + false Infertility + false Heavy menstrual flow + false Fatigue + false Weakness + false Bloating + false Gas + false Acid reflux/heartburn + false Nausea + false Vomiting + false Diarrhea + false Constipation + false Lactose intolerance + false Weight loss + false Easy bruising + false Depression + false Canker sores + false Irritability + false Learning disability + false Short stature + false Failure to thrive + false @@ -9315,24 +9769,28 @@ The cause of this syndrome is unknown, however, researchers believe that it may Dizziness + false Pain + false Fatigue + false Sleep problems + false @@ -9345,6 +9803,7 @@ The cause of this syndrome is unknown, however, researchers believe that it may Malaise + false @@ -9473,54 +9932,63 @@ The cause of this syndrome is unknown, however, researchers believe that it may Double vision + false Weakness in hip + false Unsteady gait + false Reduced reflexes + false Weakness in hands + false Pain + false Weakness in feet + false Vision problems + false Weakness + false @@ -9647,54 +10115,63 @@ Currently, the cause of interstitial cystitis is unknown. There are two main the Pain + false Increased frequency of urination + false Bladder pain + false Pain or discomfort while the bladder fills and relief after urinating + false Abdominal pain + false Pain during sexual intercourse + false Vaginal pain + false Penis pain + false Testicle pain + false @@ -9828,138 +10305,161 @@ However, in some people, the Lyme disease triggers symptoms similar to rheumatoi Pain + false Rash + false Fever + false Chills + false Fatigue + false Muscle pain + false Headache + false Joint pain + false Facial paralysis + false Weakness in facial muscles + false Sleep problems + false Malaise + false Heart palpitations + false Decreased movement + false Concentration loss + false Numbness + false Muscle stiffness + false Joint stiffness + false Nausea + false Vomiting + false Brain fog + false Stiffness + false Weakness + false @@ -10084,144 +10584,168 @@ Chronic non-bacterial osteomyelitis (CNO) is a rare auto-inflammatory bone disor Pain + false Tingling + false Hand pain + false Irritability + false Ringing in ears + false Back pain + false Leg pain + false Joint pain + false Fatigue + false Bluish coloring of hands/feet + false Foot pain + false Dizziness + false Headache + false Cold hands + false Cold feet + false Chest pain + false Irregular heartbeat + false Nausea + false Vomiting + false Diarrhea + false Weakness + false Weight loss + false Behavioral changes + false Pain or discomfort in swallowing cold foods and liquids + false @@ -10370,48 +10894,56 @@ More study is needed. Vomiting + true Weight loss + true Loose fatty stools that do not flush easily + true Nausea + true Fatigue + false Diarrhea + true Shortness of breath + false Increased thirst + true @@ -10527,102 +11059,119 @@ More study is needed. Cramps + false Hearing loss + false Ringing in ears + false Unsteady gait + false Pain + false Sensitivity to light + false Red eyes + false Blurred vision + false Dizziness + false Nausea + false Vomiting + false Fever + false Fatigue + false Eye pain + false Vertigo + false Weight loss + false Vision problems + false @@ -10771,102 +11320,119 @@ More study is needed. Pain + false Heart murmur + false Irregular heartbeat + false Fatigue + false Dizziness + false Headache + false Coldness + false Pale skin + false Dark urine + false Yellow skin + false Chest pain + false Back pain + false Leg pain + false Vomiting + false Diarrhea + false Bluish coloring of hands/feet + false Skin discoloration + false @@ -11083,84 +11649,98 @@ More study is needed. Pain + false Burning + false Throbbing pain in limbs + false Changes in nails + false Skin discoloration + false Muscle spasms + false Burning sensation + false Changes in hair + false Skin temperature changes + false Skin texture changes + false Sensitivity to touch + false Sensitivity to extreme cold + false Weakness + false Tremor + false @@ -11386,78 +11966,91 @@ Both UC and CD are caused by an autoimmune response that reflects the involvemen Pain + false Abdominal pain + false Delayed puberty + false Delayed growth + false Abdominal cramps + false Diarrhea + false Fever + false Fatigue + false Blood in stool + false Mouth sores + false Weight loss + false Eye inflammation + false Skin disorders + false @@ -11573,30 +12166,35 @@ Both UC and CD are caused by an autoimmune response that reflects the involvemen Weight loss + false Difficulty breathing + false Fever + false Fatigue + false Cough + false @@ -11767,30 +12365,35 @@ Both UC and CD are caused by an autoimmune response that reflects the involvemen Pain + false Painful rashes + false Painful sores + false Thinning of skin + false Brittle fingernails + false @@ -11803,18 +12406,21 @@ Both UC and CD are caused by an autoimmune response that reflects the involvemen Hair loss + false Skin discoloration + false Rash + false @@ -11888,36 +12494,42 @@ When mastocytosis is not limited to the skin, it is called systemic mastocytosis Pain + false Rapid heartbeat + false Abnormal growths/lesions on the skin that may be painful + false Diarrhea + false Fast breathing + false Difficulty breathing + false @@ -12011,72 +12623,84 @@ When mastocytosis is not limited to the skin, it is called systemic mastocytosis Burning + false Pain + false Rash + false Itchy rash + false Burning rash + false Stinging rash + false Sensitivity to gluten + false Abdominal bloating + false Cramps + false Abdominal pain + false Diarrhea + false Constipation + false @@ -12175,48 +12799,56 @@ When mastocytosis is not limited to the skin, it is called systemic mastocytosis Rash + false Weakness + false Progressive, symmetrical muscle weakness + false Violet/dusky red rash + false Scalp discoloration + false Difficulty swallowing + false Tenderness + false Fatigue + false @@ -12311,72 +12943,84 @@ When mastocytosis is not limited to the skin, it is called systemic mastocytosis Erectile dysfunction + false Weakness + false Bowel changes + false Dry mouth + false Bladder changes + false Eyelid drooping + false Weakness in arms + false Weakness in legs + false Fatigue + false Dry eyes + false Difficulty swallowing + false Difficulty chewing + false @@ -12571,90 +13215,105 @@ When mastocytosis is not limited to the skin, it is called systemic mastocytosis Pain + false Pain after sexual intercourse + false Painful menstrual periods + false Heavy menstrual flow + false Bleeding between menstrual cycles + false Painful cramps during menstrual periods + false Pain and/or cramps in the lower abdomen before menstruation + false Pain when urinating during menstrual periods + false Painful bowel movements during menstrual periods + false Infertility + false Fatigue + false Diarrhea + false Constipation + false Bloating during menstrual periods + false Nausea during menstrual periods + false @@ -12743,96 +13402,112 @@ When mastocytosis is not limited to the skin, it is called systemic mastocytosis Swelling + false Pain + false Toe pain + false Heel pain + false Hip pain + false Knee pain + false Back pain + false Elbow pain + false Pain on the bottom of the foot, especially noticeable when moving + false Swollen heel + false Swollen knees + false Swollen hip + false Swollen toes + false Swollen elbows + false Swollen back + false Swollen feet + false @@ -12916,48 +13591,56 @@ When mastocytosis is not limited to the skin, it is called systemic mastocytosis Chest pain + false Indigestion + false Acid reflux/heartburn + false Abdominal pain + false Poor weight gain + false Difficulty swallowing + false Vomiting + false Food getting stuck in the esophagus after swallowing + false @@ -12970,18 +13653,21 @@ When mastocytosis is not limited to the skin, it is called systemic mastocytosis Pain + false Difficulty eating + false Failure to thrive + false @@ -13075,6 +13761,7 @@ When mastocytosis is not limited to the skin, it is called systemic mastocytosis Confusion + false @@ -13087,60 +13774,70 @@ When mastocytosis is not limited to the skin, it is called systemic mastocytosis Loss of consciousness + false Seizures + false Involuntary movements + false Fear + false Anxiety + false Changes in senses + false Dizziness + false Tingling + false Seeing flashing lights + false Repetitive movements + false @@ -13218,30 +13915,35 @@ When mastocytosis is not limited to the skin, it is called systemic mastocytosis Burning + false Sensitivity to light + false Burning/gritty sensation in eyes + false Eye irritation + false Watery eyes + false @@ -13325,66 +14027,77 @@ When mastocytosis is not limited to the skin, it is called systemic mastocytosis Swelling + false Pain + false Fever + false Joint pain + false Abdominal pain + false Flu-like symptoms + false Abnormal lumps below skin + false Painful, symmetrical lumps + false Pain when standing + false Swollen ankles + false Lumps turn blue or yellow + false @@ -13471,42 +14184,49 @@ When mastocytosis is not limited to the skin, it is called systemic mastocytosis Tingling + false Skin discoloration + false Lesions + false Easy bruising + false Hives + false Numbness in the fingers or toes, especially in cold temperatures + false Tingling in the fingers or toes, especially in cold temperatures + false @@ -13596,54 +14316,63 @@ The disorder resembles a combination of autoimmune hemolytic anemia, thrombocyto Mouth sores + false Weakness + false Fatigue + false Shortness of breath + false Easy bruising + false Nosebleeds + false Skin discoloration + false Frequent infections + false Fever + false @@ -13746,114 +14475,133 @@ The disorder resembles a combination of autoimmune hemolytic anemia, thrombocyto Burning + false Tingling + false Burning sensation in hand + false Pain + false Wrist pain + false Hand pain + false Tingling of wrist + false Burning sensation in wrist + false Skin hardening + false Tingling of hand + false Pain in extremities + false Skin stiffening + false Muscle pain + false Joint pain + false Tenderness + false Redness + false Swelling + false Orange peel appearance of skin of the extremities + false Skin texture changes + false @@ -13952,54 +14700,63 @@ The disorder resembles a combination of autoimmune hemolytic anemia, thrombocyto Swelling + false Stiffness + false Pain + false Joint pain + false Joint stiffness + false Swollen joints + false Fever + false Fatigue + false Weight loss + false @@ -14154,48 +14911,56 @@ ASA is not a concern except for people trying to conceive. Findings include a se Fatigue + false Sleep problems + false Tenderness + false Pain + false Cognitive impairment + false Stiffness + false Muscle tenderness + false Tendon tenderness + false @@ -14314,126 +15079,147 @@ ASA is not a concern except for people trying to conceive. Findings include a se Finger tremor + false Sensitivity to extreme heat + false Thickened red skin + false Heavy menstrual flow + false Easy bruising + false Hand tremor + false Anxiety + false Irritability + false An increase in perspiration or warm, moist skin + false Rapid heartbeat + false Irregular heartbeat + false Weight loss + false Erectile dysfunction + false Reduced libido + false Frequent bowel movements + false Fatigue + false Sleep problems + false Bulging eyes + false Swelling + false Swelling in neck + false Tremor + false @@ -14545,150 +15331,175 @@ ASA is not a concern except for people trying to conceive. Findings include a se Tingling + false Loss of bowel control + false Difficulty speaking + false Difficulty swallowing + false Loss of bladder control + false Paralysis of eye muscles + false Lightheadedness + false Unsteady gait + false Weakness in legs + false Tingling of extremities + false Pain + false Weakness in upper body + false Facial droop + false Double vision, horizontal or vertical, that improves when one eye is closed + false Dysfunction of pupils + false Facial flushing + false Lack of sweat + false Excessive sweating + false Difficulty breathing + false Vision problems + false Weakness + false Difficulty climbing stairs + false Cramps + false Irregular heartbeat + false Double vision + false @@ -14794,30 +15605,35 @@ ASA is not a concern except for people trying to conceive. Findings include a se Blisters + false Patches of blisters + false Large blisters + false Red bumps on abdomen + false Hives + false @@ -14897,36 +15713,42 @@ ASA is not a concern except for people trying to conceive. Findings include a se Painful red bumps that enlarge, break open, and drain pus. the pus may have an unpleasant odor + false Leaking bumps or sores that heal very slowly and recur over time + false Pain + false Abnormal lumps below skin + false Scarring + false Small pitted areas of skin containing blackheads + false @@ -15006,36 +15828,42 @@ ASA is not a concern except for people trying to conceive. Findings include a se Rash with tender, purple or brownish-red spots + false Skin sores + false Skin blisters + false Hives + false Blisters + false Rash + false @@ -15193,36 +16021,42 @@ ASA is not a concern except for people trying to conceive. Findings include a se Weight loss + false Dry cough + false Shortness of breath + false Fatigue + false Swollen fingers + false Swelling + false @@ -15315,60 +16149,70 @@ ASA is not a concern except for people trying to conceive. Findings include a se Muscle pain + false Dark urine + false Joint pain + false Swollen hands + false Swollen feet + false Foamy, frothy urine + false Back pain + false Blood in urine + false Swelling + false Pain + false @@ -15649,90 +16493,105 @@ Note that thrombotic thrombocytopenic purpura, TTP, is a ***genetic*** disease t Blisters + false Nosebleeds + false Yellow skin + false Easy bruising + false Tiny reddish-purple spots, usually on lower legs + false Prolonged bleeding from cuts + false Rupturing blisters + false Blood in urine + false Purple skin where blood has collected just beneath the surface of the skin + false Headache + false Blood in stool + false Bleeding gums + false Fatigue + false Heavy menstrual flow + false Drowsiness + false @@ -15833,72 +16692,84 @@ This condition is usually temporary (4-6 weeks) with a full recovery for most pa Purplish rash, typically on the lower legs and buttocks + false Abdominal pain + false Joint pain + false Blood in urine + false Headache + false Blood in stool + false Swollen penis + false Swollen testicles + false Difficulty breathing + false Swelling + false Rash + false Pain + false @@ -16182,54 +17053,63 @@ At this time, not all IgG4 diseases are documented, and many are very rare. Howe Progressive muscle weakness + false Joint tenderness + false Muscle tenderness + false Difficulty swallowing + false Difficulty speaking + false Fatigue + false Shortness of breath + false Weakness + false Tenderness + false @@ -16545,48 +17425,56 @@ There are other forms of uveitis that can be autoimmune. Floaters in vision + false Blurred vision + false Eye pain + false Sensitivity to light + false Red eyes + false Vision loss + false Vision problems + false Pain + false @@ -16764,42 +17652,49 @@ Some patients experience full relief from symptoms with medical attention, while Swollen joints + false Pain, especially first thing in the morning or after a nap + false Limping + false Stiffness + false Clumsiness, particularly in the morning or after naps + false Swelling + false Pain + false @@ -16888,60 +17783,70 @@ Most papers on lichen planus assume all cases of the disease are autoimmune or d Nail loss + false Mouth ulcers + false Blister inside mouth + false White patches on gums + false White patches on lips + false Purplish, flat-topped bumps, on inner forearm, wrist or ankle, and sometimes on the genitals + false Itching + false Vaginal ulcers + false Hair loss + false Redness + false @@ -17037,90 +17942,105 @@ Most papers on lichen planus assume all cases of the disease are autoimmune or d Redness of anus + false Pain during bowel movements + false Easy bruising + false Watery eyes + false Abdominal cramps + false Pain during sexual intercourse + false Pain during urination + false Blisters + false Pain + false Severe itching + false Smooth white spots on skin + false Discomfort, which is generally greater if lichen sclerosus appears on or around your genital or anal areas + false Bleeding blisters + false Nausea + false Vomiting + false @@ -17205,114 +18125,133 @@ Most papers on lichen planus assume all cases of the disease are autoimmune or d Pain + false Mouth ulcers + false Watery eyes + false Red eyes + false Eye discharge + false Eye pain + false Sensitivity to light + false Thickening of eyelid mucosa with a wood-like consistency + false Fever + false Ear pain + false Hearing loss + false Sore throat + false Change in voice + false Sores or masses under eyelid + false Eye lesions + false Eye irritation + false Gum enlargement + false Loss of teeth + false Frequent infections + false @@ -17531,102 +18470,119 @@ Most papers on lichen planus assume all cases of the disease are autoimmune or d Burning + false Blisters + false Blister inside mouth + false Mouth ulcers + false Lip ulcers + false Dry eyes + false Sensitivity to light + false Blister on lips + false Blisters on skin + false Itching + false Patches of blisters + false Burning skin + false Eye irritation + false Blurred vision + false Scarring on cornea + false Blindness + false Vision problems + false @@ -17731,156 +18687,182 @@ Most papers on lichen planus assume all cases of the disease are autoimmune or d Chest pain + false Difficulty swallowing + false Constipation + false Pain + false Stiffness + false Vomiting + false Stiffness upon inactivity + false Sleep problems + false Concentration loss + false Weight gain + false Acid reflux/heartburn + false Heavy menstrual flow + false Prolonged menstrual bleeding + false Painful, fatty lumps + false Weakness + false Fatigue + false Depression + false Epilepsy + false Confusion + false Irritability + false Dementia + false Migraine headaches + false Memory problems + false Rapid heartbeat + false Joint pain + false Shortness of breath + false @@ -17991,198 +18973,231 @@ Most papers on lichen planus assume all cases of the disease are autoimmune or d Pain + false Swelling + false Fever + false Malaise + false Weight loss + false Fatigue + false Swollen, painful nodule under skin + false Itchy skin + false Skin sores + false Gangrene of extremities + false Bluish coloring of hands/feet + false Joint pain + false Swollen joints + false Cough + false Shortness of breath + false Heaviness in chest + false Cramps + false Abdominal pain + false Bloating + false Blood in stool + false Vision loss + false Blurred vision + false Headache + false Confusion + false Seizures + false Change in mental status + false Hand pain + false Foot pain + false Weakness + false Numbness + false Tingling + false Loss of sensation + false Vision problems + false @@ -18250,12 +19265,14 @@ The exact cause of both primary and secondary autoimmune orchitis is still unkno Infertility + false Unable to conceive + false @@ -18345,54 +19362,63 @@ It is under debate whether collagenous and lymphocytic colitis are different pha Pain + false Diarrhea + false Abdominal pain + false Abdominal cramps + false Abdominal bloating + false Weight loss + false Nausea + false Loss of bowel control + false Bowel movement urgency + false @@ -18491,132 +19517,154 @@ It is under debate whether collagenous and lymphocytic colitis are different pha Pain + false Abnormal lumps below skin + false Prickling sensations + false Weight loss + false Fever + false Spitting up blood + false Abdominal pain + false Nausea + false Vomiting + false Diarrhea + false Rash + false Skin sores + false Nerve pain + false Weakness + false Loss of sensation + false Seizures + false Difficulty breathing + false Cough + false Joint pain + false Muscle pain + false Tingling + false Blood in stool + false @@ -18719,102 +19767,119 @@ It is under debate whether collagenous and lymphocytic colitis are different pha Pain + false Stiffness + false Facial pain + false Weakness + false Tightness of the skin of the fingers + false Joint pain + false Swollen hands + false Stiffness of the skin of the fingers + false Foot pain + false Bluish coloring of hands/feet + false Chest pain + false Facial reddening + false Butterfly-shaped rash face that covers the cheeks and bridge of the nose + false Rash + false Swelling + false Butterfly-shaped rash + false Yellow eyes + false @@ -18905,66 +19970,77 @@ It is under debate whether collagenous and lymphocytic colitis are different pha Pain + false Vision loss + false Eye pain + false Blindness + false Red eyes + false Eye inflammation + false Watery eyes + false Eye discharge + false Sensitivity to light + false Blurred vision + false Vision problems + false @@ -19073,108 +20149,126 @@ There is no cure for morphea, but treatments are available to manage symptoms. Pain + false Facial pain + false Headache + false Vision problems + false Dry eyes + false Eye pain + false Joint pain + false Muscle pain + false Weakness + false Oval-shaped patches + false Red patches with light center + false Hair loss + false Decreased sweating + false Fatigue + false Carpal tunnel syndrome + false Difficulty swallowing + false Shortness of breath + false Seizures + false @@ -19321,54 +20415,63 @@ Although this rare disease most commonly affects children, adults may have this Headache + false Weakness + false Involuntary movements + false Recurrent transient ischemic attacks + false Seizures + false Disturbed consciousness + false Vision problems + false Cognitive impairment + false Sensory impairment + false @@ -19496,114 +20599,133 @@ Although this rare disease most commonly affects children, adults may have this Burning + false Vision problems + false Loss of bowel control + false Unsteady gait + false Weakness + false Impaired coordination + false Numbness + false Eye pain + false Pain + false Vision loss + false Tremor + false Burning sensation + false Tingling + false Electric-shock sensations that occur with certain head movements + false Double vision, horizontal or vertical, that improves when one eye is closed + false Fatigue + false Dizziness + false Difficulty speaking + false Double vision + false @@ -19711,84 +20833,98 @@ Although this rare disease most commonly affects children, adults may have this Weakness + false Double vision, horizontal or vertical, that improves when one eye is closed + false Difficulty swallowing + false Difficulty chewing + false Change in facial expression + false Shortness of breath + false Difficulty speaking + false Vision problems + false Weakness in hands + false Weakness in arms + false Eyelid drooping + false Weakness in neck + false Weakness in fingers + false Double vision + false @@ -19879,72 +21015,84 @@ Although this rare disease most commonly affects children, adults may have this Pain + false Weakness + false Weakness in arms + false Weakness in legs + false Vision loss + false Eye pain + false Blurred vision + false Difficulty seeing color + false Back pain + false Seizures + false Loss of sensation + false Vision problems + false @@ -20038,54 +21186,63 @@ Although this rare disease most commonly affects children, adults may have this Flu-like symptoms + false Chest pain + false Fatigue + false Swelling + false Shortness of breath + false Pain + false Rapid heartbeat + false Irregular heartbeat + false Lightheadedness + false @@ -20183,60 +21340,70 @@ Although this rare disease most commonly affects children, adults may have this Muscle pain + false Difficulty swallowing + false Weakness + false Trouble rising from a chair + false Pain + false Weakness in arms + false Tired feeling after standing or walking + false Muscle soreness + false Difficulty breathing + false Difficulty climbing stairs + false @@ -20329,108 +21496,126 @@ The specific location of vasculitis inflammation determines what tissue or organ Weakness + false skin sores + false Nosebleeds + false Fever + false Chills + false Fatigue + false Weight loss + false Redness + false Pain + false Tingling + false Different sized pupils + false Eyelid drooping + false Difficulty swallowing + false Movement difficulty + false Cough + false Shortness of breath + false Nasal congestion + false Coughing up blood + false @@ -20576,42 +21761,49 @@ The specific location of vasculitis inflammation determines what tissue or organ Joint pain + false High shoulder blade + false Reduced reflexes + false Weakness + false Prickling sensations + false Pain + false Winged shoulder blade + false @@ -20709,48 +21901,56 @@ The specific location of vasculitis inflammation determines what tissue or organ Eye pain + false Vision loss + false Paralysis + false Hiccups + false Nausea + false Vomiting + false Pain + false Vision problems + false @@ -20849,126 +22049,147 @@ The specific location of vasculitis inflammation determines what tissue or organ Reduced reflexes + false Hand spasms + false Personality changes + false Rapid heartbeat + false Sleep problems + false Memory problems + false Muscle spasms + false Feet spasms + false Hallucinations + false Confusion + false Muscle stiffness + false Cramps + false Delayed muscle relaxation after strong contraction + false Muscle pain + false Muscle loss + false Increased calf muscle size + false Constipation + false Psychosis + false Weight loss + false Pain + false Stiffness + false @@ -21066,78 +22287,91 @@ The specific location of vasculitis inflammation determines what tissue or organ Sleep problems + false Anxiety + false Bedwetting + false Behavioral changes + false Deterioration in school performance + false Sensory impairment + false Depression + false Aggression + false Tics + false Ocd + false Irritability + false Increased urination + false Development regression + false @@ -21232,78 +22466,91 @@ The specific location of vasculitis inflammation determines what tissue or organ Skin discoloration + false Frequent infections + false Muscle cramps + false Numbness + false Tingling + false Seizures + false Fatigue + false Abdominal pain + false Dizziness + false Weight loss + false Hyperpigmentation + false Hair loss + false Pain + false @@ -21411,96 +22658,112 @@ The specific location of vasculitis inflammation determines what tissue or organ Cold intolerance + false Eyelid drooping + false Blurred vision + false Swelling in neck + false Fatigue + false Nausea + false Vomiting + false Weakness + false Anorexia + false Dull facial expression + false Swelling around eyes + false Memory problems + false Swelling + false Vision problems + false Weight loss + false Poor skin rigidity + false @@ -21587,84 +22850,98 @@ The specific location of vasculitis inflammation determines what tissue or organ Skin texture changes + false Eyelid drooping + false Hunger + false Skin pigmentation loss + false Alopecia + false Fatigue + false Puffy face + false Weakness + false Blurred vision + false Weight loss + false Shortness of breath + false Swelling + false Vision problems + false Swelling in neck + false @@ -21747,126 +23024,147 @@ The specific location of vasculitis inflammation determines what tissue or organ Hunger + false Loss of bowel control + false Increased frequency of urination + false Bowel movement urgency + false Scaling of the scalp + false Increased thirst + false Weight loss + false Mood changes + false Fatigue + false Weakness + false Blurred vision + false Diarrhea + false Blood in stool + false Rectal bleeding + false Fever + false Skin pigmentation loss + false Pain + false Joint stiffness + false Yellow skin + false Stiffness + false Vision problems + false @@ -21953,84 +23251,98 @@ The specific location of vasculitis inflammation determines what tissue or organ Shoulder pain + false Weight loss + false Wrist pain + false Knee stiffness + false Wrist stiffness + false Fever + false Malaise + false Knee pain + false Stiffness upon inactivity + false Muscle pain + false Limited range of motion in affected areas + false Fatigue + false Stiffness + false Pain + false @@ -22131,90 +23443,105 @@ The specific location of vasculitis inflammation determines what tissue or organ Difficulty speaking + false Fatigue + false Difficulty swallowing + false Pain + false Shortness of breath + false Weakness + false Difficulty breathing + false Weight loss + false Muscle pain + false Difficulty moving from sitting to standing + false Falling + false Difficulty climbing stairs + false Weakness in joints + false Joint pain + false Fever + false @@ -22329,108 +23656,126 @@ The specific location of vasculitis inflammation determines what tissue or organ Fatigue + false Itchy skin + false Dry eyes + false Dry mouth + false Joint pain + false Muscle pain + false Bone pain + false Swollen feet + false Swollen ankles + false Accumulation of fluid in the abdomen + false Fatty deposits on the skin around your eyes, your eyelids, or in the creases in your palms, soles, elbows or knees + false Yellow skin + false Hyperpigmentation + false Diarrhea + false Weight loss + false Swelling + false Pain + false Yellow eyes + false @@ -22547,78 +23892,91 @@ The specific location of vasculitis inflammation determines what tissue or organ Fatigue + false Itchy skin + false Abdominal discomfort + false Abdominal pain + false Malaise + false Nausea + false Fever + false Chills + false Night sweats + false Weight loss + false Dark urine + false Pain + false Yellow eyes + false @@ -22713,18 +24071,21 @@ The development of psoriasis involves a complex cycle of immune activation and s Small scaling spots + false Dry, cracked skin that may bleed + false Disorders of finger and toe nails + false @@ -22822,84 +24183,98 @@ The development of psoriasis involves a complex cycle of immune activation and s Swollen feet + false Swollen ankles + false Swollen hands + false Joint pain + false Swollen toes + false Back pain + false Stiffness + false Fatigue + false Swollen wrists + false Swollen elbows + false Swollen shoulders + false Swollen knees + false Swelling + false Pain + false @@ -22991,48 +24366,56 @@ Secondary Raynaud's is a symptom experienced (and reported) by patients with aut Foot pain + false Bluish coloring of hands/feet + false Bluish coloring of hands/feet + false Numbness + false Pain + false Coldness + false Hand pain + false When blood starts to return to these areas, fingers or toes that turn red, burn, throb, experience numbness, or tingle. + false @@ -23134,108 +24517,126 @@ Secondary Raynaud's is a symptom experienced (and reported) by patients with aut Burning + false Joint pain + false Joint stiffness + false Tendon pain + false Back pain + false Eye irritation + false Blurred vision + false Sensitivity to light + false Burning with urination + false Increased frequency of urination + false Diarrhea + false Fever + false Fatigue + false Weight loss + false Rash + false Stiffness + false Pain + false Vision problems + false @@ -23343,96 +24744,112 @@ In cases where the cartilage is not visible, RP can cause heart valve abnormalit Fatigue + false Fever + false Ear pain + false Limpness of the ear + false Loss of hearing + false Dizziness + false Rib pain + false Joint pain + false Nasal congestion + false Nosebleeds + false Wheezing + false Shortness of breath + false Cough + false Hoarseness + false High-pitched sound during breathing + false Pain + false @@ -23518,18 +24935,21 @@ In cases where the cartilage is not visible, RP can cause heart valve abnormalit Discomfort in legs that is relieved by movement + false Discomfort in legs that occur mainly at night + false Discomfort in legs that begins after lying down or sitting for a long time + false @@ -23633,114 +25053,133 @@ The severity of cases may vary, with mild cases resolving in under a year and se Difficulty concentrating + false Personality changes + false Depression + false Psychosis + false Aggression + false Anxiety + false Muscle pain + false Dark spots in vision + false Loss of peripheral vision + false Hearing loss + false Ringing in ears + false Dizziness + false Difficulty speaking + false Unsteady gait + false Migraine headaches + false Memory problems + false Confusion + false Pain + false Vision problems + false @@ -23830,72 +25269,84 @@ Since antibiotics have reduced the incidence of rheumatic fever, the incidence o Unsteady gait + false Mood changes + false Involuntary movements + false Difficulty speaking + false Weakness + false Difficulty concentrating + false Obsessions + false Compulsive behavior + false Anxiety + false Confusion + false Irritability + false Difficulty walking + false @@ -24002,96 +25453,112 @@ Note: scarlet fever is another symptom of a strep infection but is not a separat Pain + false Involuntary movements + false Behavioral changes + false Joint pain + false Abnormal lumps below skin + false Swollen joints + false Joint tenderness + false Migrating joint pain + false Fever + false Chest pain + false Heart murmur + false Fatigue + false Flat or slightly raised, painless rash with a ragged edge + false Swelling + false Rash + false Tenderness + false @@ -24219,72 +25686,84 @@ There is no cure, though treatments to manage symptoms are available. Prognosis Pain + false Joint pain + false Stiffness + false Swollen joints + false Tenderness + false Nodules in fingers + false Nodules in heel + false Nodules in toes + false Fatigue + false Fever + false Weight loss + false Firm bumps of tissue under the skin on your arms + false @@ -24297,12 +25776,14 @@ There is no cure, though treatments to manage symptoms are available. Prognosis Carpal tunnel syndrome + false Swelling + false @@ -24398,90 +25879,105 @@ There is no cure, though treatments to manage symptoms are available. Prognosis Pain + false Vision problems + false Finger pain + false Toe pain + false Tingling + false Numbness + false Eye pain + false Chest pain + false Shortness of breath + false Fever + false Weight loss + false Rash + false skin sores + false Blood in stool + false Blood in urine + false @@ -24589,162 +26085,189 @@ Sarcoidosis often starts with a set of symptoms collectively referred to as Lofg Pain + false Swelling + false Weakness + false Vision problems + false Weakness in facial muscles + false Swollen legs + false Irregular heartbeat + false Weakness in arms + false Eye pain + false Chest pain + false Weakness in legs + false Shortness of breath + false Wheezing + false Fatigue + false Weight loss + false Night sweats + false Skin discoloration + false Scaly-appearing skin + false Rash + false Muscle pain + false Red eyes + false Sensitivity to light + false Blurred vision + false Cough + false Fever + false Joint pain + false Headache + false @@ -24824,48 +26347,56 @@ Patients with Schnitzler syndrome typically experience chronic rash, relapsing f Pain + false Muscle pain + false Fever + false Joint pain + false Fatigue + false Weight loss + false Bone pain + false Rash + false @@ -24956,60 +26487,70 @@ Patients with Schnitzler syndrome typically experience chronic rash, relapsing f Pain + false Vision problems + false Eye pain + false Headache + false Vision loss + false Watery eyes + false Blurred vision + false Sensitivity to light + false Eye irritation + false Double vision + false @@ -25138,156 +26679,182 @@ Patients with Schnitzler syndrome typically experience chronic rash, relapsing f Cognitive impairment + false Sinus infection + false Dry mouth + false Rash + false Burning + false Joint stiffness + false Swollen joints + false Pain + false Dry eyes + false Bluish coloring of hands/feet + false Foot pain + false Sinus inflammation + false Swelling of salivary glands + false Fatigue + false Burning/gritty sensation in eyes + false Acid reflux/heartburn + false Shortness of breath + false Depression + false Anxiety + false Dizziness + false Cough + false Stiffness + false Swelling + false Hand pain + false Dry skin + false Vaginal dryness + false @@ -25403,114 +26970,133 @@ Patients with Schnitzler syndrome typically experience chronic rash, relapsing f Skin sores + false Swollen hands + false Nose ulcers + false Swollen legs + false Mouth rash + false Swollen feet + false Nose rash + false Swollen ankles + false Swelling + false Rash + false Foamy, frothy urine + false Headache + false Dizziness + false Nausea + false Vomiting + false Weight gain + false Increased urination at night + false Blood in urine + false Mouth ulcers + false @@ -25693,192 +27279,224 @@ Patients with Schnitzler syndrome typically experience chronic rash, relapsing f Psychosis + false Disorientation + false Cognitive impairment + false Headache + false Memory problems + false Impaired coordination + false Difficulty understanding basic concepts + false Difficulty retaining information + false Difficulty finding words + false Attention-span problems + false Anxiety + false Confusion + false Altered level of consciousness + false Behavioral changes + false Coma + false Depression + false Sleep problems + false Fever + false Seizure during which the person remains conscious and alert + false Seizure during which the person remains unconscious + false Hallucinations + false Over-responsive reflexes + false Prone to infections + false Irritability + false Nausea + false Paralysis + false Paranoid delusions + false Personality changes + false Daytime sleepiness + false Fatigue + false Social withdrawal + false Vomiting + false @@ -25975,66 +27593,77 @@ Patients with Schnitzler syndrome typically experience chronic rash, relapsing f Pain + false Stiffness + false Back pain + false Lower back stiffness + false Muscle spasms + false Unsteady gait + false Leg stiffness + false Hunched posture + false Anxiety + false Weight loss + false Feeling full quickly after eating + false @@ -26130,72 +27759,84 @@ This condition most frequently occurs following surgery to a region of the body Pain + false Chest pain + false Rapid heartbeat + false Abdominal pain + false Fatigue + false Shortness of breath + false Fever + false Heart palpitations + false Weakness + false Weight loss + false Irritability + false Joint pain + false @@ -26291,72 +27932,84 @@ This condition most frequently occurs following surgery to a region of the body Pain + false Vision problems + false Floaters in vision + false Skin pigmentation loss + false Eye pain + false Red eyes + false Blurred vision + false Sensitivity to light + false Watery eyes + false Blindness + false Hearing loss + false Headache + false @@ -26473,96 +28126,112 @@ This condition most frequently occurs following surgery to a region of the body Pain + false Swelling + false Rash + false Stiffness + false Joint pain + false Bluish coloring of hands/feet + false Chest pain + false Joint stiffness + false Swollen joints + false Fatigue + false Fever + false Butterfly-shaped rash face that covers the cheeks and bridge of the nose + false Skin lesions that appear or worsen with sun exposure + false Shortness of breath + false Dry eyes + false Butterfly-shaped rash + false @@ -26645,96 +28314,112 @@ When mastocytosis is limited to the skin, it is called cutaneous mastocytosis, a Pain + false Mood changes + false Headache + false Lightheadedness + false Dizziness + false Nausea + false Bone pain + false Muscle pain + false Fatigue + false Nasal congestion + false Shortness of breath + false Depression + false Concentration loss + false Itching + false Abdominal pain + false Diarrhea + false @@ -26851,120 +28536,140 @@ When mastocytosis is limited to the skin, it is called cutaneous mastocytosis, a Pain + false Muscle pain + false Weakness + false Finger pain + false Toe pain + false Joint pain + false Swollen joints + false Chest pain + false Fatigue + false Dry eyes + false Dry mouth + false Dry cough + false Shortness of breath + false Acid reflux/heartburn + false Diarrhea + false Weight loss + false Itching + false Constipation + false Difficulty swallowing + false Swelling + false @@ -27086,108 +28791,126 @@ To be diagnosed with CREST, you must have 3 out of the 5 symptoms. Pain + false Swelling + false Hand pain + false Vision problems + false Bluish coloring of hands/feet + false Foot pain + false Difficulty breathing + false Abdominal discomfort + false Nausea + false Vomiting + false Empty feeling in the abdomen/stomach + false Tightness in the abdomen + false Churning in the stomach + false “butterflies” in the stomach + false Acid reflux/heartburn + false Abdominal pain + false Hunger + false Difficulty swallowing + false @@ -27286,42 +29009,49 @@ Early symptoms may include fever, night sweats, fatigue, joint pain, and chest d Fatigue + false Fever + false Night sweats + false Weight loss + false Muscle pain + false Joint pain + false Headache + false @@ -27329,23 +29059,27 @@ Early symptoms may include fever, night sweats, fatigue, joint pain, and chest d false Lightheadedness + false Arm weakness + Chest pain + false Shortness of breath + false @@ -27353,23 +29087,27 @@ Early symptoms may include fever, night sweats, fatigue, joint pain, and chest d false Fainting + Blurred vision + false Vision problems + false Tingling of extremities + false @@ -27478,36 +29216,42 @@ Early symptoms may include fever, night sweats, fatigue, joint pain, and chest d Pain + false Vision loss + false Shoulder pain + false Arm pain upon exertion + false Hip pain + false Weight loss + false @@ -27526,78 +29270,91 @@ Early symptoms may include fever, night sweats, fatigue, joint pain, and chest d Headache + false Jaw pain when you open your mouth + false Scalp tenderness + false Fever + false Fatigue + false Double vision + false Blurred vision + false Cough + false Throat pain + false Tongue pain + false Depression + false Vision problems + false Tenderness + false @@ -27733,30 +29490,35 @@ Early symptoms may include fever, night sweats, fatigue, joint pain, and chest d Pain + false Constant pain behind the eye + false Headache + false Double vision + false Vision problems + false @@ -27869,162 +29631,189 @@ Early symptoms may include fever, night sweats, fatigue, joint pain, and chest d Pain + false Burning + false Sensory impairment + false Weakness in arms + false Abnormal bladder control + false Numbness + false Coldness + false Weakness in legs + false Burning sensation + false Partial paralysis of the legs + false Total paralysis of the legs + false Muscle pain + false Muscle spasms + false Increased frequency of urination + false Difficulty urinating + false Constipation + false Sensitivity to extreme heat + false Sensitivity to extreme cold + false Headache + false Fever + false Depression + false Anxiety + false Painful and decreased eye movements + false Double vision + false Fatigue + false Weakness + false Vision problems + false @@ -28129,90 +29918,105 @@ Both UC and CD are caused by an autoimmune response that reflects the involvemen Pain + false Abdominal pain + false Blood in stool + false Joint pain + false Skin sores + false Urgency without having a bowel movement + false Rectal pain + false Abdominal cramps + false Fever + false Constipation + false Weight loss + false Fatigue + false Dehydration + false Stunted growth in children + false Diarrhea + false @@ -28321,114 +30125,133 @@ Both UC and CD are caused by an autoimmune response that reflects the involvemen Pain + false Hand pain + false Weakness + false Seizures + false Foot pain + false Bluish coloring of hands/feet + false Chest pain + false Dry eyes + false Dry mouth + false Joint pain + false Butterfly-shaped rash face that covers the cheeks and bridge of the nose + false Hair loss + false Interstitial pneumonia + false Mental disorders + false Sensitivity to light + false Fatigue + false Mouth ulcers + false Rash + false Butterfly-shaped rash + false @@ -28525,108 +30348,126 @@ Urticaria can also be caused by allergic reaction to plants like poison ivy, dye Burning + false Muscle pain + false Skin discoloration + false Joint pain + false Cough + false Raised purple-red spots + false Pain + false Burning sensation + false Fluid-dilled sacs + false Bumps on skin containing pus + false Abnormal lumps below skin + false Crusted ulcers + false Fever + false Weight loss + false Abdominal pain + false Vomiting + false Weakness + false Rash + false @@ -28735,48 +30576,56 @@ The most common form of autoimmune uveitis is intermediate uveitis. Pain + false Blurred vision + false Sensitivity to light + false Eye pain + false Floaters in vision + false Headache + false Red eyes + false Vision problems + false @@ -28877,30 +30726,35 @@ Normally, the color of hair, skin, and eyes is determined by melanin. Vitiligo o Premature whitening or graying of the hair on your scalp, eyelashes, eyebrows or beard + false Skin discoloration + false Loss of color in the tissues that line the inside of your mouth + false Loss of or change in color of the inner layer of your eye + false Milky white patches on skin + false @@ -28993,72 +30847,84 @@ Normally, the color of hair, skin, and eyes is determined by melanin. Vitiligo o Pain + false Headache + false Skin pigmentation loss + false Yellow skin + false Eye pain + false Dizziness + false Nausea + false Eye inflammation + false Blurred vision + false Hearing loss + false Hair loss + false Vision problems + false @@ -29152,66 +31018,77 @@ Some cases of this disease are caused by medications and are not autoimmune. Pain + false Weakness + false Muscle pain + false Fatigue + false Difficulty breathing + false Shortness of breath + false Headache + false Dizziness + false Rapid heartbeat + false Chills + false Yellow eyes + false @@ -30744,372 +32621,434 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Double vision + false Sensitivity to light + false Corneal ulceration + false Vision problems + false Forward displacement of eye + false Eye irritation + false Dry eyes + false Watery eyes + false Vision loss + false Inability to move the eye + false Anxiety in children + false Muscle spasms + false Irritability in children + false Rage attacks + false Unsteady gait + false Fast, irregular eye movements + false Brain fog + false Fatigue + false Sleep problems + false Weakness + false Impaired coordination + false Stiffness + false Restricted mobility + false Swelling + false Pain + false Swollen joints + false Tendon pain + false Fever + false Joint stiffness + false Fatigue + false Joint pain + false Dizziness + false Nausea + false Hand tremor + false Memory problems + false Tremor + false Involuntary movements + false Difficulty speaking + false Unsteady gait + false Double vision + false Vision problems + false Fast, irregular eye movements + false Vertigo + false Difficulty swallowing + false Impaired coordination + false Fatigue + false Erectile dysfunction + false Headache + false Shortness of breath + false Pain + false Irregular heartbeat + false Trouble breathing when you exercise + false Muscle spasms + false Abdominal pain + false Dark urine + false Genital blisters + false Blister inside throat + false Blisters + false Pain + false Causes blisters on the chest, back and shoulders + false Skin blisters + false Blisters are painful but do not itch + false @@ -31122,504 +33061,588 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Blisters that rupture easily, leaving open sores, which may ooze and become infected. + false Blister inside mouth + false Itchy blisters + false Skin hardening + false Weakness + false Progressive weakness in the legs + false Skin discoloration + false Problems with metabolism + false Excessive sweating + false Vision problems + false Fatigue + false Progressive weakness in the arms + false Vomiting + false Coldness + false Fatigue + false Weight loss + false Joint pain + false Night sweats + false Pain + false Vision problems + false Fever + false Weakness + false Rash + false Vision loss + false Abdominal pain + false Nausea + false Muscle pain + false Chest pain + false Heart palpitations + false Rapid heartbeat + false Shortness of breath + false Difficulty breathing + false Fever + false Irritability + false Pain + false Joint pain + false Fatigue + false Shortness of breath + false Swelling + false Fatigue + false Difficulty exercising + false Pain + false Chest pain + false Weight gain + false Heart palpitations + false Misalignment of teeth + false Skin discoloration + false Absence of eyelashes + false Burning sensation + false Misalignment of jaw + false Whitening of hair + false Curling of upper lip + false Prickling sensations + false Eyelid drooping + false Burning + false Difficulty chewing + false Backwards displacement of eye + false Pain + false Migraine headaches + false Difficulty moving jaw + false Different colored eyes + false Facial pain + false Skull depressions + false Seizures + false Bald patches + false Thinning or shrinking of facial tissues + false Dizziness + false Fatigue + false Difficulty breathing + false Shortness of breath + false Easy bruising + false Fever + false Pain + false Skin sores + false Joint pain + false Muscle pain + false Small red bumps + false Loss of motor skills + false Vision problems + false Weakness + false Mental decline + false Seizures + false Paralysis + false Progressive loss of speech + false @@ -31681,6 +33704,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Acute/subacute limbic amnesia and confusion + 85–95% false @@ -31688,6 +33712,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Marked psychiatric and behavioral changes (agitation, psychosis) + 65–80% false @@ -31695,6 +33720,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Epileptic seizures + 50–60% false @@ -31754,6 +33780,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Early intractable limbic seizures and temporal lobe status + 90–100% false @@ -31761,6 +33788,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Severe short-term memory loss / amnesia + 80–90% false @@ -31768,6 +33796,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Behavioral changes, confusion, and psychosis + 60–70% false @@ -31842,6 +33871,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Severe aortic valve regurgitation + 40–55% false @@ -31849,6 +33879,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Deep thoracic or back pain + 40–50% false @@ -31919,6 +33950,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Severe, intractable, chronic secretory diarrhea persisting during fasting + 95–100% false @@ -31933,6 +33965,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Severe malabsorption, cachexia, and involuntary weight loss + 85–95% false @@ -31940,6 +33973,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Protein-losing enteropathy with severe hypoalbuminemia and anasarca + 60–75% false @@ -32014,6 +34048,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Progressive dysphagia to both liquids and solids + 90–100% false @@ -32021,6 +34056,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Regurgitation of undigested, retained food + 75–85% false @@ -32028,6 +34064,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Retrosternal crampy chest pain + 50–65% false @@ -32035,6 +34072,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Significant weight loss + 50–60% false @@ -32042,6 +34080,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Nocturnal cough and pulmonary aspiration + 30–40% false @@ -32108,6 +34147,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Meningoencephalitis symptoms: subacute fever, severe headache, and neck stiffness + 75–85% false @@ -32115,6 +34155,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Encephalopathy, confusion, and delirium + 65–75% false @@ -32122,6 +34163,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Myelopathy with spinal paraparesis and sensory deficit + 40–50% false @@ -32129,6 +34171,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Autonomic dysregulation and neurogenic bladder + 35–45% false @@ -32136,6 +34179,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Visual impairment / bilateral optic disc edema (papillitis) + 30–40% false @@ -32200,6 +34244,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Spontaneous, extensive subcutaneous and soft-tissue hematomas + 80–90% false @@ -32207,6 +34252,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Prolonged, unprovoked post-traumatic or post-surgical hemorrhage + 70–85% false @@ -32214,6 +34260,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Mucocutaneous, hematuric, and gastrointestinal bleeding + 25–35% false @@ -32221,6 +34268,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Spontaneous hemarthrosis + <10% false @@ -32300,6 +34348,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Rapidly progressive, symmetric sensorimotor polyradiculoneuropathy + 85–95% false @@ -32314,6 +34363,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Severe sensory ataxia with gait failure + 60–75% false @@ -32321,6 +34371,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Severe quadriparesis / motor disability + 50–65% false @@ -32328,6 +34379,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Marked high-amplitude postural and action tremor + 40–50% false @@ -32389,6 +34441,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Generalized areflexia + 90–95% false @@ -32396,6 +34449,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Subacute to acute severe symmetrical distal and proximal limb weakness + 80–90% false @@ -32403,6 +34457,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Severe proprioceptive sensory ataxia and positive Romberg sign + 70–80% false @@ -32410,6 +34465,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Prominent action tremor of hands and arms + 40–55% false @@ -32476,6 +34532,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Microangiopathic hemolytic anemia with schistocytes on blood smear + 95–100% false @@ -32483,6 +34540,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Profound consumptive thrombocytopenia with purpura and bleeding + 95–100% false @@ -32490,6 +34548,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Fluctuating neurological symptoms (confusion, transient focal deficits, seizure, coma) + 60–70% false @@ -32497,6 +34556,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Renal dysfunction (azotemia, proteinuria, hematuria) + 40–50% false @@ -32504,6 +34564,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Low-grade fever + 25–35% false @@ -32557,6 +34618,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Inability to conceive after ≥1 year of unprotected intercourse with normal evaluations + 95–100% false @@ -32626,6 +34688,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Recurrent episodes of severe hypersomnia (sleeping 16–20 hours daily for days/weeks) + 100% false @@ -32640,6 +34703,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Cognitive derealization, apathy, and altered perception + 80–90% false @@ -32647,6 +34711,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Compulsive megaphagia / binge eating during episodes + 70–80% false @@ -32654,6 +34719,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Hypersexuality and disinhibited behaviors + 45–55% false @@ -32716,6 +34782,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Early-onset multi-organ autoimmunity starting in infancy/childhood + 100% false @@ -32723,6 +34790,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Autoimmune cytopenias (autoimmune thrombocytopenia, AIHA, neutropenia) + 70–80% false @@ -32730,6 +34798,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Postnatal growth failure and severe short stature + 60–75% false @@ -32737,6 +34806,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Chronic lymphadenopathy and hepatosplenomegaly + 50–60% false @@ -32744,6 +34814,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Early-onset type 1 diabetes mellitus + 40–50% false @@ -32751,6 +34822,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Severe chronic autoimmune enteropathy with intractable diarrhea + 40–50% false @@ -50809,6 +52881,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Disseminated non-tuberculous mycobacterial (NTM) infections + 80–90% false @@ -50816,6 +52889,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Chronic suppurative lymphadenitis + 65–75% false @@ -50823,6 +52897,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Reactive pustular/neutrophilic dermatoses (Sweet-like) + 40–50% false @@ -50830,6 +52905,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Opportunistic fungal infections (cryptococcosis, penicilliosis) + 30–40% false @@ -51047,6 +53123,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Severe neuropathic pain + 60–70% false @@ -51054,6 +53131,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Peripheral nerve hyperexcitability (myokymia, fasciculations, muscle cramps) + 50–60% false @@ -51061,6 +53139,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Limbic encephalitis with cognitive decline + 40–50% false @@ -51068,6 +53147,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Severe agrypnia / intractable insomnia (Morvan syndrome) + 30–40% false @@ -51110,6 +53190,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Prodromal severe diarrhea and weight loss + 80–90% false @@ -51117,6 +53198,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and CNS hyperexcitability: hyperekplexia (exaggerated startle), myoclonus, tremor + 70–80% false @@ -51124,6 +53206,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Progressive cognitive impairment and amnesia + 60–70% false @@ -51166,6 +53249,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Refractory status epilepticus / frequent multifocal seizures + 85–95% false @@ -51173,6 +53257,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Rapid cognitive and behavioral decline + 60–70% false @@ -51180,6 +53265,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Movement disorders (chorea, catatonia, opsoclonus) + 30–40% false @@ -51292,6 +53378,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Prominent sleep architecture disruption (NREM parasomnia, sleep apnea, stridor) + 80–90% false @@ -51299,6 +53386,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Bulbar dysfunction (dysphagia, dysarthria, vocal cord palsy) + 60–70% false @@ -51306,6 +53394,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Progressive gait instability and ataxia + 50–65% false @@ -51313,6 +53402,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Chorea, dystonia, or abnormal ocular movements + 30–40% false @@ -51355,6 +53445,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Rapidly progressive short-term memory impairment + 85–90% false @@ -51362,6 +53453,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Pathognomonic faciobrachial dystonic seizures (FBDS) + 60–75% false @@ -51369,6 +53461,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Refractory hyponatremia (SIADH-like) + 60–70% false @@ -51376,6 +53469,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Psychiatric disturbances (confusion, paranoia, hallucinations) + 60–70% false @@ -51418,6 +53512,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Distal lower limb numbness, paresthesias, and pain + 90–100% false @@ -51425,6 +53520,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Slowly progressive, symmetric distal sensory ataxia + 85–95% false @@ -51432,6 +53528,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Marked postural and action tremor of the hands + 60–75% false @@ -51439,6 +53536,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Mild late distal motor weakness (foot drop) + 40–50% false @@ -51481,6 +53579,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Gottron's papules / sign + 80–95% false @@ -51488,6 +53587,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Rapidly progressive interstitial lung disease with hypoxemic respiratory failure + 75–90% false @@ -51495,6 +53595,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Painful deep cutaneous ulcerations (digital, knuckles, elbows) + 60–80% false @@ -51509,6 +53610,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Palmar violaceous papules / inverse Gottron's + 40–50% false @@ -51551,6 +53653,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Severe proximal symmetrical muscle weakness + 85–95% false @@ -51558,6 +53661,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Gottron's papules + 75–85% false @@ -51565,6 +53669,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Extensive subcutaneous calcinosis (calcinosis cutis) + 40–60% false @@ -51572,6 +53677,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Severe dysphagia and neck flexor weakness + 35–45% false @@ -51579,6 +53685,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Peripheral and periorbital subcutaneous edema + 30–40% false @@ -51768,6 +53875,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Chronic disabling fatigue and unrefreshing sleep + 80–90% false @@ -51775,6 +53883,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Diffuse myalgias and muscle weakness + 70–80% false @@ -51782,6 +53891,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Arthralgias or inflammatory arthritis + 60–75% false @@ -51789,6 +53899,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Cognitive impairment, memory loss, and brain fog + 50–60% false @@ -51831,6 +53942,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Microangiopathic hemolytic anemia with fragmented schistocytes + 95–100% false @@ -51838,6 +53950,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Severe consumptive thrombocytopenia + 90–95% false @@ -51845,6 +53958,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Acute oliguric renal failure / azotemia + 85–95% false @@ -51964,6 +54078,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Severe, disabling orthostatic hypotension and syncope + 90–100% false @@ -51971,6 +54086,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Severe gastrointestinal dysmotility (gastroparesis, pseudo-obstruction, constipation) + 70–80% false @@ -51978,6 +54094,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Sicca syndrome (severe dry mouth and dry eyes) + 70–80% false @@ -51985,6 +54102,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Tonic, unreactive, or poorly reactive pupils + 60–75% false @@ -51992,6 +54110,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Anhidrosis / loss of sweating + 60–70% false @@ -51999,6 +54118,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Neurogenic urinary retention + 50–60% false @@ -52041,6 +54161,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Progressive gait instability and appendicular limb ataxia + 90–100% false @@ -52048,6 +54169,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Cerebellar dysarthria / slurred scanning speech + 70–85% false @@ -52055,6 +54177,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Nystagmus, saccadic intrusions, and ocular dysmetria + 60–75% false @@ -52062,6 +54185,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Intention and action tremor + 50–65% false @@ -52104,6 +54228,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Refractory extreme hypertriglyceridemia (>1,000–2,000 mg/dL) with lactescent/milky serum + 100% false @@ -52111,6 +54236,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Eruptive cutaneous xanthomas on extensor surfaces and buttocks + 60–75% false @@ -52118,6 +54244,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Recurrent episodes of acute pancreatitis + 50–65% false @@ -52125,6 +54252,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Lipemia retinalis on fundoscopic examination + 40–55% false @@ -52167,6 +54295,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Severe polyuria (>3–5 L/24h) with dilute urine + 95–100% false @@ -52174,6 +54303,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Compulsive polydipsia / cold water craving + 95–100% false @@ -52181,6 +54311,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Disruptive nocturia + 90–95% false @@ -52188,6 +54319,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Hypernatremic dehydration when fluid access is restricted + 40–50% false @@ -52580,6 +54712,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Perioral, lingual, and digital paresthesias / tingling + 85–95% false @@ -52587,6 +54720,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Painful carpopedal spasms and cramps + 70–80% false @@ -52594,6 +54728,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Latent tetany: positive Chvostek's sign (60–75%) & Trousseau's sign + 70–80% false @@ -52601,6 +54736,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Laryngospasm and stridor + 25–35% false @@ -52608,6 +54744,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Hypocalcemic generalized seizures + 15–25% false @@ -52650,6 +54787,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Persistent dull retro-orbital/frontal headache + 70–85% false @@ -52657,6 +54795,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Hypopituitarism + secondary adrenal insufficiency: 65–75%, secondary hypothyroidism: 50–60%, hypogonadism: 50–60% false @@ -52664,6 +54803,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Visual field deficits / bitemporal hemianopia due to chiasmal compression + 45–60% false @@ -52671,6 +54811,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Diabetes insipidus (polyuria, polydipsia) + 20–30% false @@ -52713,6 +54854,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Subacute anterograde memory loss and spatial disorientation + 85–95% false @@ -52720,6 +54862,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Temporal lobe complex partial seizures + 65–75% false @@ -52727,6 +54870,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Acute psychiatric disturbances (affective changes, anxiety, psychosis) + 60–70% false @@ -52734,6 +54878,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Disrupted sleep-wake cycles + 40–50% false @@ -52916,6 +55061,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Acute/subacute painful visual loss (unilateral or bilateral) + 90–100% false @@ -52923,6 +55069,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Impaired color vision / dyschromatopsia + 90–95% false @@ -52930,6 +55077,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Retrobulbar pain exacerbated by eye movement + 85–95% false @@ -52937,6 +55085,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Relative afferent pupillary defect (RAPD) and central scotoma + 75–85% false @@ -53063,6 +55212,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Presyncope, lightheadedness, and orthostatic dizziness + 90–95% false @@ -53070,6 +55220,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Palpitations and tremulousness upon standing + 85–95% false @@ -53077,6 +55228,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Chronic fatigue and severe post-exertional exhaustion + 80–90% false @@ -53084,6 +55236,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Cognitive dysfunction ('brain fog') + 75–85% false @@ -53168,6 +55321,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Insidious, progressive exertional dyspnea + 85–95% false @@ -53175,6 +55329,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Chronic, non-productive or mildly productive cough + 60–75% false @@ -53182,6 +55337,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Bibasilar inspiratory crackles + 50–60% false @@ -53189,6 +55345,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Weight loss, low-grade fevers, and cyanosis in advanced disease + 20–30% false @@ -53238,6 +55395,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Painless progressive visual blurriness / decrease in visual acuity + 80–90% false @@ -53245,6 +55403,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Vitreous floaters and haze + 65–75% false @@ -53252,6 +55411,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Visual field scotomas + 40–50% false @@ -53336,6 +55496,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Distal burning neuropathic pain in feet and lower extremities + 85–95% false @@ -53350,6 +55511,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Allodynia, dysesthesias, and hyperalgesia + 80–90% false @@ -53357,6 +55519,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Autonomic symptoms (altered sweating, dry mouth/eyes, gastrointestinal dysmotility) + 50–65% false @@ -53539,6 +55702,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Harsh crescendo-decrescendo systolic murmur radiating to carotids + 90–95% false @@ -53546,6 +55710,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Progressive exertional dyspnea + 75–85% false @@ -53553,6 +55718,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Angina pectoris upon exertion + 40–50% false @@ -53560,6 +55726,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Exertional presyncope or syncope + 20–30% false @@ -53707,6 +55874,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Acute progressive external ophthalmoplegia / ophthalmoparesis + 95–100% false @@ -53714,6 +55882,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Severe central cerebellar and sensory ataxia + 90–95% false @@ -53721,6 +55890,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Altered consciousness / somnolence, stupor, or coma + 85–95% false @@ -53728,6 +55898,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Generalized hypo- or areflexia + 50–60% false @@ -53735,6 +55906,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Pyramidal tract signs / extensor plantar responses (Babinski sign) + 40–50% false @@ -53777,6 +55949,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Creamy yellow-orange hypopigmented choroidal spots radiating from optic disc + 95–100% false @@ -53784,6 +55957,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Vitreous floaters and hazy vision + 75–85% false @@ -53791,6 +55965,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Retinal arteriolar attenuation and vasculitis + 70–85% false @@ -53798,6 +55973,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Bilateral blurred vision / reduced visual acuity + 70–80% false @@ -53805,6 +55981,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Nyctalopia and diminished color discrimination + 50–65% false @@ -53889,6 +56066,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Widespread, tense subepidermal vesicles and bullae on sun-exposed and trunk areas + 85–95% false @@ -53903,6 +56081,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Mucosal blister formation and erosions + 40–50% false @@ -54330,6 +56509,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Early-onset interstitial lung disease / pulmonary hemorrhage + 90–100% false @@ -54337,6 +56517,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Chronic non-erosive inflammatory polyarthritis + 80–90% false @@ -54344,6 +56525,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Recurrent hemoptysis and chronic cough + 50–60% false @@ -54351,6 +56533,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Immune complex-mediated glomerulonephritis + 40–50% false @@ -54463,6 +56646,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Hypogammaglobulinemia with recurrent sinopulmonary bacterial infections + 80–90% false @@ -54470,6 +56654,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Benign lymphadenopathy and splenomegaly + 60–70% false @@ -54477,6 +56662,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Severe autoimmune enteropathy / lymphocytic colitis with chronic diarrhea + 50–60% false @@ -54484,6 +56670,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Autoimmune cytopenias (refractory ITP, AIHA) + 40–50% false @@ -54491,6 +56678,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Lymphocytic interstitial lung disease + 30–40% false @@ -55093,6 +57281,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Unexplained primary or secondary infertility despite regular intercourse + 95–100% false @@ -55429,6 +57618,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Bilateral or unilateral painless lacrimal gland enlargement / dacryoadenitis + 70–85% false @@ -55436,6 +57626,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Upper eyelid fullness, edema, and ptosis + 60–70% false @@ -55443,6 +57634,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Painless proptosis and orbital pseudotumor mass + 40–55% false @@ -55450,6 +57642,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Diplopia due to extraocular muscle enlargement + 25–35% false @@ -55492,6 +57685,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Immune-related maculopapular dermatitis and vitiligo-like depigmentation + 40–50% false @@ -55499,6 +57693,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Immune-mediated colitis with severe watery diarrhea and abdominal cramps + 30–40% false @@ -55506,6 +57701,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Autoimmune thyroid dysfunction: thyrotoxicosis followed by hypothyroidism + 15–25% false @@ -55513,6 +57709,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Autoimmune hypophysitis with severe headache and fatigue + 5–10% false @@ -55520,6 +57717,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Autoimmune hepatitis with marked transaminitis + 5–10% false @@ -55562,6 +57760,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Severe, intractable, watery secretory diarrhea beginning in early infancy + 95–100% false @@ -55569,6 +57768,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Severe failure to thrive and cachexia + 85–95% false @@ -55576,6 +57776,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Extensive eczematous or psoriasiform dermatitis + 70–80% false @@ -55583,6 +57784,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Early-onset type 1 diabetes mellitus in male infants + 60–70% false @@ -55590,6 +57792,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Autoimmune thyroid disease (hypo- or hyperthyroidism) + 30–40% false @@ -55674,6 +57877,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Rapidly progressive, symmetric, severe proximal limb weakness + 90–95% false @@ -55688,6 +57892,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Severe neck flexor weakness and prominent dysphagia + 50–65% false @@ -55695,6 +57900,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Pronounced muscle atrophy and myalgias + 40–50% false @@ -55912,6 +58118,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Chronic, recurrent diarrhea with or without visible blood/mucus + 80–90% false @@ -55919,6 +58126,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Cramping abdominal pain and lower abdominal tenderness + 70–85% false @@ -55926,6 +58134,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Rectal urgency, tenesmus, and fecal incontinence + 50–65% false @@ -55933,6 +58142,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Involuntary weight loss, malabsorption, and chronic fatigue + 50–60% false @@ -55940,6 +58150,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Extraintestinal manifestations (peripheral arthritis, uveitis, aphthae) + 25–35% false @@ -55982,6 +58193,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Recurrent, severe spontaneous neuroglycopenic hypoglycemia (confusion, coma, seizures) + 95–100% false @@ -55989,6 +58201,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Sympathetic adrenergic symptoms (sweating, palpitations, tremors) + 85–95% false @@ -55996,6 +58209,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Hypoglycemia occurring primarily postprandially (2–4 hours after meal) or post-exercise + 70–80% false @@ -56080,6 +58294,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Progressive exertional dyspnea and exercise limitation + 80–95% false @@ -56087,6 +58302,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Bibasilar inspiratory fine Velcro-like crackles + 75–85% false @@ -56094,6 +58310,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Chronic, persistent dry non-productive cough + 70–85% false @@ -56101,6 +58318,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Systemic fatigue, asthenia, and chest tightness + 70–80% false @@ -56108,6 +58326,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Digital clubbing in advanced fibrotic variants + 20–40% false @@ -56401,6 +58620,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Early-onset refractory autoimmune enteropathy with chronic watery diarrhea + 70–85% false @@ -56408,6 +58628,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Hypogammaglobulinemia with recurrent severe sinopulmonary infections + 65–75% false @@ -56415,6 +58636,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Massive hepatosplenomegaly and chronic lymphadenopathy + 60–70% false @@ -56422,6 +58644,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Autoimmune cytopenias (autoimmune thrombocytopenia, AIHA) + 55–65% false @@ -56429,6 +58652,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Lymphocytic interstitial lung disease + 40–50% false @@ -56751,6 +58975,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Asymmetric, slowly progressive distal motor weakness without sensory deficits (wrist/finger drop) + 90–100% false @@ -56758,6 +58983,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Asymmetric hyporeflexia confined to clinically weak muscles + 70–80% false @@ -56765,6 +58991,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Muscle fasciculations, myokymia, and muscle cramps + 60–75% false @@ -56772,6 +58999,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Focal muscle atrophy in chronically denervated muscle groups + 50–65% false @@ -57030,6 +59258,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Complete (third-degree) congenital heart block with severe fetal/neonatal bradycardia + 80–90% false @@ -57037,6 +59266,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Photosensitive annular or polycyclic erythematous facial rash ('raccoon/owl eyes') + 40–50% false @@ -57044,6 +59274,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Transient neonatal cholestasis and elevated hepatic transaminases + 15–25% false @@ -57051,6 +59282,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Transient neonatal thrombocytopenia or neutropenia + 15–20% false @@ -57338,6 +59570,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Severe, painful, refractory polymorphous stomatitis and extensive oral mucosal erosions + 95–100% false @@ -57345,6 +59578,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Polymorphic cutaneous eruptions: lichenoid, bullous, or targetoid lesions + 80–90% false @@ -57352,6 +59586,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Severe pseudomembranous conjunctivitis and genital erosions + 70–85% false @@ -57359,6 +59594,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Bronchiolitis obliterans leading to progressive, fatal respiratory failure + 30–40% false @@ -57408,6 +59644,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Sudden gross dark reddish-brown / cola-colored urine after cold exposure + 90–100% false @@ -57415,6 +59652,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Acute severe intravascular hemolytic anemia, pallor, and jaundice + 80–90% false @@ -57422,6 +59660,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Abrupt shaking chills, high fever, and back/flank or abdominal pain + 75–85% false @@ -57954,6 +60193,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Marked bilateral dependent peripheral pitting edema and anasarca + 85–95% false @@ -57961,6 +60201,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Severe hypoalbuminemia (<3.0 g/dL) + 85–95% false @@ -57968,6 +60209,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Heavy nephrotic-range proteinuria (>3.5 g/24h) with foamy urine + 80–90% false @@ -57975,6 +60217,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Hyperlipidemia and lipiduria + 70–80% false @@ -57982,6 +60225,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and High incidence of deep venous thrombosis or renal vein thrombosis + 10–20% false @@ -59144,6 +61388,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Severe, extensive, photosensitive cutaneous lesions + Gottron's papules: 80–90%, heliotrope rash: 70–80% false @@ -59151,6 +61396,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Symmetrical proximal muscle weakness + 70–80% false @@ -59158,6 +61404,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Prominent 'V-sign', 'shawl sign', and extensive poikiloderma + 65–75% false @@ -59172,6 +61419,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Severe dysphagia + 50–60% false @@ -59179,6 +61427,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Palmar hyperkeratotic papules / inverse Gottron's + 35–45% false @@ -59186,6 +61435,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and 'Flagellate erythema' on trunk + 30–40% false @@ -59298,6 +61548,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Severe, refractory hyperglycemia despite extreme doses of exogenous insulin (>1,000 U/day) + 95–100% false @@ -59305,6 +61556,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Rapidly progressive, extensive, velvety acanthosis nigricans in skin folds + 80–90% false @@ -59312,6 +61564,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Unexplained marked involuntary weight loss + 60–70% false @@ -59326,6 +61579,7 @@ A third type of PRCA, Diamond-Blackfan syndrome, is due to genetic mutation and Signs of hyperandrogenism (severe hirsutism, virilization, amenorrhea) in women + 50–60% false